{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from datasets import load_dataset\n",
    "\n",
    "dataset_original = load_dataset(\"theatticusproject/cuad-qa\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "DatasetDict({\n",
       "    train: Dataset({\n",
       "        features: ['id', 'title', 'context', 'question', 'answers'],\n",
       "        num_rows: 22450\n",
       "    })\n",
       "    test: Dataset({\n",
       "        features: ['id', 'title', 'context', 'question', 'answers'],\n",
       "        num_rows: 4182\n",
       "    })\n",
       "})"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataset_original"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "    \"id\": \"LohaCompanyltd_20191209_F-1_EX-10.16_11917878_EX-10.16_Supply Agreement__Rofr/Rofo/Rofn\",\n",
      "    \"title\": \"LohaCompanyltd_20191209_F-1_EX-10.16_11917878_EX-10.16_Supply Agreement\",\n",
      "    \"context\": \"Exhibit 10.16 SUPPLY CONTRACT Contract No: Date: The buyer/End-User: Shenzhen LOHAS Supply Chain Management Co., Ltd. ADD: Tel No. : Fax No. : The seller: ADD: The Contract is concluded and signed by the Buyer and Seller on , in Hong Kong. 1. General provisions 1.1 This is a framework agreement, the terms and conditions are applied to all purchase orders which signed by this agreement (hereinafter referred to as the \\\"order\\\"). 1.2 If the provisions of the agreement are inconsistent with the order, the order shall prevail. Not stated in order content will be subject to the provisions of agreement. Any modification, supplementary, give up should been written records, only to be valid by buyers and sellers authorized representative signature and confirmation, otherwise will be deemed invalid. 2. The agreement and order 2.1 During the validity term of this agreement, The buyer entrust SHENZHEN YICHANGTAI IMPORT AND EXPORT TRADE CO., LTD or SHENZHEN LEHEYUAN TRADING CO, LTD (hereinafter referred to as the \\\"entrusted party\\\" or \\\"YICHANGTAI\\\" or \\\"LEHEYUAN\\\"), to purchase the products specified in this agreement from the seller in the form of orders. 2.2 The seller shall be confirmed within three working days after receipt of order. If the seller finds order is not acceptable or need to modify, should note entrusted party in two working days after receipt of the order, If the seller did not confirm orders in time or notice not accept orders or modifications, the seller is deemed to have been accepted the order. The orders become effective once the seller accepts, any party shall not unilaterally cancel the order before the two sides agreed . 2.3 If the seller puts forward amendments or not accept orders, the seller shall be in the form of a written notice to entrusted party, entrusted party accept the modified by written consent, the modified orders to be taken effect. 2.4 Seller's note, only the buyer entrust the entrusted party issued orders, the product delivery and payment has the force of law.\\n\\n1\\n\\nSource: LOHA CO. LTD., F-1, 12/9/2019\\n\\n\\n\\n\\n\\n3. GOODS AND COUNTRY OF ORIGIN: 4. Specific order: The products quantity, unit price, specifications, delivery time and transportation, specific content shall be subject to the purchase order issued by entrusted party which is commissioned the buyer. 5. PACKING: To be packed in new strong wooden case(s) /carton(s), suitable for long distance transportation and for the change of climate, well protected against rough handling, moisture, rain, corrosion, shocks, rust, and freezing. The seller shall be liable for any damage and loss of the commodity, expenses incurred on account of improper packing, and any damage attributable to inadequate or improper protective measures taken by the seller in regard to the packing. One full set of technical All wooden material of shipping package must be treated as the requirements of Entry-Exit Inspection and Quarantine Bureau of China, by the agent whom is certified by the government where the goods is exported. And the goods must be marked with the IPPC stamps, which are certified by the government agent of Botanical-Inspection and Quarantine Bureau. 6. SHIPPING MARK: The Sellers shall mark on each package with fadeless paint the package number, gross weight, net weight, measurements and the wordings: \\\"KEEP AWAY FROM MOISTURE\\\",\\\"HANDLE WITH CARE\\\" \\\"THIS SIDE UP\\\" etc. and the shipping mark on each package with fadeless paint. 7. DATE OF SHIPMENT: According to specific order by YICHANGTAI or LEHEYUAN. 8. PORT OF SHIPMENT:\\n\\n2\\n\\nSource: LOHA CO. LTD., F-1, 12/9/2019\\n\\n\\n\\n\\n\\n9. PORT OF DESTINATION: SHENZHEN, GUANGDONG, CHINA 10. INSURANCE: To be covered by the Seller for 110% invoice value against All Risks and War Risk. 11. PAYMENT: Under Letter of Credit or T/T: Under the Letter of Credit: The Buyer shall open an irrevocable letter of credit with the bank within 30 days after signing the contract, in favor of the Seller, for 100% value of the total contract value. The letter of credit should state that partial shipments are allowed. The Buyer's agent agrees to pay for the goods in accordance with the actual amount of the goods shipped. 80% of the system value being shipped will be paid against the documents stipulated in Clause 12.1. The remaining 20% of the system value being shipped will be paid against the documents stipulated in Clause 12.2. The Letter of Credit shall be valid until 90 days after the latest shipment is effected. Under the T/T The trustee of the buyer remitted the goods to the seller by telegraphic transfer in batches as agreed upon after signing each order. 12. DOCUMENTS: 12.1 (1) Invoice in 5 originals indicating contract number and Shipping Mark (in case of more than one shipping mark, the invoice shall be issued separately). (2) One certificate of origin of the goods. (3) Four original copies of the packing list. (4) Certificate of Quality and Quantity in 1 original issued by the agriculture products base. (5) One copy of insurance coverage (6) Copy of cable/letter to the transportation department of Buyer advising of particulars as to shipment immediately after shipment is made.\\n\\n3\\n\\nSource: LOHA CO. LTD., F-1, 12/9/2019\\n\\n\\n\\n\\n\\n12.2 (1) Invoice in 3 originals indicating contract number and L/C number. (2) Final acceptance certificate signed by the Buyer and the Seller. 13. SHIPMENT: CIP The seller shall contract on usual terms at his own expenses for the carriage of the goods to the agreed point at the named place of destination and bear all risks and expenses until the goods have been delivered to the port of destination. The Sellers shall ship the goods within the shipment time from the port of shipment to the port of destination. Transshipment is allowed. Partial Shipment is allowed. In case the goods are to be dispatched by parcel post/sea-freight, the Sellers shall, 3 days before the time of delivery, inform the Buyers by cable/letter of the estimated date of delivery, Contract No., commodity, invoiced value, etc. The sellers shall, immediately after dispatch of the goods, advise the Buyers by cable/letter of the Contract No., commodity, invoiced value and date of dispatch for the Buyers. 14. SHIPPING ADVICE: The seller shall within 72 hours after the shipment of the goods, advise the shipping department of buyer by fax or E-mail of Contract No., goods name, quantity, value, number of packages, gross weight, measurements and the estimated arrival time of the goods at the destination. 15. GUARANTEE OF QUALITY: The Sellers guarantee that the commodity hereof is complies in all respects with the quality and specification stipulated in this Contract. 16. CLAIMS: Within 7 days after the arrival of the goods at destination, should the quality, specification, or quantity be found not in conformity with the stipulations of the Contract except those claims for which the insurance company or the owners of the vessel are liable, the Buyers, on the strength of the Inspection Certificate issued by the China Commodity Inspection Bureau, have the right to claim for replacement with new goods, or for compensation, and all the expenses (such as inspection charges, freight for returning the goods and for sending the replacement, insurance premium, storage and loading and unloading charges etc.) shall be borne by the Sellers. The Certificate so issued shall be accepted as the base of a claim. The Sellers, in accordance with the Buyers' claim, shall be responsible for the immediate elimination of the defect(s), complete or partial replacement of the commodity or shall devaluate the commodity according to the state of defect(s). Where necessary, the Buyers shall be at liberty to eliminate the defect(s) themselves at the Sellers' expenses. If the Sellers fail to answer the Buyers within one weeks after receipt of the aforesaid claim, the claim shall be reckoned as having been accepted by the Sellers.\\n\\n4\\n\\nSource: LOHA CO. LTD., F-1, 12/9/2019\\n\\n\\n\\n\\n\\n17. FORCE MAJEURE: The Sellers shall not be held responsible for the delay in shipment or non-delivery, of the goods due to Force Majeure, which might occur during the process of manufacturing or in the course of loading or transit. The Sellers shall advise the Buyers immediately of the occurrence mentioned above and within fourteen days thereafter, the Sellers shall send by airmail to the Buyers a certificate of the accident issued by the competent government authorities, Chamber of Commerce or registered notary public of the place where the accident occurs as evidence thereof. Under such circumstances the Sellers, however, are still under the obligation to take all necessary measures to hasten the delivery of the goods. In case the accident lasts for more than 10 weeks, the Buyers shall have the right to cancel the Contract. 18. LATE DELIVERY AND PENALTY: Should the Sellers fail to make delivery on time as stipulated in the Contract, with exception of Force Majeure causes specified in Clause 17 of this Contract, the Buyers shall agree to postpone the delivery on condition that the Sellers agree to pay a penalty which shall be deducted by the paying bank from the payment. The penalty, however, shall not exceed 5% of the total value of the goods involved in the late delivery. The rate of penalty is charged at 0.5% for every seven days, odd days less than seven days should be counted as seven days. In case the Sellers fail to make delivery ten weeks later than the time of shipment stipulated in the Contract, the Buyers have the right to cancel the contract and the Sellers, in spite of the cancellation, shall still pay the aforesaid penalty to the Buyers without delay, the seller should refund the money received and pay the 30% of the total goods price of the penalty 19. ARBITRATION: All disputes in connection with this Contract or the execution thereof shall be settled friendly through negotiations. In case no settlement can be reached, the case may then be submitted for arbitration to the Foreign Economic and Trade Arbitration Committee of the China Beijing Council for the Promotion of International Trade in accordance with its Provisional Rules of Procedures by the said Arbitration Committee. The Arbitration shall take place in Beijing and the decision of the Arbitration Committee shall be final and binding upon both parties; neither party shall seek recourse to a law court nor other authorities to appeal for revision of the decision. Arbitration fee shall be borne by the losing party. 20. This final price is the confidential information. Dissemination, distribution or duplication of this price is strictly prohibited.\\n\\n5\\n\\nSource: LOHA CO. LTD., F-1, 12/9/2019\\n\\n\\n\\n\\n\\n21. Law application It will be governed by the law of the People's Republic of China ,otherwise it is governed by United Nations Convention on Contract for the International Sale of Goods. 22. <<Incoterms 2000>> The terms in the contract are based on (INCOTERMS 2000) of the International Chamber of Commerce. 23. The Contract is valid for 5 years, beginning from and ended on . This Contract is made out in three originals in both Chinese and English, each language being legally of the equal effect. Conflicts between these two languages arising there from, if any, shall be subject to Chinese version. One copy for the Sellers, two copies for the Buyers. The Contract becomes effective after signed by both parties. THE BUYER: THE SELLER: SIGNATURE: SIGNATURE: 6\\n\\nSource: LOHA CO. LTD., F-1, 12/9/2019\",\n",
      "    \"question\": \"Highlight the parts (if any) of this contract related to \\\"Rofr/Rofo/Rofn\\\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?\",\n",
      "    \"answers\": {\n",
      "        \"text\": [],\n",
      "        \"answer_start\": []\n",
      "    }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "\n",
    "print(json.dumps(dataset_original['test'][16], indent=4))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'text': ['SUPPLY CONTRACT'], 'answer_start': [14]},\n",
       " {'text': ['The seller:',\n",
       "   'The buyer/End-User: Shenzhen LOHAS Supply Chain Management Co., Ltd.'],\n",
       "  'answer_start': [143, 49]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The Contract is valid for 5 years, beginning from and ended on .'],\n",
       "  'answer_start': [10985]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"It will be governed by the law of the People's Republic of China ,otherwise it is governed by United Nations Convention on Contract for the International Sale of Goods.\"],\n",
       "  'answer_start': [10691]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Within 7 days after the arrival of the goods at destination, should the quality, specification, or quantity be found not in conformity with the stipulations of the Contract except those claims for which the insurance company or the owners of the vessel are liable, the Buyers, on the strength of the Inspection Certificate issued by the China Commodity Inspection Bureau, have the right to claim for replacement with new goods, or for compensation, and all the expenses (such as inspection charges, freight for returning the goods and for sending the replacement, insurance premium, storage and loading and unloading charges etc.) shall be borne by the Sellers.'],\n",
       "  'answer_start': [6665]},\n",
       " {'text': ['To be covered by the Seller for 110% invoice value against All Risks and War Risk.'],\n",
       "  'answer_start': [3659]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['WEB SITE HOSTING AGREEMENT'], 'answer_start': [225]},\n",
       " {'text': ['Centrack International',\n",
       "   'I-ON INTERACTIVE, INC.',\n",
       "   'i-on interactive',\n",
       "   'CENTRACK INTERNATIONAL, INC.',\n",
       "   'the Customer',\n",
       "   'i-on'],\n",
       "  'answer_start': [330, 14893, 398, 14853, 378, 101]},\n",
       " {'text': ['6th day of April, 1999'], 'answer_start': [292]},\n",
       " {'text': ['The term of this Agreement for the Hosted Site shall commence upon April 1, 1999 and shall continue for a period of six (6) months, unless earlier terminated in accordance with provisions hereof.'],\n",
       "  'answer_start': [10363]},\n",
       " {'text': ['The term of this Agreement for the Hosted Site shall commence upon April 1, 1999 and shall continue for a period of six (6) months, unless earlier terminated in accordance with provisions hereof.'],\n",
       "  'answer_start': [10363]},\n",
       " {'text': ['Agreement, which notice must be given not less than fifteen (15) days before the end of the respective initial or renewal term.',\n",
       "   'This Agreement shall automatically be renewed for one (1) or more one (1) month periods unless either the Customer or i-on gives notice to the other party of its intention not to renew the'],\n",
       "  'answer_start': [10751, 10559]},\n",
       " {'text': ['Agreement, which notice must be given not less than fifteen (15) days before the end of the respective initial or renewal term.',\n",
       "   'This Agreement shall automatically be renewed for one (1) or more one (1) month periods unless either the Customer or i-on gives notice to the other party of its intention not to renew the'],\n",
       "  'answer_start': [10751, 10559]},\n",
       " {'text': ['This Agreement was entered into in the State of Florida, and its validity, construction, interpretation, and legal effect shall be governed by the laws and judicial decisions of the State of Florida applicable to contracts entered into and performed entirely within the State of Florida.'],\n",
       "  'answer_start': [14093]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Either party may terminate this Agreement without cause at any time effective upon thirty (30) days' written notice.\"],\n",
       "  'answer_start': [10880]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"i-on will not be liable under any circumstances for any lost profits or other consequential damages, even if i-on has been advised as to the possibility of such damages. i-on's liability for damages to the Customer for any cause whatsoever, regardless of the form of action, and whether in contract or in tort, including negligence, shall be limited to one (1) month's fees and the remaining portion of any prepaid fees.\"],\n",
       "  'answer_start': [11273]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['CO-PROMOTION AGREEMENT'], 'answer_start': [4812]},\n",
       " {'text': ['Dova',\n",
       "   'Dova and Valeant are each referred to individually as a \"Party\" and together as the \"Parties\".',\n",
       "   'Dova Pharmaceuticals, Inc.',\n",
       "   'Valeant',\n",
       "   'Valeant Pharmaceuticals North America LLC'],\n",
       "  'answer_start': [857, 5130, 4972, 1131, 5037]},\n",
       " {'text': ['September 26, 2018'], 'answer_start': [210]},\n",
       " {'text': ['September 26, 2018',\n",
       "   '\"Effective Date\" shall have the meaning set forth in the preamble to this Agreement.'],\n",
       "  'answer_start': [210, 14469]},\n",
       " {'text': ['This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").'],\n",
       "  'answer_start': [137974]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.'],\n",
       "  'answer_start': [149858]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['[***], neither Valeant nor its Affiliates shall, directly or indirectly, [***] in the Territory other than the Product; provided that if the Agreement is terminated by Dova pursuant to [***], then any Tail Period shall be immediately terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in the Territory other than the Product during such Tail Period.'],\n",
       "  'answer_start': [32047]},\n",
       " {'text': ['During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.'],\n",
       "  'answer_start': [27927]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Notwithstanding anything to the contrary, in no event shall the restrictions set forth in this Section 2.3.2 apply to [***].',\n",
       "   'Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].'],\n",
       "  'answer_start': [33477, 32431]},\n",
       " {'text': [\"[***], neither Valeant nor Dova (nor any of their respective Affiliates) shall directly or indirectly solicit for hire or employee as an employee, consultant or otherwise any of the other Party's professional personnel who have had direct involvement with the JSC, with the Valeant Activities under this Agreement (which, in the case of Valeant, includes the Field Force Personnel) or with Dova's commercialization activities for the Product, without the other Party's prior written consent.\"],\n",
       "  'answer_start': [32985]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]); [***].'],\n",
       "  'answer_start': [140977]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Notwithstanding the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova's assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment.\"],\n",
       "  'answer_start': [146920]},\n",
       " {'text': ['Any attempted assignment not in accordance with this Section 13.2 shall be void.',\n",
       "   'Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment.',\n",
       "   'Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant Activities with any Third Party (including any contract sales force).',\n",
       "   \"In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party.\"],\n",
       "  'answer_start': [147607, 146057, 29132, 146443]},\n",
       " {'text': ['If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].',\n",
       "   'Commencing with the Calendar Quarter commencing on October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as follows:\\n\\n(a) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales;\\n\\n(b) For any portion of Net Sales in excess of [***] and up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales; and\\n\\n(c) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such portion of Net Sales.',\n",
       "   'If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].'],\n",
       "  'answer_start': [88296, 87456, 88654]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory.',\n",
       "   'If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].',\n",
       "   'A Party shall have the right to terminate this Agreement before the end of the Term as follows:',\n",
       "   '12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;',\n",
       "   'If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].'],\n",
       "  'answer_start': [45436, 88654, 138220, 139134, 88296]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The ownership, and all goodwill from the use, of any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the foregoing to Dova.',\n",
       "   'Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention.',\n",
       "   'As between the Parties, Dova shall own all right, title and interest in and to any Product Materials (and all content contained therein) and any Product Labeling (and all content contained therein), including applicable copyrights and trademarks (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling), and to the extent Valeant (or any of its Affiliates) obtains or otherwise has a claim to any of the foregoing, Valeant hereby assigns (and shall cause any applicable Affiliate to assign) all of its right, title and interest in and to such Product Materials (and content) and Product Labeling (and content) (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling) to Dova and Valeant agrees to (and shall cause its applicable Affiliate to) execute all documents and take all actions as are reasonably requested by Dova to vest title to such Product Materials (and content) and Product Labeling (and content) in Dova (or its designated Affiliate).'],\n",
       "  'answer_start': [110014, 109510, 67624]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement.',\n",
       "   'During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.',\n",
       "   \"[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.\"],\n",
       "  'answer_start': [33646, 27927, 108144]},\n",
       " {'text': [\"Except to Affiliates of Valeant, Valeant's rights and obligations under this Section 2.1 are non-transferable, non-assignable, and non-delegable.\",\n",
       "   \"[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.\"],\n",
       "  'answer_start': [28986, 108144]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova's promotion or other commercialization of the Product in the Territory.\"],\n",
       "  'answer_start': [108144]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Dova shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed over- payment for that audited period in excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse Dova for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.',\n",
       "   'Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the applicable records and books maintained by Dova for purposes of verifying Dova\\'s payment obligations within this Agreement, including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder; provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Valeant shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant problems relating to Dova\\'s payment obligations hereunder.',\n",
       "   \"Where necessary, on reasonable request, Dova's audit rights shall include interviewing Sales Representatives and other employees of Valeant.\",\n",
       "   'Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant\\'s compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant\\'s obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities.',\n",
       "   'Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.'],\n",
       "  'answer_start': [106835, 102745, 106243, 104853, 104286]},\n",
       " {'text': [\"THE FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR (2) DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 9.\"],\n",
       "  'answer_start': [136727]},\n",
       " {'text': [\"NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.\",\n",
       "   'Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.'],\n",
       "  'answer_start': [136062, 45695]},\n",
       " {'text': ['Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated.'],\n",
       "  'answer_start': [143450]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated.'],\n",
       "  'answer_start': [137034]},\n",
       " {'text': ['During the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor.',\n",
       "   'Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights.'],\n",
       "  'answer_start': [35744, 35117]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['AMENDED AND RESTATED STRATEGIC LICENSING, DISTRIBUTION AND MARKETING AGREEMENT'],\n",
       "  'answer_start': [322]},\n",
       " {'text': ['PACIRA PHARMACEUTICALS, INC.',\n",
       "   'EKR',\n",
       "   'EKR THERAPEUTICS, INC.',\n",
       "   'F/K/A SKYEPHARMA, INC.',\n",
       "   'PPI'],\n",
       "  'answer_start': [166, 201, 201, 574, 748]},\n",
       " {'text': ['October 15, 2009'], 'answer_start': [431]},\n",
       " {'text': ['August 10, 2007'], 'answer_start': [1389]},\n",
       " {'text': ['This Agreement shall commence on the Effective Date and, subject to earlier termination in accordance with the provisions of Section 16, shall continue in force for a period being the longer of fifteen (15) years from first Commercial Launch of the Product in the Territory or until  the expiration of the last valid claim in the PPI Patents covering the Product in any country of the Territory (the \"Initial Term\").'],\n",
       "  'answer_start': [93722]},\n",
       " {'text': ['Thereafter  the term of this Agreement shall automatically renew for consecutive periods of two (2) years each.'],\n",
       "  'answer_start': [94139]},\n",
       " {'text': ['Notwithstanding the foregoing, this  Agreement can be terminated by EKR at the end of the Initial Term by delivery of written notice to PPI at least one hundred eighty (180)  days prior to the end of the Initial Term or any renewal term.'],\n",
       "  'answer_start': [94251]},\n",
       " {'text': ['This Agreement and the relationship between the Parties shall be governed by, and interpreted in accordance with New  York law without regard to provisions related to conflicts of laws, and, except as provided in Section 21.2 above, the Parties agree to submit  any dispute to the exclusive jurisdiction of the federal and state courts sitting in New York.'],\n",
       "  'answer_start': [118160]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['EKR shall not, during [**], market, distribute or sell a Competing Product in the Territory unless during such time an A/B  rated generic product of the Product(s) is launched in such country of the Territory or in the event this Agreement is terminated or EKR  exercises its rights under Section 17.4 hereof.',\n",
       "   'During the Term, PPI and its Affiliates shall not: (i) file for Marketing Authorization with respect to any Competing Product in  any country in the Territory, (ii) manufacture or have manufactured any Competing Product in any country in the Territory, (iii) market or  have marketed any Competing Product in any country in the Territory or (iv) license any Third Party to do any of the foregoing.'],\n",
       "  'answer_start': [48150, 25723]},\n",
       " {'text': ['PPI hereby grants EKR the exclusive right and license (with the right to sublicense) to use, market, promote, sell, distribute and warehouse the Products (the \"Distribution Rights\") in the Field in the Territory during the Term, as  well as to make or have made the Products anywhere in the world for import or sale in the Field in the Territory in each case, under the PPI  IP provided that PPI retains all rights necessary to manufacture and supply the Products to EKR in accordance with this Agreement and the  Supply Agreement.',\n",
       "   'Subject to the terms of this Agreement, PPI hereby appoints EKR and EKR agrees to be retained as the exclusive  distributor, and Authorized Distributor of Record, of the Products in the Field in the Territory during the Term to market, distribute,  warehouse and sell the Products.',\n",
       "   'PPI hereby grants to EKR a royalty free and exclusive license (with the right to sublicense) to use the  Trademarks in the Territory solely in connection with the exercise of the Distribution Rights in the Territory during the Term (and thereafter  as set forth in Section 17.4) and EKR shall market and sell the Products under the Trademarks.'],\n",
       "  'answer_start': [15906, 15479, 16750]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['At any time between the Agreement Date and July 1, 2015, EKR shall have the right, exercisable upon sixty (60) days prior written  notice to PPI, to terminate the Lease Term and sell the Transferred Equipment back to PPI, subject to payment by PPI to EKR within  five (5) days of such notice of $[**] in cash, which if exercised shall result in (i) an offset against the unpaid balance of principal and  interest under the Promissory Note pursuant to Section 3.20(f) below; and (ii) the termination of the Step-in Right described in  Section 17.5.',\n",
       "   'At any time after July 1, 2015, PPI shall have the right, exercisable upon sixty (60) days prior written notice to EKR, to terminate the Lease Term and repurchase the Transferred Equipment from EKR, subject to payment by PPI to EKR within five (5) days of such  notice of any principal paid by EKR under the Promissory Note, which if exercised shall result in the termination of the Step-in Right  set forth in Section 17.5.',\n",
       "   'EKR may terminate this Agreement for convenience at any time upon [**] ([**]) days prior, written notice to PPI.'],\n",
       "  'answer_start': [32719, 33274, 99021]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['(iii) upon any Change of Control (as defined in Section 20.4) of PPI, by repayment to EKR in full of the balance of the  Advanced Royalty Payment not previously used for offsets, which payment shall be made to EKR by PPI within ten  (10) days after the closing date (without any conditions) of any such Change of Control.',\n",
       "   'Either Party shall be entitled forthwith to terminate this Agreement by notice to the other if:',\n",
       "   'Offsets and/or repayment of the Advanced Royalty Payment shall commence on [**] and shall continue, unless sooner  paid, through [**] (the \"Royalty Offset Period\") and such offsets will be taken by EKR (and such repayment will be made  by PPI) as follows:',\n",
       "   'Should there be a Change of Control of either Party resulting in the control of such Party by a Third Party which  markets or sells a Competing Product in any part of the Territory, then the rights under this Agreement may not be assigned without the  express consent of the other Party which consent shall not be unreasonably withheld. \"Change of Control\" shall mean (a) the sale, lease,  exchange, license or disposition of all or substantially all of the Party\\'s assets in one transaction or series of related transactions or (b) a  merger or consolidation with an unaffiliated Third Party as a result of which the holders of the Party\\'s issued and outstanding voting  securities immediately before such transaction own or control less than a majority of the voting securities of the continuing or surviving  entity immediately after such transaction.',\n",
       "   '(i) the other Party ceases or threatens to cease to carry on the whole or any material part of its business;'],\n",
       "  'answer_start': [57328, 94645, 56022, 112442, 96972]},\n",
       " {'text': ['Should there be a Change of Control of either Party resulting in the control of such Party by a Third Party which  markets or sells a Competing Product in any part of the Territory, then the rights under this Agreement may not be assigned without the  express consent of the other Party which consent shall not be unreasonably withheld.',\n",
       "   'Subject to Section 20.2, neither Party shall, nor shall it purport to, assign, license, transfer or change any of its rights or  obligations under this Agreement without the prior written consent of the other, such consent not to be unreasonably withheld  conditioned or delayed; provided, however, that except as provided in Section 20.4 either Party may assign its rights hereunder to an  Affiliate or to any successor by merger, consolidation, sale of stock or other equity interests or the sale of substantially all of the assets of  such Party without the consent of the other Party.'],\n",
       "  'answer_start': [112442, 110480]},\n",
       " {'text': ['As further consideration for the license and grant of Distribution Rights and other rights under this Agreement, EKR shall pay to PPI a royalty (\"Royalty\") equal to (a) $[**] for each [**] mg Vial of Product sold during the Term and $[**] for each [**] mg Vial of Product  sold during the Term (the \"Minimum Royalty\")  plus (b) an additional [**]% of any post Effective Date incremental price increase  implemented by EKR over the Current Base Price of $[**] for the [**] mg Vial and $[**] for the [**] mg Vial (the \"Additional Royalty\");  provided, however, that Additional Royalty shall not be payable to the extent that the sum of (i) the Minimum Royalty and Additional  Royalty payable hereunder and (ii) the Supply Price (as defined in the Supply Agreement) shall at any time during the Term exceed [**]  percent ([**]%) of the net average selling price of the Product (the \"Royalty Cap\"); provided, however, that the Royalty Cap shall be [**]  percent ([**]%) of the net average selling price of the Product during certain periods as described in Section 6.3(e) above.'],\n",
       "  'answer_start': [59691]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['(d) EKR shall assign to PPI free of charge any domain name registrations it has registered pursuant to Section 8.5;',\n",
       "   'Upon termination of this Agreement for any reason except by EKR pursuant to Section 16.1(a), EKR shall promptly transfer the Transferred NDA and related regulatory documentation to PPI in accordance with Section 17.1(e).',\n",
       "   'On the Effective Date, PPI has transferred the Domain Names to EKR for use in connection with the exercise of  the Distribution Rights.',\n",
       "   'Promptly after the Agreement  Date, PPI shall provide EKR with copies of all agreements relating to the Required Studies and shall assign such agreements to EKR if and  to the extent (i) such agreements are assignable in accordance with their terms and (ii) requested by EKR.',\n",
       "   'Upon any termination or expiration of this Agreement, EKR shall promptly transfer the Domain Names back to PPI.',\n",
       "   'Effective as of the Agreement Date, PPI hereby sells, transfers, conveys and assigns to EKR all right, title  and interest in and to [**] (the \"Transferred NDA\").',\n",
       "   'Upon termination of this Agreement for any reason except as set forth in Section 17.4 below (and, if applicable, in respect of that country in  respect of which termination occurs):'],\n",
       "  'answer_start': [100780, 19872, 17691, 22377, 17941, 18673, 99578]},\n",
       " {'text': [\"Joint Improvements  shall be owned jointly by the Parties, and PPI's interest therein shall be licensed to EKR hereunder.\"],\n",
       "  'answer_start': [69194]},\n",
       " {'text': [\"The Step-in Right shall include, without limitation, and to the extent allowable under Applicable Law, PPI's grant to EKR of  such additional license rights, rights of access, rights of observation and rights of management, direction and control, in  each case solely with respect to the manufacture and supply of Product and as reasonably necessary to enable and permit  EKR (or EKR's designee) to ensure that the supply of Product shall continue to be available to EKR under this Agreement  and the Supply Agreement; provided that EKR in exercising the Step-in Right shall not (i) unreasonably interfere with PPI's  other activities at the facilities at which the Product is manufactured, tested, labeled, stored or\",\n",
       "   'EKR Improvements shall be owned by EKR  and upon termination of this Agreement by PPI pursuant to Section, shall be deemed be licensed to PPI on a worldwide, non-exclusive,  irrevocable basis, at a royalty or for such other consideration as may be mutually agreed upon by the parties in writing.',\n",
       "   'otherwise handled (\"Product Facilities\") or (ii) require PPI to take any action or fail to take any action that does or could  reasonably be expected to interfere with PPI\\'s other activities at the Product Facilities.',\n",
       "   'PPI hereby grants EKR the exclusive right and license (with the right to sublicense) to use, market, promote, sell, distribute and warehouse the Products (the \"Distribution Rights\") in the Field in the Territory during the Term, as  well as to make or have made the Products anywhere in the world for import or sale in the Field in the Territory in each case, under the PPI  IP provided that PPI retains all rights necessary to manufacture and supply the Products to EKR in accordance with this Agreement and the  Supply Agreement.',\n",
       "   \"Such grant by PPI shall include the right of EKR to market the Product in the Territory during the Term as an EKR  product using in addition to the Trademarks, EKR's own trademarks, trade dress, trade names and other proprietary designations in  combination with the Trademarks.\",\n",
       "   \"Joint Improvements  shall be owned jointly by the Parties, and PPI's interest therein shall be licensed to EKR hereunder.\",\n",
       "   'PPI hereby grants to EKR a royalty free and exclusive license (with the right to sublicense) to use the  Trademarks in the Territory solely in connection with the exercise of the Distribution Rights in the Territory during the Term (and thereafter  as set forth in Section 17.4) and EKR shall market and sell the Products under the Trademarks.',\n",
       "   'PPI Improvements shall be owned by PPI and be licensed to EKR hereunder.'],\n",
       "  'answer_start': [105473, 68898, 106211, 15906, 16438, 69194, 16750, 68825]},\n",
       " {'text': ['(b) obtain a confidential nondisclosure agreement with the prospective Sub-Distributor in a form acceptable to PPI, which  acceptance shall not be unreasonably withheld or delayed and containing terms at least as stringent as those terms  included in Article 11 of this Agreement;\\n\\n  (c) deliver to the prospective Sub-Distributor a redacted copy of this Agreement (\"Redacted Agreement\") .  Any sub- distribution agreement shall provide that such agreement is subject and subordinate to the rights of PPI under this  Agreement; and\\n\\n  (d) provides PPI with a copy of written sub-distribution agreement as soon as reasonably practicable after the execution  thereof by EKR.',\n",
       "   'EKR may appoint sub-distributors under this Agreement provided that EKR:\\n\\n  (a) informs PPI of the identity of any Third Party sub-distributor (other than Affiliate companies) prior to the execution of any  sub-distribution agreement;'],\n",
       "  'answer_start': [111536, 111277]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['PPI Improvements shall be owned by PPI and be licensed to EKR hereunder. EKR Improvements shall be owned by EKR  and upon termination of this Agreement by PPI pursuant to Section, shall be deemed be licensed to PPI on a worldwide, non-exclusive,  irrevocable basis, at a royalty or for such other consideration as may be mutually agreed upon by the parties in writing.'],\n",
       "  'answer_start': [68825]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"The Step-in Right shall include, without limitation, and to the extent allowable under Applicable Law, PPI's grant to EKR of  such additional license rights, rights of access, rights of observation and rights of management, direction and control, in  each case solely with respect to the manufacture and supply of Product and as reasonably necessary to enable and permit  EKR (or EKR's designee) to ensure that the supply of Product shall continue to be available to EKR under this Agreement  and the Supply Agreement; provided that EKR in exercising the Step-in Right shall not (i) unreasonably interfere with PPI's  other activities at the facilities at which the Product is manufactured, tested, labeled, stored or\",\n",
       "   'Such insurance shall be with a reputable insurance company and where  reasonably possible (taking into account the availability of such insurance) shall be maintained for not less than [**] ([**]) years following  the expiry or termination of this Agreement.',\n",
       "   'EKR shall maintain and shall procure the maintenance of accurate and up to date records and books of account  showing the quantity, description and value of the Products supplied in each country of the Territory during the previous six (6) Calendar  Years.',\n",
       "   'PPI shall provide such advice as necessary for EKR to arrange for an alternative manufacturer and shall provide EKR with access to all relevant PPI  Know-How, and any other information necessary for EKR to transfer such manufacturing to an alternate manufacturer.',\n",
       "   'otherwise handled (\"Product Facilities\") or (ii) require PPI to take any action or fail to take any action that does or could  reasonably be expected to interfere with PPI\\'s other activities at the Product Facilities.',\n",
       "   'In the event that this Agreement is terminated by PPI in accordance with Section 16.1 or EKR in accordance with Section 16.3(b), EKR and its Affiliates, sub-distributors and sub-licensees shall be entitled to continue to sell',\n",
       "   \"In such event, the Royalty payments payable hereunder shall continue to be paid; provided,  however, that all costs  incurred by EKR in the transfer of manufacturing information from PPI and obtaining FDA approval of the manufacture of the Products by  EKR or EKR's designee, and any other amounts due to EKR, shall be deducted from any royalties payable to PPI.\",\n",
       "   'existing stocks of the Product in the Territory for so long as PPI deems necessary to ensure that sale of the Product is not disrupted  provided that EKR and its Affiliates shall cease such sale immediately upon notification from PPI and in any event EKR shall not so sell for  a period of longer than three (3) months following the date of termination. Immediately upon notification from PPI, such post termination  sales shall cease.',\n",
       "   \"Notwithstanding anything contained herein to the contrary, in the event that EKR is entitled to exercise its right to terminate this Agreement pursuant to Section 16.1(a), in addition to the right to terminate as provided therein and any other remedies EKR  may have hereunder, PPI shall assist EKR in the transfer of the manufacture of the Products, including the Specifications from PPI to EKR  or EKR's designee.\",\n",
       "   '(b) the following provisions of this Agreement shall continue in full force and effect: Article 1 (\"Definitions\"), Section 3.20(k),  Section 3.20(l), Article 9 (\"Representations and Warranties\"), Article 10 (\"Liability, Insurance and Indemnities\") (excluding  Section 10.6 (\"Insurance\")), Article 11 (\"Confidentiality, Press Releases and Publications\"), Article 13 (\"Infringement of  Third Party Rights\"), Section 16.4 (\"Effect of Termination\"), Article 17 (\"Consequences of Termination\"), Article 18 (\"Force  Majeure\"), Article 19 (\"Notices\"), Article 20 (\"Assignment and Change of Control\") and Article 21 (\"General Provisions\");     (c) EKR shall return to PPI all PPI IP in its possession;     (d) EKR shall assign to PPI free of charge any domain name registrations it has registered pursuant to Section 8.5; and\\n\\n  (e) Except in the event of termination of this Agreement by EKR pursuant to Section 16.1(a), EKR shall promptly transfer to PPI  or its nominee, each and every Marketing Authorization (to the extent not held by PPI) relating to the Product, together  with all communications with the relevant Regulatory Authorities, and all notes and record thereof.',\n",
       "   \"In the event EKR exercises the Step-in Right, PPI shall, at EKR's cost and expense, cooperate in the exercise of such rights  and EKR shall reimburse PPI for the reasonable costs PPI incurs in assisting EKR in the exercise of such rights within thirty  (30) days of EKR's receipt of invoice.\",\n",
       "   'Where this Agreement has expired or has been terminated for any reason other than by PPI in accordance  with Section 16.1 or EKR in accordance with Section 16.3(b), EKR and its Affiliates and sub-distributors and sales agents shall be entitled  to continue to sell existing stocks of the Product in the Territory for a period of not longer than 12 months following the date of termination,  provided that, EKR continues to make any Royalty payments due to PPI in respect of such sales in accordance with the provisions of this  Agreement.',\n",
       "   'The Parties acknowledge that effective upon the termination or expiration of the Transition Services and Inventory Agreement, PPI has',\n",
       "   'In addition, (i) PPI  shall transfer to EKR any Marketing Authorizations held by PPI and (ii) the Trademark license granted under Section 2.3 shall continue in  effect following such termination on a perpetual basis and EKR shall be responsible for all costs associated with the maintenance of such  Trademark.',\n",
       "   'In addition, PPI shall  during the remainder of the Term and for a period of up to [**] ([**]) years thereafter continue to manufacture and supply the Product to  EKR at cost without mark-up until such time that EKR can secure an FDA approved manufacturing facility for the Product',\n",
       "   'During the Term, in the event EKR has the right to terminate this Agreement under Section 16.1(a) - (i) hereof (the \"Step-in  Right Trigger Event\"), and EKR does not exercise its right to terminate this Agreement under such Section, EKR shall  have the option to exercise step-in rights to manufacture the Product for the remainder of the Term (the \"Step-in Right\") by  providing PPI written notice of such election within ninety (90) days after the Step-in Right Trigger Event (or such longer  period as mutually agreed by the Parties) (the \"Step-in Right Notice\"); provided that in the event such Step-in Right  Trigger Event has been cured prior to EKR\\'s exercise of the Step-in Right, the Step-in Right shall terminate with respect to  such Step-in Right Trigger Event. The Step-in Right Notice shall specify the date which EKR intends to exercise the rights  associated with the Step-in Right.',\n",
       "   'Upon termination of this Agreement for any reason except as set forth in Section 17.4 below (and, if applicable, in respect of that country in  respect of which termination occurs):',\n",
       "   'assigned to EKR all of PPI\\'s right, title and interest under that certain Commercial Outsourcing Services Agreement between PPI (f/k/a  SkyePharma, Inc.) and Integrated Commercialization Solutions, Inc. (\"ICS\")  dated April 3, 2007 (the \"ICS Agreement\"), and EKR has  assumed all obligations and liabilities under the ICS Agreement arising after the Effective Date.'],\n",
       "  'answer_start': [105473,\n",
       "   82591,\n",
       "   64846,\n",
       "   103639,\n",
       "   106211,\n",
       "   101867,\n",
       "   102993,\n",
       "   102111,\n",
       "   102577,\n",
       "   100082,\n",
       "   105174,\n",
       "   101290,\n",
       "   27823,\n",
       "   103903,\n",
       "   103356,\n",
       "   104268,\n",
       "   99578,\n",
       "   27979]},\n",
       " {'text': ['Such inspection shall be undertaken by an independent auditor appointed by PPI and reasonably  acceptable to EKR for the purpose of verifying the accuracy of any statement or report given by EKR to PPI and/or the amount of Royalties  due.',\n",
       "   'Upon completion of such inspection, PPI shall not be entitled to inspect nor shall EKR be required to make available the records and  books for any Calendar Year for which such inspection was previously undertaken.',\n",
       "   \"EKR shall during business hours, on no less than 14 day's notice from PPI and not more than once in any Calendar Year, make available for inspection the records\",\n",
       "   'In connection with the promotion, marketing and sale of the Product, EKR shall, without limitation:',\n",
       "   \"(b) from time to time consult with PPI's representatives for the purpose of assessing the state of the market in each country of  the Territory and permit representatives of PPI, on reasonable prior notice, to inspect any premises or documents used in  connection with the marketing, distribution and sale of the Products;\",\n",
       "   'and books referred to in Section 7.2.'],\n",
       "  'answer_start': [65344, 65583, 65121, 46269, 46582, 65306]},\n",
       " {'text': [\"however that such limitation shall not apply to the extent that EKR or any EKR Indemnified Party is required to pay in excess of such  amount to a third party in respect of a final judgment or order obtained by the third party or as a result of PPI's breach of Section 7.2.12 of  the Supply Agreement.\",\n",
       "   'Any and all liability of PPI to EKR howsoever arising in respect of this Agreement, the Transition Services and Inventory Agreement or the Supply Agreement and their performance, in contract tort or otherwise, shall be limited (except for death or  personal injury caused by the negligence of PPI or its employees while acting in the course of their employment) to [**] US Dollars ($[**]);  provided',\n",
       "   'Any and all liability of EKR to PPI howsoever arising in respect of this Agreement, the Transition Services and Inventory Agreement or the Supply Agreement and their performance in contract tort or otherwise shall be limited (except for death or  personal injury caused by the negligence of EKR or its employees while acting in the course of their employment, and except in relation to  any specified payment, lump sum, milestone or royalty payment unpaid) to [**] US Dollars ($[**]); provided however that such limitation  shall not apply to the extent that PPI or any PPI Indemnified Party is required to pay in excess of such amount to a third party in respect of a  final judgment or order obtained by the third party.'],\n",
       "  'answer_start': [84207, 83783, 84542]},\n",
       " {'text': [\"Notwithstanding anything contained in this Agreement or the Transition Services and Inventory Agreement or the  Supply Agreement in no circumstance shall either Party be liable to the other in contract, tort (including negligence or breach of statutory  duty) or otherwise howsoever, and whatever the cause thereof, for any special, indirect or consequential loss or damage of any nature  whatsoever except in the cases of fraud or intentional misconduct or in the case of PPI as a result of PPI's breach of Section 7.2.12 of the  Supply Agreement.\",\n",
       "   \"however that such limitation shall not apply to the extent that EKR or any EKR Indemnified Party is required to pay in excess of such  amount to a third party in respect of a final judgment or order obtained by the third party or as a result of PPI's breach of Section 7.2.12 of  the Supply Agreement.\",\n",
       "   'Any and all liability of PPI to EKR howsoever arising in respect of this Agreement, the Transition Services and Inventory Agreement or the Supply Agreement and their performance, in contract tort or otherwise, shall be limited (except for death or  personal injury caused by the negligence of PPI or its employees while acting in the course of their employment) to [**] US Dollars ($[**]);  provided',\n",
       "   'Any and all liability of EKR to PPI howsoever arising in respect of this Agreement, the Transition Services and Inventory Agreement or the Supply Agreement and their performance in contract tort or otherwise shall be limited (except for death or  personal injury caused by the negligence of EKR or its employees while acting in the course of their employment, and except in relation to  any specified payment, lump sum, milestone or royalty payment unpaid) to [**] US Dollars ($[**]); provided however that such limitation  shall not apply to the extent that PPI or any PPI Indemnified Party is required to pay in excess of such amount to a third party in respect of a  final judgment or order obtained by the third party.'],\n",
       "  'answer_start': [85296, 84207, 83783, 84542]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Such insurance shall be with a reputable insurance company and where  reasonably possible (taking into account the availability of such insurance) shall be maintained for not less than [**] ([**]) years following  the expiry or termination of this Agreement.',\n",
       "   'During the Lease Term, PPI shall:',\n",
       "   'Each Party will provide to the other Party evidence of its insurance and thirty (30) days  prior written notice of any cancellation of its coverage or reduction in coverage from the requirements stated herein.',\n",
       "   'Each Party shall maintain, at its own cost, comprehensive product liability insurance, general commercial liability insurance and business interruption insurance at a level which is reasonable and customary taking into account the nature of the Product but which shall  have combined limits of not less than $[**] per occurrence.',\n",
       "   \"maintain property damage and liability insurance and insurance against  loss or damage to the Transferred Equipment as part of PPI's general liability insurance.\"],\n",
       "  'answer_start': [82591, 35123, 82991, 82261, 35570]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['ENDORSEMENT'], 'answer_start': [30]},\n",
       " {'text': ['Thrivent Financial for Lutherans'], 'answer_start': [334]},\n",
       " {'text': ['July 1, 2019'], 'answer_start': [59]},\n",
       " {'text': ['July 1, 2019'], 'answer_start': [59]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Society membership rights and privileges cannot be transferred or assigned.'],\n",
       "  'answer_start': [4016]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['INTELLECTUAL PROPERTY AGREEMENT'], 'answer_start': [54]},\n",
       " {'text': ['HERC RENTALS INC.',\n",
       "   'THC',\n",
       "   'HERTZ SYSTEM, INC.',\n",
       "   'THE HERTZ CORPORATION',\n",
       "   'HSI',\n",
       "   'HERC',\n",
       "   '(hereinafter referred to collectively as the \"Parties\" and individually as a \"Party\").'],\n",
       "  'answer_start': [470, 308, 315, 186, 460, 470, 639]},\n",
       " {'text': ['30  day of June 2016'], 'answer_start': [136]},\n",
       " {'text': ['30  day of June 2016'], 'answer_start': [136]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of New York, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of New York.'],\n",
       "  'answer_start': [24511]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"During the Interim Period, neither HERC nor any of its affiliates or subsidiaries shall, directly or indirectly, engage in the business of renting or leasing cars, crossovers or light trucks (including sport utility vehicles and light commercial vehicles) in [any country in which THC or any of its affiliates or subsidiaries rents or leases cars, crossovers or light trucks (including sport utility vehicles and light commercial vehicles) as of the date of this Agreement] without THC's prior written consent, except to the extent materially consistent in type and scope with HERC's operations immediately prior to the date of this IPA.\"],\n",
       "  'answer_start': [23766]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['HERC may not assign, transfer, sublicense or delegate any of its rights hereunder or delegate its obligations hereunder without the prior written consent of HSI, and any such purported assignment, transfer, sublicense or delegation, in the absence of such consent, shall be void and without effect.'],\n",
       "  'answer_start': [26321]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['THC will assign all right, title and interest in and to the THC ERB Domains (those domains owned by THC related to the ERB that do not incorporate the mark/name HERTZ) as set forth on Schedule H to HERC and as more fully set forth in the Domain Name Assignment attached hereto as Exhibit D.',\n",
       "   'HSI will assign all right, title and interest in and to the HSI HERC Foreign ERB Trademarks (those foreign trademarks owned by HSI related to the ERB for the HERC trademarks) as set forth on Schedule C to HERC as more fully set forth in the Trademark Assignment Agreements attached hereto as Exhibit B-1 (Canada) and Exhibit B-2 (all other foreign countries).'],\n",
       "  'answer_start': [11369, 8500]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['THC and/or HSI will retain ownership and will grant a royalty-free, non-exclusive license to HERC to use such Other Intellectual Property for the Interim Period, as more fully set forth in the Trademark, Trade Name, Domain and Related Rights License Agreement attached as Exhibit A.',\n",
       "   'owned by HSI related to the ERB that incorporate the mark/name HERTZ) as set forth on Schedule B, for the Interim Period, in the United States and Puerto Rico, as more fully set forth in the Trademark, Trade Name, Domain and Related Rights License Agreement attached as Exhibit A.',\n",
       "   'THC will retain ownership and will, subject to compliance with the terms of this Agreement, grant a royalty-free, non-exclusive license to HERC to use the THC (HERTZ) ERB Domains (those domains owned by THC related to the ERB that',\n",
       "   'incorporate the mark/name HERTZ) as set forth on Schedule G, for the Interim Period, as more fully set forth in the Trademark, Trade Name, Domain and Related Rights License Agreement.',\n",
       "   'HSI will retain ownership and will grant a royalty-free, non-exclusive, license to HERC to use the HSI (HERTZ) US ERB Trademarks (those US trademarks',\n",
       "   'HSI will, subject to compliance with the terms of this Agreement, grant a royalty-free, non-exclusive worldwide license to HERC to use the mark/name HERTZ as part of company names for the Interim Period, as more fully set forth in the Trademark, Trade Name, Domain and Related Rights License Agreement attached as Exhibit A.',\n",
       "   'HSI will retain ownership and will grant a royalty-free, non-exclusive license to HERC to use the HSI (HERTZ) Foreign ERB Trademarks (those foreign trademarks owned by HSI related to the ERB that incorporate the mark/name HERTZ) as set forth on Schedule A, for the Interim Period, outside the United States and Puerto Rico, as more fully set forth in the Trademark, Trade Name, Domain and Related Rights License Agreement attached as Exhibit A.'],\n",
       "  'answer_start': [12603, 7918, 10409, 10651, 7757, 11785, 7008]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Such policy shall provide, in addition to other protection, protection against any and all claims, demands, and causes of action arising out of any act, omission, negligence or otherwise giving rise to a third party claim.',\n",
       "   'HERC shall, throughout the term of this Agreement, obtain and maintain at its own cost and expense, from a qualified AAA-rated insurance company, a standard liability insurance and business interruption policy along with advertising injury',\n",
       "   'HERC shall provide for ten (10) days notice to THC and HSI in the event of any modification, cancellation or termination.',\n",
       "   'protection, all of which must be acceptable to THC and HSI, and which must name THC and HSI as additional insureds.',\n",
       "   'The amount of coverage shall be a minimum of three million dollars ($3,000,000) combined single limit, with no deductible amount for each single occurrence for bodily injury and/or property damage.',\n",
       "   'In no event shall HERC perform or promote the carry out the activities contemplated under this Agreement or the Trademark, Trade Name, Domain and Related Rights License Agreement prior to receipt by THC and HSI of evidence of insurance.',\n",
       "   'HERC agrees to furnish THC and HSI Certificates of Insurance evidencing same within thirty (30) days after the execution of this Agreement.'],\n",
       "  'answer_start': [20002, 19635, 20423, 19886, 20225, 20685, 20545]},\n",
       " {'text': ['The Parties acknowledge and affirm their respective rights in and to the relevant trademark and related rights subject to this Agreement and neither Party shall directly or indirectly attack, challenge or impair the title and related rights of the other Party during the Interim Period or any time thereafter.'],\n",
       "  'answer_start': [15823]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Cooperation Agreement (2014 Amendment)'], 'answer_start': [60]},\n",
       " {'text': ['Nanjing Tuniu Technology Co., Ltd.,',\n",
       "   'Beijing Tuniu Technology Co., Ltd.',\n",
       "   'Party B',\n",
       "   'Party A'],\n",
       "  'answer_start': [186, 420, 617, 404]},\n",
       " {'text': ['January 24, 2014'], 'answer_start': [137]},\n",
       " {'text': ['January 24, 2014',\n",
       "   'This Agreement shall take effect as of the date when the authorized representatives of the Parties sign hereon.'],\n",
       "  'answer_start': [137, 13530]},\n",
       " {'text': ['Party A and Party B agree and confirm that the term of cooperation under this Agreement shall commence from the execution date hereof and end on the expiration date of the operation term of Party B (\"Term of Cooperation\").'],\n",
       "  'answer_start': [6917]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"This Agreement shall be governed by and interpreted pursuant to the laws of the People's Republic of China that are promulgated and are publicly available, provided that the general international business practices shall apply if the laws of the People's Republic of China that are promulgated and are publicly available do not involve any matter in relation to this Agreement.\"],\n",
       "  'answer_start': [11232]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Party A irrevocably undertakes that, without Party B's consent, Party A shall not conduct any other business or make any commercial arrangement, including without limitation being engaged in or otherwise participating in any commercial activities and businesses independently or together with any other person or entity, nor shall it carry out any activities that may be competitive with or cause adverse effect to Party B's business.\"],\n",
       "  'answer_start': [3588]},\n",
       " {'text': ['Party A irrevocably undertakes that Party A will take Party B as its exclusive and sole partner to provide the business consultancy and technical services as well as technical consultancy to Party A and its subsidiaries',\n",
       "   'Party A shall not establish any same or similar cooperative relationship with any third party in respect of such businesses nor shall it make any same or similar arrangement, unless with the prior written consent of Party B.',\n",
       "   \"Party A irrevocably undertakes that, without Party B's consent, Party A shall not conduct any other business or make any commercial arrangement, including without limitation being engaged in or otherwise participating in any commercial activities and businesses independently or together with any other person or entity, nor shall it carry out any activities that may be competitive with or cause adverse effect to Party B's business.\",\n",
       "   'Party A irrevocably undertakes that it will make best efforts to assist and endeavor to achieve the exclusive operation of thecooperative business to the extent permitted by laws.'],\n",
       "  'answer_start': [2948, 3169, 3588, 3401]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Party B shall have the right to terminate this Agreement in advance without the prior written consent from Party A, bysending a written notice to Party A but Party A may not terminate or rescind this Agreement;'],\n",
       "  'answer_start': [7316]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The rights and obligations of each Party under this Agreement shall not be transferred, except for the transfer by Party B to its affiliates.'],\n",
       "  'answer_start': [13987]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The Parties agree that any and all intellectual property researched and developed, created and invented by the Parties (including their employees) in the course of performance of this Agreement shall be owned by Party B. For the purpose of this Article 12.3, \"Intellectual Property\" means the patent, patent application right, trademark, service mark, logo, image, trade name, internet domain name, design right, copyright (including copyright of computer software) and moral rights, database right, right of semiconductor design drawing, utility model, proprietary technology and other intellectual property that are registered and unregistered including those that have applied for registration, as well as all other rights or protection methods with same or similar effect on a global scope.'],\n",
       "  'answer_start': [14141]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Notwithstanding the foregoing provisions, neither Party shall be responsible to the other Party in respect of any indirect loss or damage caused hereunder.',\n",
       "   'The demand for liquidated damages and specific performance in respect of any breach during the Term of Cooperation are all remedies that the non-breaching Party shall have under this Agreement.'],\n",
       "  'answer_start': [10654, 10817]},\n",
       " {'text': ['Except as otherwise agreed hereunder, if Party A or its subsidiaries fail to pay the Service Fee in full on schedule according to provisions of Article 4.1 and Article 4.2, then Party A or its subsidiaries shall, in addition to the continuance of the payment of Service Fee in full, it shall pay Party B the liquidated damages at a daily interest rate of 0.03% in respect of the outstanding Service Fee.'],\n",
       "  'answer_start': [6486]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Promotion Agreement'], 'answer_start': [505]},\n",
       " {'text': ['CNET', 'Cyberian Outpost, Inc.', 'CNET, Inc.', 'Company'],\n",
       "  'answer_start': [583, 31, 583, 636]},\n",
       " {'text': ['January 26, 1998'], 'answer_start': [558]},\n",
       " {'text': ['The term of this Agreement (the \"Term\") will begin on      February 1, 1998 and end on the first anniversary of the date of this      Agreement; provided that (a) either party may terminate this Agreement,      effective at any time after the first three\\n\\n       months of the Term, by giving 30 days\\' written notice of termination to the      other party, and (b) either party may terminate this Agreement at any time      by giving written notice of termination to the other party, if the other      party commits a material breach of its obligations hereunder that is not      cured within 30 days after notice thereof from the non-breaching party.'],\n",
       "  'answer_start': [11733]},\n",
       " {'text': ['The term of this Agreement (the \"Term\") will begin on      February 1, 1998 and end on the first anniversary of the date of this      Agreement; provided that (a) either party may terminate this Agreement,      effective at any time after the first three\\n\\n       months of the Term, by giving 30 days\\' written notice of termination to the      other party, and (b) either party may terminate this Agreement at any time      by giving written notice of termination to the other party, if the other      party commits a material breach of its obligations hereunder that is not      cured within 30 days after notice thereof from the non-breaching party.'],\n",
       "  'answer_start': [11733]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement will be construed in accordance with           and governed by the laws of the State of California, without regard to           principles of  conflicts of law.'],\n",
       "  'answer_start': [21783]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"During the Term, CNET will not enter into more than      two other agreements under which CNET receives consideration from a      Competing Computer Products Retailer for displaying permanent links to or      other fixed promotions for such Competing Computer Products Retailer on any      CNET Site; provided that the foregoing will not restrict the display of(a)      standard advertisements for any Competing Computer Products Retailer or its      products or (b) any promotions within COMPUTERS.COM or within CNET's Snap!      Online service (which are expressly excluded from this provision).\"],\n",
       "  'answer_start': [12898]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The      parties acknowledge that the foregoing will not prevent CNET from      displaying text links and other references to Competing Computer Products      Retailers as reasonably necessary to provide appropriate editorial and      search related services on the CNET Sites. The Retail Promotions granted to      the Company shall be placed in such a way as to provide no more or less      prominence to the Company than is provided to any other Competing Computer      Retailer signing an agreement with CNET.',\n",
       "   \"During the Term, CNET will not enter into more than      two other agreements under which CNET receives consideration from a      Competing Computer Products Retailer for displaying permanent links to or      other fixed promotions for such Competing Computer Products Retailer on any      CNET Site; provided that the foregoing will not restrict the display of(a)      standard advertisements for any Competing Computer Products Retailer or its      products or (b) any promotions within COMPUTERS.COM or within CNET's Snap!      Online service (which are expressly excluded from this provision).\"],\n",
       "  'answer_start': [13496, 12898]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"provided that (a) either party may terminate this Agreement,      effective at any time after the first three\\n\\n       months of the Term, by giving 30 days' written notice of termination to the      other party,\"],\n",
       "  'answer_start': [11878]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement may not be assigned by either party, except           (a) to the transferee of substantially all of the business operations           of such party (whether by asset sale, stock sale, merger or otherwise)           or (b) to any entity that controls, is controlled by or is under           common control with such party.'],\n",
       "  'answer_start': [19869]},\n",
       " {'text': ['For each month during the Term, the Company will pay CNET a                  minimum of [XXXX] in cash, plus [XXX] of CNET Sales.'],\n",
       "  'answer_start': [9018]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['For each month during the Term, the Company will pay CNET a                  minimum of [XXXX] in cash, plus [XXX] of CNET Sales.'],\n",
       "  'answer_start': [9018]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The Company hereby grants to CNET a non-exclusive, royalty-free           license, effective throughout the Term, to use, display and publish           any of the Company trademarks, tradenames, service marks and logos           that may be delivered by the Company to CNET expressly for inclusion           in the Promotions, solely for use in connection with the Promotions.'],\n",
       "  'answer_start': [14046]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Each party will have the right to engage an independent           third party to audit the books and records of the other party relevant           to the calculation of Retail Impressions or CNET Sales, upon           reasonable notice and during normal business hours, and the other           party will provide reasonable cooperation in connection with any such           audit.'],\n",
       "  'answer_start': [21112]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The Company shall indemnify and hold           CNET harmless from and against any Losses that CNET may suffer, incur           or be subjected to by reason of any legal action, proceeding,\\n\\n\\n\\n\\n\\n          arbitration or other claim by a third party, whether commenced or           threatened, arising out of or as a result of (a) any breach or alleged           breach by the Company of its representations, warranties or covenants           hereunder; (b) the use by CNET of the Company Marks or any content           provided by the Company to CNET expressly for display in connection           with or as part of the Promotions, including claims of infringement or           misappropriation of intellectual property rights; or (c) the operation           of the Company Site or the offer or sale of the Products by the           Company or through the Company Sit',\n",
       "   'The Company shall indemnify and hold           CNET harmless from and against any Losses that CNET may suffer, incur           or be subjected to by reason of any legal action, proceeding,\\n\\n\\n\\n\\n\\n          arbitration or other claim by a third party, whether commenced or           threatened, arising out of or as a result of (a) any breach or alleged           breach by the Company of its representations, warranties or covenants           hereunder; (b) the use by CNET of the Company Marks or any content           provided by the Company to CNET expressly for display in connection           with or as part of the Promotions, including claims of infringement or           misappropriation of intellectual property rights; or (c) the operation           of the Company Site or the offer or sale of the Products by the           Company or through the Company Site.',\n",
       "   'CNET shall indemnify and hold the Company           harmless from and against any costs, losses, liabilities and expenses,           including all court costs, reasonable expenses and reasonable           attorney\\'s fees (collectively, \"Losses\") that the Company may suffer,           incur or be subjected to by reason of any legal action, proceeding,           arbitration or other claim by a third party, whether commenced or           threatened, arising out of or as a result of (a) any breach or alleged           breach by CNET of its representations, warranties or covenants           hereunder; or (b) the operation of the CNET Sites (except in cases           where the Company is required to indemnify CNET under the following           paragraph), including claims of infringement or misappropriation of           intellectual property rights.',\n",
       "   'NEITHER PARTY WILL BE LIABLE FOR ANY SPECIAL,           INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING OUT OF OR           RELATED TO THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF           LIABILITY (INCLUDING NEGLIGENCE), AND EVEN IF SUCH PARTY HAS BEEN           ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.'],\n",
       "  'answer_start': [16887, 16887, 15988, 19523]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Intellectual Property Agreement'], 'answer_start': [11439]},\n",
       " {'text': ['Morgan Stanley & Co. Incorporated',\n",
       "   '(MS and MSCI individually referred to as a \"Party\" and collectively as the \"Parties\").',\n",
       "   '(\"MS\")',\n",
       "   'MSCI Inc',\n",
       "   '(\"MSCI\")'],\n",
       "  'answer_start': [202, 315, 260, 271, 305]},\n",
       " {'text': ['November 20, 2007'], 'answer_start': [145]},\n",
       " {'text': ['November 20, 2007'], 'answer_start': [145]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement shall be construed in accordance with and governed by the substantive internal laws of the State of New York.'],\n",
       "  'answer_start': [6590]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['MS hereby grants (subject to any existing third party contractual obligations) to MSCI a non-exclusive, perpetual, irrevocable, world- wide, royalty-free license for MSCI to use, modify, copy, create derivative works of and sublicense, for any business purpose, the MS Licensed Materials.',\n",
       "   'MSCI hereby grants (subject to any existing third party contractual obligations) to MS a non-exclusive, perpetual, irrevocable, world- wide, royalty-free license for MS to use, modify, copy, create derivative works of and sublicense, for any business purpose, the MSCI Licensed Materials.'],\n",
       "  'answer_start': [2752, 3062]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['MS hereby grants (subject to any existing third party contractual obligations) to MSCI a non-exclusive, perpetual, irrevocable, world- wide, royalty-free license for MSCI to use, modify, copy, create derivative works of and sublicense, for any business purpose, the MS Licensed Materials.',\n",
       "   'MSCI hereby grants (subject to any existing third party contractual obligations) to MS a non-exclusive, perpetual, irrevocable, world- wide, royalty-free license for MS to use, modify, copy, create derivative works of and sublicense, for any business purpose, the MSCI Licensed Materials.'],\n",
       "  'answer_start': [2752, 3062]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['otherwise, to MS for or in connection with this Agreement or the transactions contemplated hereby or any actions or inactions by or on behalf of the MSCI Provider Group in connection with this Agreement and such transactions.',\n",
       "   'MS agrees that neither MSCI nor its subsidiaries (collectively, the \"MSCI Provider Group\") and the respective directors, officers, agents, and employees of the MSCI Provider Group shall have any liability, whether direct or indirect, in contract or tort or',\n",
       "   \"Notwithstanding the provisions of Section 5(a) and (b), none of the members of the MS Provider Group and the MSCI Provider Group shall be liable for any special, indirect, incidental, consequential or punitive damages of any kind whatsoever in any way due to, resulting from or arising in connection with the performance of or failure to perform MS's or MSCI's obligations under this Agreement.\",\n",
       "   'This disclaimer applies without limitation (i) to claims for lost profits, (ii) regardless of the form of action, whether in contract, tort (including negligence), strict liability, or otherwise, and (iii) regardless of whether such damages are foreseeable or whether any member of the MS Provider Group or the MSCI Provider Group has been advised of the possibility of such damages.',\n",
       "   'MSCI agrees that neither MS nor its affiliates or subsidiaries (other than MSCI) (collectively, the \"MS Provider Group\") and the respective directors, officers, agents, and employees of the MS Provider Group shall have any liability, whether direct or indirect, in contract or tort or otherwise, to MSCI for or in connection with this Agreement or the transactions contemplated hereby or any actions or inactions by or on behalf of the MS Provider Group in connection with this Agreement and such transactions.'],\n",
       "  'answer_start': [5149, 4881, 5382, 5777, 4363]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Strategic Alliance Agreement'], 'answer_start': [1911]},\n",
       " {'text': ['Freedom Mortgage Corporation',\n",
       "   'Freedom Mortgage',\n",
       "   'Cherry Hill Mortgage Investment Corp.',\n",
       "   'Cherry Hill'],\n",
       "  'answer_start': [82, 82, 163, 163]},\n",
       " {'text': [', 2013'], 'answer_start': [66]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Unless earlier terminated as provided below, this Agreement shall remain in effect until the later to occur of the date that is (x) three (3) years from the date hereof and (y) the date on which an affiliate of Freedom Mortgage is not acting as the external manager of Cherry Hill.'],\n",
       "  'answer_start': [19533]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement shall be governed by the laws of the State of New York, without giving effect to its principles of conflicts of laws, other than Section 5-1401 of the New York General Obligations Law.'],\n",
       "  'answer_start': [23921]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns; provided, however, that neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any Party without the prior written consent of the other Party.'],\n",
       "  'answer_start': [21315]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['STRATEGIC ALLIANCE AGREEMENT'], 'answer_start': [86]},\n",
       " {'text': ['W2E',\n",
       "   'SHBV',\n",
       "   'SHBV (HONG KONG) LTD',\n",
       "   'each a \"Party\" and together the \"Parties',\n",
       "   'WASTE2ENERGY GROUP HOLDINGS PLC'],\n",
       "  'answer_start': [548, 16, 16, 559, 50]},\n",
       " {'text': ['19  DAY OF MAY , 2010'], 'answer_start': [164]},\n",
       " {'text': ['19  DAY OF MAY , 2010',\n",
       "   'Commencement Date means the date of this Agreement'],\n",
       "  'answer_start': [164, 2374]},\n",
       " {'text': ['This Agreement shall commence on the Commencement Date and shall continue for a term of ten (10) years, unless previously terminated in  accordance with Clause 15 (Termination).'],\n",
       "  'answer_start': [7405]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement is governed by English law.'],\n",
       "  'answer_start': [39914]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['W2E agrees not to engage in business dealings, discussions, or otherwise work directly with any third parties introduced to W2E  through SHBV, or to exploit any pre-existing relationship of SHBV with any third party that has been represented to W2E by SHBV,  without the prior consent and/or direct participation of SHBV.',\n",
       "   'SHBV agrees not to engage in business dealings, discussions, or otherwise work directly with any third parties introduced to SHBV  through W2E, or to exploit any pre-existing relationship of W2E with any third party that has been represented to SHBV by W2E,  without the prior consent and/or direct participation of W2E.'],\n",
       "  'answer_start': [15592, 15922]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Each Party agrees that during the Term of this Agreement and for a period of six (6) months thereafter it shall not, without the prior written  consent of the other Party, either on its own account or through its employees or agents or otherwise or on behalf of any other person,  firm, company or other organisation and other than by general advertising, solicit, interfere with, procure or entice away (or, in each case,  attempt so to do), either directly or indirectly, any employee or contractor of the other Party.'],\n",
       "  'answer_start': [15038]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Each Party grants to the other Party a non-exclusive, non-transferable, royalty-free licence to use the other Party's Intellectual Property Rights  as far is strictly necessary to comply with its marketing and promotional obligations under this Agreement.\"],\n",
       "  'answer_start': [16726]},\n",
       " {'text': [\"Each Party grants to the other Party a non-exclusive, non-transferable, royalty-free licence to use the other Party's Intellectual Property Rights  as far is strictly necessary to comply with its marketing and promotional obligations under this Agreement.\"],\n",
       "  'answer_start': [16726]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['ENDORSEMENT AGREEMENT ADDENDUM I'], 'answer_start': [15]},\n",
       " {'text': ['National Football League Alumni - Northern California Chapter',\n",
       "   '(\"NFLA\")',\n",
       "   'Food For Athletes, Inc',\n",
       "   'Gridiron BioNutrients',\n",
       "   '(collectively the \"Company\").',\n",
       "   'National Football League Alumni, Inc',\n",
       "   '(\"NFLA-NC\")'],\n",
       "  'answer_start': [159, 407, 576, 655, 810, 369, 221]},\n",
       " {'text': ['November 7, 2017'], 'answer_start': [127]},\n",
       " {'text': ['November 7, 2017'], 'answer_start': [127]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['A *donation of $0.05 per Unit sold of Licensed Products within the Contract Territory payable to the **NFL Alumni Northern California Chapter.',\n",
       "   'The NFLA-NC will donate 15% of the above described proceeds to the NFLA.'],\n",
       "  'answer_start': [1956, 2799]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Corporate Sponsorship Agreement'], 'answer_start': [14]},\n",
       " {'text': ['American Diabetes Association, Inc.',\n",
       "   'Association',\n",
       "   'Freeze Tag Inc.',\n",
       "   'Company'],\n",
       "  'answer_start': [336, 72, 183, 225]},\n",
       " {'text': ['March 22, 2018'], 'answer_start': [152]},\n",
       " {'text': ['This Agreement shall commence on March 15, 2018 and will expire on March 14, 2020 unless terminated earlier pursuant to Section 13 of the Agreement (the \"Term\").'],\n",
       "  'answer_start': [2113]},\n",
       " {'text': ['This Agreement shall commence on March 15, 2018 and will expire on March 14, 2020 unless terminated earlier pursuant to Section 13 of the Agreement (the \"Term\")'],\n",
       "  'answer_start': [2113]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement is subject to and shall be construed in accordance with the laws of the Commonwealth of Virginia with jurisdiction and venue in federal and Virginia courts in Alexandria and Arlington, Virginia.'],\n",
       "  'answer_start': [16616]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Before expiration of the Term, either Party may terminate this Agreement upon: (i) any material breach of the Agreement by the other Party, if such breach is not remedied to the reasonable satisfaction of the non-breaching Party within ten (10) business days after written notice; (ii) ten (10) business days written notice to the other Party whenever the notifying Party in its sole discretion determines that the continuation of the Agreement will damage its reputation or good will; or (iii) written notice in the event one Party (a) becomes or is declared insolvent or bankrupt or is subject to the appointment of a trustee or receiver or any equivalent thereof, (b) is the subject of any proceeding related to its liquidation or insolvency (whether voluntary or involuntary) which is not dismissed within ninety (90) days, (c) makes an assignment for the benefit of creditors, or (d) is subject to any sale, lease or other transfer of all or substantially all of its assets to any entity; or (e) is subject to a change of control (whether by merger, stock transfer or otherwise), except in the case of an initial public offering.'],\n",
       "  'answer_start': [9884]},\n",
       " {'text': ['This Agreement may not be assigned by either Party without the prior written consent of the other Party.'],\n",
       "  'answer_start': [12707]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"The Association will also share/retweet up to three (3) social media posts on Facebook, Twitter and Instagram-one before National Get Fit Don't Sit Day, one on May 2 and one after the campaign.\"],\n",
       "  'answer_start': [21124]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Any display of Association Mark must be accompanied by one of the following relationship statements: a. \"Freeze Tag is a national sponsor of Get Fit Don\\'t Sit DayTM, a wellness engagement day of American Diabetes Association\" b. \"Freeze Tag is a national sponsor of American Diabetes Association\"',\n",
       "   'The Company grants the Association a non-exclusive, limited, revocable and conditional license during the term to use the Company Marks, solely to identify Company as a supporter of the Association.',\n",
       "   'The Association hereby grants Company the right to use the Association Name and Logo (\"the Association Marks\") on educational, promotional and or advertising materials throughout the Term (see Attachment \"B\").',\n",
       "   \"The Association Marks shall not be placed adjacent to the mark of another organization concerned with diabetes, or those of a company that manufactures products or provides services related to diabetes, without the Association's specific prior written consent, which may be withheld for any reason.\",\n",
       "   'The Association grants Company a non-exclusive, limited, revocable and conditional license during the term to use the Association Marks, solely to identify Company as a supporter of the Association.'],\n",
       "  'answer_start': [18749, 4694, 18278, 5027, 3376]},\n",
       " {'text': ['Company may not permit any third party to use the Association Marks without the express prior written approval of the Association, which may be withheld for any reason.'],\n",
       "  'answer_start': [4387]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Such insurance shall be primary and non-contributory.',\n",
       "   \"The Association must be a named additional insured, and shall be provided at least 30 days' notice for cancellation of policy and 10 days' notice for non-payment of premium.\",\n",
       "   \"During the term of this Agreement, and before any sponsorship or promotional activities are conducted under this Agreement, Company shall obtain and maintain at its expense, Commercial General Liability Insurance coverage with an insurance carrier with a Best's rating of A+.\",\n",
       "   'The insurance shall be in an amount of: $2,000,000 per occurrence and $2,000,000 aggregate with a $2,000,000 aggregate for products and completed operations.'],\n",
       "  'answer_start': [9813, 9639, 9205, 9481]},\n",
       " {'text': [\"Company shall not, during the period of this Agreement, or any time thereafter, challenge Association's exclusive ownership or registration of Association's Marks, including any and all moral rights.\"],\n",
       "  'answer_start': [2918]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['HOSTING AGREEMENT'], 'answer_start': [7575]},\n",
       " {'text': ['eGain',\n",
       "   'eGain Communications Corporation',\n",
       "   'Eliance Corporation',\n",
       "   'Customer'],\n",
       "  'answer_start': [191, 191, 238, 260]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement shall continue in effect from the Effective Date for a one (1) year period, unless earlier terminated as set forth below, and thereafter shall renew automatically for successive one (1) year periods unless either party gives the other party at least thirty (30) days prior written notice of its intent not to renew the Agreement.'],\n",
       "  'answer_start': [14322]},\n",
       " {'text': ['This Agreement shall continue in effect from the Effective Date for a one (1) year period, unless earlier terminated as set forth below, and thereafter shall renew automatically for successive one (1) year periods unless either party gives the other party at least thirty (30) days prior written notice of its intent not to renew the Agreement.'],\n",
       "  'answer_start': [14322]},\n",
       " {'text': ['This Agreement shall continue in effect from the Effective Date for a one (1) year period, unless earlier terminated as set forth below, and thereafter shall renew automatically for successive one (1) year periods unless either party gives the other party at least thirty (30) days prior written notice of its intent not to renew the Agreement.'],\n",
       "  'answer_start': [14322]},\n",
       " {'text': ['This Agreement shall be governed by and construed in accordance with the laws of the State of California exclusive of its conflict of laws principles.'],\n",
       "  'answer_start': [17241]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Neither party may assign or otherwise transfer its rights and/or obligations under this Agreement without the prior written consent of the other party.'],\n",
       "  'answer_start': [18255]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Customer hereby grants eGain a right to use Customer's trademarks (name and logo only) designated by Customer for such limited uses, subject to Customer's trademark/logo usage guidelines, if any, provided by Customer to eGain.\",\n",
       "   \"To the extent that certain components of the Software may be downloaded to Customer's or User's computer as a result of accessing the Software as part of the Hosting Services, eGain grants Customers a non-exclusive, non-transferable, limited license, with right to sublicense solely to Users, to use such Software only in connection with the Hosting Services.\"],\n",
       "  'answer_start': [16388, 2918]},\n",
       " {'text': [\"To the extent that certain components of the Software may be downloaded to Customer's or User's computer as a result of accessing the Software as part of the Hosting Services, eGain grants Customers a non-exclusive, non-transferable, limited license, with right to sublicense solely to Users, to use such Software only in connection with the Hosting Services.\"],\n",
       "  'answer_start': [2918]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Except in the event of termination for Customer's breach, eGain shall provide Customer with an electronic copy of the final Reports (covering the month just prior to termination of this Agreement).\"],\n",
       "  'answer_start': [15329]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['EXCLUDING LIABILITY FOR INFRINGEMENT CLAIMS AS DISCUSSED IN SECTION 9 OF THIS AGREEMENT, IN NO EVENT SHALL eGAIN BE LIABLE TO CUSTOMER FOR CONSEQUENTIAL, EXEMPLARY, INDIRECT, SPECIAL OR INCIDENTAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS), OR BE LIABLE TO ANY THIRD PARTY FOR ANY DAMAGES WHATSOEVER, EVEN IF eGAIN HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.'],\n",
       "  'answer_start': [11065]},\n",
       " {'text': ['In the event of Downtime (as defined in this Section 6.1 below), as Customer\\'s sole and exclusive remedy and eGain\\'s sole and exclusive liability, the monthly fee payable for the Hosting Services shall be reduced as follows:\\n\\na) For the first sixty (60) minutes of Downtime during Normal Business       Hours or the first four (4) hours of Downtime outside of Normal Business       Hours (\"Initial Downtime\"), eGain will credit Customer\\'s account for one       (1) day of service.\\n\\nb) For each eight (8) hour period of Downtime per day in addition to the       Initial Downtime, eGain will credit Customer\\'s account for one (1)       additional day of service.',\n",
       "   \"In the event of a breach (other than Downtime) of the warranty set forth in Section 6.1(i) above, Customer's sole and exclusive remedy, and eGain's sole and exclusive liability shall be, at eGain's option, repair or replacement of the Software.\",\n",
       "   \"In the event that the Software or eGain System is not Year 2000 Compliant, Customer's sole and exclusive remedy and eGain's sole and exclusive liability shall be for eGain, at no additional cost to Customer, to promptly modify the Software or the eGain System so that the Software or eGain System is Year 2000 Compliant.\",\n",
       "   \"EXCLUDING LIABILITY FOR INFRINGEMENT CLAIMS AS DISCUSSED IN SECTION 9 OF THIS AGREEMENT, IN NO EVENT SHALL eGAIN BE LIABLE TO CUSTOMER FOR CONSEQUENTIAL, EXEMPLARY, INDIRECT, SPECIAL OR INCIDENTAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS), OR BE LIABLE TO ANY THIRD PARTY FOR ANY DAMAGES WHATSOEVER, EVEN IF eGAIN HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. eGain's entire liability under this Agreement for any damages from any cause whatsoever, regardless of form or action, whether in contract, negligence or otherwise, shall in no event exceed an amount equal to the price paid for the Services out of which the claim arose.\",\n",
       "   \"THE FOREGOING CONSTITUTES CUSTOMER'S SOLE AND EXCLUSIVE REMEDY, AND eGAIN'S ENTIRE LIABILITY, FOR DOWNTIME AND FOR BREACH OF THE HOSTING SERVICES WARRANTY PROVIDED IN THIS SECTION 6.1.\"],\n",
       "  'answer_start': [6408, 8007, 8895, 11065, 8253]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['AMENDMENT NO. 2 TO MANUFACTURING AND SUPPLY AGREEMENT'],\n",
       "  'answer_start': [372]},\n",
       " {'text': ['Fleet',\n",
       "   'Fleet Laboratories Limited',\n",
       "   'Columbia',\n",
       "   'Columbia Laboratories, (Bermuda) Ltd.'],\n",
       "  'answer_start': [855, 855, 642, 642]},\n",
       " {'text': ['2018'], 'answer_start': [1081]},\n",
       " {'text': ['2018'], 'answer_start': [1081]},\n",
       " {'text': ['Unless terminated earlier pursuant to Section 12.2 below, the initial term of this Agreement shall expire on 31 December 2024 (the \"Initial Term\") unless the Parties mutually agree in writing any extension to the Initial Term.'],\n",
       "  'answer_start': [31562]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Amendment and and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the laws of England.'],\n",
       "  'answer_start': [43626]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['(ii) a Change of Control Event with respect to Fleet occurs;',\n",
       "   'Columbia shall have the right to terminate this Agreement upon [***] notice to Fleet in the event:'],\n",
       "  'answer_start': [32693, 32084]},\n",
       " {'text': [\"Neither party shall, without the prior written consent (not to be unreasonably withheld or delayed) of the other party having been obtained, assign or transfer this Agreement to any person or entity, in whole or in part (and any attempt to do so shall be void), provided that, each party may assign or transfer this Agreement without such consent to any Affiliate or to any successor by merger of such party, or upon a sale or other transfer of all or substantially all of such party's assets or business to which the subject matter of this Agreement pertains, provided that the acquirer of the business confirms to the Supplier in writing its agreement to be bound by all of the terms and conditions of this Agreement and that the assignor shall remain liable for the obligations hereunder.\",\n",
       "   'Notwithstanding the foregoing, it shall not be deemed unreasonable for Columbia to withhold consent, to any proposed or attempted assignment (including by merger or sale) by Fleet to a party which is not an Affiliate, if Columbia is not reasonably satisfied that the assignee possesses the management, finances, personnel, capabilities and facilities to perform fully the obligations of Fleet hereunder.'],\n",
       "  'answer_start': [36964, 37756]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Fleet shall ensure that it has sufficient experienced production staff available to meet the requirements set out in each Production Schedule and at a minimum, to meet the expected non-binding forecast set out below:\\n\\n[***] [***] [***] [***] [***] [***]\\n\\nN u m b e r  o f batches',\n",
       "   'The amounts set forth for the [***] in each Production Schedule shall constitute a firm purchase order and shall be binding upon Columbia (each a \"Purchase Order\") unless otherwise agreed in writing by both parties.'],\n",
       "  'answer_start': [13919, 12940]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Upon termination of this Agreement, Fleet agrees to perform its obligations under this Agreement until the earlier of [***].'],\n",
       "  'answer_start': [31789]},\n",
       " {'text': ['Columbia or any other person appointed by Columbia shall have the right, in connection with any such audit, to inspect and obtain copies of any records or other documents and materials associated with or related to the manufacture of the Product.',\n",
       "   'Columbia QA, any other person appointed by Columbia, Columbia\\'s customer, and/or any Regulatory Authority may conduct inspections and audits of Fleet\\'s manufacturing facility, Columbia Equipment, quality control laboratories, and other quality systems relating to the manufacture and storage of the Product according to Columbia\\'s reasonable procedures upon reasonable prior written notice, during normal business hours, provided, however, that Columbia QA, any other person appointed by Columbia and/or any Regulatory Authority may conduct a \"For Cause\" audit during normal business hours upon three (3) business days prior written notice to Fleet.',\n",
       "   \"Any such audit undertaken by Columbia QA or any other person appointed by Columbia shall be at Columbia's sole cost and expense.\"],\n",
       "  'answer_start': [16363, 15584, 16234]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Fleet and Columbia shall maintain comprehensive general liability insurance, including product liability insurance against claims regarding the manufacture of Product under this Agreement and sufficient cover to meet its liabilities under this Agreement in respect of the Columbia Equipment, with insurers having an AM Best rating within the top 2 categories at the time (at the date of this Agreement known as \"superior\" or \"excellent\") or reasonably comparable coverage, in such amounts as it customarily maintains for similar products and activities, but in no event less than [***] per individual claim and [***] in the aggregate.',\n",
       "   'Each party shall maintain such insurance during the Term and thereafter for so long as it customarily maintains insurance for itself for similar products and activities (but in no event less than [***] following termination or expiration).'],\n",
       "  'answer_start': [22112, 22747]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['SPONSORSHIP AGREEMENT'], 'answer_start': [371]},\n",
       " {'text': ['Excite', 'N2K Inc.', 'Excite, Inc.', 'Sponsor'],\n",
       "  'answer_start': [512, 624, 512, 730]},\n",
       " {'text': ['23rd day of September, 1997'], 'answer_start': [449]},\n",
       " {'text': ['23rd day of September, 1997'], 'answer_start': [449]},\n",
       " {'text': ['The term of this Agreement will begin on the Effective Date and                  will end on the second (2nd) anniversary of the Commencement                  Date.'],\n",
       "  'answer_start': [4775]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement will be governed by and                   construed in accordance with the laws of the State of New York'],\n",
       "  'answer_start': [44752]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Sponsor will be the exclusive retail music store sponsor of                   the Excite Site and the Excite Broadcast Pages.',\n",
       "   'In no event will Excite enter                  into arrangements to make available opportunities to purchase                  Music Products from parties other than Sponsor that would                  prevent Sponsor from being the exclusive source of such Music                  Products on the Excite Site once the Music Products become                  available through Sponsor.',\n",
       "   'Excite will                   not permit the display of advertising banners, promotional                   buttons, promotional links or other promotional materials for                   any retail sale of Music Products on the Excite Site, except                   those Music Products offered by Sponsor, nor advertising by                   any other Retail Music Store.'],\n",
       "  'answer_start': [2222, 4377, 2348]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Notwithstanding the foregoing, Excite may make available                  opportunities on the Excite Site to purchase Music Products                  from parties other than Sponsor if such Music Products are not                  available from Sponsor so long as, prior to entering into                  arrangements to make available opportunities to purchase Music                  Products from parties other than Sponsor, Excite notifies                  Sponsor of its interest in the Music Products and gives Sponsor                  thirty (30) days to make the desired Music Products available                  through the Sponsor Site.'],\n",
       "  'answer_start': [3413]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Excite will                   negotiate exclusively with Sponsor for the next [****] in good                   faith effort to negotiate and execute a written sponsorship                   renewal agreement.',\n",
       "   'Excite will not propose, solicit or negotiate offers from                   entities other than Sponsor for any retail music store                   sponsorships of the Excite Site, if at all, until [****] prior                   to the expiration of the term of this Agreement.',\n",
       "   'If, [****] prior to the expiration of the                   term of the Agreement, the parties have not entered into a                   written sponsorship renewal agreement. Excite may enter into                   negotiations with any third party with respect to retail music                   store sponsorships of the Excite Site.',\n",
       "   'Although                   Excite will not be required to disclose any information in                   violation of any nondisclosure agreement between Excite and                   any third party, the notice will include information                   sufficient to permit Sponsor to evaluate the requirements for                   meeting the competing offer for retail music store sponsorship                   of the Excite Site and to formulate a meaningful response.',\n",
       "   'In the event that Excite intends to enter into an                   agreement with a third party with respect to retail music                   store sponsorships of the Excite Site before the expiration of                   the term of the Agreement, Excite will deliver to Sponsor a                   written notice describing the relevant opportunity.',\n",
       "   'Sponsor will have [****] after receipt of such written notice                   to provide notice to Excite that it is prepared to enter into                   an agreement with Excite on the same terms and conditions as                   Excite proposes to accept from such third party.',\n",
       "   'If Sponsor rejects said offer or fails to notify Excite of                   its acceptance within the [****] period, Excite shall have                   the right thereafter to enter into the agreement with such                   third party, provided the terms and conditions of the                   agreement (if entered into within the subsequent ninety (90)                   days) are not less favorable to Excite than previously offered                   by Sponsor.',\n",
       "   'Excite will offer Sponsor the right of first refusal to                  negotiate with Excite for renewal of this sponsorship.',\n",
       "   'Commencing not later than [****] prior to the expiration                   of the term of the Agreement, Excite will negotiate with                   Sponsor in good faith with respect to the terms and conditions                   under which this Agreement would be renewed.',\n",
       "   'Notwithstanding the foregoing, Excite may make available                  opportunities on the Excite Site to purchase Music Products                  from parties other than Sponsor if such Music Products are not                  available from Sponsor so long as, prior to entering into                  arrangements to make available opportunities to purchase Music                  Products from parties other than Sponsor, Excite notifies                  Sponsor of its interest in the Music Products and gives Sponsor                  thirty (30) days to make the desired Music Products available                  through the Sponsor Site.'],\n",
       "  'answer_start': [6660,\n",
       "   6085,\n",
       "   6868,\n",
       "   7580,\n",
       "   7225,\n",
       "   8071,\n",
       "   8513,\n",
       "   5813,\n",
       "   6384,\n",
       "   3413]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Any attempt to assign this                   Agreement other than as permitted above will be null and void.',\n",
       "   \"Neither party may assign this Agreement, in whole                   or in part, without the other party's written consent (which                   will not be unreasonably withheld), except that no such                   consent will be required in connection with (i) a merger,                   reorganization or sale of all, or substantially all, of such                   party's assets or (ii) either party's assignment and/or                   delegation of its rights and responsibilities hereunder to a                   wholly-owned subsidiary or joint venture in which such party                   holds a controlling interest.\"],\n",
       "  'answer_start': [44613, 43975]},\n",
       " {'text': ['Sponsor will pay Excite a share of all gross margins Sponsor                   realizes on transactions, advertising, sponsorship, promotions                   and any other revenue generated during each year of the term                   of the Agreement on the Sponsor Site as a result of users                   referred from the Excite Site (\"Total Revenue\"), subject to                   the following conditions:\\n\\n               i)       \"Gross margin\" is defined as [****].\\n\\n               ii)      Total Revenue will be measured at the end of every                            three months after the Commencement Date. This                            three-month Total Revenue amount will be compared to                            an amount equal to two (2) times the corresponding                            three-month share of the applicable sponsorship fee                            described in Sections 6(c) and 6(d) (each pro rata                            share a \"Revenue Floor\").',\n",
       "   'iii)     If the Total Revenue earned by Sponsor during the                            three-month period exceeds the total of the Revenue                            Floor applicable to the same three-month period,                            Sponsor will pay Excite [****] of the gross margin                            Sponsor realizes on the gross revenue amount equal to                            the excess of the Total Revenue over the Revenue                             Floor during the three-month period.                   iv)      If the Total Revenue earned by Sponsor during the                            three-month period does not exceed the Revenue Floor                            applicable to the same three-month period, Sponsor                            will not be obligated to pay Excite any share of the                            gross revenue realized during the three-month period.'],\n",
       "  'answer_start': [21354, 22494]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['If Excite fails to deliver the guaranteed number of                   Impressions on the Excite Site during the first year, Excite                   will use commercially reasonable efforts to \"make good\" the                   shortfall.',\n",
       "   'During the second year of the sponsorship following the first                   anniversary of the Commencement Date, Excite will deliver not                   less than [****] Impressions on the Excite Site.',\n",
       "   'If Excite fails to deliver the guaranteed number of                   Impressions on the Excite Site during the second year, Excite                   will use commercially reasonable efforts to \"make good\" the                   shortfall within [****] following the second year end.',\n",
       "   'During the first year of the sponsorship following the                   Commencement Date, Excite will deliver not less than                   [****] Impressions on the Excite Site.'],\n",
       "  'answer_start': [29248, 11845, 29698, 11646]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Data relating to the use of the Co-Branded Pages will                   be jointly owned and shared by both parties.'],\n",
       "  'answer_start': [25074]},\n",
       " {'text': [\"Subject to the terms and conditions of this                   Agreement, Sponsor hereby grants to Excite a royalty-free,                   non-exclusive, worldwide license to use, reproduce,                   distribute, transmit and publicly display the Content in                   accordance with this Agreement and to sub-license the Content                   to Excite's wholly-owned subsidiaries or to joint ventures in                   which Excite participates for the sole purpose of using,                   reproducing, distributing, transmitting and publicly                   displaying the Content in accordance with this Agreement\",\n",
       "   'Each party hereby grants to the other a non-exclusive, limited                   license to use its trademarks, service marks or trade names                   only as specifically described in this Agreement.'],\n",
       "  'answer_start': [26820, 28455]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Subject to the terms and conditions of this                   Agreement, Sponsor hereby grants to Excite a royalty-free,                   non-exclusive, worldwide license to use, reproduce,                   distribute, transmit and publicly display the Content in                   accordance with this Agreement and to sub-license the Content                   to Excite's wholly-owned subsidiaries or to joint ventures in                   which Excite participates for the sole purpose of using,                   reproducing, distributing, transmitting and publicly                   displaying the Content in accordance with this Agreement\"],\n",
       "  'answer_start': [26820]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Excite                   may, upon no less than thirty (30) days prior written notice                   to Sponsor, cause an independent Certified Public Accountant                   to inspect the records of Sponsor reasonably related to the                   calculation of such payments during Sponsor's normal business                   hours.\",\n",
       "   'The fees charged by such Certified Public Accountant in                   connection with the inspection will be paid by Excite unless                   the payments made to Excite are determined to have been less                   than ninety percent (90%) of the payment owed to Excite, in                   which case Sponsor will be responsible for the payment of the                   reasonable fees for such inspection.'],\n",
       "  'answer_start': [23933, 24281]},\n",
       " {'text': ['EXCEPT UNDER SECTION 13(c) and (d), IN NO EVENT WILL EITHER                   PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL OR                   CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT,                   TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, WHETHER OR NOT THAT                   PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.'],\n",
       "  'answer_start': [41099]},\n",
       " {'text': ['EXCEPT UNDER SECTION 13(c) and (d), IN NO EVENT WILL EITHER                   PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL OR                   CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT,                   TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, WHETHER OR NOT THAT                   PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.',\n",
       "   'THE                   LIABILITY OF EXCITE FOR DAMAGES OR ALLEGED DAMAGES HEREUNDER,                   WHETHER IN CONTRACT, TORT OR ANY OTHER LEGAL THEORY, IS                   LIMITED TO, AND WILL NOT EXCEED, THE AMOUNTS ACTUALLY PAID BY                   SPONSOR TO EXCITE HEREUNDER.'],\n",
       "  'answer_start': [41099, 41471]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['FORM OF TRADEMARK LICENSE AGREEMENT'], 'answer_start': [12]},\n",
       " {'text': ['ARCONIC INC.',\n",
       "   'Licensor',\n",
       "   'ARCONIC ROLLED PRODUCTS CORP.',\n",
       "   'Licensee'],\n",
       "  'answer_start': [193, 359, 275, 260]},\n",
       " {'text': ['[ ] day of [ ], 2020 ('], 'answer_start': [133]},\n",
       " {'text': ['[ ] day of [ ], 2020'], 'answer_start': [133]},\n",
       " {'text': ['The Term of this Agreement will commence on the Effective Date and shall continue for the time periods set forth in Schedules 1 and 2 unless sooner terminated in accordance with the terms of this Agreement.'],\n",
       "  'answer_start': [9124]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to its conflicts of law principles.'],\n",
       "  'answer_start': [12927]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Notwithstanding the foregoing, no such consent of Licensor is required under this Agreement in the event of a Change of Control of Licensee so long as: (a) the resulting, surviving or transferee Person assumes all the obligations of the Licensee by operation of Law or pursuant to an agreement in form and substance reasonably satisfactory to the Licensor; and (b) the licenses granted herein shall not be transferrable or sublicensable to Affiliates of such Person unless such Affiliates were Affiliates of Licensee prior to such Change of Control.'],\n",
       "  'answer_start': [16928]},\n",
       " {'text': ['This Agreement may not be assigned by Licensee without the consent of Licensor which consent shall not be unreasonably withheld.'],\n",
       "  'answer_start': [16799]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Licensor on behalf of itself and its Affliates hereby grants to Licensee the limited licenses to use and have used the Licensed Mark: (i) for the Licensed Products as set forth on Schedule 2; and (ii) as set forth on Schedule 1, concerning agreements entered into by Licensee prior to the Effective Date (\"Existing Agreements\").',\n",
       "   'For the avoidance of doubt, Licensor also grants to Licensee and its subsidiaries and affiliates a non-exclusive, worldwide royalty-free license for continued use of the Licensed Mark for the production and sale of inventory containing the Licensed Mark applied to such products during the Transition Period as set forth in section 8.2 of the Separation and Distribution Agreement and in Schedule 2 of this Agreement.',\n",
       "   'Licensee will not, however, use the Licensed Mark except for the production and sale of inventory as provided in this Section 1.1 and in Section 8.2 of the Separation and Distribution Agreement and Schedule 2 of this Agreement.'],\n",
       "  'answer_start': [2099, 2428, 2846]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Licensor on behalf of itself and its Affliates hereby grants to Licensee the limited licenses to use and have used the Licensed Mark: (i) for the Licensed Products as set forth on Schedule 2; and (ii) as set forth on Schedule 1, concerning agreements entered into by Licensee prior to the Effective Date (\"Existing Agreements\"). For the avoidance of doubt, Licensor also grants to Licensee and its subsidiaries and affiliates a non-exclusive, worldwide royalty-free license for continued use of the Licensed Mark for the production and sale of inventory containing the Licensed Mark applied to such products during the Transition Period as set forth in section 8.2 of the Separation and Distribution Agreement and in Schedule 2 of this Agreement.'],\n",
       "  'answer_start': [2099]},\n",
       " {'text': [\"For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.\",\n",
       "   'For the avoidance of doubt, Licensor also grants to Licensee and its subsidiaries and affiliates a non-exclusive, worldwide royalty-free license for continued use of the Licensed Mark for the production and sale of inventory containing the Licensed Mark applied to such products during the Transition Period as set forth in section 8.2 of the Separation and Distribution Agreement and in Schedule 2 of this Agreement.'],\n",
       "  'answer_start': [3074, 2428]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['No more frequently than once per year, a third party auditor chosen by Licensor and approved by Licensee, such approval not to be unreasonably withheld, shall be entitled at any time on reasonable notice to the Licensee to enter, during regular business hours, any premises used by the Licensee or its manufacturers for the manufacture, packaging or storage of the Licensed Products, to inspect such premises, all plant, workforce and machinery used for manufacture, packaging or storage of Licensed Products and all other aspects of the manufacture, packaging and storage of Licensed Products (\"Access Rights\")',\n",
       "   \"Licensor, as owner of the Licensed Mark, shall have the right at all times to control and approve the nature and quality of the Licensed Products (and the Licensed Mark thereon), and to inspect Licensee's business operations upon reasonable prior notice for the purpose of ensuring that a high level of quality of the Licensed Products is being maintained by Licensee.\"],\n",
       "  'answer_start': [5368, 4607]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Licensee agrees and covenants that it shall not challenge, contest, or take any actions inconsistent with Licensor's exclusive rights of ownership of the Licensed Mark.\"],\n",
       "  'answer_start': [3513]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['COOPERATION AGREEMENT'], 'answer_start': [15]},\n",
       " {'text': ['City of Fort Stockton',\n",
       "   '(\"COFS\")',\n",
       "   'STW Resources Holding Corp',\n",
       "   '(\"STW\")',\n",
       "   'STW and COFS are sometimes individually referred to as a \"Party\" and collectively referred to as the \"Parties.\"'],\n",
       "  'answer_start': [321, 383, 396, 446, 528]},\n",
       " {'text': ['day of , 2014'], 'answer_start': [27078]},\n",
       " {'text': ['effective as of the last date of signature on the signature pages below',\n",
       "   'day of , 2014'],\n",
       "  'answer_start': [455, 27078]},\n",
       " {'text': [\"Subject to the other provisions contained herein, this AGREEMENT shall be for a term of thirty (30) years from the Effective Date, which shall automatically renew from year-to-year thereafter unless terminated by a Party upon sixty (60) days' written notice after the end of the term.\"],\n",
       "  'answer_start': [3935]},\n",
       " {'text': [\"Subject to the other provisions contained herein, this AGREEMENT shall be for a term of thirty (30) years from the Effective Date, which shall automatically renew from year-to-year thereafter unless terminated by a Party upon sixty (60) days' written notice after the end of the term.\"],\n",
       "  'answer_start': [3935]},\n",
       " {'text': [\"Subject to the other provisions contained herein, this AGREEMENT shall be for a term of thirty (30) years from the Effective Date, which shall automatically renew from year-to-year thereafter unless terminated by a Party upon sixty (60) days' written notice after the end of the term.\"],\n",
       "  'answer_start': [3935]},\n",
       " {'text': ['This AGREEMENT is controlled by the laws of the State of Texas, and venue for any actions brought to enforce this AGREEMENT shall be brought exclusively in a court of competent jurisdiction in Pecos County, Texas.'],\n",
       "  'answer_start': [19804]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['If STW exercises its option to produce and transport the CRA water, STW will construct additional facilities or expand existing facilities, as necessary, to be able to produce and transport the CRA water for sale.',\n",
       "   'STW will have one year from completion of the last of the Post-Well Study (ies) completed on the Existing CRA Well or Replacement CRA Well to exercise its option to produce and transport the water produced from the CRA on the Property (\"Option to Produce\"). The AGREEMENT shall thereafter terminate as to both Parties if STW has not exercised its Option to Produce at the expiration of the one-year period unless STW pays as royalty on the first day of each month the sum of Five Hundred and 00/100 Dollars ($500.00) per month. STW shall have no right to maintain this AGREEMENT through payment of such a royalty for any one period greater than three consecutive years.'],\n",
       "  'answer_start': [17359, 16082]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['STW shall pay COFS a seven percent (7%) royalty of the price STW receives per 1,000 gallons of CRA water produced from other properties within Pecos County and sold as consideration for the rights provided by COFS to STW under this subsection.',\n",
       "   'STW shall pay COFS a seventeen percent (17%) royalty of the price STW receives per 1,000 gallons of CRA water produced from the Property and sold.'],\n",
       "  'answer_start': [18195, 14049]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The Post-Well Study shall provide information on the feasibility of developing a water well field in that location that would produce water from the CRA for: (a) the availability of a minimum 1,200 gallons per minute (\"GPM\") per day CRA water production for STW, its successors or assignees, to sell to communities and users within a 500-mile radius outside of COFS (the \"Permitted Sale Water\") during the Term, with the further requirement that STW would be responsible for the pipelines and pumping facilities required to transport the Permitted Sale Water to the intended end-users; and that all such water obtained from the Existing CRA Well contains acceptable levels of Total Dissolved Solids (\"TDS\") to meet municipal use standards. I',\n",
       "   'For purposes of this section, the Post-Well Study must show that the Existing CRA Well or Replacement CRA Well can produce CRA water at a minimum of 1,200 GPM or more or a combination of 1,200 GPM from one or more wells on the Property in order for STW to proceed with the obligations set forth in this section (\"Critical Criterion\").'],\n",
       "  'answer_start': [4653, 12748]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Notwithstanding the 30-year term of this agreement, should STW procure sales agreements with customers for a duration of longer than 30 years, STW shall be authorized to maintain and service such contract(s) to the extent of the water volume(s) purchased, and this AGREEMENT shall not terminate during the initial term of any such water supply agreement with a term extending beyond this AGREEMENT.',\n",
       "   'Should COFS unilaterally terminate the provisions of this AGREEMENT related to COFS Property only, with the right to do so beginning on a period beginning no sooner than ninety (90) days following the Post-Well Study (ies), and ending at the one year period following the Post-Well Study (ies), during which STW may exercise its Option to Produce Water, in accordance with Section 15 of this AGREEMENT, COFS shall reimburse STW for 100% of the costs paid by STW up to the point of such termination, pursuant to the AGREEMENT, according to a reasonable accounting schedule of costs prepared by STW and submitted to COFS.',\n",
       "   'Upon termination of the provisions of this AGREEMENT related to the Property only, STW, or its successors or assigns, shall transfer title of all water conveyance pipelines from the Property to COFS.'],\n",
       "  'answer_start': [4220, 9691, 3523]},\n",
       " {'text': ['allow COFS or its authorized representatives to enter upon the premises at reasonable times to be arranged in advance of entry'],\n",
       "  'answer_start': [12390]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['STW shall administer and provide all necessary and reasonable insurance to insure its activities on the Property in relation to the AGREEMENT and shall list COFS as additional insured.'],\n",
       "  'answer_start': [3723]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Nothing in this AGREEMENT shall be construed to confer any right, privilege or benefit on, or to otherwise create any vested right or third-party beneficiary relationship with any person or entity not a party to the AGREEMENT, unless otherwise provided in this AGREEMENT.'],\n",
       "  'answer_start': [24770]},\n",
       " {'text': ['DEVELOPMENT AND OPTION AGREEMENT'], 'answer_start': [4709]},\n",
       " {'text': ['Harpoon',\n",
       "   'AbbVie',\n",
       "   'AbbVie Biotechnology Ltd',\n",
       "   'Harpoon Therapeutics, Inc.'],\n",
       "  'answer_start': [1345, 839, 4964, 4896]},\n",
       " {'text': ['November 20, 2019'], 'answer_start': [343]},\n",
       " {'text': ['November 20, 2019'], 'answer_start': [343]},\n",
       " {'text': ['This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect until (a) the date of expiration of the last Royalty Term for the last Licensed Product, or (b) the expiration of the License Option Period and the failure of AbbVie to exercise the License Option (such period, the \"Term\").'],\n",
       "  'answer_start': [210365]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement or the performance, enforcement, breach or termination hereof shall be interpreted, governed by and construed in accordance with the laws of the State of Delaware, United States, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction; provided that all questions concerning (a) inventorship of Patents under this Agreement shall be determined in accordance with Section 7.1.3 and (b) the construction or effect of Patents shall be determined in accordance with the laws of the country or other jurisdiction in which the particular Patent has been filed or granted, as the case may be.'],\n",
       "  'answer_start': [233345]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Harpoon shall not, and shall cause its Affiliates not to (a) directly or indirectly, develop, commercialize or otherwise exploit any Competing Product in any country or other jurisdiction in the Territory, or (b) license, authorize, appoint, or otherwise enable any Third Party to directly or indirectly, develop, commercialize or otherwise exploit any Competing Product in any country or other jurisdiction in the Territory, except, in each case ((a) and (b)), as otherwise expressly provided in this Agreement.'],\n",
       "  'answer_start': [103821]},\n",
       " {'text': [\"Effective upon the date that AbbVie commences performing Initial Development Activities pursuant to Section 3.1.2, Harpoon (on behalf of itself and its Affiliates) shall grant and hereby grants AbbVie a co- exclusive (with Harpoon), royalty-free license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, solely to the extent necessary for AbbVie to conduct Initial Development Activities assumed by AbbVie in accordance with Section 3.1.2 (if any).\",\n",
       "   \"Upon the [***], Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie a co-exclusive (with Harpoon), royalty-free (subject to [***] [***]) license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know- How, to Develop and Manufacture the Licensed Compounds and Licensed Products solely to the extent necessary for AbbVie to perform [***].\",\n",
       "   'Upon the Effective Date, Harpoon hereby grants to AbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the \"License Option\").',\n",
       "   \"Upon the License Option Exercise Closing Date, Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie:\\n\\n(a) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license (or sublicense), with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory;\\n\\n(b) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license and right of reference, with the right to grant sublicenses and further rights of reference in accordance with Section 5.3, under the Regulatory Approvals and any other Regulatory Documentation that Harpoon or its Affiliates may Control with respect to the Licensed Compounds or Licensed Products solely for purposes of Exploiting the Licensed Compounds and Licensed Products in the Field in the Territory.\"],\n",
       "  'answer_start': [96452, 97045, 69281, 97757]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"AbbVie may terminate this Agreement in its entirety, or on a country or other jurisdiction -by-country or other jurisdiction basis, for any or no reason, upon ninety (90) days' prior written notice to Harpoon.\"],\n",
       "  'answer_start': [213706]},\n",
       " {'text': [\"If AbbVie does not provide a License Option Exercise Notice within the License Option Period, then (a) Harpoon shall have no further obligations to perform any Initial Development Activities, (b) AbbVie's License Option shall expire, and this Agreement shall terminate in accordance with Section 12.1.1, and (c) AbbVie shall have no further rights in connection with Licensed Compounds of the Licensed Products.\",\n",
       "   'If AbbVie [***] and does not subsequently exercise the License Option, then AbbVie shall [***].',\n",
       "   'Upon the Effective Date, Harpoon hereby grants to AbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the \"License Option\").',\n",
       "   \"The Parties shall each, as soon as practicable after the date of Harpoon's receipt of the License Option Exercise Notice, file or cause to be filed with the U.S. Federal Trade Commission and the U.S. Department of Justice and any relevant foreign governmental authority any such notifications.\",\n",
       "   'AbbVie shall have the right to exercise its License Option by providing written notice of such election to Harpoon (\"License Option Exercise Notice\") at any time on or after the Effective Date and on or prior to the date that is [***] from AbbVie\\'s receipt of the Opt-In Development Report containing all items required pursuant to Section 1.112, as such period may be extended pursuant to Section 3.2.1 (the \"License Option Period\").',\n",
       "   'If Harpoon decides not to prepare, file, prosecute, or maintain a Harpoon Patent or Joint Patent in a country or other jurisdiction in the Territory, Harpoon shall provide reasonable prior written notice to AbbVie of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to such Harpoon Patent or Joint Patent in such country or other jurisdiction), AbbVie shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Harpoon Patent or Joint Patent at its expense in such country or other jurisdiction.',\n",
       "   'If AbbVie decides not to prepare, file, prosecute, or maintain a Product-Specific Patent or Joint Patent in a country or other jurisdiction in the Territory, AbbVie shall provide reasonable prior written notice to Harpoon of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to such Product-Specific Patent or Joint Patent in such country or other jurisdiction), and Harpoon shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Product-Specific Patent or Joint Patent at its sole cost and expense in such country or other jurisdiction.',\n",
       "   'Following the License Option Exercise Closing Date, if [***] owned or controlled by a Third Party in a particular country or jurisdiction is necessary to Exploit a Licensed Compound or Licensed Product, AbbVie shall have the first right, but not the obligation, to negotiate and enter into an agreement with a Third Party in order to obtain a license or right under such Patent or intellectual property right.',\n",
       "   \"If AbbVie notifies Harpoon in writing within [***] after receipt of such copy that AbbVie wishes to receive a license or sublicense (as applicable) under, and be subject to the rights and obligations of, the Proposed Future In-Licensed Rights as they apply to AbbVie and this Agreement, then the Proposed Future In-Licensed Rights shall automatically be included in the Harpoon Patents and/or Harpoon Know-How (as applicable) hereunder and AbbVie agrees to abide by all applicable terms and conditions of such license, sublicense or other agreement, as it relates to AbbVie and this Agreement, including payment of any financial obligations based upon AbbVie's practice of such intellectual property rights.\",\n",
       "   'If AbbVie provides the License Option Exercise Notice during the License Option Period, upon AbbVie\\'s request, the Parties shall work together in good faith to conduct an analysis of whether any filings or notifications are or may be required to be filed under the HSR Act (the \"HSR Filing\") or any similar applicable foreign law or regulation in connection with AbbVie\\'s exercise of the License Option.'],\n",
       "  'answer_start': [69892,\n",
       "   73018,\n",
       "   69281,\n",
       "   71199,\n",
       "   69457,\n",
       "   134017,\n",
       "   135794,\n",
       "   106818,\n",
       "   108029,\n",
       "   70795]},\n",
       " {'text': ['Notwithstanding the provisions of Section 5.8, if, during the Term, (a) Harpoon or any of its Affiliates acquires, as the result of an Acquisition, rights to a Competing Product, such Acquisition, and the development, manufacture or commercialization of such Competing Product thereafter, shall not constitute a breach of Section 5.8 if Harpoon or such Affiliate, as applicable, [***]; or (b) Harpoon undergoes a Change in Control and the relevant acquirer is either then commercializing a Competing Product, or has in development any Competing Product, such Change in Control, and the commercialization (or development and subsequent commercialization, if such Competing Product receives Regulatory Approval) of such Competing Product by such relevant acquirer or any of its Affiliates, shall not constitute a breach of Section 5.8; provided that such (x) acquirer Segregates the Competing Product and (y) AbbVie shall have the right, in its sole and absolute discretion, by written notice delivered to Harpoon (or its successor) at any time during the [***] following the written notice contemplated by Section 13.2.1, to (i) terminate any or all provisions of this Agreement providing for any delivery by AbbVie to Harpoon of Confidential Information of AbbVie relating to activities contemplated by this Agreement, save only for (A) Article 6, (B) information regarding sublicenses pursuant to Section 5.3, (C) information regarding the prosecution, enforcement, defense, litigation, infringement and licensing of Patents pursuant to (1) Sections 7.2.1, 7.2.3, 7.3.1, 7.3.5, 7.4, and 7.5.2, (2) solely with respect to Joint Patents, Sections 7.2.2, 7.3.2, and 7.5.3, and (3) solely with respect to Joint Patents and Harpoon Patents, Sections 7.3.4 and 7.5.1, (D) notice of any license pursuant to Section 5.9.2, (E) safety data pursuant to Section 8.1, (F) proposed disclosures pursuant to Section 9.5, (G) communications under Section 11.4 and (H) notices pursuant to Sections 11.3 and 13.1; and (ii) disband the JGC and terminate its activities, in which case the provisions set forth in the last sentence of Section 2.3 shall apply.',\n",
       "   'Harpoon (or its successor) shall provide AbbVie with written notice of any Change in Control of Harpoon or Acquisition by Harpoon within [***] following the closing date of such transaction.'],\n",
       "  'answer_start': [104341, 229512]},\n",
       " {'text': ['AbbVie may use one (1) or more of its Affiliates to perform its obligations and duties hereunder and such AbbVie Affiliates are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of AbbVie and, subject to an assignment to such Affiliate pursuant to Section 13.4, AbbVie shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder.',\n",
       "   'Any attempted assignment or delegation in violation of this Section 13.4 shall be void and of no effect.',\n",
       "   \"Without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned, or delayed, neither Party shall sell, transfer, assign, delegate, pledge, or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided that either Party may make such an assignment without the other Party's consent to its Affiliate or to a successor, whether in a merger, sale of stock, sale of assets or any other transaction, of the business to which this Agreement relates.\"],\n",
       "  'answer_start': [245445, 231266, 230505]},\n",
       " {'text': ['AbbVie shall pay to Harpoon the royalty amounts due with respect to a given [***] within [***] after the end of such [***].',\n",
       "   'As further consideration for the rights granted to AbbVie hereunder, subject to Section 6.5.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory, on a Licensed Product- by-Licensed Product basis, AbbVie shall pay to Harpoon a royalty on Net Sales of each Licensed Product in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during [***] at the following rates:\\n\\nNet Sales in the Territory of each Licensed Product in a [***] Royalty Rate\\n\\nFor that portion of aggregate Net Sales of each Licensed Product[***] [***]\\n\\nFor that portion of aggregate Net Sales of each Licensed Product[***] [***]\\n\\nFor that portion of aggregate Net Sales of each Licensed Product[***] [***]\\n\\nWith respect to each Licensed Product in each country or other jurisdiction in the Territory, [***].'],\n",
       "  'answer_start': [117716, 112888]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"For clarity, if AbbVie does not exercise its License Option, Harpoon retains all rights under Harpoon's interests in the Joint Patents and the Joint Know-How, if any, to Exploit the Licensed Compounds and Licensed Products in its sole discretion without duty to account to AbbVie in connection with such use or Exploitation.\",\n",
       "   'Each Party will promptly disclose to the other Party in writing, the conception, discovery, development or making of any Joint Know-How or Joint Patents by Persons who perform activities for it under this Agreement. Each Party will execute and record assignments and other necessary documents consistent with such ownership promptly upon request.',\n",
       "   'Subject to the licenses and rights of reference granted under Sections 5.1 and 5.2 and, in the case of Harpoon, its exclusivity obligations hereunder, each Party shall have the right to Exploit the Joint Intellectual Property Rights without a duty of seeking consent from or accounting to the other Party.',\n",
       "   'Subject to Section 3.8.2(c), as between the Parties, each Party, or their respective Affiliates, shall own an equal, undivided interest in and to any and all (a) Information and inventions that are conceived, discovered, developed or otherwise made jointly by or on behalf of Harpoon or its Affiliates (including subcontractors thereof), on the one hand, and AbbVie or its Affiliates (including subcontractors thereof), on the other hand, in connection with the work conducted under or in connection with this Agreement, in each case whether or not patented or patentable (the \"Joint Know-How\"), and (b) Patents (the \"Joint Patents\") and other intellectual property rights with respect to the Information and inventions described in subclause (a) (together with Joint Know-How and Joint Patents, the \"Joint Intellectual Property Rights\").',\n",
       "   'Each Party shall promptly disclose to the other Party in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the development, making, conception or reduction to practice of any Joint Know-How or Joint Patents.'],\n",
       "  'answer_start': [102405, 131906, 130323, 129242, 130081]},\n",
       " {'text': [\"Upon the Effective Date, AbbVie hereby grants to Harpoon a non-exclusive, royalty-free license, without the right to grant sublicenses (other than to permitted subcontractors of Harpoon in accordance with Section 3.7), under the AbbVie Patents, AbbVie Know-How, and AbbVie's interests in the Joint Patents and the Joint Know-How, to Develop and Manufacture the Licensed Compounds or Licensed Products in the Territory solely to the extent necessary for Harpoon to perform its obligations as set forth in, and subject to, the Initial Development Plan.\",\n",
       "   'Upon the Effective Date, Harpoon hereby grants to AbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the \"License Option\").',\n",
       "   \"Upon the License Option Exercise Closing Date, Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie:\\n\\n(a) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license (or sublicense), with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory;\\n\\n(b) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license and right of reference, with the right to grant sublicenses and further rights of reference in accordance with Section 5.3, under the Regulatory Approvals and any other Regulatory Documentation that Harpoon or its Affiliates may Control with respect to the Licensed Compounds or Licensed Products solely for purposes of Exploiting the Licensed Compounds and Licensed Products in the Field in the Territory.\",\n",
       "   \"Upon the [***], Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie a co-exclusive (with Harpoon), royalty-free (subject to [***] [***]) license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know- How, to Develop and Manufacture the Licensed Compounds and Licensed Products solely to the extent necessary for AbbVie to perform [***].\",\n",
       "   'Notwithstanding the foregoing, to the extent required by Applicable Law in a country or other jurisdiction in the Territory, the promotional materials, packaging, and Product Labeling for the Licensed Products used by AbbVie and its Affiliates in connection with the Licensed Products in such country or other jurisdiction shall contain (a) the corporate name of Harpoon (and to the extent required, Harpoon grants AbbVie a license, with the right to sublicense, to use the same solely for such purpose), and (b) the logo and corporate name of the manufacturer (if other than AbbVie or an Affiliate).',\n",
       "   \"Effective upon the date that AbbVie commences performing Initial Development Activities pursuant to Section 3.1.2, Harpoon (on behalf of itself and its Affiliates) shall grant and hereby grants AbbVie a co- exclusive (with Harpoon), royalty-free license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, solely to the extent necessary for AbbVie to conduct Initial Development Activities assumed by AbbVie in accordance with Section 3.1.2 (if any).\",\n",
       "   'At Harpoon\\'s sole election by written notice to AbbVie, AbbVie shall grant, and hereby grants to Harpoon, effective as of the effective date of termination, [***] (the \"AbbVie Reversion IP\"); provided that the foregoing license shall exclude (1) any license or other rights with respect to any active ingredient that is not a Licensed Compound and (2) any license or other rights with respect to any other Patents or Know-How owned or controlled by AbbVie or any of its Affiliates.'],\n",
       "  'answer_start': [99111, 69281, 97757, 97045, 90309, 96452, 220793]},\n",
       " {'text': [\"Upon the Effective Date, AbbVie hereby grants to Harpoon a non-exclusive, royalty-free license, without the right to grant sublicenses (other than to permitted subcontractors of Harpoon in accordance with Section 3.7), under the AbbVie Patents, AbbVie Know-How, and AbbVie's interests in the Joint Patents and the Joint Know-How, to Develop and Manufacture the Licensed Compounds or Licensed Products in the Territory solely to the extent necessary for Harpoon to perform its obligations as set forth in, and subject to, the Initial Development Plan.\"],\n",
       "  'answer_start': [99111]},\n",
       " {'text': [\"Upon the Effective Date, AbbVie hereby grants to Harpoon a non-exclusive, royalty-free license, without the right to grant sublicenses (other than to permitted subcontractors of Harpoon in accordance with Section 3.7), under the AbbVie Patents, AbbVie Know-How, and AbbVie's interests in the Joint Patents and the Joint Know-How, to Develop and Manufacture the Licensed Compounds or Licensed Products in the Territory solely to the extent necessary for Harpoon to perform its obligations as set forth in, and subject to, the Initial Development Plan.\",\n",
       "   '\"Harpoon Patents\" means all of the Patents that are (a) Controlled by Harpoon or any of its Affiliates as of the Effective Date or at any time during the Term and (b) necessary or reasonably useful (or, with respect to Patent applications, would be necessary or reasonably useful if such Patent applications were to issue as Patents) for the Exploitation of any Licensed Compound or any Licensed Product, but excluding Joint Patents. The Harpoon Patents include the Existing Patents.',\n",
       "   \"Upon the License Option Exercise Closing Date, Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie:\\n\\n(a) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license (or sublicense), with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory;\\n\\n(b) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license and right of reference, with the right to grant sublicenses and further rights of reference in accordance with Section 5.3, under the Regulatory Approvals and any other Regulatory Documentation that Harpoon or its Affiliates may Control with respect to the Licensed Compounds or Licensed Products solely for purposes of Exploiting the Licensed Compounds and Licensed Products in the Field in the Territory.\",\n",
       "   \"Upon the [***], Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie a co-exclusive (with Harpoon), royalty-free (subject to [***] [***]) license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know- How, to Develop and Manufacture the Licensed Compounds and Licensed Products solely to the extent necessary for AbbVie to perform [***].\",\n",
       "   '\"AbbVie Know-How\" means all Information that is (a) Controlled by AbbVie or any of its Affiliates during the Term, (b) developed or acquired by AbbVie or any of its Affiliates during the Term as a result of performance under this Agreement, (c) not generally known and (d) necessary or reasonably useful for the Exploitation of the Licensed Compound or a Licensed Product, but excluding any Joint Know-How or Information published in any AbbVie Patents or Joint Patents.',\n",
       "   \"Effective upon the date that AbbVie commences performing Initial Development Activities pursuant to Section 3.1.2, Harpoon (on behalf of itself and its Affiliates) shall grant and hereby grants AbbVie a co- exclusive (with Harpoon), royalty-free license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, solely to the extent necessary for AbbVie to conduct Initial Development Activities assumed by AbbVie in accordance with Section 3.1.2 (if any).\",\n",
       "   'patent applications were to issue as patents) for the Exploitation of the Licensed Compound or a Licensed Product, but excluding any Joint Patents.',\n",
       "   '\"AbbVie Patents\" means all of the Patents that (a) are Controlled by AbbVie or any of its Affiliates during the Term, (b) claim inventions made or conceived by or on behalf of AbbVie or any of its Affiliates during the Term as a result of performance under this Agreement, and (c) are necessary or reasonably useful (or, with respect to patent applications, would be necessary or reasonably useful if such',\n",
       "   '\"Harpoon Know-How\" means all Information that is (a) Controlled by Harpoon or any of its Affiliates as of the Effective Date or at any time during the Term, (b) not generally known and (c) necessary or reasonably useful for the Exploitation of any Licensed Compound or any Licensed Product, but excluding any Joint Know-How or Information published in any (i) Harpoon Patents or (ii) Joint Patents.'],\n",
       "  'answer_start': [99111,\n",
       "   25931,\n",
       "   97757,\n",
       "   97045,\n",
       "   6482,\n",
       "   96452,\n",
       "   7422,\n",
       "   6958,\n",
       "   25526]},\n",
       " {'text': ['AbbVie shall have the right to grant sublicenses (or further rights of reference), through multiple tiers of Sublicensees, under the licenses and rights of reference granted in Sections 5.1.1, 5.1.2 and 5.1.3, to its Affiliates and other Persons; provided that any such sublicenses shall be consistent with the terms and conditions of this Agreement and AbbVie shall remain liable for its obligations under this Agreement and for the performance of all Sublicensees.',\n",
       "   'AbbVie shall have the right, in its sole discretion, to appoint its Affiliates, and AbbVie and its Affiliates shall have the right, in their sole discretion, to appoint any other Persons, in the Territory or in any country or other jurisdiction of the Territory, to distribute, market, and sell the Licensed Products.',\n",
       "   'For purposes of clarity, AbbVie and its Affiliates shall have the right, in their sole discretion, to co-promote the Licensed Products with any other Person(s), or to appoint one (1) or more Third Parties to promote the Licensed Products without AbbVie in all or any part of the Territory.',\n",
       "   'AbbVie may use one (1) or more of its Affiliates to perform its obligations and duties hereunder and such AbbVie Affiliates are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of AbbVie and, subject to an assignment to such Affiliate pursuant to Section 13.4, AbbVie shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder.'],\n",
       "  'answer_start': [99680, 100390, 101091, 245445]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Following the expiration of the Term pursuant to clause (a) (but not clause (b)) of Section 12.1.1, the grants in Section 5.1.3 shall become non-exclusive, fully-paid, royalty-free and irrevocable.'],\n",
       "  'answer_start': [210773]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"If AbbVie terminates this Agreement with respect to a country or other jurisdiction, or in its entirety pursuant to Section 12.3, AbbVie shall have the right for at least [***] and no more than [***], which period shall be determined by Harpoon in its sole discretion, after the effective date of such termination with respect to such country or other jurisdiction to sell or otherwise dispose of all Licensed Compound or Licensed Product then in its inventory and any in-progress inventory, in each case that is intended for sale or disposition in such country or other jurisdiction, as though this Agreement had not terminated with respect to such country or other jurisdiction, and such sale or disposition shall not constitute infringement of Harpoon's or its Affiliates' Patent or other intellectual property or other proprietary rights.\",\n",
       "   'The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to maintain such insurance after the expiration or termination of this Agreement for the longer of (a) a period of [***] following termination or expiration of this Agreement in its entirety, or (b) with respect to a particular Party, [***] by a Party.'],\n",
       "  'answer_start': [226926, 209764]},\n",
       " {'text': ['At the request of Harpoon, AbbVie shall permit an independent public accounting firm of nationally recognized standing designated by Harpoon and reasonably acceptable to AbbVie, [***], to audit the books and records maintained pursuant to this Section 6.11 to ensure the accuracy of all reports and payments made hereunder, including any permitted deductions from Net Sales pursuant to Section 1.108.'],\n",
       "  'answer_start': [124334]},\n",
       " {'text': [\"EXCEPT (A) FOR FRAUD, WILLFUL MISCONDUCT OR GROSS NEGLIGENCE, (B) FOR A PARTY'S BREACH OF ITS OBLIGATIONS UNDER [ARTICLE 9 OR SECTION 5.8], (C) AS PROVIDED UNDER [***] AND (D) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 11, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS INTERRUPTION, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY OUT OF THE TERMS OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE USE OF THE LICENSED COMPOUNDS OR LICENSED PRODUCTS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.\"],\n",
       "  'answer_start': [207487]},\n",
       " {'text': [\"EXCEPT (A) FOR FRAUD, WILLFUL MISCONDUCT OR GROSS NEGLIGENCE, (B) FOR A PARTY'S BREACH OF ITS OBLIGATIONS UNDER [ARTICLE 9 OR SECTION 5.8], (C) AS PROVIDED UNDER [***] AND (D) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 11, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS INTERRUPTION, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY OUT OF THE TERMS OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE USE OF THE LICENSED COMPOUNDS OR LICENSED PRODUCTS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.\"],\n",
       "  'answer_start': [207487]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Upon request by a Party, the other Party shall provide Certificates of Insurance evidencing compliance with this Section. The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to maintain such insurance after the expiration or termination of this Agreement for the longer of (a) a period of [***] following termination or expiration of this Agreement in its entirety, or (b) with respect to a particular Party, [***] by a Party.',\n",
       "   \"The types of insurance, and minimum limits shall be:\\n\\n(a) Worker's Compensation with statutory limits in compliance with the Worker's Compensation laws of the state or states in which the Party has employees in the United States (excluding Puerto Rico).\\n\\n(b) Employer's Liability coverage with a minimum limit of [***] provided that a Party has employees in the United States (excluding Puerto Rico).\",\n",
       "   'Each Party shall obtain and carry in full force and effect the minimum insurance requirements set forth herein.',\n",
       "   '(c) General Liability Insurance with a minimum limit of [***] and [***] in the aggregate. General Liability Insurance shall include Clinical Trial Insurance. The limits may be met with a combination of primary and commercial umbrella insurance.',\n",
       "   'Such insurance (a) shall be primary insurance with respect to each Party\\'s own participation under this Agreement, (b) shall be issued by a recognized insurer rated by A.M. Best \"A-VII\" (or its equivalent) or better, or an insurer pre- approved in writing by the other Party, and (c) shall list the other Party as an additional insured under the General Liability Policy.'],\n",
       "  'answer_start': [209642, 208895, 208377, 209362, 208489]},\n",
       " {'text': ['Harpoon shall not, and shall not permit its Affiliates to, attack, dispute, or contest the validity of or ownership of such Product Trademark anywhere in the Territory or any registrations issued or issuing with respect thereto or use in their respective businesses, any Trademark that is confusingly similar to, misleading or deceptive with respect to or that dilutes any (or any part) of the Product Trademarks.'],\n",
       "  'answer_start': [89895]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['SCHEDULE TO Software License, Customization and Maintenance Agreement'],\n",
       "  'answer_start': [0]},\n",
       " {'text': ['Cardlytics, Inc.',\n",
       "   'Bank of America, N. A',\n",
       "   'Bank of America',\n",
       "   'Supplier'],\n",
       "  'answer_start': [89, 505, 505, 73]},\n",
       " {'text': ['3/4/11'], 'answer_start': [1638]},\n",
       " {'text': ['March 3, 2011'], 'answer_start': [297]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Distributor Agreement'], 'answer_start': [395]},\n",
       " {'text': ['Airspan',\n",
       "   'Distributor',\n",
       "   'GLS LLC',\n",
       "   'Airspan Networks Incorporated'],\n",
       "  'answer_start': [526, 316, 729, 526]},\n",
       " {'text': ['31st day of March, 2000'], 'answer_start': [463]},\n",
       " {'text': ['31st day of March, 2000'], 'answer_start': [463]},\n",
       " {'text': ['This Agreement shall remain in effect for sixty (60) months from the Effective Date (the \"Initial Term\").'],\n",
       "  'answer_start': [42233]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['South Dakota',\n",
       "   'This Agreement shall be construed in accordance with and governed by the laws of the State of South Dakota.'],\n",
       "  'answer_start': [826, 64901]},\n",
       " {'text': ['Airspan warrants that during the term of this Agreement, the prices at      which Airspan sells to Distributor products supplied under this Agreement      shall be no less favorable to the Distributor than those prices at which      Airspan sells, at substantially the same time in the United States, similar      products and pursuant to similar terms and conditions as those by which      Airspan sells Products to the Distributor under this Agreement.'],\n",
       "  'answer_start': [18050]},\n",
       " {'text': [\"During the term of this Agreement Distributor agrees that neither it      nor any organization or entity controlled or directed by it will, without      Airspan's prior, written consent, represent a manufacturer or supplier of      products similar in design or performance to or which are of such a nature      as to be competitive with any products contained in the Airspan Products.\",\n",
       "   'During the performance of this Agreement and for three (3) months after termination of services under this Agreement, Airspan will not offer products or services to third parties which compete with the products or services provided by Distributor under this Agreement, or otherwise use the knowledge acquired from Distributor in order to compete with Distributor its customers',\n",
       "   \"Distributor will give Airspan thirty (30) days' prior, written notice of each new potential representation role being considered by Distributor, and Distributor will not undertake such representation without Airspan's prior, written consent, such consent not to be unreasonably withheld.\",\n",
       "   \"During the term of this Agreement, and for a period of three (3) months following the expiration or termination of this Agreement, Distributor agrees that neither it nor any organization or entity controlled or directed by it will, without Airspan's prior, written consent, represent a manufacturer or supplier of products similar in design or performance to or which are of such a nature as to be competitive with any products contained in the Airspan Products, nor will Distributor market or otherwise promote the sale of such products.\",\n",
       "   \"Except as\\n\\n\\n\\n\\n\\nprovided above, in no event will Airspan consent to Distributor's consultation for or representation of a manufacturer or supplier, which is directly or indirectly, a competitor of Airspan.\"],\n",
       "  'answer_start': [12860, 37858, 4687, 4148, 4975]},\n",
       " {'text': ['Subject to the provisions of this Agreement, Airspan hereby appoints Distributor as an independent, exclusive distributor to assist Airspan in marketing the Airspan Products to customers in the Territory, and Distributor hereby accepts such appointment as of the Effective Date of this Agreement.'],\n",
       "  'answer_start': [2046]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Neither party may assign this Agreement or subcontract its obligations under this Agreement to another party without the other party's prior, written consent executed by a duly authorized officer.\"],\n",
       "  'answer_start': [64547]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Airspan shall provide a single technical course in the English language for up to two (2) qualified technicians of Distributor during the first year of this Agreement.'],\n",
       "  'answer_start': [58840]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Distributor's appointment as a distributor of the Airspan Products grants to Distributor only a license to resell the\",\n",
       "   'Airspan grants Distributor, and Distributor hereby accepts, a nonexclusive, non-transferable license to use, and to sublicense as set forth below, Software provided by Airspan hereunder only on a single System or unit of Equipment, as may be applicable.',\n",
       "   \"Airspan Products to Distributor's customers in the Territory, and does not transfer any right, title, or interest in any of the Airspan Software to Distributor.\"],\n",
       "  'answer_start': [2343, 38370, 2553]},\n",
       " {'text': ['Airspan grants Distributor, and Distributor hereby accepts, a nonexclusive, non-transferable license to use, and to sublicense as set forth below, Software provided by Airspan hereunder only on a single System or unit of Equipment, as may be applicable.'],\n",
       "  'answer_start': [38370]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['For at least two (2) years after termination of this Agreement,      Distributor will maintain its records, contracts, and accounts relating to      distribution of Airspan Products, and will permit examination thereof by      authorized representatives of Airspan at all reasonable times.',\n",
       "   'Airspan will recognize payments due to Distributor for orders received up to ninety (90) days after the termination or expiration of this Agreement.'],\n",
       "  'answer_start': [16653, 45333]},\n",
       " {'text': ['For at least two (2) years after termination of this Agreement,      Distributor will maintain its records, contracts, and accounts relating to      distribution of Airspan Products, and will permit examination thereof by      authorized representatives of Airspan at all reasonable times.'],\n",
       "  'answer_start': [16653]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['In any event, Airspan shall not be liable      for any direct, indirect, consequential, or special losses or damages      (including, but not limited to, loss of income or profit and loss of data)      that may be suffered by the Distributor or by any other person for failure      to deliver or for any delay or error in delivery of Equipment or Software      for any reason whatsoever.',\n",
       "   'Airspan shall not be liable to Distributor on account of termination or expiration of this Agreement for reimbursement or damages for loss of goodwill, prospective profits, or anticipated orders, or on account of any expenditures, investments, leases, or commitments made by either party, or for any other reason whatsoever based upon or growing out of such termination or expiration.',\n",
       "   'Without prejudice to Sections 16.3 and 16.4, the liability of the Airspan Parties, taken as a whole, for each event or series of connected events\\n\\n\\n\\n\\n\\narising out of or in connection with this Agreement, any purchase order placed pursuant to this Agreement, or any other collateral contract, or from or in connection with the Equipment or Software or the use thereof, or the inability to use them either separately or in combination with other equipment or software, or from any other cause, whether caused by negligence, breach of contract, strict liability, breach of warranty, on grounds of failure of essential purpose, or otherwise, shall in no circumstance exceed the total amount payable by Distributor to Airspan under this Agreement for the provision of',\n",
       "   'WITHOUT PREJUDICE TO SECTION 16.4, NEITHER Airspan, NOR ANY OF ITS OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, REPRESENTATIVES, SHAREHOLDERS, OR AFFILIATES (Airspan AND SUCH OTHER PERSONS, THE \"Airspan PARTIES\"), SHALL HAVE ANY LIABILITY TO DISTRIBUTOR FOR LOSS OF PROFITS, INCOME, REVENUE OR DATA, OR INCIDENTAL, CONSEQUENTIAL, INDIRECT OR PUNITIVE DAMAGES OR LOSSES, ARISING FROM OR IN CONNECTION WITH THIS AGREEMENT, ANY PURCHASE ORDER PLACED PURSUANT TO THIS AGREEMENT OR ANY OTHER COLLATERAL CONTRACT, OR FROM OR IN CONNECTION WITH THE EQUIPMENT OR THE SOFTWARE OR THE USE THEREOF OR THE INABILITY TO USE THEM EITHER SEPARATELY OR IN COMBINATION WITH OTHER EQUIPMENT OR SOFTWARE, OR FROM ANY OTHER CAUSE, WHETHER CAUSED BY NEGLIGENCE, BREACH OF CONTRACT, STRICT LIABILITY, BREACH OF WARRANTY, ON GROUNDS OF FAILURE OF ESSENTIAL PURPOSE OR OTHERWISE.',\n",
       "   'Airspan shall not be liable to Distributor for damages of any kind, including incidental or consequential damages, on account of the termination of this agreement in accordance with this section 13.',\n",
       "   \"Airspan's obligation and Distributor's sole remedy under this warranty are limited to the replacement or repair, at Airspan's option, of the defective Equipment or Software within the Initial Warranty Period.\",\n",
       "   'the Equipment or Software which gave rise to the loss or damage or in connection with which the loss or damage was incurred.',\n",
       "   \"And Distributor, taken as a whole, shall be liable for physical damage to Airspan's property resulting from Distributor's negligence under or in connection with this Agreement up to a maximum aggregate amount of one million US Dollars (US$1,000,000).\",\n",
       "   \"Airspan Parties, taken as a whole, shall be liable for physical damage to Distributor's property resulting from Airspan's negligence under or in connection with this Agreement up to a maximum aggregate amount of one million US Dollars (US$1,000,000).\"],\n",
       "  'answer_start': [26476,\n",
       "   44947,\n",
       "   51323,\n",
       "   50465,\n",
       "   44747,\n",
       "   47419,\n",
       "   52179,\n",
       "   52563,\n",
       "   52311]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [\"Airspan's obligation and Distributor's sole remedy under this warranty are limited to the replacement or repair, at Airspan's option, of the defective Equipment or Software within the Initial Warranty Period.\",\n",
       "   \"Subject to the provisions of this warranty clause, defective parts or components must be returned by Distributor to Airspan's designated facility located within the contiguous 48 states in the United States, freight prepaid, within the Initial Warranty Period, and said defective parts will be repaired or replaced by Airspan at no charge to Distributor.\",\n",
       "   'The warranty period for any item of Equipment and related Software shall be twelve (12) months from the date of delivery of such Equipment and related Software to Distributor as set forth in Paragraph 8.1 (hereinafter, this period of time shall be referred to as the \"Initial Warranty Period.\")',\n",
       "   \"Airspan warrants that, following repair or replacement, the repaired or replaced Equipment or Software by Airspan shall be free from defects in materials and faulty workmanship and that the Software will conform in all material respects to Airspan's published specifications therefor for ninety (90) days from date of shipment from Airspan to Distributor or until the end of the Initial Warranty Period, whichever is longer.\"],\n",
       "  'answer_start': [47419, 48376, 47118, 50002]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Distributor admits Airspan\\'s exclusive ownership of the name \"Airspan Networks Incorporated\", \"Airspan Communications Ltd.\", \"ANI\", \"ACL\", and any abbreviations or derivations thereof and all of Airspan\\'s Trademarks (whether registered or not).',\n",
       "   'Distributor acknowledges Airspan\\'s exclusive right, title, and interest in and to any trademarks, trade names, logos and designations which Airspan may at any time have adopted, used, or registered in the United States of America and in the Territory (the \"Trademarks\"), and will not at any time do or cause to be done any act or thing contesting or in any way impairing or tending to impair any part of said right, title, and interest.',\n",
       "   \"In connection with any reference to the Trademarks, Distributor shall not in any manner represent that it has an ownership interest in the Trademarks or registration(s) thereof, and Distributor acknowledges that no action by it or on its behalf shall create in Distributor's favor any right, title, or interest in or to the Trademarks.\",\n",
       "   \"Distributor recognizes the validity of Airspan's copyright in any written material to which Airspan shall have made a claim to copyright protection, and Distributor specifically recognizes Airspan's exclusive right to copyright protection and/or registration of any translation of any advertising, promotional, or descriptive material furnished to Distributor by Airspan.\"],\n",
       "  'answer_start': [30946, 26903, 27341, 27683]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['TRANSPORTATION CONTRACT  GENERAL CONDITIONS'],\n",
       "  'answer_start': [3964]},\n",
       " {'text': ['SHIPPER',\n",
       "   'ECOPETROL',\n",
       "   'SOLANA PETROLEUM EXPLORATION  COLOMBIA LIMITED',\n",
       "   'ECOPETROL S.A.',\n",
       "   'SENDER'],\n",
       "  'answer_start': [324, 332, 254, 332, 247]},\n",
       " {'text': ['January 30, 2012'], 'answer_start': [202]},\n",
       " {'text': ['January 30, 2012'], 'answer_start': [202]},\n",
       " {'text': ['TERM OF EXECUTION From January 30, 2012 until July 29, 2012'],\n",
       "  'answer_start': [1053]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Manual is governed in all its parts by the applicable regulations of the Republic of Colombia.'],\n",
       "  'answer_start': [139506]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['c) The unauthorized assignment of the Contract by the SENDER.',\n",
       "   'The SENDER shall not assign totally or partially the Contract hereof, without the previous written consent by ECOPETROL.',\n",
       "   'The assignment may be authorized by ECOPETROL, when the SENDER sufficiently demonstrates to ECOPETROL that:\\n\\n  a) The assignee is a legal person duly organized and the duration of the same shall not be less that the term of the Contract and three (3)  more years.    b) The assignee has an adequate financial capacity to meet the obligations derived from the Contract assigned.    c) The assignee has Crude of its own/production.    d) The assignee provides and adequate and acceptable Bond payment to ECOPETROL for the fulfillment of the obligations derived from the  Contract.',\n",
       "   'The Parties agree that ECOPETROL may declare the termination in advance of the Contract at any time, without any indemnity in favor of the  SENDER in the following events:'],\n",
       "  'answer_start': [27739, 32092, 32320, 27385]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Sender with Contracted Capacity in Firm:     22.2.1 If by any reason the delivery is less than 95% or more than 105% of their Scheduled Capacity, the Sender shall Pay:     22.2.1.1.1 The Transportation fee for volumes delivered when they are higher than the Contracted Capacity in firm. When they are equal or less the  Sender shall Pay Transportation fee on the Contracted Capacity in firm.     22.2.1.1.2 The Transporter may decide to charge the Sender a sanction equivalent to 5% of the Transportation Fee of the Scheduled Capacity.\\n\\n\\n\\n   22.2.1.2 If by any reason, delivery is between 95% and up to 105% of its scheduled Capacity, the Transporter shall charge the Transportation fee  for volumes delivered when these are above the Contracted Capacity in firm. When they are equal or less the Sender shall pay the Transportation  fee on the Contracted Capacity in firm. In this case there shall not be any sanction, without prejudice of the application of other types of sanctions.     22.2.2 Sender without Contracted Capacity in firm:     22.2.2.1 If by any reason, the delivery is less than 95% or more than 105% of its scheduled Capacity, the Sender shall Pay:     22.2.2.1.1 The Transportation fee for volumes delivered     22.2.2.1.1 The Transporter may decide to charge the Sender a sanction equivalent to 5% of the Transportation Fee of the Scheduled Capacity.     22.2.2.2 If by any reason, delivery is between 95% and up to 105% of its scheduled Capacity, the Transporter shall charge the Transportation fee  for volumes delivered. In this case there shall not be any sanction, without prejudice of the application of other types of sanctions.',\n",
       "   'MINIMUM SPECIFICATIONS OF QUALITY PER SYSTEM',\n",
       "   'The minimum values of quality that the Crude delivered by the Senders must have to be accepted for Transportation in the Pipeline are:\\n\\n   For specific systems the Transporter defines minimum parameters for quality which are listed in Annex 4 Minimum Quality Specifications by  System.',\n",
       "   'The basket of Crude Oil to be used shall always include a minimum of ten (10) Crude Oils.',\n",
       "   'The Sender shall notify the Transporter as soon as possible, if it is found that: (i) its deliveries during a month of Operation at a Point of  Entrance will be less than 95% of the Scheduled Capacity or (ii) its withdrawals at any Point of Exit shall be less than 95% of the Scheduled  Capacity.',\n",
       "   'The Transporter and the Sender may agree on the delivery of Hydrocarbons with lower characteristics than the minimum required, in which  case the Sender shall pay all costs and expenses to improve the Hydrocarbon and to bring it to acceptable Transportation specifications for the  Transporter.',\n",
       "   'The Transporter reserves the right to reject any Transportation request in addition to the reasons mentioned during the nomination process  and the Transportation schedule, those coming from a Sender who has breached a Transportation contract, this Manual or any applicable  regulations, including but without being limited to:     11.1.1 Delivery of Hydrocarbons without the minimum quality specifications indicated in this Manual.     11.1.2 Failing to deliver sufficient Hydrocarbons to fill in the line in the proportion that corresponds,',\n",
       "   'The Transporter reserves the right to receive or reject a Hydrocarbon that fails to meet the minimum specified values; in case of reception,  the Sender shall Pay the Transporter any costs incurred in the analysis and eventual treatment of this Hydrocarbon to place it within the required  specifications or to implement the scheme required for its Transportation.',\n",
       "   'The minimum characteristics of the Hydrocarbon which must be included in the certificate are: Viscosity cST and SSU at 86F, 100F and  140F, gravity API at 60F, sulfur content, salt content, BSW, Acidity and Point of fluidity.'],\n",
       "  'answer_start': [124050,\n",
       "   47043,\n",
       "   91100,\n",
       "   145738,\n",
       "   84172,\n",
       "   92192,\n",
       "   89966,\n",
       "   109190,\n",
       "   91930]},\n",
       " {'text': ['Bases on the operating conditions of the \"Trasandino\" Pipeline, ECOPETROL shall only receive daily crude oil from the SENDER up to a maximum  equivalent to 12% of the total light crude received in the day at the Orito Plant.',\n",
       "   'Contracted Capacity: means the Capacity of the Pipeline committed through Transportation Contracts.'],\n",
       "  'answer_start': [1444, 51471]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Save the event of gross negligence or willful misconduct, pursuant to the provisions in this numeral 11.2, the responsibility of  ECOPETROL under the Contract hereof under no circumstance shall exceed seventy five per cent (75%) of the value of the Crude lost or  damaged by causes attributable to ECOPETROL.',\n",
       "   'Save the event of gross negligence or willful misconduct, if any claims arise by the SENDER such as the loss of profit, this shall not  exceed twenty five percent (25%) of the value that ECOPETROL is obliged to indemnify the SENDER under this numeral 11.2(d) of the  Contract hereof.'],\n",
       "  'answer_start': [20069, 21872]},\n",
       " {'text': ['In case of failing to fulfill the obligations of the SENDER as a result of any actions or illegal omissions or deviations from the Contract, the  SENDER agrees to pay ECOPETROL as a penalty, an amount equivalent to ten percent (10%) of the final value of the Contract.',\n",
       "   'The Transporter shall only accept extemporary nominations as long as the Pipeline  has available Capacity. If the nomination is accepted, the Third Party or Sender shall Pay to the Transporter as a penalty, two (2%) of the  applicable rate to the volumes in barrels delivered in the Pipeline in the respective month.'],\n",
       "  'answer_start': [24803, 84905]},\n",
       " {'text': ['For claims regarding the quantity or quality of Hydrocarbons, these shall be presented in writing at the latest within fifteen (15) calendar days  after the date of delivery or withdrawal of the Hydrocarbon or the date in which the report for the Volumetric Compensation for Quality is issued.'],\n",
       "  'answer_start': [122824]},\n",
       " {'text': ['Performance Insurance Policy Four thousand forty seven millions of Colombian pesos ($4.047.000.000)',\n",
       "   'Bonds and Insurance: the Transporter and the interested Senders in the Sole Risk Proposal shall obtain the necessary bonds and insurance  to cover any Risk derived from the Sole Risk Proposal under terms reasonably acceptable for the Transporter, without prejudice of obtaining all  other bonds and insurance requested by the Transporter.',\n",
       "   'The policy hereof shall not expire by failure of payment of the premium and said premium shall not be revocable in a unilateral manner neither by  the insurance company nor by the contractor.'],\n",
       "  'answer_start': [3001, 133483, 222290]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['NON-COMPETITION AGREEMENT AMENDMENT NO. 1'], 'answer_start': [62]},\n",
       " {'text': ['VIVINT SOLAR, INC.',\n",
       "   'together with its successors and permitted assigns, \"Vivint Solar\"',\n",
       "   'Each of Vivint Solar and Vivint may also be referred to herein individually as a \"Party\", and collectively as the \"Parties\".',\n",
       "   'together with its successors and permitted assigns \"Vivint\"',\n",
       "   'VIVINT, INC.'],\n",
       "  'answer_start': [177, 221, 390, 328, 294]},\n",
       " {'text': ['August 16, 2017'], 'answer_start': [145]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement will become effective on the Effective Date, and will continue until the expiration of the \"Sales Term\" as that term is defined in the Sales Dealer Agreement dated as of August 16, 2017 between Vivint and Vivint Solar Developer, LLC (the \"Term\").\"'],\n",
       "  'answer_start': [2179]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Strategic Alliance Agreement'], 'answer_start': [98]},\n",
       " {'text': ['Tsinghua Unigroup',\n",
       "   'ChipMOS TECHNOLOGIES INC.',\n",
       "   'Tsinghua Unigroup Ltd.',\n",
       "   'ChipMOS',\n",
       "   'ChipMOS and Tsinghua Unigroup shall collectively be referred to as the \"Parties.\"'],\n",
       "  'answer_start': [314, 222, 314, 222, 441]},\n",
       " {'text': ['11th day of December, 2015'], 'answer_start': [161]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Except as otherwise provided herein, the term of this Agreement is three (3) years from the Execution Date (\"Cooperation Period\").'],\n",
       "  'answer_start': [5145]},\n",
       " {'text': ['The Parties may negotiate for an extension of this Agreement six (6) months before the expiration of the Cooperation Period.'],\n",
       "  'answer_start': [5276]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['This Agreement shall be governed by, and construed in accordance with the laws of Taiwan.'],\n",
       "  'answer_start': [6632]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Neither Party shall assign any rights or obligations provided herein without the prior written consent of the other Party.'],\n",
       "  'answer_start': [8067]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['DISTRIBUTION AND DEVELOPMENT AGREEMENT'],\n",
       "  'answer_start': [106392]},\n",
       " {'text': ['Sekisui Diagnostics, LLC and its Affiliates',\n",
       "   'Sekisui',\n",
       "   'Qualigen, Inc. and its Affiliates',\n",
       "   'Qualigen'],\n",
       "  'answer_start': [174, 174, 348, 348]},\n",
       " {'text': ['May 1, 2016'], 'answer_start': [147]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless earlier terminated pursuant to Section 14 hereof (the \"Term\").'],\n",
       "  'answer_start': [9042]},\n",
       " {'text': ['The initial term of this Agreement and any renewal term thereof shall be automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this Agreement.'],\n",
       "  'answer_start': [9234]},\n",
       " {'text': ['The initial term of this Agreement and any renewal term thereof shall be automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this Agreement'],\n",
       "  'answer_start': [9234]},\n",
       " {'text': ['This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, without reference to its conflicts of laws principles.'],\n",
       "  'answer_start': [94573]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory.',\n",
       "   'Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the Products exclusively to Sekisui, in each case for the Territory.',\n",
       "   \"Qualigen shall supply Sekisui with all of Sekisui's commercial requirements for the Product in the Applicable Markets.\"],\n",
       "  'answer_start': [7996, 8408, 10843]},\n",
       " {'text': ['However, Qualigen shall not engage any distributors (whether exclusive or non-exclusive) other than Sekisui for the Qualigen Retained Customers',\n",
       "   'Sekisui shall not, and shall cause its subdistributors not to, market, rent or sell any Products to the Qualigen Retained Customers. 3. Supply;'],\n",
       "  'answer_start': [10534, 10679]},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': [], 'answer_start': []},\n",
       " {'text': ['Sekisui may terminate this Agreement upon prior written notice',\n",
       "   \"at any other time upon ninety (90) days' prior written notice of impending termination.\"],\n",
       "  'answer_start': [86618, 86844]},\n",
       " ...]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataset_original['test']['answers']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a34e615a14de46f782e9fbd534930d9d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map (num_proc=48):   0%|          | 0/1000 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d80f68f712d84ae18d59095cdec5937e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map (num_proc=48):   0%|          | 0/4182 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# import spacy\n",
    "from datasets import DatasetDict\n",
    "import os\n",
    "\n",
    "num_proc=os.cpu_count()\n",
    "\n",
    "from more_itertools import windowed\n",
    "# nlp = spacy.load(\"en_core_web_sm\")\n",
    "\n",
    "# def chunk_document(document):\n",
    "#     doc = nlp(document)\n",
    "#     sentences = [sent.text for sent in doc.sents]\n",
    "#     return sentences\n",
    "\n",
    "def process_record(record):\n",
    "    document_id = \"REFERENCE\"\n",
    "    document = record['context']\n",
    "    answers = record['answers']\n",
    "    answers = record['answers']\n",
    "    if len(answers['text']) > 0:\n",
    "        gold_text = \"Highlights:\\n\" + \"\\n\".join([f\"- {answer}\" for answer in answers['text']])\n",
    "    else:\n",
    "        gold_text = \"No Highlights\"\n",
    "    citations = [[document_id, document]]\n",
    "    # sentences = chunk_document(document)\n",
    "    # oracle_documents_passages = []\n",
    "    # # max limit of chunk - tells us number of words, fill in the sentences until max is reached\n",
    "    # for sentence in windowed(sentences, 5, fillvalue=\"\", step=2):\n",
    "    #     section = \" \".join([s for s in sentence if (s is not None and len(s.strip()) > 0)])\n",
    "    #     oracle_documents_passages.append([document_id, section])\n",
    "    \n",
    "    return {\n",
    "        'docid': str(record['id']),\n",
    "        'previous_text': record['question'],\n",
    "        'gold_text': gold_text,\n",
    "        'citations': citations,\n",
    "        # 'oracle_documents_passages': oracle_documents_passages,\n",
    "    }\n",
    "\n",
    "dataset_train = dataset_original['train'].select(range(1000))\n",
    "dataset_test = dataset_original['test']\n",
    "\n",
    "dataset = DatasetDict({\n",
    "    'train': dataset_train,\n",
    "    'test': dataset_test,\n",
    "})\n",
    "dataset = dataset.map(process_record, num_proc=num_proc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "44ec48a659f34eff8e96f67ee0db313e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Uploading the dataset shards:   0%|          | 0/1 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "347ae11413de48f1bbaa733b34feb7c2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Creating parquet from Arrow format:   0%|          | 0/1 [00:00<?, ?ba/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "234fd3c7326d4b6eb3c156c6ba42cabe",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Uploading the dataset shards:   0%|          | 0/1 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a00648f09e834265817017d0e00fb66c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Creating parquet from Arrow format:   0%|          | 0/5 [00:00<?, ?ba/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "CommitInfo(commit_url='https://huggingface.co/datasets/ylkhayat/CUAD-generation-workshop/commit/4bf0741a43e3380d63711f9eaa12481f21dcb741', commit_message='Upload dataset', commit_description='', oid='4bf0741a43e3380d63711f9eaa12481f21dcb741', pr_url=None, repo_url=RepoUrl('https://huggingface.co/datasets/ylkhayat/CUAD-generation-workshop', endpoint='https://huggingface.co', repo_type='dataset', repo_id='ylkhayat/CUAD-generation-workshop'), pr_revision=None, pr_num=None)"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "ename": "",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31mThe Kernel crashed while executing code in the current cell or a previous cell. \n",
      "\u001b[1;31mPlease review the code in the cell(s) to identify a possible cause of the failure. \n",
      "\u001b[1;31mClick <a href='https://aka.ms/vscodeJupyterKernelCrash'>here</a> for more info. \n",
      "\u001b[1;31mView Jupyter <a href='command:jupyter.viewOutput'>log</a> for further details."
     ]
    }
   ],
   "source": [
    "dataset = dataset.select_columns(['docid', 'previous_text', 'gold_text', 'citations'])\n",
    "dataset.push_to_hub('ylkhayat/CUAD-generation-workshop', data_dir='data')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset_train = dataset['train'].add_column('answers', dataset_original['train'].select(range(1000))['answers'])\n",
    "dataset_test = dataset['test'].add_column('answers', dataset_original['test']['answers'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cfed6621540e4c7f8e0ff34c859381ee",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map (num_proc=48):   0%|          | 0/1000 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ce9eeab167e44bd2a5c933f212a15fc8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map (num_proc=48):   0%|          | 0/4182 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "new_dataset = DatasetDict({\n",
    "    'train': dataset_train,\n",
    "    'test': dataset_test,\n",
    "})\n",
    "\n",
    "\n",
    "def process_record(record):\n",
    "    answers = record['answers']\n",
    "    if len(answers['text']) > 0:\n",
    "        gold_text = \"Highlights:\\n\" + \"\\n\".join([f\"- {answer}\" for answer in answers['text']])\n",
    "    else:\n",
    "        gold_text = \"No Highlights\"\n",
    "    return {\n",
    "        'gold_text': gold_text,\n",
    "    }\n",
    "    \n",
    "new_dataset = new_dataset.map(process_record, num_proc=num_proc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "new_dataset = new_dataset.select_columns(['docid', 'previous_text', 'gold_text', 'citations', 'oracle_documents_passages'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'docid': 'DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement__Anti-Assignment',\n",
       " 'previous_text': 'Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?',\n",
       " 'gold_text': \"Highlights:\\n- Any attempted assignment not in accordance with this Section 13.2 shall be void.\\n- Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment.\\n- Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant Activities with any Third Party (including any contract sales force).\\n- In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party.\",\n",
       " 'citations': [['REFERENCE',\n",
       "   'Exhibit 10.2\\n\\n______________________________________________________________________________\\n\\nCO-PROMOTION AGREEMENT\\n\\nby and between\\n\\nDOVA PHARMACEUTICALS, INC.\\n\\nand\\n\\nVALEANT PHARMACEUTICALS NORTH AMERICA LLC\\n\\nSeptember 26, 2018\\n\\n______________________________________________________________________________\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS\\n\\nPage\\n\\nARTICLE 1 DEFINITIONS 1\\n\\nARTICLE 2 RIGHTS AND OBLIGATIONS 8\\n\\n2.1 Engagement; Grant of Rights. 8\\n\\n2.2 Retention of Rights. 9\\n\\n2.3 Non-Competition; Non-Solicitation. 9\\n\\n2.4 Dova Trademarks and Copyrights. 10\\n\\nARTICLE 3 JOINT STEERING COMMITTEE 11\\n\\n3.1 Formation of the JSC. 11\\n\\n3.2 Meetings and Minutes. 11\\n\\n3.3 Purpose of the JSC. 11\\n\\n3.4 Decision Making. 13\\n\\n3.5 Marketing Sub-Committee. 13\\n\\nARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14\\n\\n4.1 Valeant Activities. 14\\n\\n4.2 Detailing. 15\\n\\n4.3 Compliance with Applicable Law. 17\\n\\n4.4 Field Force Personnel Training; Product Materials. 19\\n\\n4.5 Provisions Related to Field Force Personnel. 21\\n\\n4.6 Responsibility for Valeant Activity Costs and Expenses. 22\\n\\n4.7 Data Sharing. 22\\n\\nARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23\\n\\n5.1 Dova Responsibility. 23\\n\\n5.2 Valeant Involvement. 23\\n\\n5.3 Inspections. 23\\n\\n5.4 Pharmacovigilance. 24\\n\\n5.5 Unsolicited Requests for Medical Information. 24\\n\\n5.6 Recalls and Market Withdrawals. 25\\n\\n5.7 Certain Reporting Responsibilities. 25\\n\\n5.8 Booking of Sales Revenues. 25\\n\\n5.9 Returns. 25\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ni\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n5.10 Manufacturing; Distribution; Marketing. 25\\n\\nARTICLE 6 FINANCIAL PROVISIONS 26\\n\\n6.1 Promotion Fee. 26\\n\\n6.2 Milestone Payment. 27\\n\\n6.3 Reports; Payments. 27\\n\\n6.4 Taxes. 28\\n\\n6.5 Determination of Specialty. 29\\n\\nARTICLE 7 AUDIT RIGHTS 30\\n\\n7.1 Recordkeeping. 30\\n\\n7.2 Valeant Rights. 30\\n\\n7.3 Dova Rights. 31\\n\\nARTICLE 8 INTELLECTUAL PROPERTY 32\\n\\n8.1 Ownership of Intellectual Property. 32\\n\\n8.2 Title to Trademarks and Copyrights. 32\\n\\n8.3 Protection of Trademarks and Copyrights. 32\\n\\n8.4 Disclosure of Know-How. 33\\n\\nARTICLE 9 CONFIDENTIALITY 33\\n\\n9.1 Confidential Information. 33\\n\\n9.2 Public Announcements. 34\\n\\nARTICLE 10 REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS 35\\n\\n10.1 Representations and Warranties of Dova. 35\\n\\n10.2 Representations and Warranties of Valeant. 37\\n\\n10.3 Disclaimer of Warranty. 38\\n\\n10.4 Additional Covenants. 39\\n\\nARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39\\n\\n11.1 Indemnification by Dova. 39\\n\\n11.2 Indemnification by Valeant. 39\\n\\n11.3 Indemnification Procedures. 40\\n\\n11.4 Limitation of Liability. 40\\n\\n11.5 Insurance. 40\\n\\nARTICLE 12 TERM AND TERMINATION 41\\n\\n12.1 Term. 41\\n\\n12.2 Early Termination for Cause. 41\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.3 Other Early Termination. 42\\n\\n12.4 Effects of Termination. 42\\n\\n12.5 Tail Period. 42\\n\\nii\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n12.6 Survival. 43\\n\\nARTICLE 13 MISCELLANEOUS 43\\n\\n13.1 Force Majeure. 43\\n\\n13.2 Assignment. 43\\n\\n13.3 Severability. 44\\n\\n13.4 Notices. 44\\n\\n13.5 Governing Law. 45\\n\\n13.6 Dispute Resolution. 45\\n\\n13.7 Waiver of Jury Trial. 45\\n\\n13.8 Entire Agreement; Amendments. 46\\n\\n13.9 Headings. 46\\n\\n13.10 Independent Contractors. 46\\n\\n13.11 Third Party Beneficiaries. 46\\n\\n13.12 Waiver. 46\\n\\n13.13 Cumulative Remedies. 46\\n\\n13.14 Waiver of Rule of Construction. 46\\n\\n13.15 Use of Names. 46\\n\\n13.16 Further Actions and Documents. 47\\n\\n13.17 Certain Conventions. 47\\n\\n13.18 Counterparts. 47\\n\\niii\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nCO-PROMOTION AGREEMENT\\n\\nThis Co-Promotion Agreement (this \"Agreement\") is entered into and dated as of September 26, 2018 (the \"Effective Date\") by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova\"), and Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (\"Valeant\"). Dova and Valeant are each referred to individually as a \"Party\" and together as the \"Parties\".\\n\\nRECITALS\\n\\nWHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;\\n\\nWHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such activities, for the Product in the Territory;\\n\\nNOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 1   DEFINITIONS\\n\\n1.1 \"Act\" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C.  301 et seq., as it may be amended from time to time, and the regulations promulgated thereunder.\\n\\n1.2 \"Adverse Event\" shall mean any untoward medical occurrence in a patient or clinical investigation subject who is administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is used. An \"Adverse Event\" can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that worsened in severity after administration of the Product would be considered an \"Adverse Event\".\\n\\n1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting securities of such Person, by contract or otherwise.\\n\\n1.4 \"Agreement\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n1.5 \"Alliance Managers\" shall have the meaning set forth in Section 4.1.4.\\n\\n1.6 \"Alternate Product\" shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the Territory and that is part of the Salix business segment of Valeant\\'s parent company, Bausch Health Companies, Inc. (or, in the event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to the Product with regard to Target Professionals in the Specialty.\\n\\n1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this Agreement, including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C.  335a et seq.), the Anti- Kickback Statute (42 U.S.C.  1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal False Claims Act (31 U.S.C.  3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii) governing the provision of meals and other gifts to medical professionals, including pharmacists, or (iii) governing consumer\\n\\n2\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprotection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time to time.\\n\\n1.8 \"Business Day\" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in New York, New York, USA are closed.\\n\\n1.9 \"Calendar Quarter\" shall mean each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.\\n\\n1.10 \"Calendar Year\" shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.\\n\\n1.11 \"Claims\" shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority).\\n\\n1.12 \"Code\" shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.\\n\\n1.13 \"Compensation Report\" shall have the meaning set forth in Section 4.2.2(b).\\n\\n1.14 \"Compliance Manager\" shall have the meaning set forth in Section 4.3.9.\\n\\n1.15 \"Compliance Report\" shall have the meaning set forth in Section 4.2.2(c).\\n\\n1.16 \"Confidential Information\" shall mean all secret, confidential, non-public or proprietary Know-How, whether provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party pursuant to this Agreement, including information relating to the disclosing Party\\'s existing or proposed research, development efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such Party\\'s Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova\\'s Confidential Information shall include all Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this Agreement shall be considered Confidential Information of both Parties.\\n\\n1.17 \"Confidentiality Agreement\" shall have the meaning set forth in Section 9.1.1.\\n\\n3\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.18 \"Designated Product\" shall mean a specific pharmaceutical product marketed by Valeant which is agreed to in writing by the Parties on or prior to the Effective Date.\\n\\n1.19 \"Detail(s)\" shall mean a Product presentation during a face-to-face sales call between a Target Professional and a Sales Representative, during which a presentation of the Product\\'s attributes, benefits, prescribing information and safety information are orally presented, for use in the Field in the Territory. Neither e-details, nor presentations made at conventions, exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.\\n\\n1.20 \"Detail Report\" shall have the meaning set forth in Section 4.2.2.\\n\\n1.21 \"Dispute\" shall have the meaning set forth in Section 13.6.1.\\n\\n1.22 \"Dollar\" or \"$\" shall mean United States dollar.\\n\\n1.23 \"Dova Trademarks and Copyrights\" shall mean the logos, trade dress, slogans, domain names and housemarks of Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from time to time by Dova.\\n\\n1.24 \"Dova\\'s Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with which Dova enters into an agreement, at its cost.\\n\\n1.25 \"Effective Date\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable functions.\\n\\n1.27 \"Field\" shall mean the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and any and all additional indications for which the Product is approved in the Territory.\\n\\n1.28 \"Field Force Personnel\" shall mean collectively, the Sales Representatives, the members of the institutional account management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant engaged in the Valeant Activities.\\n\\n1.29 \"GAAP\" shall mean United States generally accepted accounting principles.\\n\\n1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member, which has competent and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this Agreement.\\n\\n4\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.31 \"Gross to Net Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as determined in accordance with Dova\\'s revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for quarterly financial reporting purposes, as reported in Dova\\'s quarterly filings with the U.S. Securities Exchange Commission.\\n\\n1.32 \"Indemnified Party\" shall have the meaning set forth in Section 11.3.\\n\\n1.33 \"Indemnifying Party\" shall have the meaning set forth in Section 11.3.\\n\\n1.34 \"Intellectual Property\" shall have the meaning set forth in Section 8.1.2.\\n\\n1.35 \"Intermediary\" shall mean any wholesaler or distributor who sells Product to Retail Pharmacies and Non-Retail Institutions, but not patients, and with which Dova (or its Affiliates) has entered into an agreement or otherwise has arrangements.\\n\\n1.36 \"Inventions\" shall have the meaning set forth in Section 8.1.2.\\n\\n1.37 \"JSC\" shall have the meaning set forth in Section 3.1.\\n\\n1.38 \"Know-How\" shall mean information, whether or not in written form, including biological, chemical, pharmacological, toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information, including processes, methods, procedures, techniques, plans, programs and data.\\n\\n1.39 \"Losses\" shall mean any and all amounts paid or payable to Third Parties with respect to a Claim (including any and all losses, damages, obligations, liabilities, fines, fees, penalties, awards, judgments, interest), together with all documented out-of- pocket costs and expenses, including attorney\\'s fees, reasonably incurred.\\n\\n1.40 \"Net Sales\" shall mean, for an applicable period, the aggregate amount, without duplication, equal to the Specialty Pharmacy Net Sales for each SKU, the Retail Net Sales for each SKU, if any, and the Non-Retail Net Sales for each SKU.\\n\\n1.41 \"Non-Retail Institution\" shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.\\n\\n1.42 \"Non-Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n5\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of Products shipped by Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions in the Territory during an applicable period (excluding any shipments in excess of one unit of either SKU shipped to such Non-Retail Institutions based on the initial orders from such Non-Retail Institutions):\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable Specialty Fraction for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iv) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n1.43 \"Party\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n1.44 \"Person\" shall mean any individual, corporation, partnership, limited liability company, association, joint-stock company, trust, unincorporated organization or other entity, or government or political subdivision thereof.\\n\\n1.45 \"Product\" shall mean the product approved pursuant to New Drug Application (NDA) No. 210238, as such approval may be supplemented from time to time (including by way of supplemental new drug application (sNDA)), currently marketed as DOPTELET (avatrombopag) in the Territory and shall include an authorized generic version of such Product.\\n\\n1.46 \"Product Labeling\" shall mean the labels and other written, printed or graphic matter upon (a) any container or wrapper utilized with the Product or (b) any written material accompanying the Product, including Product package inserts, in each case as approved by the FDA.\\n\\n1.47 \"Product Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n1.48 \"Product Training Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n1.49 \"Quarterly Average Sales Force Size\" shall have the meaning set forth in Section 4.2.2.\\n\\n1.50 \"Quarterly Minimum Details\" for an applicable Calendar Quarter shall mean [***].\\n\\n1.51 \"Regulatory Approval\" shall mean any and all necessary approvals, licenses, registrations or authorizations from any Governmental Authority, in each case, necessary to commercialize the Product in the Territory.\\n\\n1.52 \"Retail Pharmacy\" shall mean an outlet which dispenses the Product directly to a patient in a retail setting or through mail order services.\\n\\n6\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.53 \"Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n(i) the number of units of such SKU of the Product shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported by data aggregator) or such other data source with which Dova enters into an agreement at its cost),\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n1.54 \"Sales Representative\" shall mean an individual employed and compensated by Valeant as a full-time employee as part of its sales forces and who engages in Detailing of the Designated Product (or the Alternate Product, as the case may be) in the Territory, and who is also trained with respect to the Product in accordance with this Agreement (including the Product Labeling and the use of the Promotional Materials) to deliver Details for the Product in the Field in the Territory.\\n\\n1.55 \"Senior Officer\" shall mean, with respect to Dova, its President and Chief Executive Officer (or such officer\\'s designee), and with respect to Valeant, its [***] (or such officer\\'s designee). From time to time, each Party may change its Senior Officer by giving written notice to the other Party.\\n\\n1.56 \"Specialty\" shall mean (i) Target Professionals with a primary or secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology (excluding any such Target Professionals with a primary or secondary specialty designation of Hepatology (including Transplant Hepatology), in each case, as determined by data reported by Dova\\'s Third Party Data Source, subject to any adjustments determined pursuant to the process set out in Section 6.5, and (ii) all healthcare professionals with Nurse or Physician Assistant specialty designations affiliated with the Target Professionals described in subsection (i), as adjusted.\\n\\n1.57 \"Specialty Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, applicable), and (ii) the denominator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to all patients in the Territory (namely based on prescriptions written by the Specialty and outside the Specialty) (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable).\\n\\n1.58 \"Specialty Pharmacy Net Sales\" shall mean, for each SKU of the Product:\\n\\n7\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of the Product shipped from the Specialty Pharmacies to all patients based on prescriptions written by the Specialty in the Territory during an applicable period (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable); and\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n1.59 \"Specialty Pharmacy\" shall mean those specialty pharmacies to which Dova (or its Affiliates) sells and/or ships units of Product during the Term and for which Dova or its Affiliates have agreements with that include data provisions or provide for separate data agreements which enables Dova to track shipments of Product from such Specialty Pharmacy to patients based on the Target Professional prescribing such Product.\\n\\n1.60 \"Tail Period\" shall mean the period commencing on the day after the last day of the Term and ending on the earlier of (i) [***] and (ii) [***], unless terminated early pursuant to Section 2.3.1(a) of the Agreement.\\n\\n1.61 \"Target Professionals\" shall mean physicians, nurse practitioners, physician assistants and any other medical professionals in the Territory with prescribing authority (as authorized under Applicable Law) in the Territory for the Product.\\n\\n1.62 \"Term\" shall have the meaning set forth in Section 12.1.\\n\\n1.63 \"Territory\" shall mean the United States of America and its territories and possessions.\\n\\n1.64 \"Third Party(ies)\" shall mean any person or entity other than Dova and Valeant and their respective Affiliates.\\n\\n1.65 \"Third Party Agreements\" shall mean the agreements described on Schedule 1.65 hereto.\\n\\n1.66 \"Valeant Activities\" shall mean any and all promotional activities (including Detailing) conducted by Valeant to encourage the appropriate use of the Product in the Specialty in the Field in the Territory in accordance with the terms of this Agreement.\\n\\n1.67 \"Valeant Property\" shall have the meaning set forth in Section 8.1.1.\\n\\n1.68 \"WAC\" shall mean, for each SKU of the Product, Dova\\'s list price for a unit of the SKU of the Product to wholesalers or direct purchasers in the Territory, as reported in wholesale price guides or other nationally recognized publications of drug pricing data.\\n\\nARTICLE 2  RIGHTS AND OBLIGATIONS\\n\\n2.1 Engagement; Grant of Rights. During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant\\'s rights and obligations under this Section 2.1 are non-transferable, non-assignable, and non-delegable. Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant Activities with any Third Party (including any contract sales force). Any obligation of Valeant under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in part, at Valeant\\'s sole and exclusive option, either by Valeant or its Affiliates. Valeant guarantees the performance of all actions, agreements and obligations to be performed by its Affiliates under the terms and conditions of this Agreement. For clarity, Valeant shall not have any license rights hereunder nor any rights to sublicense any rights hereunder.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n2.2 Retention of Rights. Except with respect to the exclusive rights granted to Valeant to conduct the Valeant Activities for the Product in the Specialty in the Territory in the Field pursuant to Section 2.1 and, and if agreed upon, outside the Specialty in the Territory in the Field pursuant to Section 4.1.5, Dova retains all rights in and to the Product. Without limiting the generality of the foregoing (and without limiting Dova\\'s retained rights set forth in Section 2.1), Dova specifically retains the following rights (and Valeant and its Affiliates shall have no rights to the following, except as set forth below in this Section 2.2):\\n\\n2.2.1 responsibility for promoting the Product outside the Specialty;\\n\\n2.2.2 responsibility for the manufacture and distribution of the Product, and any future development of the Product;\\n\\n2.2.3 responsibility for all decisions regarding regulatory submissions and, except as expressly set forth herein, for interactions with any Governmental Authority, including but not limited to FDA, with respect to the Product;\\n\\n2.2.4 responsibility for final approval of all Product Materials content (including submission of Promotional Materials to FDA\\'s Office of Prescription Drug Promotion) with respect to the conduct of the Valeant Activities for Product, except as expressly set forth herein;\\n\\n2.2.5 selling and booking all sales of the Product; and\\n\\n2.2.6 responsibility for handling all safety related activities related to Product as set forth in ARTICLE 5 (including submitting all safety reports and interacting with Governmental Authorities with respect thereto) and initiating and managing any Product recalls.\\n\\nFor clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any license or other intellectual property interest, by implication or otherwise, in any technology, Know-How or other intellectual property owned or controlled by Dova or any of its Affiliates, and Dova is not providing any such technology, Know-How or other intellectual property, or any assistance related thereto, to Valeant for any use other than for the mutual benefit of the Parties as expressly contemplated hereby.\\n\\n2.3 Non-Competition; Non-Solicitation.\\n\\n2.3.1 Non-Competition. (a) [***], neither Valeant nor its Affiliates shall, directly or indirectly, [***] in the Territory other than the Product; provided that if the Agreement is terminated by Dova pursuant to [***], then any Tail Period shall be immediately terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in the Territory other than the Product during such Tail Period. Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].\\n\\n(a) [***], neither Dova nor is Affiliates shall, directly or indirectly, [***]. Notwithstanding the foregoing, this Section 2.3.1(b) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons[***].\\n\\n2.3.2 Non-Solicitation. [***], neither Valeant nor Dova (nor any of their respective Affiliates) shall directly or indirectly solicit for hire or employee as an employee, consultant or otherwise any of the other Party\\'s professional personnel who have had direct involvement with the JSC, with the Valeant Activities under this Agreement (which, in the case of Valeant, includes the Field Force Personnel) or with Dova\\'s commercialization activities for the Product, without the other Party\\'s prior written consent. Notwithstanding anything to the contrary, in no event shall the restrictions set forth in this Section 2.3.2 apply to [***].\\n\\n2.4 Dova Trademarks and Copyrights.\\n\\n2.4.1 Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement. Dova shall promptly notify Valeant of any updates or changes to the Dova Trademarks and Copyrights on the Product Materials, and Valeant shall thereafter solely use such updated Product Materials in performing its obligations under this Agreement. Valeant shall promptly notify Dova upon becoming aware of any violation of this Section 2.4.1.\\n\\n2.4.2 Valeant shall follow all instructions and guidelines of Dova (of which Dova has provided Valeant copies) in connection with the use of any Dova Trademarks and Copyrights, and, if Dova reasonably objects to the manner in which any such Dova Trademarks and Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and Copyrights in such manner upon written notice from Dova thereof. Without limiting the foregoing, Valeant shall also adhere to at least the same quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights. In all cases, Valeant shall use the Dova Trademarks and Copyrights with the necessary trademark (and copyright, as applicable) designations, and shall use the Dova Trademarks and Copyrights in a manner that does not derogate from Dova\\'s rights in the Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights. All goodwill and\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nimproved reputation generated by Valeant\\'s use of the Dova Trademarks and Copyrights shall inure to the benefit of Dova, and any use of the Dova Trademarks and Copyrights by Valeant shall cease at the end of the Term. Valeant shall have no rights under this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein. During the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor. During the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are confusingly similar to the Dova Trademarks and Copyrights.\\n\\nARTICLE 3  JOINT STEERING COMMITTEE\\n\\n3.1 Formation of the JSC. As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"JSC\") whose responsibilities during the Term shall be to oversee the activities set forth in Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule; provided, that, in any event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend meetings of the JSC; provided, that such attendees (i) shall not participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure equivalent to those set forth in ARTICLE 9.\\n\\n3.2 Meetings and Minutes. Meetings of the JSC may be called by either Party on no less than thirty (30) days\\' notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at least ten (10) days in advance to the applicable meeting; provided that under exigent circumstances requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty (30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.\\n\\n3.3 Purpose of the JSC. The purposes of the JSC shall be to, subject to Section 3.4:\\n\\n3.3.1 provide a forum to discuss and coordinate the Parties\\' activities under this Agreement;\\n\\n3.3.2 provide a forum to discuss and coordinate the promotion of the Product in the Territory, including in and outside the Specialty;\\n\\n3.3.3 provide a forum to discuss Product Materials (it being understood that the JSC shall not have the right to approve such Product Materials);\\n\\n3.3.4 facilitate the flow of information and otherwise promote the communications and collaboration within and among the Parties relating to this Agreement and the promotion of the Product;\\n\\n3.3.5 discuss planning and implementation of all Valeant Activities, including but not limited to training of Sales Representatives and, if agreed upon, the activities of the institutional account management team referred to in Section 4.1.5;\\n\\n3.3.6 decide on the acceptable form of and review and discuss the Detail Reports and reports of Net Sales;\\n\\n3.3.7 decide on the acceptable form of and review and discuss the Compensation Reports and the incentive compensation matters described in Section 4.1.3, including any applicable adjustments to the Product-related sales goals and targets of the Sales Representatives;\\n\\n3.3.8 review and discuss any matters brought to its attention by either Party\\'s Alliance Manager;\\n\\n3.3.9 review, discuss and decide on the Alternate Product described in Section 4.2.1(c) or any additional product that may be Detailed by Valeant described in Section 4.2.1(d);\\n\\n3.3.10 discuss the Promotional Materials matters described in Section 4.4.1(b);\\n\\n3.3.11 discuss supply or distribution issues relating to the Product, such as any supply shortages;\\n\\n3.3.12 discuss the pricing of the Product (provided that Dova shall have sole authority to determine pricing of the Product); Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n3.3.13 act as a first level escalation to address disagreements or disputes between the Parties;\\n\\n3.3.14 form and oversee any sub-committee or working group in furtherance of the activities contemplated by this Agreement;\\n\\n3.3.15 decide on the acceptable form of and review and discuss the Compliance Reports; and\\n\\n3.3.16 perform such other responsibilities as may be mutually agreed upon by the Parties in writing from time to time; provided, however, for clarity the JSC shall have no authority to amend or modify any provisions of this Agreement and no authority to waive or definitively interpret the provisions of this Agreement.\\n\\n3.4 Decision Making. Meetings of the JSC will occur only if at least one representative of each Party is present at the meeting. Each Party shall have one (1) vote. The JSC will use good faith efforts to reach consensus on all matters properly brought before it. If the JSC does not reach unanimous consensus on an issue at a meeting or within a period of [***] thereafter, then the JSC shall submit in writing the respective positions of the Parties to the Senior Officers of the Parties. Such Senior Officers shall use good faith efforts to resolve promptly such matter, which good faith efforts shall include at least one (1) teleconference between such Senior Officers within [***] after the JSC\\'s submission of such matter to them. Any final decision mutually agreed to in writing by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to agree on the resolution of any such issue within [***] after such issue was first referred to them, then (i) Valeant shall have the right to conclusively determine all matters related to Valeant Activities and Detailing of the Product, including matters relating to the institutional account manager team, the incentive compensation of the Sales Representatives and targeting for Details, provided that such determination and any related activities comply with the terms and conditions of this Agreement, and (ii) Dova shall have the right to conclusively determine all other matters; provided, however, for clarity any such determination shall not amend, modify or waive any provisions of this Agreement or definitively interpret the provisions of this Agreement.\\n\\n3.5 Marketing Sub-Committee.\\n\\n3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss, among other things:\\n\\n(a) the number of speaker programs for the Product to be conducted by Dova in each Calendar Year;\\n\\n(b) the Promotional Materials and quantities thereof;\\n\\n(c) the annual brand plan; and\\n\\n(d) the annual conference strategy.\\n\\n3.5.2 [***] shall constitute the \"Speaker Program Threshold\". If Dova wishes to conduct speaker programs in any Calendar Year after 2018 in excess of the Speaker Program Threshold, then the Parties shall meet, through the Marketing Sub-Committee, to discuss such excess speaker programs and the costs thereof. If the Marketing Sub-Committee unanimously agrees that such excess speaker programs should be conducted, then the following costs and expenses will be shared equally by the Parties: (i) the costs and expenses associated with conducting the excess number of speaker programs and (ii) the additional incremental costs and expenses associated with training necessary to address the number of the speaker programs above and below the Speaker Program Threshold. In addition, if the Parties unanimously agree that such excess speaker programs should be conducted, then, as a condition of the payment by Valeant of its share of such costs, Valeant shall have the right to review and approve (acting reasonably and in good faith) any such excess speaker programs, including with respect to the number of speakers approved to speak on the Product as part of the speaker programs, the rates paid to speakers at such speaker programs and the rules regarding attendees who may attend such speaker programs (including frequency of attendance). For greater certainty, if Valeant does not agree to conduct speaker programs above the Speaker Program Threshold, then the costs described herein for any speaker programs conducted by Dova in excess of the Speaker Program Threshold shall not be shared by the Parties, but shall be borne solely by Dova. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 3.5.2, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.\\n\\nARTICLE 4  VALEANT ACTIVITIES FOR THE PRODUCT\\n\\n4.1 Valeant Activities.\\n\\n4.1.1 General. Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTerritory in accordance with this Agreement.\\n\\n4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.\\n\\n4.1.3 Target Incentive Compensation. In addition, [***] and continuing throughout the remainder of the Term, Valeant shall ensure the incentive compensation package for each Sales Representatives requires that at least fifty percent (50%) of the target incentive compensation is derived from achieving target sales of the Product. On at least a quarterly basis, the Parties will meet, through the JSC, to review the target incentive compensation and the actual incentive compensation paid out to the Sales Representatives to discuss, in good faith, any appropriate adjustments to the sales targets and goals related to the Product (but not to the above-mentioned fifty percent (50%) threshold of the target incentive compensation), with the intent of achieving, on average, an actual payout to the Sales Representatives of 50% of their incentive compensation relating to sales of the Product.\\n\\n4.1.4 Alliance Managers. Each Party shall appoint a person who shall oversee interactions between the Parties for all matters related to this Agreement, and any related agreements between the Parties (each an \"Alliance Manager\"). The Alliance Managers shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as a single point of contact for all matters arising under this Agreement. The Alliance Managers shall have the right to attend all JSC meetings and if applicable, subcommittee meetings as non-voting participants and may bring to the attention of the JSC or, if applicable, subcommittee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. Each Party may designate different Alliance Mangers by notice in writing to the other Party.\\n\\n4.1.5 Institutional Account Management Team. Upon prior mutual agreement of the Parties in writing, Valeant may maintain a team of institutional account managers who, among other products, promote the Product in the Territory at liver transplant centers and large academic institutions only, and for purposes of this Section 4.1.5 only, both inside and outside the Specialty. Prior to any promotion of the Product by any institutional account managers, the Parties will discuss in good faith (acting reasonably) the number of institutional account managers that will promote the Product in the Territory, the appropriate portion of such institutional account managers\\' target incentive compensation to be derived from sales of the Product and the liver transplant centers or large academic institutions such institutional account managers will be responsible for. Such institutional account managers shall not be counted for purposes of determining the Quarterly Average Sales Force Size or the Quarterly Minimum Details. The Parties agree that these institutional account managers shall not be required to achieve any minimum number of Details. The Parties agree that such team may be added or removed by the mutual written agreement of the Parties without the need to amend this Agreement in accordance with Section 13.8.\\n\\n4.2 Detailing.\\n\\n4.2.1 Detail Requirements.\\n\\n(a) Commencing promptly upon completion of training of the Field Force Personnel that are engaged in Detailing the Product as described in Section 4.4.1 (but on the condition that Promotional Materials have been approved and delivered), Valeant shall deploy its Field Force Personnel that are engaged in Detailing to Detail the Product in accordance with the terms of this Agreement. Subject to compliance with the terms of this Agreement, Valeant shall be responsible, in its discretion, acting reasonably, for determining the manner in which it allocates and prioritizes the Details, provided that, in so allocating the Details, Valeant shall take into consideration geographic territory, frequency of calls, prescribing levels and other reasonable considerations. Except as set forth in this Agreement, without the prior written consent of Dova (not to be unreasonably withheld, delayed or conditioned), Valeant shall not conduct any Valeant Activities, other than Detailing, with respect to the Product.\\n\\n(b) [***]\\n\\n(c) Beginning after [***], Valeant may initiate discussions with Dova, upon at least [***] notice to Dova (which notice shall specify the proposed Alternate Product), regarding the potential replacement of the Designated Product with an Alternate Product. Following such notice period the Parties shall meet, through the JSC, and discuss in good faith (acting reasonably), for a period of up to [***], the potential replacement of the Designated Product with the Alternate Product. If the Parties agree on an Alternate Product, then the Parties shall make such agreement in writing and thereafter such Alternate Product shall be the Designated Product for purposes of this Agreement. If the Parties cannot agree on the Alternate Product during such period, then Valeant may give to Dova a written notice (the \"Alternate Product Notice\") designating the proposed Alternate Product as the Alternate Product and, effective [***] after the Alternate Product Notice, such designated Alternate Product shall be the Designated Product for purposes of this Agreement; provided however that, notwithstanding the foregoing, Dova shall have the right to terminate this Agreement upon [***] written notice to Valeant after the Alternate Product Notice, provided further that if the Alternate Product is being proposed by Valeant as a result of an anticipated or the existence of a generic version of the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nDesignated Product, a decision, judgment, ruling or other requirement of a Government Authority, including the FDA relating to or impacting the Designated Product in the Territory, a material safety concern regarding the Designated Product or a mandatory recall or withdrawal of the Designated Product, then Dova shall have no right to terminate this Agreement pursuant to this Section 4.2.1(c).\\n\\n(d) [***]\\n\\n(e) Notwithstanding the terms of this Section 4.2.1, Valeant shall have the right, from time to time, during the Term, to include in the incentive compensation package of all or some of the Sales Representatives a spiff, spiv or other similar incentive bonus that is based on [***], provided that the actual, maximum payout from such incentive bonuses does not exceed, in the aggregate, an amount equal to [***] for each Sales Representative for each Calendar Quarter. Any such spiff, spiv or other similar incentive bonus shall not be included in the calculation of the applicable Sales Representatives incentive compensation package in determining Valeant\\'s compliance with the terms of Section 4.1.3.\\n\\n4.2.2 Records and Reports.\\n\\n(a) Valeant shall keep accurate and complete records, consistent with pharmaceutical industry standards, of each Detail and its obligations hereunder in connection therewith. Such records shall be kept for the longer of (i) [***] after the end of the Calendar Year to which they relate and (ii) such period of time as required by Applicable Laws. Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Detail Report\"), setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such Calendar Quarter) (the \"Quarterly Average Sales Force Size\"), and (ii) the aggregate actual number of Details for the Product made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the Target Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.\\n\\n(b) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compensation Report\"), which describes (i) the details of the incentive compensation package of each Sales Representative as it relates to the Product and the Designated Product (or Alternate Product, as the case may be) (but, in the case of the Designated Product or Alternate Product, such details shall be limited to information regarding what portion of the Sales Representatives\\' target incentive compensation package is derived from achieving sales targets or goals of the Designated Product (or Alternate Product) , but shall not include any sales targets or goals for the Designated Product (or Alternate Product)), and (ii) the actual incentive compensation payouts for each Sales Representatives as described in Section 4.1.3. Through the JSC, the Parties shall agree on a mutually acceptable form of Compensation Report.\\n\\n(c) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compliance Report\"), which sets out a summary of Valeant\\'s compliance monitoring and auditing of the Field Force Personnel that are engaged in Detailing (as such monitoring is further described in Section 4.5.1(b)), a summary of any compliance-related disciplinary actions relating to any Field Force Personnel that are engaged in Detailing and any associated remedial actions, a summary of all compliance investigations conducted by Valeant of any of the Field Force Personnel that are engaged in Detailing and any associated outcome, and, for the fourth Calendar Quarter only, a summary of the compliance-related training (including a reasonable description of each training topic) received by each Field Force Personnel that are engaged in Detailing during the Calendar Year. Through the JSC, the Parties shall agree on a mutually acceptable form of Compliance Report.\\n\\n4.3 Compliance with Applicable Law.\\n\\n4.3.1 In conducting the Valeant Activities hereunder, Valeant shall, and shall require all Field Force Personnel to, comply in all respects with Applicable Laws. In addition, Dova shall, and shall require all of its sales representatives to, comply in all respects with Applicable Laws in connection with its promotion of the Product in the Territory.\\n\\n4.3.2 Neither Valeant nor Field Force Personnel shall offer, pay, solicit or receive any remuneration to or from Target Professionals, in order to induce referrals of or purchase of the Product.\\n\\n4.3.3 In performing the activities contemplated by this Agreement, neither Valeant nor Field Force Personnel shall make any payment, either directly or indirectly, of money or other assets to government or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing where such payment would constitute violation of any Applicable Law. In addition, Valeant shall not make any payment either directly or indirectly to officials if such payment is for the purpose of unlawfully influencing decisions or actions with respect to the subject matter of this Agreement.\\n\\n4.3.4 No employee of Valeant or its Affiliates shall have authority to give any direction, either written or oral,\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nrelating to the making of any commitment by Dova or its agents to any Third Party in violation of terms of this or any other provision of this Agreement\\n\\n4.3.5 Neither Valeant nor Dova shall undertake any activity under or in connection with this Agreement which violates any Applicable Law.\\n\\n4.3.6 Valeant\\'s or Dova\\'s material failure to abide by the provisions of this Section 4.3 shall be deemed a material breach of this Agreement by Valeant or Dova (as the case may be) and subject to the terms of Section 12.2 hereof.\\n\\n4.3.7 Dova shall ensure that any patient assistance program used in connection with the Product (and the services performed thereby in connection with the Product) shall be operated in accordance with Applicable Law. Notwithstanding the immediately preceding sentence, Dova shall have no liability with respect to any breach or non-compliance with Applicable Law relating to any patient assistance program used in connection with the Product to the extent caused by the act or omission of any Field Force Personnel, which act or omission is not in compliance with the terms of this Agreement, Applicable Law or instructions of Dova.\\n\\n4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support from Dova with respect to the Product.\\n\\n4.3.9 Dova shall ensure that its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product are in full compliance with all Applicable Laws.\\n\\n4.3.10 If, during the Term, Valeant becomes aware of a material violation or failure to comply with Applicable Law or the terms of this Agreement by a member of the Field Force Personnel that are engaged in Detailing, it shall promptly, but no later than two (2) Business Days after it becomes aware, notify Dova of such violation and, as promptly as possible thereafter, shall notify the steps it has taken or intends to take to remediate such violation.\\n\\n4.3.11 Compliance Managers. As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise (each, a \"Compliance Manager\"). From time to time, each Party may change its Compliance Manager by giving written notice to the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant\\'s compliance program policies and compliance training materials which are applicable to the Field Force Personnel\\'s promotion of the Product. Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection with the compliance-related provisions herein.\\n\\n4.4 Field Force Personnel Training; Product Materials.\\n\\n4.4.1 Training, Training Materials and Promotional Materials.\\n\\n(a) Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product training materials for Field Force Personnel (the \"Product Training Materials\") and (ii) all Product marketing and educational materials (the \"Promotional Materials\") (the Product Training Materials and the Promotional Materials, collectively, the \"Product Materials\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova, the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable in the promotion of the Product; provided that in any event, to the extent that Dova reasonably believes that such changes are not in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product Materials approved by Dova in the performance of Valeant Activities under this Agreement; provided, however, that Valeant shall not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprovided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as reasonably practical.\\n\\n(b) Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of Valeant regarding the Promotional Materials.\\n\\n(c) Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\\n\\n(d) Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the applicable provisions of the Code, and shall be trained on Valeant\\'s compliance policies, including those that are consistent with the applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\\n\\n(e) Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on- going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the pharmaceutical industry.\\n\\n4.4.2 Ownership of Product Materials. As between the Parties, Dova shall own all right, title and interest in and to any Product Materials (and all content contained therein) and any Product Labeling (and all content contained therein), including applicable copyrights and trademarks (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling), and to the extent Valeant (or any of its Affiliates) obtains or otherwise has a claim to any of the foregoing, Valeant hereby assigns (and shall cause any applicable Affiliate to assign) all of its right, title and interest in and to such Product Materials (and content) and Product Labeling (and content) (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling) to Dova and Valeant agrees to (and shall cause its applicable Affiliate to) execute all documents and take all actions as are reasonably requested by Dova to vest title to such Product Materials (and content) and Product Labeling (and content) in Dova (or its designated Affiliate).\\n\\n4.5 Provisions Related to Field Force Personnel.\\n\\n4.5.1 Activities of Field Force Personnel. Valeant hereby agrees and acknowledges that the following shall apply with respect to itself and the Field Force Personnel that are engaged in Detailing:\\n\\n(a) Valeant shall instruct and cause the Field Force Personnel that are engaged in Detailing to use only the Product Labeling and, subject to the terms of Section 4.4, Product Materials approved by Dova for the conduct of the Valeant Activities for the Product and consistent with Applicable Laws. Valeant shall instruct the Field Force Personnel that are engaged in Detailing to, and will monitor the Field Force Personnel that are engaged in Detailing to ensure that such Field Force Personnel, limit their claims of efficacy and safety for the Product to those claims which are consistent with and do not exceed the Product Labeling and any Promotional Materials.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) Valeant shall instruct the Field Force Personnel that are engaged in Detailing to conduct the Valeant Activities for the Product, and will monitor and audit (in accordance with Valeant\\'s standard practice) the Field Force Personnel that are engaged in Detailing so that such personnel conduct the Valeant Activities for the Product in adherence in all respects with Applicable Laws.\\n\\n(c) Valeant shall instruct the Field Force Personnel that are engaged in Detailing regarding provisions of this Agreement applicable to Details of the Product, including Section 4.2 and this Section 4.5.1.\\n\\n(d) Valeant acknowledges and agrees that Dova will not maintain or procure any worker\\'s compensation, healthcare, or other insurance for or on behalf of the Field Force Personnel, all of which shall be Valeant\\'s sole responsibility.\\n\\n(e) Valeant acknowledges and agrees that all Field Force Personnel are employees of Valeant and are not, and are not intended to be treated as, employees of Dova or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any \"employee benefit plans\" (as such term is defined in section 3(3) of ERISA) that are sponsored by Dova or any of its Affiliates or that are offered from time to time by Dova or its Affiliates to their own employees. All matters of compensation, benefits and other terms of employment for any such Field Force Personnel shall be solely a matter between Valeant and such individual. Dova shall not be responsible to Valeant, or to the Field Force Personnel, for any compensation, expense reimbursements or benefits (including vacation and holiday remuneration, healthcare coverage or insurance, life insurance, severance or termination of employment benefits, pension or profit-sharing benefits and disability benefits), payroll-related taxes or withholdings, or any governmental charges or benefits (including unemployment and disability insurance contributions or benefits and workmen\\'s compensation contributions or benefits) that may be imposed upon or be related to the performance by Valeant or such individuals of this Agreement, all of which shall be the sole responsibility of Valeant, even if it is subsequently determined by any Governmental Authority that any such individual may be an employee or a common law employee of Dova or any of its Affiliates or is otherwise entitled to such payments and benefits.\\n\\n(f) Valeant shall be solely responsible for the acts or omissions of the Field Force Personnel that are not in compliance with Applicable Law and the terms of this Agreement while performing any of the activities under this Agreement. Valeant shall be solely responsible and liable for all probationary and termination actions taken by it, as well as for the formulation, content and dissemination (including content) of all employment policies and rules (including written probationary and termination policies) applicable to its employees.\\n\\n4.5.2 Termination of Employment; Cessation of Valeant Activities. If any Field Force Personnel leaves the employ of Valeant (or any of its Affiliates), or otherwise ceases to conduct the Valeant Activities for the Product, Valeant shall, to the extent consistent with, and in a manner similar to, its practices with respect to departures of the sales representatives or other field force personnel, as applicable, promoting, marketing or detailing other products for Valeant, account for, and shall cause such departing Field Force Personnel to return to Valeant and delete from his/her computer files (to the extent such materials or information have been provided in, or converted into, electronic form) all materials relating to the Product that have been provided to such individual, including the Product Materials and account level information, including all copies of the foregoing.\\n\\n4.5.3 Discipline. If Dova has a reasonable basis for believing any member of the Field Force Personnel that are engaged in Detailing has violated any Applicable Laws, or failed to comply with this Agreement, then Dova shall notify Valeant of the alleged violation and Valeant shall promptly investigate the matter and, if the allegation turns out to be true, shall take the appropriate remedial action. Subject to the foregoing, Valeant shall be solely responsible for taking any disciplinary actions in connection with its Field Force Personnel that are engaged in Detailing. If, at any time, Dova has any other compliance-related concerns regarding any Field Force Personnel Detailing, Dova\\'s Compliance Manager shall notify Valeant\\'s Compliance Manager of such concerns in writing and the Compliance Managers will discuss and resolve such matters pursuant to Section 4.3.9.\\n\\n4.6 Responsibility for Valeant Activity Costs and Expenses. Other than as expressly set out herein, Valeant shall be solely responsible for any and all costs and expenses incurred by Valeant or any of its Affiliates in connection with the conduct of the Valeant Activities for the Product hereunder, including all costs and expenses in connection with Sales Representatives, including salaries, travel expenses and other expenses, credentialing, licensing, providing benefits, deducting federal, state and local payroll taxes, and paying workers\\' compensation premiums, unemployment insurance contributions and any other payments required by Applicable Laws to be made on behalf of employees.\\n\\n4.7 Data Sharing. Dova shall provide to Valeant certain information relating to the sale, commercialization, marketing and promotion of the Product, as may be mutually agreed by the Parties from time to time, for use by Valeant and the Field Force Personnel in connection with the Valeant Activities. Such information may include data from the applicable reimbursement HUB, specialty data aggregator, market research, and market access contracting and Third Party-provided brand performance data ([***]). The timing of the delivery of such information shall be mutually agreed upon by the Parties, acting reasonably.\\n\\nARTICLE 5  REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n5.1 Dova Responsibility. As between the Parties, except as expressly set out herein, all regulatory matters regarding the Product shall be the responsibility of Dova, including responsibility for all communications with Governmental Authorities, including but not limited to FDA, related to the Product, and Dova shall have sole responsibility to seek and/or obtain any necessary approvals of any Product Labeling and the Promotional Materials used in connection with the Product, and for determining whether the same requires approval. As between the Parties, Dova shall be responsible for any reporting of matters regarding the manufacture, sale or promotion of the Product (including Adverse Events) to or with the FDA and other relevant regulatory authorities, in accordance with Applicable Laws. Dova shall maintain, at its cost, the Regulatory Approvals for the Product and shall comply with all Applicable Law relevant to the conduct of Dova\\'s business with respect to the Product or pursuant to this Agreement, including, without limitation, all applicable requirements under the Act.\\n\\n5.2 Valeant Involvement. Except as expressly permitted herein, Valeant shall not, without Dova\\'s prior written consent, correspond or communicate with the FDA or with any other Governmental Authority concerning the Product, or otherwise take any action concerning any Regulatory Approval or other authorization under which the Product is marketed or sold. If not prohibited by any Government Authority or Applicable Law, Valeant shall provide to Dova, promptly upon receipt, copies of any communication from the FDA or other Governmental Authority related to the Product. If not prohibited by any Government Authority or Applicable Law, Dova has the right to review and comment on Valeant\\'s draft responses to any Governmental Authorities relevant to Detail of the Product prior to Valeant\\'s issuance of such response; and Valeant agrees to consider any comments or suggestions from Dova in good faith.\\n\\n5.3 Inspections.\\n\\n5.3.1 If not prohibited by any Government Authority or Applicable Law, Valeant shall notify Dova immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Valeant reasonably believes may impact any aspect of the Valeant Activities. If not prohibited by any Government Authority or Applicable Law, Dova shall have the right to have a representative present at any such portion of the inspection involving any Valeant Activities. In such cases, Valeant shall (i) keep Dova fully informed of the progress and status of any such inspection or investigation, (ii) prior to undertaking any action pursuant to this Section 5.3.1, notify Dova of the inspection or investigation, and disclose to Dova in writing the Governmental Authorities\\' assertions, findings and related results of such inspection or investigation pertaining to the Valeant Activities, and (iii) provide full disclosure to Dova with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.1 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n5.3.2 If not prohibited by any Government Authority or Applicable Law, Dova shall notify Valeant immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Dova reasonably believes may impact the Valeant Activities. In such cases, Dova shall (i) keep Valeant fully informed of the progress and status of any such inspection or investigation, (ii) disclose to Valeant in writing the Governmental Authorities\\' assertions, findings and related results of such inspection or investigation pertaining to the Product or its promotion, and (iii) provide full disclosure to Valeant with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.2 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n5.4 Pharmacovigilance. Subject to the terms of this Agreement, as soon as practicable following the Effective Date (but in no event later than [***]), Dova and Valeant (under the guidance of their respective pharmacovigilance departments, or equivalent thereof) shall identify and finalize the responsibilities the Parties shall employ to protect patients and promote their well- being in a separate safety data exchange agreement (\"Pharmacovigilance Agreement\"). These responsibilities shall include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication and exchange (as between the Parties) of safety information such as Adverse Events, lack of efficacy, misuse/abuse, and any other information concerning the safety of the Product. Such guidelines and procedures will be in accordance with, and enable the Parties and their Affiliates to fulfill, regulatory reporting obligations to Governmental Authorities. The Pharmacovigilance Agreement shall provide that: (i) Dova shall be responsible for all pharmacovigilance activities regarding the Product, including signal detection, medical surveillance, risk management, medical literature review and monitoring, Adverse Event reporting and responses to Governmental Authority requests or enquiries, and shall provide information related thereto to Valeant, and (ii) in the event Valeant receives safety information regarding the Product, or information regarding any safety-related regulatory request or inquiry, Valeant shall notify Dova as soon as practicable, but, in any event, within the timelines set forth in the Pharmacovigilance Agreement.\\n\\n5.5 Unsolicited Requests for Medical Information. Valeant shall direct to Dova any unsolicited requests for off-label medical information from health care professionals with respect to the Product promptly following receipt by Valeant (but in no\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nevent later than [***] after receipt). Dova shall, within [***] following receipt of any such request from Valeant, address any such requests directly.\\n\\n5.6 Recalls and Market Withdrawals. As between the Parties, Dova shall have the sole right to determine whether to implement, and to implement, a recall, field alert, withdrawal or other corrective action related to the Product. Dova shall bear the cost and expense of any such recall, field alert, withdrawal or other corrective action. Each Party shall promptly (but in any case, not later than [***]) notify the other Party in writing of any order, request or directive of a court or other Governmental Authority to recall or withdraw the Product.\\n\\n5.7 Certain Reporting Responsibilities. Notwithstanding the foregoing provisions of this ARTICLE 5, each Party shall be responsible for its own federal, state and local government pricing reporting and payment transparency reporting in the Territory arising from its Product promotional activities and related expenditures pursuant to Applicable Law. It is the intention of the Parties that any payments or transfer of value by a Party as it relates to the Product shall constitute transfers of value by that Party and such Party shall be responsible for the reporting described in the immediately preceding sentence. However, if a Party is deemed to have provided any payments or transfers of value to a Third Party on behalf of the other Party as it relates to the Product, then such Party shall provide to the other Party, in a format reasonably acceptable to such other Party, the data and other information on a timely basis (i.e., in the case of manual reporting of such data and other information, within [***] following the end of each Calendar Quarter, and, in the case of automated reporting of such data and other information, on a periodic basis during each Calendar Quarter as reasonably requested by such other Party) for such other Party\\'s reporting under the Physician Payments Sunshine Act and other Applicable Laws.\\n\\n5.8 Booking of Sales Revenues. Dova shall retain ownership of the rights to the Product and record on its books all revenues from sales of the Product. Dova shall be exclusively responsible for accepting and filling purchase orders, billing, and returns with respect to the Product. If Valeant receives an order for the Product, it shall promptly transmit such order to Dova (or its designee) for acceptance or rejection. Dova shall have sole responsibility for shipping, distribution and warehousing of Product, and for the invoicing and billing of purchasers of the Product and for the collection of receivables resulting from the sales of the Product in the Territory.\\n\\n5.9 Returns. Valeant is not authorized to accept any Product returns. Valeant shall advise any customer who attempts to return any Product to Valeant (or its Affiliates) that such Product must be shipped by the customer to the facility designated by Dova from time to time (and in accordance with other instructions provided by Dova). Dova shall provide to Valeant written instructions as to how Valeant should handle any Product that is actually physically returned to Valeant. Valeant shall take no other actions with respect to such return without the prior written consent of Dova.\\n\\n5.10 Manufacturing; Distribution; Marketing. Dova shall have the sole authority, at its cost, to manufacture, package, label, warehouse, sell and distribute the Product in the Territory. Dova shall use commercially reasonable efforts to cause sufficient quantities of the Product to be available in inventory to promptly fill orders throughout the Territory and otherwise meet the forecasted demand for the Product in the Territory. If, despite such efforts, there is insufficient supply of Product to meet demand, then Dova shall use commercially reasonable efforts to promptly address such insufficiency. Dova shall contractually require (and shall use commercially reasonable efforts to enforce such contractual provisions) that all Product is manufactured, shipped, sold and distributed in accordance with all Product specifications and all Applicable Law and that its contract manufacturers and/or suppliers of Product operate their facilities in accordance with Applicable Law. Dova shall ensure that all Product Labeling complies with the applicable Regulatory Approval for the Product and Applicable Law. Other than as set forth in this Agreement, Dova shall be responsible for all marketing of the Product in the Territory, provided that Dova shall continue to invest in marketing that is targeted towards the Specialty.\\n\\nARTICLE 6  FINANCIAL PROVISIONS\\n\\n6.1 Promotion Fee.\\n\\n6.1.1 Calculation of Promotion Fee. Commencing with the Calendar Quarter commencing on October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as follows:\\n\\n(a) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales;\\n\\n(b) For any portion of Net Sales in excess of [***] and up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales; and\\n\\n(c) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such portion of Net Sales.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n6.1.2 Adjustment of Promotion Fee. The percentages set forth in Section 6.1.1 [***] shall each be referred to as an \"Applicable Percentage\".\\n\\n(a) If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\\n\\n(b) If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\\n\\n(c) In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated under subsections (a) and (b).\\n\\n6.2 Milestone Payment. In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\\n\\n6.3 Reports; Payments.\\n\\n6.3.1 Quarterly Reports and Payments. Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii) the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries) to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for such Calendar Quarter). Within sixty (60) days after the end of each Calendar Quarter during the Term, Dova shall pay to Valeant the undisputed portion of the promotion fee payable in respect of such Net Sales in accordance with Section 6.1. If this Agreement terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.\\n\\n6.3.2 Monthly Reports. Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova\\'s good faith estimate of the Net Sales and the estimated promotion fee payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the promotion fee pursuant to Section 6.1.2). The Parties acknowledge and agree that the monthly reports will only set forth Dova\\'s good faith estimates of the items contained therein and are being provided to Valeant for information purposes only and shall not be determinative of the any amounts due hereunder.\\n\\n6.3.3 Disputes. Promptly upon receipt of the quarterly or monthly reports described in this Section 6.3, Valeant shall review such reports and, in the event that Valeant disputes any of the items described in such report, Valeant shall promptly notify Dova of any such disputes. The Parties shall meet promptly thereafter to attempt to resolve such disputes.\\n\\n6.3.4 Data for Net Sales. During the Term, in the event Dova (or its Affiliates) enters into agreements with any specialty pharmacies (other than Non-Retail Institutions) in order to sell and/or ship units of the Product directly to such specialty pharmacies, Dova shall use commercially reasonable efforts to include in the agreements provisions relating to the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales or shall use commercially reasonable efforts to enter into separate data agreements with such specialty pharmacies that provide for the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales.\\n\\n6.3.5 Manner of Payment. All payments under this Agreement shall be made in US Dollars by wire transfer or\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nACH to a bank account designated in writing by Valeant or Dova, as applicable, which shall be designated at least five (5) Business Days before such payment is due.\\n\\n6.3.6 Late Payments. If Valeant does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Valeant from the due date until the date of payment at the Prime Rate plus [***] or the maximum rate allowable by Applicable Law, whichever is less; provided, however, if it is discovered that any payment is past due as of the result of any audit conduct by Valeant pursuant to Section 7.2, such interest shall not accrue until [***] after the completion of such audit and not at the time the payment was originally due. Notwithstanding the foregoing, if the reason for any late payment is resulting from or arising out of any act or omission on the part of Valeant, including but not limited to any delay providing the requisite reports in Section 4.2.2, or the payment instructions pursuant to Section 6.3.4, such interest shall not accrue.\\n\\n6.4 Taxes. To the extent Dova is required to deduct and withhold taxes from any payment to Valeant, Dova shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Valeant an official tax receipt or other evidence of timely payment sufficient to enable Valeant to claim the payment of such taxes as a deduction or tax credit. Valeant may provide to Dova any tax forms that may be reasonably necessary in order for Dova to not withhold tax and Dova shall dispense with withholding, as applicable. Dova shall provide Valeant with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes.\\n\\n6.5 Determination of Specialty.\\n\\n6.5.1 No later than [***] (or in the case of the first full Calendar Quarter following the Effective Date, promptly following the Effective Date), Dova shall provide Valeant with a list of Target Professionals in the Territory, together with their primary and secondary specialty designation, as generated by Dova\\'s Third Party Data Source. Promptly following receipt by Valeant of such list, but no later than [***] after receipt of the list of Target Professionals, Valeant may present to Dova a list of Target Professionals that, acting in good faith, it reasonably believes have a primary specialty designation of or otherwise currently practice in the specialty of Gastroenterology, Colorectal Surgery or Proctology. For greater certainty, this list may include, but not be limited to, Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, for which Valeant wishes to confirm the primary specialty.\\n\\n6.5.2 Promptly following receipt by Dova of such list from Valeant, the Parties shall meet and discuss, acting reasonably and in good faith, such list and their appropriate primary specialty. If the parties agree that the Target Professional included on such list has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova\\'s Third Party Data Source for each such Target Professional, requesting that Dova\\'s Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional. In addition, if the Parties do not agree, but Valeant, acting reasonably and in good faith, still believes that the Target Professional has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova\\'s Third Party Data Source for each such Target Professional, requesting that Dova\\'s Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional. The Parties shall equally share in the incremental costs to Dova of any such investigations by Dova\\'s Third Party Data Source. For greater certainty, if, under Dova\\'s agreement with Dova\\'s Third Party Data Source, Dova is entitled to a certain number of investigations at no additional cost, and such investigations requested by Valeant causes Dova to incur additional costs that it would not have, but for such investigations requested by Valeant, then Valeant shall still be required to share in any costs of investigations (pursuant to Dova\\'s Third Party Data Source\\'s standard rates) that would otherwise be a no-cost investigations. In the event that Dova incurs costs for which Valeant is responsible under this Section 6.5, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.\\n\\n6.5.3 In the event that Dova\\'s Third Party Data Source agrees to conduct such investigation, and then based on the results of such investigation, Dova\\'s Third Party Data Source changes the primary designation of the Target Professional to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, confirms that the primary specialty designation should remain Gastroenterology, Colorectal Surgery or Proctology, then, commencing with the Calendar Quarter in which such investigations were conducted, such Target Professionals shall be deemed to be in the Specialty (regardless of whether their secondary specialty designation remains or becomes Hepatology). In the event that, following such investigation, Dova\\'s Third Party Data source does not change the primary specialty designation to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, changes the primary specialty designation to a specialty other than Gastroenterology, Colorectal Surgery or Proctology, then those Target Professionals shall be deemed not to be in the Specialty. For those Target Professionals that were not the subject of an inquiry to or an investigation by Dova\\'s Third Party Data Source, then the specialty designations set out in the original list generated by Dova\\'s Third Party Data Source shall apply for such Calendar Quarter, namely those Target Professionals that have either a\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprimary or a secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and that do not have either a primary or a secondary specialty designation of Hepatology shall be deemed to be in the Specialty.\\n\\n6.5.4 The process described in this Section 6.5 shall be repeated for each Calendar Quarter of the Term; provided, however, that, pursuant to the process described above, if Dova\\'s Third Party Data Source has confirmed that a Target Professional\\'s primary specialty designation should be or should remain Gastroenterology, Colorectal Surgery or Proctology, it is not necessary for Valeant to seek this confirmation in subsequent Calendar Quarters; provided, further, that, if Dova\\'s Third Party Data Source is subsequently updated (by Dova or any Third Party) to change the specialty designation (primary or secondary) of a Target Professional, pursuant to a request by Dova or a Third Party, then the process described in this Section 6.5 shall be repeated with respect to such Target Professional.\\n\\nARTICLE 7  AUDIT RIGHTS\\n\\n7.1 Recordkeeping. Each Party shall maintain complete and accurate books and records in sufficient detail, in accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable verification of the performance of such Party\\'s obligations under this Agreement and any payments due to a Party under this Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\\n\\n7.2 Valeant Rights. Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the applicable records and books maintained by Dova for purposes of verifying Dova\\'s payment obligations within this Agreement, including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder; provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Valeant shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant problems relating to Dova\\'s payment obligations hereunder. Dova shall reasonably cooperate in any such inspection or audit conducted by Valeant. Any undisputed adjustments required as a result of overpayments or underpayments identified through the exercise of audit rights shall be made by payment to the Party owed such adjustment within [***] after identification of such adjustment. Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\n7.3 Dova Rights. Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant\\'s compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant\\'s obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities. For purposes of clarity, any such inspection or audit described in this Section 7.3 shall be limited to only those books and records of Valeant that are applicable to Valeant\\'s performance of its obligations under this Agreement. Where necessary, on reasonable request, Dova\\'s audit rights shall include interviewing Sales Representatives and other employees of Valeant. Valeant shall reasonably cooperate in any such inspection or audit conducted by Dova. Any undisputed adjustments required as a result of overreporting the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter or the Quarterly Average Sales Force Size identified through the exercise of audit rights shall be made by payment by Valeant to Dova within [***] after identification of such adjustment. Dova shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed over- payment for that audited period in excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse Dova for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\nARTICLE 8  INTELLECTUAL PROPERTY\\n\\n8.1 Ownership of Intellectual Property.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n8.1.1 Valeant Property. Dova acknowledges that Valeant owns or is licensed to use certain Know-How relating to the proprietary sales and marketing information, methods and plans that has been independently developed or licensed by Valeant (such Know-How, the \"Valeant Property\"). The Parties agree that any improvement, enhancement or modification made, discovered, conceived, or reduced to practice by Valeant to any Valeant Property in performing its activities pursuant to this Agreement which is not primarily related to the Product, or which is not otherwise derived from the Confidential Information of Dova, shall be deemed Valeant Property. [***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova\\'s promotion or other commercialization of the Product in the Territory.\\n\\n8.1.2 Dova Property. Subject to the terms of Section 8.1.1, Dova shall have and retain sole and exclusive right, title and interest in and to all inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs, improvements and other technology, whether or not patentable or copyrightable, and any patent applications, patents, or copyrights based thereon (collectively, \"Intellectual Property\") relating to the Product that are (i) owned or controlled by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice or generated by Dova (or its employees or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice or generated by Valeant (or its employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily related to the Product or which is otherwise derived from the Confidential Information of Dova (\"Inventions\"). Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention. For clarity, any and all Inventions and any information contained therein or related thereto shall constitute Confidential Information of Dova.\\n\\n8.2 Title to Trademarks and Copyrights. The ownership, and all goodwill from the use, of any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the foregoing to Dova.\\n\\n8.3 Protection of Trademarks and Copyrights. As between the Parties, Dova shall have the sole right (but not the obligation), as determined by Dova in its sole discretion, to (i) maintain the Dova Trademarks and Copyrights and/or (ii) protect, enforce and defend the Dova Trademarks and Copyrights. Valeant shall give notice to Dova of any infringement of, or challenge to, the validity or enforceability of the Dova Trademarks and Copyrights promptly after learning of such infringement or challenge. If Dova institutes an action against Third Party infringers or takes action to defend the Dova Trademarks and Copyrights, Valeant shall reasonably cooperate with Dova, at Dova\\'s cost and expense. Any recovery obtained by Dova as a result of such proceeding or other actions, whether obtained by settlement or otherwise, shall be retained by Dova. Valeant shall not have any right to institute any action to defend or enforce the Dova Trademarks and Copyrights.\\n\\n8.4 Disclosure of Know-How. For clarity, the Parties hereby agree and acknowledge that to the extent that either Party hereto has disclosed, or in the future discloses, to the other Party any Know-How or other intellectual property of such Party or its Affiliates pursuant to this Agreement, the other Party shall not acquire any ownership rights in such Know-How or other intellectual property by virtue of this Agreement or otherwise, and as between the Parties, all ownership rights therein shall remain with the disclosing Party (or its Affiliate).\\n\\nARTICLE 9  CONFIDENTIALITY\\n\\n9.1 Confidential Information.\\n\\n9.1.1 Confidentiality and Non-Use. Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the other\\'s Confidential Information. Any and all information and materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality Agreement\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party\\'s Confidential Information that the receiving Party can demonstrate by competent tangible evidence:\\n\\n(a) was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;\\n\\n(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement;\\n\\n(d) was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate); or\\n\\n(e) was independently discovered or developed by the receiving Party or its Affiliate without access to or aid, application, use of the other Party\\'s Confidential Information, as evidenced by a contemporaneous writing.\\n\\n9.1.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party\\'s Confidential Information and the terms of this Agreement to the extent:\\n\\n(a) such disclosure is reasonably necessary (x) to comply with the requirements of Governmental Authorities; or (y) for the prosecuting or defending litigation as contemplated by this Agreement;\\n\\n(b) such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality and non-use; or\\n\\n(c) such disclosure is reasonably necessary to comply with Applicable Laws, including regulations promulgated by applicable securities exchanges, court order, administrative subpoena or order.\\n\\nNotwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party\\'s Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party\\'s cost) in obtaining, a protective order preventing or limiting the required disclosure.\\n\\n9.2 Public Announcements. The press release announcing the execution of this Agreement shall be issued in the form attached hereto as Exhibit A. No public announcement or statements (including presentations to investor meetings and customer updates) concerning the existence of or terms of this Agreement or incorporating the marks of the other Party or their respective Affiliates shall be made, either directly or indirectly, by either Party or a Party\\'s Affiliates, without first obtaining the written approval of the other Party and agreement upon the nature, text and timing of such announcement or disclosure. Either Party shall have the right to make any such public announcement or other disclosure required by Applicable Law after such Party has provided to the other Party a copy of such announcement or disclosure and an opportunity to comment thereon and the disclosing Party shall reasonably consider the other Party\\'s comments. Each Party agrees that it shall cooperate fully with the other with respect to all disclosures regarding this Agreement to the Securities Exchange Commission and any other Governmental Authorities, including requests for confidential treatment of proprietary information of either Party included in any such disclosure. Once any written statement is approved for disclosure by the Parties or information is otherwise made public in accordance with this Section 9.2, either Party may make a subsequent public disclosure of the same contents of such statement in the same context as such statement without further approval of the other Party. Notwithstanding anything to the contrary contained herein, in no event shall either Party disclose any financial information of the other without the prior written consent of such other Party, unless such financial information already has been publicly disclosed by the Party owning the financial information or otherwise has been made part of the public domain by no breach of a Party of its obligations under this ARTICLE 9.\\n\\n8\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 10  REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS\\n\\n10.1 Representations and Warranties of Dova. Dova represents and warrants to Valeant as of the Effective Date that:\\n\\n10.1.1 it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.1.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.1.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.1.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.1.5 the execution, delivery and performance of this Agreement by Dova does not require the consent of any Person (including under the Third Party Agreements) or the authorization of (by notice or otherwise) any Governmental Authority including the FDA;\\n\\n10.1.6 there is no action, suit or proceeding pending or, to the knowledge of Dova, threatened, against Dova or any of its Affiliates, or to the knowledge of Dova, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement, including its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product have been in compliance with all Applicable Laws;\\n\\n10.1.8 it has the right to market and sell the Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.1.9 it has the exclusive right to promote the Product in the Territory to the Target Professionals in the Specialty and the rights granted by it to Valeant hereunder do not conflict with any rights granted by Dova to any Third Party;\\n\\n10.1.10 to the knowledge of Dova, all manufacturing, stability testing, labeling, packaging, storing, shipping and distribution operations conducted by or on behalf of Dova relating to the commercial supply of the Product have been conducted in compliance with Applicable Law and it has no knowledge of any information indicating that Dova would be unable to manufacture and supply (or have manufactured and supplied) the Product in sufficient quantities to meet the reasonable demands in the Territory;\\n\\n10.1.11 it has no knowledge of any information relating to the safety or efficacy of the Product or any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Dova\\'s ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.12 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.1.13 each of the Third Party Agreements constitutes a valid and binding obligation of Dova or its Affiliate, as applicable, and is enforceable against Dova or its Affiliate, as applicable, and, to the knowledge of Dova, each of the Third Party Agreements constitutes a valid and binding obligation of the counterparty thereto and is enforceable against such counterparty, except in each case as may be limited by bankruptcy, insolvency, fraudulent transfer, moratorium, reorganization, preference or similar laws of general applicability relating to or affecting the rights of creditors generally and subject to general principles of equity (regardless of whether enforcement is sought in equity or at law). Dova or its Affiliate, as applicable, and to the knowledge of Dova, the applicable counterparty thereto, are not in material breach of or default under either of the Third Party Agreements. The\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncounterparty to each of the Third Party Agreements has not exercised or, to the knowledge of Dova, threatened in writing to exercise any termination right with respect to the applicable Third Party Agreement.\\n\\n10.1.14 neither Dova nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration\\'s List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Dova or any of its personnel becomes or is the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration\\'s List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Dova shall immediately notify Valeant, and Valeant shall have the option to prohibit such Person from performing work relating to this Agreement or the Product; and\\n\\n10.1.15 any patient assistance program used in connection with the Product used in connection with the Product have each been operated in accordance with Applicable Law.\\n\\n10.2 Representations and Warranties of Valeant. Valeant represents and warrants to Dova as of the Effective Date that:\\n\\n10.2.1 it is a limited liability company duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.2.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.2.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.2.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.2.5 the execution, delivery and performance of this Agreement by Valeant does not require the consent of any Person or the authorization of (by notice or otherwise) any Governmental Authority or the FDA;\\n\\n10.2.6 there is no action, suit or proceeding pending or, to the knowledge of Valeant, threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement;\\n\\n10.2.8 it has the right to market and sell the Designated Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.2.9 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.2.10 it has no knowledge of any information relating to any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Valeant\\'s ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.11 neither Valeant nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nexcluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration\\'s List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Valeant or any of its personnel become or are the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration\\'s List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Valeant shall immediately notify Dova, and Dova shall have the option to prohibit such Person from performing work under this Agreement; and\\n\\n10.2.12 all Field Force Personnel that are engaged in Detailing are, and will be, licensed to the extent required and in accordance with all Applicable Laws.\\n\\n10.3 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) MAKE NO REPRESENTATIONS AND NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) EACH SPECIFICALLY DISCLAIM ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY INTELLECTUAL PROPERTY OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.\\n\\n10.4 Additional Covenants.\\n\\n10.4.1 Initial Orders to Non-Retail Institutions. For initial orders of Product from Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions, Dova shall not engage in any \"channel stuffing\" or any similar program, activity or other action (including any rebate, discount, chargeback or refund policy or practice) that in each case is intended by Dova to result in purchases by the Non-Retail Institutions that are materially in excess of purchases in the ordinary course of business or that is intended to materially adversely impact Valeant\\'s promotion fee pursuant to this Agreement; provided, however, this Section10.4.1 shall not be applicable to any activity or action taken by Dova which applies to all or substantially all customers for the Product, or any activity or action taken by Dova in good faith and consistent with customary sales and marketing practices in the pharmaceutical industry.\\n\\n10.4.2 Third Party Agreements. Dova shall remain solely responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties on (or in connection with) the sale of Product in the Territory, including under the Third Party Agreements.\\n\\nARTICLE 11  INDEMNIFICATION; LIMITATIONS ON LIABILITY\\n\\n11.1 Indemnification by Dova. Dova shall defend, indemnify and hold harmless Valeant and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims, and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Dova under this Agreement, (b) the negligence, willful misconduct or violation of Applicable Laws by Dova (or any of its Affiliates or its or their respective officers, directors, employees, agents or representatives), (c) the infringement of the intellectual property rights of any Third Party in connection with the Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling or Product Materials in accordance with this Agreement, (d) death or personal injury to any person related to use of the Product, or (e) the failure to comply with Applicable Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501(c)(3) charitable foundation used in connection with the Product; except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Valeant is obligated to indemnify Dova pursuant to Section 11.2.\\n\\n11.2 Indemnification by Valeant. Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b) the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nofficers, directors, employees, agents or representatives); except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\\n\\n11.3 Indemnification Procedures. The Party seeking indemnification under Section 11.1 or 11.2, as applicable (the \"Indemnified Party\") shall give prompt notice to the Party against whom indemnity is sought (the \"Indemnifying Party\") of the assertion or commencement of any Claim in respect of which indemnity may be sought under Section 11.1 or 11.2, as applicable, and will provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request. The failure to give such notice will relieve the Indemnifying Party of any liability hereunder only to the extent that the Indemnifying Party has suffered actual prejudice thereby. The Indemnifying Party shall assume and control the defense and settlement of any such action, suit or proceeding at its own expense. The Indemnified Party shall, if requested by the Indemnifying Party, cooperate in all reasonable respects in such defense, at the Indemnifying Party\\'s expense. The Indemnified Party will be entitled at its own expense to participate in such defense and to employ separate counsel for such purpose. For so long as the Indemnifying Party is diligently defending any proceeding pursuant to this Section 11.3, the Indemnifying Party will not be liable under Section 11.1 or 11.2, as applicable, for any settlement effected without its consent. No Party shall enter into any compromise or settlement which commits the other Party to take, or to forbear to take, any action without the other Party\\'s prior written consent (and unless such compromise or settlement includes no payments by the Indemnified Party, an unconditional release of, and no admission of liability by, the Indemnified Party from all liability in respect of such Claim).\\n\\n11.4 Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY\\'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR (2) DAMAGES AVAILABLE FOR A PARTY\\'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 9.\\n\\n11.5 Insurance. Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated. Each Party shall provide reasonable written proof of the existence of such insurance to the other Party upon request. Dova does not and will not maintain or procure any worker\\'s compensation, healthcare, or other insurance for or on behalf of any Field Force Personnel, all of which shall be Valeant\\'s sole responsibility. For clarity, the insurance requirements of this Section 11.5 shall not be construed to create a limit of either Party\\'s liability with respect to its indemnification obligations under this ARTICLE 11.\\n\\nARTICLE 12  TERM AND TERMINATION\\n\\n12.1 Term. This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").\\n\\n12.2 Early Termination for Cause. A Party shall have the right to terminate this Agreement before the end of the Term as follows:\\n\\n12.2.1 by a Party upon written notice to the other Party in the event of a material breach of this Agreement by such other Party where such breach is not cured (if able to be cured) within [***] following such other Party\\'s receipt of written notice of such breach (and any such termination shall become effective at the end of such [***] period unless the breaching Party has cured such breach prior to the expiration of such [***] period);\\n\\n12.2.2 by Dova if the Quarterly Average Sales Force Size is less than [***] Sales Representatives for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the Quarterly Average Sales Force Size is less than [***] Sales Representatives;\\n\\n12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.2.4 by either Party upon [***] written notice to the other Party following the withdrawal of the Product from the market by Dova (or the decision by Dova to withdraw the Product from the market) due to (i) any decision, judgment, ruling or other requirement of the FDA, or (ii) material safety concern;\\n\\n12.2.5 by Dova upon [***] written notice to Valeant upon the cessation of marketing by Valeant of the Designated Product (or the Alternate Product in accordance with Section 4.2.1(c), as the case may be);\\n\\n12.2.6 by Dova pursuant to Section 4.2.1(c); and\\n\\n12.2.7 by a Party immediately upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to such other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by such other Party, or in the event a receiver or custodian is appointed for such other Party\\'s business or a substantial portion of such other Party\\'s business is subject to attachment or similar process; provided, however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.\\n\\n12.3 Other Early Termination.\\n\\n12.3.1 Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]); [***].\\n\\n12.3.2 Either Party shall have the right to terminate this Agreement before the end of the Term upon [***] written notice to the other Party delivered within [***] after the conclusion of any Calendar Quarter, beginning with the Calendar Quarter commencing on [***], in which the Net Sales in such Calendar Quarter are less [***] (and any such termination shall become effective at the end of such [***] period); provided that Valeant shall not have the right to terminate this Agreement pursuant to this Section 12.3.2 with respect to any Calendar Quarter for which the Quarterly Average Sales Force Size is less than [***] Sales Representatives.\\n\\n12.4 Effects of Termination. Upon the expiration or effective date of termination of this Agreement, (i) all rights and obligations of both Parties hereunder shall immediately terminate, subject to any survival as set forth in Sections 12.5 and 12.6, (ii) Valeant, at Dova\\'s direction, shall immediately return to Dova or destroy in accordance with all Applicable Laws all Product Materials, reports and other tangible items provided by or on behalf of Dova to Valeant or otherwise developed or obtained by Valeant pursuant to the terms of this Agreement (other than Valeant Property) (and at the request of Dova, Valeant shall certify destruction of such materials if Valeant does not to return such materials to Dova), (iii) Valeant shall immediately cease all Valeant Activities with respect to the Product, and (iv) each of Dova and Valeant shall, at the other Party\\'s direction, either return to such other Party or destroy all Confidential Information of such other Party. Notwithstanding the foregoing, each Party may retain archival copies of any Confidential Information to the extent required by law, regulation or professional standards or copies of Confidential Information created pursuant to the automatic backing-up of electronic files where the delivery or destruction of such files would cause undue hardship to the receiving Party, so long as any such archival or electronic file back-up copies are accessible only to its legal or IT personnel, provided that such Confidential Information will continue to be subject to the terms of this Agreement.\\n\\n12.5 Tail Period. Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated. Such payments shall be made within [***] following the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall apply, mutatis mutandis, to such Tail Period payments. For clarity, no tail payment shall be due following any expiration or termination of this Agreement except as set forth in this Section 12.5.\\n\\n12.6 Survival. Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement, such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6, Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and, solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\\n\\nARTICLE 13  MISCELLANEOUS\\n\\n13.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncaused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances and re-commence its performance hereunder as soon as practicable.\\n\\n13.2 Assignment. Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment. In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party\\'s written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party. Notwithstanding the foregoing, (a) either Party may, without the other Party\\'s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova\\'s assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. Any attempted assignment not in accordance with this Section 13.2 shall be void. This Agreement shall be binding on, and inure to the benefit of, each Party, and its permitted successors and assigns.\\n\\n13.3 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.\\n\\n13.4 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by e-mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier, or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:\\n\\nif to Dova, to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707 Attention: Chief Executive Officer Email: asapir@dova.com\\n\\nWith a copy to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707 Attention: General Counsel Email: mbanjak@dova.com\\n\\nif to Valeant, to: Valeant Pharmaceuticals North America LLC 400 Somerset Corporate Boulevard Bridgewater, NJ 08807 Attention: XXXXXXXXX Email: XXXXXXXX\\n\\nWith a copy to: XXXXXXXX Attention: XXXXXXXX Fax: XXXXXXXX Email: XXXXXXXX\\n\\nor to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered; (b) on the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nBusiness Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) Business Day following the date of mailing, if sent by mail.\\n\\n13.5 Governing Law. This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.\\n\\n13.6 Dispute Resolution.\\n\\n13.6.1 JSC; Escalation for Other Disputes. Except for disputes resolved by the procedures set forth in Section 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"Dispute\"), then either Party shall have the right to refer such dispute to the Senior Officers who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith negotiations. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. If such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\\n\\n13.6.2 Arbitration of Other Disputes. If a Dispute is not resolved by the Senior Officers pursuant to Section 13.6.1, such Dispute shall be submitted to and finally settled by [***] The Parties hereby submit to the exclusive jurisdiction of the federal and state courts located in [***] for the purposes of an order to compel arbitration, for preliminary relief in aid of arbitration and for a preliminary injunction to maintain the status quo or prevent irreparable harm prior to the appointment of the arbitrators and to the non-exclusive jurisdiction of such courts for the enforcement of any ward issued hereunder.\\n\\n13.7 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.\\n\\n13.8 Entire Agreement; Amendments. This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof (including the Confidentiality Agreement, but solely with respect to information which is deemed Confidential Information hereunder) are superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto.\\n\\n13.9 Headings. The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof.\\n\\n13.10 Independent Contractors. It is expressly agreed that Valeant and Dova shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.\\n\\n13.11 Third Party Beneficiaries. Except as set forth in ARTICLE 11, no Person other than Dova or Valeant (and their respective Affiliates and permitted successors and assignees hereunder) shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.\\n\\n13.12 Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.\\n\\n13.13 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.\\n\\n13.14 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.\\n\\n13.15 Use of Names. Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement.\\n\\n13.16 Further Actions and Documents. Each Party agrees to execute, acknowledge and deliver all such further\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ninstruments, and to do all such further acts, as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.\\n\\n13.17 Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as \"herein\", \"hereof\", and \"hereunder\" refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term \"including\" (or \"includes\"), such term shall be deemed to mean \"including without limitation\" (or \"includes without limitations\"), and (e) references to any Articles or Sections include Sections and subsections that are part of the references\\' Article or Section (e.g., a section numbered \"Section 2.2.1\" would be part of \"Section 2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section 2.2.1\").\\n\\n13.18 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or electronic mail (including pdf) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes and shall have the same force and effect as original signatures.\\n\\n[signature page follows]\\n\\n[Signature page to Co-Promotion Agreement]\\n\\nIN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.\\n\\nDOVA PHARMACEUTICALS, INC.\\n\\nBy: __/s/ Alex C. Sapir______________________\\n\\nName: Alex C. Sapir\\n\\nTitle: CEO\\n\\nVALEANT PHARMACEUTICALS NORTH AMERICA LLC\\n\\nBy: ___/s/ Joseph C. Papa_______________\\n\\nName: Joseph C. Papa\\n\\nTitle: Chief Executive Officer and President\\n\\n9\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nEXHIBIT A\\n\\nJoint Press Release\\n\\nDURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (\"Dova\") (DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (\"Salix\"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that they have entered into an exclusive agreement to co-promote Dova\\'s DOPTELET (avatrombopag) in the United States (U.S.). The U.S. Food and Drug Administration (\"FDA\") approved DOPTELET on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. DOPTELET represents the first thrombopoietin (TPO) receptor agonist approved in the United States for this indication.\\n\\nThrombocytopenia, a condition in which patients have a low platelet count, is the most common hematological abnormality in patients with CLD that often worsens with the severity of liver disease. It is estimated that approximately 15 percent of the 7.5 million patients with CLD have some form of thrombocytopenia. In a study published in 2010, patients with severe thrombocytopenia (<75,000/L) had a 31 percent incidence of procedure-related bleeding. As a result of the associated increased rate of bleeding, there is an increased risk for the CLD patient when undergoing common scheduled medical procedures such as liver biopsy, colonoscopy, endoscopy, and routine dental procedures.\\n\\nAs part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals. The Salix sales force will begin selling DOPTELET in mid-October 2018. Dova will continue its commercial efforts targeting primarily hepatologists and interventional radiologists and certain other specialties. Pursuant to the agreement, Dova will pay Salix a quarterly fee based on net sales (as defined in the agreement) of DOPTELET prescribed by gastroenterologists in the U.S.\\n\\n\"We are delighted to be working with Salix, a company considered by many to have the preeminent gastroenterology sales force in the United States,\" said Alex C. Sapir, president and chief executive officer, Dova Pharmaceuticals. \"Given Salix\\'s presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to DOPTELET and to patients.\"\\n\\n\"Salix considers liver disease a strategic therapeutic area of focus, given our history and knowledge with XIFAXAN (rifaximin), an innovative medicine indicated for the treatment of overt hepatic encephalopathy (HE), a condition that is often a consequence of chronic liver disease,\" said Mark McKenna, president, Salix Pharmaceuticals. \"Adding DOPTELET to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet need in the marketplace.\"\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nAbout DOPTELET  DOPTELET (avatrombopag) is a second generation, once daily, orally administered TPO receptor agonist approved for the treatment of thrombocytopenia in adult patients with CLD who are scheduled to undergo a procedure. DOPTELET is designed to mimic the effects of TPO, the primary regulator of normal platelet production.\\n\\nTwo global Phase 3, double-blind, placebo-controlled trials (ADAPT-1 [N=231] and ADAPT-2 [N=204]), conducted in adults with thrombocytopenia (platelet count of less than 50,000/L) and CLD, supported the FDA approval. Patients were assigned to either 40 mg or 60 mg of avatrombopag daily for five days based on their Baseline platelet counts (40 to <50,000/mL or <40,000/mL, respectively). Avatrombopag was shown to be superior to placebo in increasing the proportion of patients not requiring platelet transfusions or rescue procedures for bleeding up to seven days following a scheduled procedure in both trials in both the 40 mg (ADAPT-1, 88% vs. 38%, p <0.0001; ADAPT-2, 88% vs. 33%; p<0.0001), and 60 mg (ADAPT-1, 66% vs. 23%, p <0.0001; ADAPT-2, 69% vs. 35%; p=0.0006) treatment groups. Avatrombopag was also superior to placebo at the two secondary efficacy endpoints in each trial. In the avatrombopag treatment groups, there was an increased proportion of patients achieving the target platelet count of 50,000/mL on procedure day, and a greater magnitude of the change in mean platelet count from baseline to procedure day; all treatment differences between the avatrombopag and placebo treatment groups for each secondary endpoint were highly statistically significant with p values <0.0001. The most common adverse reactions with avatrombopag included pyrexia, abdominal pain, nausea, headache, fatigue and edema peripheral. Portal vein thromboses have been reported in patients with CLD and in patients receiving TPO receptor agonists. One treatment-emergent event of portal vein thrombosis was reported in the ADAPT trials in an avatrombopag-treated patient.\\n\\nINDICATION\\n\\nDOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.\\n\\nIMPORTANT SAFETY INFORMATION\\n\\nWARNINGS AND PRECAUTIONS\\n\\nDOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was one treatment- emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET.\\n\\nConsider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).\\n\\nDOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.\\n\\nCONTRAINDICATIONS: None\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nADVERSE REACTIONS\\n\\nMost common adverse reactions ( 3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.\\n\\nPlease see full Prescribing Information for DOPTELET (avatrombopag) www.doptelet.com\\n\\nAbout XIFAXAN  XIFAXAN is a nonsystemic* antibiotic that slows the growth of bacteria in the gut that are believed to be linked to symptoms of overt hepatic encephalopathy (HE). It has been proven to reduce the risk of overt HE recurrence and HE-related hospitalizations in adults.\\n\\n*There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.\\n\\nINDICATION  XIFAXAN (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.\\n\\nIMPORTANT SAFETY INFORMATION\\n\\nXIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.\\n\\nIf you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.\\n\\nTalk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.\\n\\nTell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.\\n\\nIn clinical studies, the most common side effects of XIFAXAN were: HE: Peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen)  IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes\\n\\nXIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if you are taking warfarin because the dose of warfarin may need to be adjusted to maintain proper blood-thinning effect.\\n\\nIf you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800- FDA-1088.\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nFor product information, adverse event reports, and product complaint reports, please contact:  Salix Product Information Call Center  Phone: 1-800-321-4576  Fax: 1-510-595-8183  Email: salixmc@dlss.com  Please click here for full Prescribing Information.\\n\\nAbout Dova Pharmaceuticals, Inc.  Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova\\'s proprietary pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia in adult patients with CLD scheduled to undergo a procedure.\\n\\nAbout Salix  Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed, and marketed innovative products to improve patients\\' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.\\n\\nAbout Bausch Health  Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people\\'s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.\\n\\nDova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \"anticipated\", \"believe\", \"expect\", \"may\", \"plan\", \"potential\", \"will\", and similar expressions, and are based on Dova\\'s current beliefs and expectations. These forward-looking statements include the potential benefits of the collaboration, the timing of the Salix sales force beginning to sell DOPTELET and other information relating to the transaction between Dova and Salix. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Dova\\'s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Dova\\'s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2018, and Dova\\'s other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nof the date of this release, and Dova assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.\\n\\nBausch Health Forward-looking Statements  This news release may contain forward-looking statements, which may generally be identified by the use of the words \"anticipates,\" \"expects,\" \"intends,\" \"plans,\" \"should,\" \"could,\" \"would,\" \"may,\" \"will,\" \"believes,\" \"estimates,\" \"potential,\" \"target,\" or \"continue\" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Bausch Health\\'s most recent annual or quarterly report and detailed from time to time in Bausch Health\\'s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Bausch Health believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health and Salix undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.\\n\\nDova Investor Contacts:  Mark W. Hahn  Chief Financial Officer  mhahn@dova.com  (919) 338-7936\\n\\nSalix Investor Contact:  Arthur Shannon  Arthur.Shannon@bauschhealth.com  514-856-3855  877-281-6642 (toll free)\\n\\nWestwicke Partners  John Woolford  john.woolford@westwicke.com  (443) 213-0506\\n\\nSalix Media Contacts:  Lainie Keller  Lainie.Keller@bauschhealth.com  908-927-0617\\n\\nKaren Paff\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nKaren.Paff@salix.com  908-927-1190\\n\\nAkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc., is the exclusive licensee and distributor of DOPTELET in the United States and its territories. 2018  DOPTELET is a registered trademark of AkaRx, Inc.\\n\\nPM-US-DOP-0072\\n\\nThe Xifaxan 550 mg product and the Xifaxan trademark are licensed by Alfasigma S.p.A.to Salix Pharmaceuticals or its affiliates.\\n\\nSAL.0103.USA.18\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nSchedule 1.65\\n\\nThird Party Agreements\\n\\n1. Stock Purchase Agreement dated March 29, 2016 (as amended) between PBM AKX Holdings, LLC and Eisai, Inc.\\n\\n2. License Agreement dated August 15, 2005 (as amended) between Astellas Pharma Inc. and AkaRx, Inc.\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018']],\n",
       " 'oracle_documents_passages': [['REFERENCE',\n",
       "   'Exhibit 10.2\\n\\n______________________________________________________________________________\\n\\nCO-PROMOTION AGREEMENT\\n\\nby and between\\n\\nDOVA PHARMACEUTICALS, INC.\\n\\nand\\n\\nVALEANT PHARMACEUTICALS NORTH AMERICA LLC\\n\\nSeptember 26, 2018\\n\\n______________________________________________________________________________\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS\\n\\nPage\\n\\nARTICLE 1 DEFINITIONS 1\\n\\nARTICLE 2 RIGHTS AND OBLIGATIONS 8\\n\\n2.1 Engagement; Grant of Rights. 8\\n\\n2.2 Retention of Rights.'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS\\n\\nPage\\n\\nARTICLE 1 DEFINITIONS 1\\n\\nARTICLE 2 RIGHTS AND OBLIGATIONS 8\\n\\n2.1 Engagement; Grant of Rights. 8\\n\\n2.2 Retention of Rights. 9\\n\\n2.3 Non-Competition; Non-Solicitation. 9\\n\\n2.4 Dova Trademarks and Copyrights. 10\\n\\nARTICLE 3 JOINT STEERING COMMITTEE 11\\n\\n3.1 Formation of the JSC. 11\\n\\n3.2 Meetings and Minutes.'],\n",
       "  ['REFERENCE',\n",
       "   '8\\n\\n2.2 Retention of Rights. 9\\n\\n2.3 Non-Competition; Non-Solicitation. 9\\n\\n2.4 Dova Trademarks and Copyrights. 10\\n\\nARTICLE 3 JOINT STEERING COMMITTEE 11\\n\\n3.1 Formation of the JSC. 11\\n\\n3.2 Meetings and Minutes. 11\\n\\n3.3 Purpose of the JSC. 11\\n\\n3.4 Decision Making. 13\\n\\n3.5 Marketing Sub-Committee.'],\n",
       "  ['REFERENCE',\n",
       "   '10\\n\\nARTICLE 3 JOINT STEERING COMMITTEE 11\\n\\n3.1 Formation of the JSC. 11\\n\\n3.2 Meetings and Minutes. 11\\n\\n3.3 Purpose of the JSC. 11\\n\\n3.4 Decision Making. 13\\n\\n3.5 Marketing Sub-Committee. 13\\n\\nARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14\\n\\n4.1 Valeant Activities. 14\\n\\n4.2 Detailing.'],\n",
       "  ['REFERENCE',\n",
       "   '13\\n\\n3.5 Marketing Sub-Committee. 13\\n\\nARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14\\n\\n4.1 Valeant Activities. 14\\n\\n4.2 Detailing. 15\\n\\n4.3 Compliance with Applicable Law. 17\\n\\n4.4 Field Force Personnel Training; Product Materials.'],\n",
       "  ['REFERENCE',\n",
       "   '14\\n\\n4.2 Detailing. 15\\n\\n4.3 Compliance with Applicable Law. 17\\n\\n4.4 Field Force Personnel Training; Product Materials. 19\\n\\n4.5 Provisions Related to Field Force Personnel. 21\\n\\n4.6 Responsibility for Valeant Activity Costs and Expenses.'],\n",
       "  ['REFERENCE',\n",
       "   '17\\n\\n4.4 Field Force Personnel Training; Product Materials. 19\\n\\n4.5 Provisions Related to Field Force Personnel. 21\\n\\n4.6 Responsibility for Valeant Activity Costs and Expenses. 22\\n\\n4.7 Data Sharing. 22\\n\\nARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23\\n\\n5.1 Dova Responsibility.'],\n",
       "  ['REFERENCE',\n",
       "   '21\\n\\n4.6 Responsibility for Valeant Activity Costs and Expenses. 22\\n\\n4.7 Data Sharing. 22\\n\\nARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23\\n\\n5.1 Dova Responsibility. 23\\n\\n5.2 Valeant Involvement. 23\\n\\n5.3 Inspections.'],\n",
       "  ['REFERENCE',\n",
       "   '22\\n\\nARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23\\n\\n5.1 Dova Responsibility. 23\\n\\n5.2 Valeant Involvement. 23\\n\\n5.3 Inspections. 23\\n\\n5.4 Pharmacovigilance. 24\\n\\n5.5 Unsolicited Requests for Medical Information.'],\n",
       "  ['REFERENCE',\n",
       "   '23\\n\\n5.3 Inspections. 23\\n\\n5.4 Pharmacovigilance. 24\\n\\n5.5 Unsolicited Requests for Medical Information. 24\\n\\n5.6 Recalls and Market Withdrawals. 25\\n\\n5.7 Certain Reporting Responsibilities.'],\n",
       "  ['REFERENCE',\n",
       "   '24\\n\\n5.5 Unsolicited Requests for Medical Information. 24\\n\\n5.6 Recalls and Market Withdrawals. 25\\n\\n5.7 Certain Reporting Responsibilities. 25\\n\\n5.8 Booking of Sales Revenues. 25\\n\\n5.9 Returns.'],\n",
       "  ['REFERENCE',\n",
       "   '25\\n\\n5.7 Certain Reporting Responsibilities. 25\\n\\n5.8 Booking of Sales Revenues. 25\\n\\n5.9 Returns. 25\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ni\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   '25\\n\\n5.9 Returns. 25\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ni\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n5.10 Manufacturing; Distribution; Marketing.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n5.10 Manufacturing; Distribution; Marketing. 25\\n\\nARTICLE 6 FINANCIAL PROVISIONS 26\\n\\n6.1 Promotion Fee. 26\\n\\n6.2 Milestone Payment. 27\\n\\n6.3 Reports; Payments.'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n5.10 Manufacturing; Distribution; Marketing. 25\\n\\nARTICLE 6 FINANCIAL PROVISIONS 26\\n\\n6.1 Promotion Fee. 26\\n\\n6.2 Milestone Payment. 27\\n\\n6.3 Reports; Payments. 27\\n\\n6.4 Taxes. 28\\n\\n6.5 Determination of Specialty.'],\n",
       "  ['REFERENCE',\n",
       "   '27\\n\\n6.3 Reports; Payments. 27\\n\\n6.4 Taxes. 28\\n\\n6.5 Determination of Specialty. 29\\n\\nARTICLE 7 AUDIT RIGHTS 30\\n\\n7.1 Recordkeeping. 30\\n\\n7.2 Valeant Rights.'],\n",
       "  ['REFERENCE',\n",
       "   '28\\n\\n6.5 Determination of Specialty. 29\\n\\nARTICLE 7 AUDIT RIGHTS 30\\n\\n7.1 Recordkeeping. 30\\n\\n7.2 Valeant Rights. 30\\n\\n7.3 Dova Rights. 31\\n\\nARTICLE 8 INTELLECTUAL PROPERTY 32\\n\\n8.1 Ownership of Intellectual Property.'],\n",
       "  ['REFERENCE',\n",
       "   '30\\n\\n7.2 Valeant Rights. 30\\n\\n7.3 Dova Rights. 31\\n\\nARTICLE 8 INTELLECTUAL PROPERTY 32\\n\\n8.1 Ownership of Intellectual Property. 32\\n\\n8.2 Title to Trademarks and Copyrights. 32\\n\\n8.3 Protection of Trademarks and Copyrights.'],\n",
       "  ['REFERENCE',\n",
       "   '31\\n\\nARTICLE 8 INTELLECTUAL PROPERTY 32\\n\\n8.1 Ownership of Intellectual Property. 32\\n\\n8.2 Title to Trademarks and Copyrights. 32\\n\\n8.3 Protection of Trademarks and Copyrights. 32\\n\\n8.4 Disclosure of Know-How. 33\\n\\nARTICLE 9 CONFIDENTIALITY 33\\n\\n9.1 Confidential Information. 33\\n\\n9.2 Public Announcements.'],\n",
       "  ['REFERENCE',\n",
       "   '32\\n\\n8.3 Protection of Trademarks and Copyrights. 32\\n\\n8.4 Disclosure of Know-How. 33\\n\\nARTICLE 9 CONFIDENTIALITY 33\\n\\n9.1 Confidential Information. 33\\n\\n9.2 Public Announcements. 34\\n\\nARTICLE 10 REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS 35\\n\\n10.1 Representations and Warranties of Dova. 35\\n\\n10.2 Representations and Warranties of Valeant. 37\\n\\n10.3 Disclaimer of Warranty.'],\n",
       "  ['REFERENCE',\n",
       "   '33\\n\\n9.2 Public Announcements. 34\\n\\nARTICLE 10 REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS 35\\n\\n10.1 Representations and Warranties of Dova. 35\\n\\n10.2 Representations and Warranties of Valeant. 37\\n\\n10.3 Disclaimer of Warranty. 38\\n\\n10.4 Additional Covenants. 39\\n\\nARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39\\n\\n11.1 Indemnification by Dova. 39\\n\\n11.2 Indemnification by Valeant.'],\n",
       "  ['REFERENCE',\n",
       "   '37\\n\\n10.3 Disclaimer of Warranty. 38\\n\\n10.4 Additional Covenants. 39\\n\\nARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39\\n\\n11.1 Indemnification by Dova. 39\\n\\n11.2 Indemnification by Valeant. 39\\n\\n11.3 Indemnification Procedures. 40\\n\\n11.4 Limitation of Liability.'],\n",
       "  ['REFERENCE',\n",
       "   '39\\n\\nARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39\\n\\n11.1 Indemnification by Dova. 39\\n\\n11.2 Indemnification by Valeant. 39\\n\\n11.3 Indemnification Procedures. 40\\n\\n11.4 Limitation of Liability. 40\\n\\n11.5 Insurance. 40\\n\\nARTICLE 12 TERM AND TERMINATION 41\\n\\n12.1 Term.'],\n",
       "  ['REFERENCE',\n",
       "   '40\\n\\n11.4 Limitation of Liability. 40\\n\\n11.5 Insurance. 40\\n\\nARTICLE 12 TERM AND TERMINATION 41\\n\\n12.1 Term. 41\\n\\n12.2 Early Termination for Cause. 41\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.3 Other Early Termination.'],\n",
       "  ['REFERENCE',\n",
       "   '40\\n\\nARTICLE 12 TERM AND TERMINATION 41\\n\\n12.1 Term. 41\\n\\n12.2 Early Termination for Cause. 41\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.3 Other Early Termination. 42\\n\\n12.4 Effects of Termination. 42\\n\\n12.5 Tail Period.'],\n",
       "  ['REFERENCE',\n",
       "   '41\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.3 Other Early Termination. 42\\n\\n12.4 Effects of Termination. 42\\n\\n12.5 Tail Period. 42\\n\\nii\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   '42\\n\\n12.5 Tail Period. 42\\n\\nii\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n12.6 Survival.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n12.6 Survival. 43\\n\\nARTICLE 13 MISCELLANEOUS 43\\n\\n13.1 Force Majeure. 43\\n\\n13.2 Assignment.'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTABLE OF CONTENTS (continued)\\n\\n12.6 Survival. 43\\n\\nARTICLE 13 MISCELLANEOUS 43\\n\\n13.1 Force Majeure. 43\\n\\n13.2 Assignment. 43\\n\\n13.3 Severability. 44\\n\\n13.4 Notices.'],\n",
       "  ['REFERENCE',\n",
       "   '43\\n\\n13.2 Assignment. 43\\n\\n13.3 Severability. 44\\n\\n13.4 Notices. 44\\n\\n13.5 Governing Law. 45\\n\\n13.6 Dispute Resolution.'],\n",
       "  ['REFERENCE',\n",
       "   '44\\n\\n13.4 Notices. 44\\n\\n13.5 Governing Law. 45\\n\\n13.6 Dispute Resolution. 45\\n\\n13.7 Waiver of Jury Trial. 45\\n\\n13.8 Entire Agreement; Amendments.'],\n",
       "  ['REFERENCE',\n",
       "   '45\\n\\n13.6 Dispute Resolution. 45\\n\\n13.7 Waiver of Jury Trial. 45\\n\\n13.8 Entire Agreement; Amendments. 46\\n\\n13.9 Headings. 46\\n\\n13.10 Independent Contractors.'],\n",
       "  ['REFERENCE',\n",
       "   '45\\n\\n13.8 Entire Agreement; Amendments. 46\\n\\n13.9 Headings. 46\\n\\n13.10 Independent Contractors. 46\\n\\n13.11 Third Party Beneficiaries. 46\\n\\n13.12 Waiver.'],\n",
       "  ['REFERENCE',\n",
       "   '46\\n\\n13.10 Independent Contractors. 46\\n\\n13.11 Third Party Beneficiaries. 46\\n\\n13.12 Waiver. 46\\n\\n13.13 Cumulative Remedies. 46\\n\\n13.14 Waiver of Rule of Construction.'],\n",
       "  ['REFERENCE',\n",
       "   '46\\n\\n13.12 Waiver. 46\\n\\n13.13 Cumulative Remedies. 46\\n\\n13.14 Waiver of Rule of Construction. 46\\n\\n13.15 Use of Names. 46\\n\\n13.16 Further Actions and Documents.'],\n",
       "  ['REFERENCE',\n",
       "   '46\\n\\n13.14 Waiver of Rule of Construction. 46\\n\\n13.15 Use of Names. 46\\n\\n13.16 Further Actions and Documents. 47\\n\\n13.17 Certain Conventions. 47\\n\\n13.18 Counterparts.'],\n",
       "  ['REFERENCE',\n",
       "   '46\\n\\n13.16 Further Actions and Documents. 47\\n\\n13.17 Certain Conventions. 47\\n\\n13.18 Counterparts. 47\\n\\niii\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   '47\\n\\n13.18 Counterparts. 47\\n\\niii\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nCO-PROMOTION AGREEMENT\\n\\nThis Co-Promotion Agreement (this \"Agreement\") is entered into and dated as of September 26, 2018 (the \"Effective Date\") by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova\"), and Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (\"Valeant\").'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nCO-PROMOTION AGREEMENT\\n\\nThis Co-Promotion Agreement (this \"Agreement\") is entered into and dated as of September 26, 2018 (the \"Effective Date\") by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova\"), and Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (\"Valeant\"). Dova and Valeant are each referred to individually as a \"Party\" and together as the \"Parties\".\\n\\n RECITALS\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nCO-PROMOTION AGREEMENT\\n\\nThis Co-Promotion Agreement (this \"Agreement\") is entered into and dated as of September 26, 2018 (the \"Effective Date\") by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova\"), and Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (\"Valeant\"). Dova and Valeant are each referred to individually as a \"Party\" and together as the \"Parties\".\\n\\n RECITALS\\n\\n WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;\\n\\nWHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such activities, for the Product in the Territory;\\n\\nNOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   'RECITALS\\n\\n WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;\\n\\nWHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such activities, for the Product in the Territory;\\n\\nNOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 1   DEFINITIONS\\n\\n1.1 \"Act\" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C.  301 et seq., as it may be amended from time to time, and the regulations promulgated thereunder.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 1   DEFINITIONS\\n\\n1.1 \"Act\" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C.  301 et seq., as it may be amended from time to time, and the regulations promulgated thereunder.\\n\\n 1.2 \"Adverse Event\" shall mean any untoward medical occurrence in a patient or clinical investigation subject who is administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is used. An \"Adverse Event\" can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the Product, whether or not related to the Product.'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 1   DEFINITIONS\\n\\n1.1 \"Act\" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C.  301 et seq., as it may be amended from time to time, and the regulations promulgated thereunder.\\n\\n 1.2 \"Adverse Event\" shall mean any untoward medical occurrence in a patient or clinical investigation subject who is administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is used. An \"Adverse Event\" can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that worsened in severity after administration of the Product would be considered an \"Adverse Event\".\\n\\n 1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person.'],\n",
       "  ['REFERENCE',\n",
       "   'An \"Adverse Event\" can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that worsened in severity after administration of the Product would be considered an \"Adverse Event\".\\n\\n 1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting securities of such Person, by contract or otherwise.\\n\\n 1.4 \"Agreement\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting securities of such Person, by contract or otherwise.\\n\\n 1.4 \"Agreement\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n 1.5 \"Alliance Managers\" shall have the meaning set forth in Section 4.1.4.\\n\\n 1.6 \"Alternate Product\" shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the Territory and that is part of the Salix business segment of Valeant\\'s parent company, Bausch Health Companies, Inc. (or, in the event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to the Product with regard to Target Professionals in the Specialty.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.4 \"Agreement\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n 1.5 \"Alliance Managers\" shall have the meaning set forth in Section 4.1.4.\\n\\n 1.6 \"Alternate Product\" shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the Territory and that is part of the Salix business segment of Valeant\\'s parent company, Bausch Health Companies, Inc. (or, in the event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to the Product with regard to Target Professionals in the Specialty.\\n\\n 1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this Agreement, including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C.  335a et seq.), the Anti- Kickback Statute (42 U.S.C.  1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal False Claims Act (31 U.S.C.  3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii) governing the provision of meals and other gifts to medical professionals, including pharmacists, or (iii) governing consumer\\n\\n2\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   '1.6 \"Alternate Product\" shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the Territory and that is part of the Salix business segment of Valeant\\'s parent company, Bausch Health Companies, Inc. (or, in the event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to the Product with regard to Target Professionals in the Specialty.\\n\\n 1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this Agreement, including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C.  335a et seq.), the Anti- Kickback Statute (42 U.S.C.  1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal False Claims Act (31 U.S.C.  3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii) governing the provision of meals and other gifts to medical professionals, including pharmacists, or (iii) governing consumer\\n\\n2\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprotection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time to time.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprotection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time to time.\\n\\n 1.8 \"Business Day\" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in New York, New York, USA are closed.\\n\\n 1.9 \"Calendar Quarter\" shall mean each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprotection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time to time.\\n\\n 1.8 \"Business Day\" means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in New York, New York, USA are closed.\\n\\n 1.9 \"Calendar Quarter\" shall mean each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.\\n\\n 1.10 \"Calendar Year\" shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.\\n\\n 1.11 \"Claims\" shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority).\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.9 \"Calendar Quarter\" shall mean each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.\\n\\n 1.10 \"Calendar Year\" shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.\\n\\n 1.11 \"Claims\" shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority).\\n\\n 1.12 \"Code\" shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.\\n\\n 1.13 \"Compensation Report\" shall have the meaning set forth in Section 4.2.2(b).\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.11 \"Claims\" shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority).\\n\\n 1.12 \"Code\" shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.\\n\\n 1.13 \"Compensation Report\" shall have the meaning set forth in Section 4.2.2(b).\\n\\n 1.14 \"Compliance Manager\" shall have the meaning set forth in Section 4.3.9.\\n\\n 1.15 \"Compliance Report\" shall have the meaning set forth in Section 4.2.2(c).\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.13 \"Compensation Report\" shall have the meaning set forth in Section 4.2.2(b).\\n\\n 1.14 \"Compliance Manager\" shall have the meaning set forth in Section 4.3.9.\\n\\n 1.15 \"Compliance Report\" shall have the meaning set forth in Section 4.2.2(c).\\n\\n 1.16 \"Confidential Information\" shall mean all secret, confidential, non-public or proprietary Know-How, whether provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party pursuant to this Agreement, including information relating to the disclosing Party\\'s existing or proposed research, development efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such Party\\'s Confidential Information disclosed hereunder.'],\n",
       "  ['REFERENCE',\n",
       "   '1.15 \"Compliance Report\" shall have the meaning set forth in Section 4.2.2(c).\\n\\n 1.16 \"Confidential Information\" shall mean all secret, confidential, non-public or proprietary Know-How, whether provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party pursuant to this Agreement, including information relating to the disclosing Party\\'s existing or proposed research, development efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such Party\\'s Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova\\'s Confidential Information shall include all Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this Agreement shall be considered Confidential Information of both Parties.\\n\\n 1.17 \"Confidentiality Agreement\" shall have the meaning set forth in Section 9.1.1.\\n\\n3\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   'All such information related to this Agreement disclosed by or on behalf of a Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such Party\\'s Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova\\'s Confidential Information shall include all Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this Agreement shall be considered Confidential Information of both Parties.\\n\\n 1.17 \"Confidentiality Agreement\" shall have the meaning set forth in Section 9.1.1.\\n\\n3\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED'],\n",
       "  ['REFERENCE',\n",
       "   '1.17 \"Confidentiality Agreement\" shall have the meaning set forth in Section 9.1.1.\\n\\n3\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.18 \"Designated Product\" shall mean a specific pharmaceutical product marketed by Valeant which is agreed to in writing by the Parties on or prior to the Effective Date.\\n\\n1.19 \"Detail(s)\" shall mean a Product presentation during a face-to-face sales call between a Target Professional and a Sales Representative, during which a presentation of the Product\\'s attributes, benefits, prescribing information and safety information are orally presented, for use in the Field in the Territory. Neither e-details, nor presentations made at conventions, exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.18 \"Designated Product\" shall mean a specific pharmaceutical product marketed by Valeant which is agreed to in writing by the Parties on or prior to the Effective Date.\\n\\n1.19 \"Detail(s)\" shall mean a Product presentation during a face-to-face sales call between a Target Professional and a Sales Representative, during which a presentation of the Product\\'s attributes, benefits, prescribing information and safety information are orally presented, for use in the Field in the Territory. Neither e-details, nor presentations made at conventions, exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.\\n\\n 1.20 \"Detail Report\" shall have the meaning set forth in Section 4.2.2.\\n\\n1.21 \"Dispute\" shall have the meaning set forth in Section 13.6.1.\\n\\n 1.22 \"Dollar\" or \"$\" shall mean United States dollar.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Neither e-details, nor presentations made at conventions, exhibit booths, a sample drop, educational programs or speaker meetings, or similar gatherings, shall constitute a Detail.\\n\\n 1.20 \"Detail Report\" shall have the meaning set forth in Section 4.2.2.\\n\\n1.21 \"Dispute\" shall have the meaning set forth in Section 13.6.1.\\n\\n 1.22 \"Dollar\" or \"$\" shall mean United States dollar.\\n\\n 1.23 \"Dova Trademarks and Copyrights\" shall mean the logos, trade dress, slogans, domain names and housemarks of Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from time to time by Dova.\\n\\n1.24 \"Dova\\'s Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with which Dova enters into an agreement, at its cost.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.22 \"Dollar\" or \"$\" shall mean United States dollar.\\n\\n 1.23 \"Dova Trademarks and Copyrights\" shall mean the logos, trade dress, slogans, domain names and housemarks of Dova or any of its Affiliates as may appear on any Product Materials or Product Labeling, in each case, as may be updated from time to time by Dova.\\n\\n1.24 \"Dova\\'s Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with which Dova enters into an agreement, at its cost.\\n\\n 1.25 \"Effective Date\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n 1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable functions.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '\"Dova\\'s Third Party Data Source\" shall mean [***] or such other data source as selected by Dova and with which Dova enters into an agreement, at its cost.\\n\\n 1.25 \"Effective Date\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n 1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable functions.\\n\\n 1.27 \"Field\" shall mean the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and any and all additional indications for which the Product is approved in the Territory.\\n\\n 1.28 \"Field Force Personnel\" shall mean collectively, the Sales Representatives, the members of the institutional account management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant engaged in the Valeant Activities.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.26 \"FDA\" shall mean the United States Food and Drug Administration or any successor agency performing comparable functions.\\n\\n 1.27 \"Field\" shall mean the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and any and all additional indications for which the Product is approved in the Territory.\\n\\n 1.28 \"Field Force Personnel\" shall mean collectively, the Sales Representatives, the members of the institutional account management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant engaged in the Valeant Activities.\\n\\n 1.29 \"GAAP\" shall mean United States generally accepted accounting principles.\\n\\n 1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member, which has competent and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this Agreement.\\n\\n4\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   '1.28 \"Field Force Personnel\" shall mean collectively, the Sales Representatives, the members of the institutional account management team described in Section 4.1.5, if any, that are engaged in Detailing the Product and any other employees of Valeant engaged in the Valeant Activities.\\n\\n 1.29 \"GAAP\" shall mean United States generally accepted accounting principles.\\n\\n 1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member, which has competent and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this Agreement.\\n\\n4\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED'],\n",
       "  ['REFERENCE',\n",
       "   '1.30 \"Governmental Authority\" shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member, which has competent and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this Agreement.\\n\\n4\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.31 \"Gross to Net Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as determined in accordance with Dova\\'s revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for quarterly financial reporting purposes, as reported in Dova\\'s quarterly filings with the U.S. Securities Exchange Commission.\\n\\n 1.32 \"Indemnified Party\" shall have the meaning set forth in Section 11.3.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.31 \"Gross to Net Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the net sales of the SKU of the Product in the Territory for an applicable period (based on the gross-to-net discounts for all sales of such SKU of the Product (i.e., sales attributable to the Specialty, as well as all other sales of such SKU of the Product), and (ii) the denominator of which is gross sales of such SKU of the Product in the Territory for an applicable period, in each case, as determined in accordance with Dova\\'s revenue recognition policies, which is in accordance with GAAP (on a consistent basis), for quarterly financial reporting purposes, as reported in Dova\\'s quarterly filings with the U.S. Securities Exchange Commission.\\n\\n 1.32 \"Indemnified Party\" shall have the meaning set forth in Section 11.3.\\n\\n 1.33 \"Indemnifying Party\" shall have the meaning set forth in Section 11.3.\\n\\n 1.34 \"Intellectual Property\" shall have the meaning set forth in Section 8.1.2.\\n\\n1.35 \"Intermediary\" shall mean any wholesaler or distributor who sells Product to Retail Pharmacies and Non-Retail Institutions, but not patients, and with which Dova (or its Affiliates) has entered into an agreement or otherwise has arrangements.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.32 \"Indemnified Party\" shall have the meaning set forth in Section 11.3.\\n\\n 1.33 \"Indemnifying Party\" shall have the meaning set forth in Section 11.3.\\n\\n 1.34 \"Intellectual Property\" shall have the meaning set forth in Section 8.1.2.\\n\\n1.35 \"Intermediary\" shall mean any wholesaler or distributor who sells Product to Retail Pharmacies and Non-Retail Institutions, but not patients, and with which Dova (or its Affiliates) has entered into an agreement or otherwise has arrangements.\\n\\n 1.36 \"Inventions\" shall have the meaning set forth in Section 8.1.2.\\n\\n 1.37 \"JSC\" shall have the meaning set forth in Section 3.1.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.34 \"Intellectual Property\" shall have the meaning set forth in Section 8.1.2.\\n\\n1.35 \"Intermediary\" shall mean any wholesaler or distributor who sells Product to Retail Pharmacies and Non-Retail Institutions, but not patients, and with which Dova (or its Affiliates) has entered into an agreement or otherwise has arrangements.\\n\\n 1.36 \"Inventions\" shall have the meaning set forth in Section 8.1.2.\\n\\n 1.37 \"JSC\" shall have the meaning set forth in Section 3.1.\\n\\n 1.38 \"Know-How\" shall mean information, whether or not in written form, including biological, chemical, pharmacological, toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information, including processes, methods, procedures, techniques, plans, programs and data.\\n\\n 1.39 \"Losses\" shall mean any and all amounts paid or payable to Third Parties with respect to a Claim (including any and all losses, damages, obligations, liabilities, fines, fees, penalties, awards, judgments, interest), together with all documented out-of- pocket costs and expenses, including attorney\\'s fees, reasonably incurred.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.37 \"JSC\" shall have the meaning set forth in Section 3.1.\\n\\n 1.38 \"Know-How\" shall mean information, whether or not in written form, including biological, chemical, pharmacological, toxicological, medical or clinical, analytical, quality, manufacturing, research, or sales and marketing information, including processes, methods, procedures, techniques, plans, programs and data.\\n\\n 1.39 \"Losses\" shall mean any and all amounts paid or payable to Third Parties with respect to a Claim (including any and all losses, damages, obligations, liabilities, fines, fees, penalties, awards, judgments, interest), together with all documented out-of- pocket costs and expenses, including attorney\\'s fees, reasonably incurred.\\n\\n 1.40 \"Net Sales\" shall mean, for an applicable period, the aggregate amount, without duplication, equal to the Specialty Pharmacy Net Sales for each SKU, the Retail Net Sales for each SKU, if any, and the Non-Retail Net Sales for each SKU.\\n\\n1.41 \"Non-Retail Institution\" shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.\\n\\n 1.42 \"Non-Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n5\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   '1.39 \"Losses\" shall mean any and all amounts paid or payable to Third Parties with respect to a Claim (including any and all losses, damages, obligations, liabilities, fines, fees, penalties, awards, judgments, interest), together with all documented out-of- pocket costs and expenses, including attorney\\'s fees, reasonably incurred.\\n\\n 1.40 \"Net Sales\" shall mean, for an applicable period, the aggregate amount, without duplication, equal to the Specialty Pharmacy Net Sales for each SKU, the Retail Net Sales for each SKU, if any, and the Non-Retail Net Sales for each SKU.\\n\\n1.41 \"Non-Retail Institution\" shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.\\n\\n 1.42 \"Non-Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n5\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED'],\n",
       "  ['REFERENCE',\n",
       "   '1.42 \"Non-Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n5\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of Products shipped by Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions in the Territory during an applicable period (excluding any shipments in excess of one unit of either SKU shipped to such Non-Retail Institutions based on the initial orders from such Non-Retail Institutions):\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable Specialty Fraction for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iv) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n 1.43 \"Party\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of Products shipped by Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions in the Territory during an applicable period (excluding any shipments in excess of one unit of either SKU shipped to such Non-Retail Institutions based on the initial orders from such Non-Retail Institutions):\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable Specialty Fraction for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iv) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n 1.43 \"Party\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n 1.44 \"Person\" shall mean any individual, corporation, partnership, limited liability company, association, joint-stock company, trust, unincorporated organization or other entity, or government or political subdivision thereof.\\n\\n 1.45 \"Product\" shall mean the product approved pursuant to New Drug Application (NDA) No. 210238, as such approval may be supplemented from time to time (including by way of supplemental new drug application (sNDA)), currently marketed as DOPTELET (avatrombopag) in the Territory and shall include an authorized generic version of such Product.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.43 \"Party\" shall have the meaning set forth in the preamble to this Agreement.\\n\\n 1.44 \"Person\" shall mean any individual, corporation, partnership, limited liability company, association, joint-stock company, trust, unincorporated organization or other entity, or government or political subdivision thereof.\\n\\n 1.45 \"Product\" shall mean the product approved pursuant to New Drug Application (NDA) No. 210238, as such approval may be supplemented from time to time (including by way of supplemental new drug application (sNDA)), currently marketed as DOPTELET (avatrombopag) in the Territory and shall include an authorized generic version of such Product.\\n\\n 1.46 \"Product Labeling\" shall mean the labels and other written, printed or graphic matter upon (a) any container or wrapper utilized with the Product or (b) any written material accompanying the Product, including Product package inserts, in each case as approved by the FDA.\\n\\n 1.47 \"Product Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.45 \"Product\" shall mean the product approved pursuant to New Drug Application (NDA) No. 210238, as such approval may be supplemented from time to time (including by way of supplemental new drug application (sNDA)), currently marketed as DOPTELET (avatrombopag) in the Territory and shall include an authorized generic version of such Product.\\n\\n 1.46 \"Product Labeling\" shall mean the labels and other written, printed or graphic matter upon (a) any container or wrapper utilized with the Product or (b) any written material accompanying the Product, including Product package inserts, in each case as approved by the FDA.\\n\\n 1.47 \"Product Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n 1.48 \"Product Training Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n 1.49 \"Quarterly Average Sales Force Size\" shall have the meaning set forth in Section 4.2.2.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.47 \"Product Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n 1.48 \"Product Training Materials\" shall have the meaning set forth in Section 4.4.1(a).\\n\\n 1.49 \"Quarterly Average Sales Force Size\" shall have the meaning set forth in Section 4.2.2.\\n\\n 1.50 \"Quarterly Minimum Details\" for an applicable Calendar Quarter shall mean [***].\\n\\n 1.51 \"Regulatory Approval\" shall mean any and all necessary approvals, licenses, registrations or authorizations from any Governmental Authority, in each case, necessary to commercialize the Product in the Territory.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.49 \"Quarterly Average Sales Force Size\" shall have the meaning set forth in Section 4.2.2.\\n\\n 1.50 \"Quarterly Minimum Details\" for an applicable Calendar Quarter shall mean [***].\\n\\n 1.51 \"Regulatory Approval\" shall mean any and all necessary approvals, licenses, registrations or authorizations from any Governmental Authority, in each case, necessary to commercialize the Product in the Territory.\\n\\n 1.52 \"Retail Pharmacy\" shall mean an outlet which dispenses the Product directly to a patient in a retail setting or through mail order services.\\n\\n 6\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   '1.51 \"Regulatory Approval\" shall mean any and all necessary approvals, licenses, registrations or authorizations from any Governmental Authority, in each case, necessary to commercialize the Product in the Territory.\\n\\n 1.52 \"Retail Pharmacy\" shall mean an outlet which dispenses the Product directly to a patient in a retail setting or through mail order services.\\n\\n 6\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED'],\n",
       "  ['REFERENCE',\n",
       "   '6\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.53 \"Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n(i) the number of units of such SKU of the Product shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported by data aggregator) or such other data source with which Dova enters into an agreement at its cost),\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n 1.54 \"Sales Representative\" shall mean an individual employed and compensated by Valeant as a full-time employee as part of its sales forces and who engages in Detailing of the Designated Product (or the Alternate Product, as the case may be) in the Territory, and who is also trained with respect to the Product in accordance with this Agreement (including the Product Labeling and the use of the Promotional Materials) to deliver Details for the Product in the Field in the Territory.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n1.53 \"Retail Net Sales\" shall mean, for each SKU of the Product:\\n\\n(i) the number of units of such SKU of the Product shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported by data aggregator) or such other data source with which Dova enters into an agreement at its cost),\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n 1.54 \"Sales Representative\" shall mean an individual employed and compensated by Valeant as a full-time employee as part of its sales forces and who engages in Detailing of the Designated Product (or the Alternate Product, as the case may be) in the Territory, and who is also trained with respect to the Product in accordance with this Agreement (including the Product Labeling and the use of the Promotional Materials) to deliver Details for the Product in the Field in the Territory.\\n\\n 1.55 \"Senior Officer\" shall mean, with respect to Dova, its President and Chief Executive Officer (or such officer\\'s designee), and with respect to Valeant, its [***] (or such officer\\'s designee). From time to time, each Party may change its Senior Officer by giving written notice to the other Party.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.54 \"Sales Representative\" shall mean an individual employed and compensated by Valeant as a full-time employee as part of its sales forces and who engages in Detailing of the Designated Product (or the Alternate Product, as the case may be) in the Territory, and who is also trained with respect to the Product in accordance with this Agreement (including the Product Labeling and the use of the Promotional Materials) to deliver Details for the Product in the Field in the Territory.\\n\\n 1.55 \"Senior Officer\" shall mean, with respect to Dova, its President and Chief Executive Officer (or such officer\\'s designee), and with respect to Valeant, its [***] (or such officer\\'s designee). From time to time, each Party may change its Senior Officer by giving written notice to the other Party.\\n\\n 1.56 \"Specialty\" shall mean (i) Target Professionals with a primary or secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology (excluding any such Target Professionals with a primary or secondary specialty designation of Hepatology (including Transplant Hepatology), in each case, as determined by data reported by Dova\\'s Third Party Data Source, subject to any adjustments determined pursuant to the process set out in Section 6.5, and (ii) all healthcare professionals with Nurse or Physician Assistant specialty designations affiliated with the Target Professionals described in subsection (i), as adjusted.\\n\\n 1.57 \"Specialty Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, applicable), and (ii) the denominator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to all patients in the Territory (namely based on prescriptions written by the Specialty and outside the Specialty) (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable).\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'From time to time, each Party may change its Senior Officer by giving written notice to the other Party.\\n\\n 1.56 \"Specialty\" shall mean (i) Target Professionals with a primary or secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology (excluding any such Target Professionals with a primary or secondary specialty designation of Hepatology (including Transplant Hepatology), in each case, as determined by data reported by Dova\\'s Third Party Data Source, subject to any adjustments determined pursuant to the process set out in Section 6.5, and (ii) all healthcare professionals with Nurse or Physician Assistant specialty designations affiliated with the Target Professionals described in subsection (i), as adjusted.\\n\\n 1.57 \"Specialty Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, applicable), and (ii) the denominator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to all patients in the Territory (namely based on prescriptions written by the Specialty and outside the Specialty) (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable).\\n\\n 1.58 \"Specialty Pharmacy Net Sales\" shall mean, for each SKU of the Product:\\n\\n7\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   '1.57 \"Specialty Fraction\" shall mean, for each SKU of the Product, a fraction (i) the numerator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, applicable), and (ii) the denominator of which is the number of units of such SKU of the Product shipped from the Specialty Pharmacies or the Retail Pharmacies to all patients in the Territory (namely based on prescriptions written by the Specialty and outside the Specialty) (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable).\\n\\n 1.58 \"Specialty Pharmacy Net Sales\" shall mean, for each SKU of the Product:\\n\\n7\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of the Product shipped from the Specialty Pharmacies to all patients based on prescriptions written by the Specialty in the Territory during an applicable period (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable); and\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n1.59 \"Specialty Pharmacy\" shall mean those specialty pharmacies to which Dova (or its Affiliates) sells and/or ships units of Product during the Term and for which Dova or its Affiliates have agreements with that include data provisions or provide for separate data agreements which enables Dova to track shipments of Product from such Specialty Pharmacy to patients based on the Target Professional prescribing such Product.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of the Product shipped from the Specialty Pharmacies to all patients based on prescriptions written by the Specialty in the Territory during an applicable period (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable); and\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n1.59 \"Specialty Pharmacy\" shall mean those specialty pharmacies to which Dova (or its Affiliates) sells and/or ships units of Product during the Term and for which Dova or its Affiliates have agreements with that include data provisions or provide for separate data agreements which enables Dova to track shipments of Product from such Specialty Pharmacy to patients based on the Target Professional prescribing such Product.\\n\\n 1.60 \"Tail Period\" shall mean the period commencing on the day after the last day of the Term and ending on the earlier of (i) [***] and (ii) [***], unless terminated early pursuant to Section 2.3.1(a) of the Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(i) the number of units of such SKU of the Product shipped from the Specialty Pharmacies to all patients based on prescriptions written by the Specialty in the Territory during an applicable period (as determined by data reported pursuant to agreements between Dova (or its Affiliates) and the Specialty Pharmacies or the data aggregators, as applicable); and\\n\\nMULTIPLIED BY\\n\\n(ii) the applicable WAC for such SKU of the Product for the applicable period,\\n\\nMULTIPLIED BY\\n\\n(iii) the Gross to Net Fraction for such SKU of the Product for the applicable period.\\n\\n1.59 \"Specialty Pharmacy\" shall mean those specialty pharmacies to which Dova (or its Affiliates) sells and/or ships units of Product during the Term and for which Dova or its Affiliates have agreements with that include data provisions or provide for separate data agreements which enables Dova to track shipments of Product from such Specialty Pharmacy to patients based on the Target Professional prescribing such Product.\\n\\n 1.60 \"Tail Period\" shall mean the period commencing on the day after the last day of the Term and ending on the earlier of (i) [***] and (ii) [***], unless terminated early pursuant to Section 2.3.1(a) of the Agreement.\\n\\n 1.61 \"Target Professionals\" shall mean physicians, nurse practitioners, physician assistants and any other medical professionals in the Territory with prescribing authority (as authorized under Applicable Law) in the Territory for the Product.\\n\\n 1.62 \"Term\" shall have the meaning set forth in Section 12.1.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***] and (ii) [***], unless terminated early pursuant to Section 2.3.1(a) of the Agreement.\\n\\n 1.61 \"Target Professionals\" shall mean physicians, nurse practitioners, physician assistants and any other medical professionals in the Territory with prescribing authority (as authorized under Applicable Law) in the Territory for the Product.\\n\\n 1.62 \"Term\" shall have the meaning set forth in Section 12.1.\\n\\n 1.63 \"Territory\" shall mean the United States of America and its territories and possessions.\\n\\n 1.64 \"Third Party(ies)\" shall mean any person or entity other than Dova and Valeant and their respective Affiliates.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.62 \"Term\" shall have the meaning set forth in Section 12.1.\\n\\n 1.63 \"Territory\" shall mean the United States of America and its territories and possessions.\\n\\n 1.64 \"Third Party(ies)\" shall mean any person or entity other than Dova and Valeant and their respective Affiliates.\\n\\n 1.65 \"Third Party Agreements\" shall mean the agreements described on Schedule 1.65 hereto.\\n\\n1.66 \"Valeant Activities\" shall mean any and all promotional activities (including Detailing) conducted by Valeant to encourage the appropriate use of the Product in the Specialty in the Field in the Territory in accordance with the terms of this Agreement.\\n\\n 1.67 \"Valeant Property\" shall have the meaning set forth in Section 8.1.1.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '1.64 \"Third Party(ies)\" shall mean any person or entity other than Dova and Valeant and their respective Affiliates.\\n\\n 1.65 \"Third Party Agreements\" shall mean the agreements described on Schedule 1.65 hereto.\\n\\n1.66 \"Valeant Activities\" shall mean any and all promotional activities (including Detailing) conducted by Valeant to encourage the appropriate use of the Product in the Specialty in the Field in the Territory in accordance with the terms of this Agreement.\\n\\n 1.67 \"Valeant Property\" shall have the meaning set forth in Section 8.1.1.\\n\\n 1.68 \"WAC\" shall mean, for each SKU of the Product, Dova\\'s list price for a unit of the SKU of the Product to wholesalers or direct purchasers in the Territory, as reported in wholesale price guides or other nationally recognized publications of drug pricing data.\\n\\n ARTICLE 2  RIGHTS AND OBLIGATIONS\\n\\n2.1 Engagement; Grant of Rights.'],\n",
       "  ['REFERENCE',\n",
       "   '1.67 \"Valeant Property\" shall have the meaning set forth in Section 8.1.1.\\n\\n 1.68 \"WAC\" shall mean, for each SKU of the Product, Dova\\'s list price for a unit of the SKU of the Product to wholesalers or direct purchasers in the Territory, as reported in wholesale price guides or other nationally recognized publications of drug pricing data.\\n\\n ARTICLE 2  RIGHTS AND OBLIGATIONS\\n\\n2.1 Engagement; Grant of Rights. During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and its Affiliates to promote the Product in the Territory including in the Specialty.'],\n",
       "  ['REFERENCE',\n",
       "   \"ARTICLE 2  RIGHTS AND OBLIGATIONS\\n\\n2.1 Engagement; Grant of Rights. During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the right for Dova and its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section 2.1 are non-transferable, non-assignable, and non-delegable.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Notwithstanding the foregoing, Dova retains and reserves the right for Dova and its Affiliates to promote the Product in the Territory including in the Specialty. Valeant shall have no other rights relating to the Product, except as specifically set forth in this Agreement and, without limiting the foregoing, except as set out in Section 4.1.5, if agreed upon, Valeant shall have no right to, and shall not, conduct the Valeant Activities for the Product outside the Specialty or outside the Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights and obligations under this Section 2.1 are non-transferable, non-assignable, and non-delegable. Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant Activities with any Third Party (including any contract sales force). Any obligation of Valeant under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in part, at Valeant's sole and exclusive option, either by Valeant or its Affiliates.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Except to Affiliates of Valeant, Valeant's rights and obligations under this Section 2.1 are non-transferable, non-assignable, and non-delegable. Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant Activities with any Third Party (including any contract sales force). Any obligation of Valeant under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in part, at Valeant's sole and exclusive option, either by Valeant or its Affiliates. Valeant guarantees the performance of all actions, agreements and obligations to be performed by its Affiliates under the terms and conditions of this Agreement. For clarity, Valeant shall not have any license rights hereunder nor any rights to sublicense any rights hereunder.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"Any obligation of Valeant under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in part, at Valeant's sole and exclusive option, either by Valeant or its Affiliates. Valeant guarantees the performance of all actions, agreements and obligations to be performed by its Affiliates under the terms and conditions of this Agreement. For clarity, Valeant shall not have any license rights hereunder nor any rights to sublicense any rights hereunder.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n2.2 Retention of Rights. Except with respect to the exclusive rights granted to Valeant to conduct the Valeant Activities for the Product in the Specialty in the Territory in the Field pursuant to Section 2.1 and, and if agreed upon, outside the Specialty in the Territory in the Field pursuant to Section 4.1.5, Dova retains all rights in and to the Product.\"],\n",
       "  ['REFERENCE',\n",
       "   \"For clarity, Valeant shall not have any license rights hereunder nor any rights to sublicense any rights hereunder.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n2.2 Retention of Rights. Except with respect to the exclusive rights granted to Valeant to conduct the Valeant Activities for the Product in the Specialty in the Territory in the Field pursuant to Section 2.1 and, and if agreed upon, outside the Specialty in the Territory in the Field pursuant to Section 4.1.5, Dova retains all rights in and to the Product. Without limiting the generality of the foregoing (and without limiting Dova's retained rights set forth in Section 2.1), Dova specifically retains the following rights (and Valeant and its Affiliates shall have no rights to the following, except as set forth below in this Section 2.2):\\n\\n2.2.1 responsibility for promoting the Product outside the Specialty;\\n\\n2.2.2 responsibility for the manufacture and distribution of the Product, and any future development of the Product;\\n\\n2.2.3 responsibility for all decisions regarding regulatory submissions and, except as expressly set forth herein, for interactions with any Governmental Authority, including but not limited to FDA, with respect to the Product;\\n\\n2.2.4 responsibility for final approval of all Product Materials content (including submission of Promotional Materials to FDA's Office of Prescription Drug Promotion) with respect to the conduct of the Valeant Activities for Product, except as expressly set forth herein;\\n\\n2.2.5 selling and booking all sales of the Product; and\\n\\n2.2.6 responsibility for handling all safety related activities related to Product as set forth in ARTICLE 5 (including submitting all safety reports and interacting with Governmental Authorities with respect thereto) and initiating and managing any Product recalls.\\n\\n For clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any license or other intellectual property interest, by implication or otherwise, in any technology, Know-How or other intellectual property owned or controlled by Dova or any of its Affiliates, and Dova is not providing any such technology, Know-How or other intellectual property, or any assistance related thereto, to Valeant for any use other than for the mutual benefit of the Parties as expressly contemplated hereby.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"Except with respect to the exclusive rights granted to Valeant to conduct the Valeant Activities for the Product in the Specialty in the Territory in the Field pursuant to Section 2.1 and, and if agreed upon, outside the Specialty in the Territory in the Field pursuant to Section 4.1.5, Dova retains all rights in and to the Product. Without limiting the generality of the foregoing (and without limiting Dova's retained rights set forth in Section 2.1), Dova specifically retains the following rights (and Valeant and its Affiliates shall have no rights to the following, except as set forth below in this Section 2.2):\\n\\n2.2.1 responsibility for promoting the Product outside the Specialty;\\n\\n2.2.2 responsibility for the manufacture and distribution of the Product, and any future development of the Product;\\n\\n2.2.3 responsibility for all decisions regarding regulatory submissions and, except as expressly set forth herein, for interactions with any Governmental Authority, including but not limited to FDA, with respect to the Product;\\n\\n2.2.4 responsibility for final approval of all Product Materials content (including submission of Promotional Materials to FDA's Office of Prescription Drug Promotion) with respect to the conduct of the Valeant Activities for Product, except as expressly set forth herein;\\n\\n2.2.5 selling and booking all sales of the Product; and\\n\\n2.2.6 responsibility for handling all safety related activities related to Product as set forth in ARTICLE 5 (including submitting all safety reports and interacting with Governmental Authorities with respect thereto) and initiating and managing any Product recalls.\\n\\n For clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any license or other intellectual property interest, by implication or otherwise, in any technology, Know-How or other intellectual property owned or controlled by Dova or any of its Affiliates, and Dova is not providing any such technology, Know-How or other intellectual property, or any assistance related thereto, to Valeant for any use other than for the mutual benefit of the Parties as expressly contemplated hereby.\\n\\n 2.3 Non-Competition; Non-Solicitation.\\n\\n2.3.1 Non-Competition. (a)\"],\n",
       "  ['REFERENCE',\n",
       "   'For clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any license or other intellectual property interest, by implication or otherwise, in any technology, Know-How or other intellectual property owned or controlled by Dova or any of its Affiliates, and Dova is not providing any such technology, Know-How or other intellectual property, or any assistance related thereto, to Valeant for any use other than for the mutual benefit of the Parties as expressly contemplated hereby.\\n\\n 2.3 Non-Competition; Non-Solicitation.\\n\\n2.3.1 Non-Competition. (a) [***], neither Valeant nor its Affiliates shall, directly or indirectly, [***] in the Territory other than the Product; provided that if the Agreement is terminated by Dova pursuant to [***], then any Tail Period shall be immediately terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in the Territory other than the Product during such Tail Period. Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '(a) [***], neither Valeant nor its Affiliates shall, directly or indirectly, [***] in the Territory other than the Product; provided that if the Agreement is terminated by Dova pursuant to [***], then any Tail Period shall be immediately terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in the Territory other than the Product during such Tail Period. Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].\\n\\n (a) [***], neither Dova nor is Affiliates shall, directly or indirectly, [***].'],\n",
       "  ['REFERENCE',\n",
       "   'Notwithstanding the foregoing, this Section 2.3.1(a) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons, [***].\\n\\n (a) [***], neither Dova nor is Affiliates shall, directly or indirectly, [***]. Notwithstanding the foregoing, this Section 2.3.1(b) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons[***].\\n\\n 2.3.2 Non-Solicitation.'],\n",
       "  ['REFERENCE',\n",
       "   \"[***], neither Dova nor is Affiliates shall, directly or indirectly, [***]. Notwithstanding the foregoing, this Section 2.3.1(b) shall not apply to any products marketed, promoted, detailed, offered for sale, or sold by any business (or any portion thereof), other Person, or group of Persons[***].\\n\\n 2.3.2 Non-Solicitation. [***], neither Valeant nor Dova (nor any of their respective Affiliates) shall directly or indirectly solicit for hire or employee as an employee, consultant or otherwise any of the other Party's professional personnel who have had direct involvement with the JSC, with the Valeant Activities under this Agreement (which, in the case of Valeant, includes the Field Force Personnel) or with Dova's commercialization activities for the Product, without the other Party's prior written consent. Notwithstanding anything to the contrary, in no event shall the restrictions set forth in this Section 2.3.2 apply to [***].\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"2.3.2 Non-Solicitation. [***], neither Valeant nor Dova (nor any of their respective Affiliates) shall directly or indirectly solicit for hire or employee as an employee, consultant or otherwise any of the other Party's professional personnel who have had direct involvement with the JSC, with the Valeant Activities under this Agreement (which, in the case of Valeant, includes the Field Force Personnel) or with Dova's commercialization activities for the Product, without the other Party's prior written consent. Notwithstanding anything to the contrary, in no event shall the restrictions set forth in this Section 2.3.2 apply to [***].\\n\\n 2.4 Dova Trademarks and Copyrights.\\n\\n 2.4.1 Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement.\"],\n",
       "  ['REFERENCE',\n",
       "   'Notwithstanding anything to the contrary, in no event shall the restrictions set forth in this Section 2.3.2 apply to [***].\\n\\n 2.4 Dova Trademarks and Copyrights.\\n\\n 2.4.1 Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement. Dova shall promptly notify Valeant of any updates or changes to the Dova Trademarks and Copyrights on the Product Materials, and Valeant shall thereafter solely use such updated Product Materials in performing its obligations under this Agreement. Valeant shall promptly notify Dova upon becoming aware of any violation of this Section 2.4.1.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '2.4.1 Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights solely on Product Materials in order to perform the Valeant Activities and solely in accordance with the terms and conditions of this Agreement. Dova shall promptly notify Valeant of any updates or changes to the Dova Trademarks and Copyrights on the Product Materials, and Valeant shall thereafter solely use such updated Product Materials in performing its obligations under this Agreement. Valeant shall promptly notify Dova upon becoming aware of any violation of this Section 2.4.1.\\n\\n 2.4.2 Valeant shall follow all instructions and guidelines of Dova (of which Dova has provided Valeant copies) in connection with the use of any Dova Trademarks and Copyrights, and, if Dova reasonably objects to the manner in which any such Dova Trademarks and Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and Copyrights in such manner upon written notice from Dova thereof. Without limiting the foregoing, Valeant shall also adhere to at least the same quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights.'],\n",
       "  ['REFERENCE',\n",
       "   \"Valeant shall promptly notify Dova upon becoming aware of any violation of this Section 2.4.1.\\n\\n 2.4.2 Valeant shall follow all instructions and guidelines of Dova (of which Dova has provided Valeant copies) in connection with the use of any Dova Trademarks and Copyrights, and, if Dova reasonably objects to the manner in which any such Dova Trademarks and Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and Copyrights in such manner upon written notice from Dova thereof. Without limiting the foregoing, Valeant shall also adhere to at least the same quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights. In all cases, Valeant shall use the Dova Trademarks and Copyrights with the necessary trademark (and copyright, as applicable) designations, and shall use the Dova Trademarks and Copyrights in a manner that does not derogate from Dova's rights in the Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Without limiting the foregoing, Valeant shall also adhere to at least the same quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights. In all cases, Valeant shall use the Dova Trademarks and Copyrights with the necessary trademark (and copyright, as applicable) designations, and shall use the Dova Trademarks and Copyrights in a manner that does not derogate from Dova's rights in the Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights. All goodwill and\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nimproved reputation generated by Valeant's use of the Dova Trademarks and Copyrights shall inure to the benefit of Dova, and any use of the Dova Trademarks and Copyrights by Valeant shall cease at the end of the Term. Valeant shall have no rights under this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights. All goodwill and\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nimproved reputation generated by Valeant's use of the Dova Trademarks and Copyrights shall inure to the benefit of Dova, and any use of the Dova Trademarks and Copyrights by Valeant shall cease at the end of the Term. Valeant shall have no rights under this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein. During the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor. During the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are confusingly similar to the Dova Trademarks and Copyrights.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Valeant shall have no rights under this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein. During the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor. During the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are confusingly similar to the Dova Trademarks and Copyrights.\\n\\n ARTICLE 3  JOINT STEERING COMMITTEE\\n\\n3.1 Formation of the JSC. As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"JSC\") whose responsibilities during the Term shall be to oversee the activities set forth in Section 3.3.'],\n",
       "  ['REFERENCE',\n",
       "   'During the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are confusingly similar to the Dova Trademarks and Copyrights.\\n\\n ARTICLE 3  JOINT STEERING COMMITTEE\\n\\n3.1 Formation of the JSC. As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"JSC\") whose responsibilities during the Term shall be to oversee the activities set forth in Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may change any of its representatives on the JSC by giving written notice to the other Party.'],\n",
       "  ['REFERENCE',\n",
       "   'As soon as practicable, but no later than twenty (20) days after the Effective Date, the Parties shall form a joint steering committee (\"JSC\") whose responsibilities during the Term shall be to oversee the activities set forth in Section 3.3. The JSC shall consist of three (3) representatives from each Party, each with suitable seniority and relevant experience and expertise to enable such person to address matters falling within the purview of the JSC. From time to time, each Party may change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule; provided, that, in any event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the Parties.'],\n",
       "  ['REFERENCE',\n",
       "   'From time to time, each Party may change any of its representatives on the JSC by giving written notice to the other Party. The meetings of the JSC will be chaired by a representative from Dova or Valeant, on an alternating basis. The JSC shall determine a meeting schedule; provided, that, in any event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend meetings of the JSC; provided, that such attendees (i) shall not participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure equivalent to those set forth in ARTICLE 9.\\n\\n3.2 Meetings and Minutes.'],\n",
       "  ['REFERENCE',\n",
       "   \"The JSC shall determine a meeting schedule; provided, that, in any event, meetings shall be conducted no less frequently than quarterly by teleconference or in person, or as otherwise agreed by the Parties. In person meetings shall occur at such places as mutually agreed by the Parties. Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend meetings of the JSC; provided, that such attendees (i) shall not participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure equivalent to those set forth in ARTICLE 9.\\n\\n3.2 Meetings and Minutes. Meetings of the JSC may be called by either Party on no less than thirty (30) days' notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at least ten (10) days in advance to the applicable meeting; provided that under exigent circumstances requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend meetings of the JSC; provided, that such attendees (i) shall not participate in the decision-making process of the JSC, and (ii) are bound by obligations of confidentiality and non-disclosure equivalent to those set forth in ARTICLE 9.\\n\\n3.2 Meetings and Minutes. Meetings of the JSC may be called by either Party on no less than thirty (30) days' notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at least ten (10) days in advance to the applicable meeting; provided that under exigent circumstances requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty (30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at least ten (10) days in advance to the applicable meeting; provided that under exigent circumstances requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty (30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.\\n\\n 3.3 Purpose of the JSC. The purposes of the JSC shall be to, subject to Section 3.4:\\n\\n3.3.1 provide a forum to discuss and coordinate the Parties' activities under this Agreement;\\n\\n3.3.2 provide a forum to discuss and coordinate the promotion of the Product in the Territory, including in and outside the Specialty;\\n\\n3.3.3 provide a forum to discuss Product Materials (it being understood that the JSC shall not have the right to approve such Product Materials);\\n\\n3.3.4 facilitate the flow of information and otherwise promote the communications and collaboration within and among the Parties relating to this Agreement and the promotion of the Product;\\n\\n3.3.5 discuss planning and implementation of all Valeant Activities, including but not limited to training of Sales Representatives and, if agreed upon, the activities of the institutional account management team referred to in Section 4.1.5;\\n\\n3.3.6 decide on the acceptable form of and review and discuss the Detail Reports and reports of Net Sales;\\n\\n3.3.7 decide on the acceptable form of and review and discuss the Compensation Reports and the incentive compensation matters described in Section 4.1.3, including any applicable adjustments to the Product-related sales goals and targets of the Sales Representatives;\\n\\n3.3.8 review and discuss any matters brought to its attention by either Party's Alliance Manager;\\n\\n3.3.9 review, discuss and decide on the Alternate Product described in Section 4.2.1(c) or any additional product that may be Detailed by Valeant described in Section 4.2.1(d);\\n\\n3.3.10 discuss the Promotional Materials matters described in Section 4.4.1(b);\\n\\n3.3.11 discuss supply or distribution issues relating to the Product, such as any supply shortages;\\n\\n3.3.12 discuss the pricing of the Product (provided that Dova shall have sole authority to determine pricing of the Product);\"],\n",
       "  ['REFERENCE',\n",
       "   \"Each Party shall bear its own costs for its members to attend such meetings.\\n\\n 3.3 Purpose of the JSC. The purposes of the JSC shall be to, subject to Section 3.4:\\n\\n3.3.1 provide a forum to discuss and coordinate the Parties' activities under this Agreement;\\n\\n3.3.2 provide a forum to discuss and coordinate the promotion of the Product in the Territory, including in and outside the Specialty;\\n\\n3.3.3 provide a forum to discuss Product Materials (it being understood that the JSC shall not have the right to approve such Product Materials);\\n\\n3.3.4 facilitate the flow of information and otherwise promote the communications and collaboration within and among the Parties relating to this Agreement and the promotion of the Product;\\n\\n3.3.5 discuss planning and implementation of all Valeant Activities, including but not limited to training of Sales Representatives and, if agreed upon, the activities of the institutional account management team referred to in Section 4.1.5;\\n\\n3.3.6 decide on the acceptable form of and review and discuss the Detail Reports and reports of Net Sales;\\n\\n3.3.7 decide on the acceptable form of and review and discuss the Compensation Reports and the incentive compensation matters described in Section 4.1.3, including any applicable adjustments to the Product-related sales goals and targets of the Sales Representatives;\\n\\n3.3.8 review and discuss any matters brought to its attention by either Party's Alliance Manager;\\n\\n3.3.9 review, discuss and decide on the Alternate Product described in Section 4.2.1(c) or any additional product that may be Detailed by Valeant described in Section 4.2.1(d);\\n\\n3.3.10 discuss the Promotional Materials matters described in Section 4.4.1(b);\\n\\n3.3.11 discuss supply or distribution issues relating to the Product, such as any supply shortages;\\n\\n3.3.12 discuss the pricing of the Product (provided that Dova shall have sole authority to determine pricing of the Product); Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n3.3.13 act as a first level escalation to address disagreements or disputes between the Parties;\\n\\n3.3.14 form and oversee any sub-committee or working group in furtherance of the activities contemplated by this Agreement;\\n\\n3.3.15 decide on the acceptable form of and review and discuss the Compliance Reports; and\\n\\n3.3.16 perform such other responsibilities as may be mutually agreed upon by the Parties in writing from time to time; provided, however, for clarity the JSC shall have no authority to amend or modify any provisions of this Agreement and no authority to waive or definitively interpret the provisions of this Agreement.\\n\\n 3.4 Decision Making.\"],\n",
       "  ['REFERENCE',\n",
       "   \"The purposes of the JSC shall be to, subject to Section 3.4:\\n\\n3.3.1 provide a forum to discuss and coordinate the Parties' activities under this Agreement;\\n\\n3.3.2 provide a forum to discuss and coordinate the promotion of the Product in the Territory, including in and outside the Specialty;\\n\\n3.3.3 provide a forum to discuss Product Materials (it being understood that the JSC shall not have the right to approve such Product Materials);\\n\\n3.3.4 facilitate the flow of information and otherwise promote the communications and collaboration within and among the Parties relating to this Agreement and the promotion of the Product;\\n\\n3.3.5 discuss planning and implementation of all Valeant Activities, including but not limited to training of Sales Representatives and, if agreed upon, the activities of the institutional account management team referred to in Section 4.1.5;\\n\\n3.3.6 decide on the acceptable form of and review and discuss the Detail Reports and reports of Net Sales;\\n\\n3.3.7 decide on the acceptable form of and review and discuss the Compensation Reports and the incentive compensation matters described in Section 4.1.3, including any applicable adjustments to the Product-related sales goals and targets of the Sales Representatives;\\n\\n3.3.8 review and discuss any matters brought to its attention by either Party's Alliance Manager;\\n\\n3.3.9 review, discuss and decide on the Alternate Product described in Section 4.2.1(c) or any additional product that may be Detailed by Valeant described in Section 4.2.1(d);\\n\\n3.3.10 discuss the Promotional Materials matters described in Section 4.4.1(b);\\n\\n3.3.11 discuss supply or distribution issues relating to the Product, such as any supply shortages;\\n\\n3.3.12 discuss the pricing of the Product (provided that Dova shall have sole authority to determine pricing of the Product); Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n3.3.13 act as a first level escalation to address disagreements or disputes between the Parties;\\n\\n3.3.14 form and oversee any sub-committee or working group in furtherance of the activities contemplated by this Agreement;\\n\\n3.3.15 decide on the acceptable form of and review and discuss the Compliance Reports; and\\n\\n3.3.16 perform such other responsibilities as may be mutually agreed upon by the Parties in writing from time to time; provided, however, for clarity the JSC shall have no authority to amend or modify any provisions of this Agreement and no authority to waive or definitively interpret the provisions of this Agreement.\\n\\n 3.4 Decision Making. Meetings of the JSC will occur only if at least one representative of each Party is present at the meeting. Each Party shall have one (1) vote.\"],\n",
       "  ['REFERENCE',\n",
       "   '3.4 Decision Making. Meetings of the JSC will occur only if at least one representative of each Party is present at the meeting. Each Party shall have one (1) vote. The JSC will use good faith efforts to reach consensus on all matters properly brought before it. If the JSC does not reach unanimous consensus on an issue at a meeting or within a period of [***] thereafter, then the JSC shall submit in writing the respective positions of the Parties to the Senior Officers of the Parties.'],\n",
       "  ['REFERENCE',\n",
       "   \"Each Party shall have one (1) vote. The JSC will use good faith efforts to reach consensus on all matters properly brought before it. If the JSC does not reach unanimous consensus on an issue at a meeting or within a period of [***] thereafter, then the JSC shall submit in writing the respective positions of the Parties to the Senior Officers of the Parties. Such Senior Officers shall use good faith efforts to resolve promptly such matter, which good faith efforts shall include at least one (1) teleconference between such Senior Officers within [***] after the JSC's submission of such matter to them. Any final decision mutually agreed to in writing by the Senior Officers shall be conclusive and binding on the Parties.\"],\n",
       "  ['REFERENCE',\n",
       "   \"If the JSC does not reach unanimous consensus on an issue at a meeting or within a period of [***] thereafter, then the JSC shall submit in writing the respective positions of the Parties to the Senior Officers of the Parties. Such Senior Officers shall use good faith efforts to resolve promptly such matter, which good faith efforts shall include at least one (1) teleconference between such Senior Officers within [***] after the JSC's submission of such matter to them. Any final decision mutually agreed to in writing by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to agree on the resolution of any such issue within [***] after such issue was first referred to them, then (i) Valeant shall have the right to conclusively determine all matters related to Valeant Activities and Detailing of the Product, including matters relating to the institutional account manager team, the incentive compensation of the Sales Representatives and targeting for Details, provided that such determination and any related activities comply with the terms and conditions of this Agreement, and (ii) Dova shall have the right to conclusively determine all other matters; provided, however, for clarity any such determination shall not amend, modify or waive any provisions of this Agreement or definitively interpret the provisions of this Agreement.\\n\\n 3.5 Marketing Sub-Committee.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Any final decision mutually agreed to in writing by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to agree on the resolution of any such issue within [***] after such issue was first referred to them, then (i) Valeant shall have the right to conclusively determine all matters related to Valeant Activities and Detailing of the Product, including matters relating to the institutional account manager team, the incentive compensation of the Sales Representatives and targeting for Details, provided that such determination and any related activities comply with the terms and conditions of this Agreement, and (ii) Dova shall have the right to conclusively determine all other matters; provided, however, for clarity any such determination shall not amend, modify or waive any provisions of this Agreement or definitively interpret the provisions of this Agreement.\\n\\n 3.5 Marketing Sub-Committee.\\n\\n 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss, among other things:\\n\\n(a) the number of speaker programs for the Product to be conducted by Dova in each Calendar Year;\\n\\n(b) the Promotional Materials and quantities thereof;\\n\\n(c) the annual brand plan; and\\n\\n(d) the annual conference strategy.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '3.5 Marketing Sub-Committee.\\n\\n 3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a Marketing Sub-Committee comprised of an equal number of representatives from each Party. Such sub-committee shall meet from time to time and discuss, among other things:\\n\\n(a) the number of speaker programs for the Product to be conducted by Dova in each Calendar Year;\\n\\n(b) the Promotional Materials and quantities thereof;\\n\\n(c) the annual brand plan; and\\n\\n(d) the annual conference strategy.\\n\\n 3.5.2 [***] shall constitute the \"Speaker Program Threshold\".'],\n",
       "  ['REFERENCE',\n",
       "   'Such sub-committee shall meet from time to time and discuss, among other things:\\n\\n(a) the number of speaker programs for the Product to be conducted by Dova in each Calendar Year;\\n\\n(b) the Promotional Materials and quantities thereof;\\n\\n(c) the annual brand plan; and\\n\\n(d) the annual conference strategy.\\n\\n 3.5.2 [***] shall constitute the \"Speaker Program Threshold\". If Dova wishes to conduct speaker programs in any Calendar Year after 2018 in excess of the Speaker Program Threshold, then the Parties shall meet, through the Marketing Sub-Committee, to discuss such excess speaker programs and the costs thereof. If the Marketing Sub-Committee unanimously agrees that such excess speaker programs should be conducted, then the following costs and expenses will be shared equally by the Parties: (i) the costs and expenses associated with conducting the excess number of speaker programs and (ii) the additional incremental costs and expenses associated with training necessary to address the number of the speaker programs above and below the Speaker Program Threshold.'],\n",
       "  ['REFERENCE',\n",
       "   '[***] shall constitute the \"Speaker Program Threshold\". If Dova wishes to conduct speaker programs in any Calendar Year after 2018 in excess of the Speaker Program Threshold, then the Parties shall meet, through the Marketing Sub-Committee, to discuss such excess speaker programs and the costs thereof. If the Marketing Sub-Committee unanimously agrees that such excess speaker programs should be conducted, then the following costs and expenses will be shared equally by the Parties: (i) the costs and expenses associated with conducting the excess number of speaker programs and (ii) the additional incremental costs and expenses associated with training necessary to address the number of the speaker programs above and below the Speaker Program Threshold. In addition, if the Parties unanimously agree that such excess speaker programs should be conducted, then, as a condition of the payment by Valeant of its share of such costs, Valeant shall have the right to review and approve (acting reasonably and in good faith) any such excess speaker programs, including with respect to the number of speakers approved to speak on the Product as part of the speaker programs, the rates paid to speakers at such speaker programs and the rules regarding attendees who may attend such speaker programs (including frequency of attendance). For greater certainty, if Valeant does not agree to conduct speaker programs above the Speaker Program Threshold, then the costs described herein for any speaker programs conducted by Dova in excess of the Speaker Program Threshold shall not be shared by the Parties, but shall be borne solely by Dova.'],\n",
       "  ['REFERENCE',\n",
       "   'If the Marketing Sub-Committee unanimously agrees that such excess speaker programs should be conducted, then the following costs and expenses will be shared equally by the Parties: (i) the costs and expenses associated with conducting the excess number of speaker programs and (ii) the additional incremental costs and expenses associated with training necessary to address the number of the speaker programs above and below the Speaker Program Threshold. In addition, if the Parties unanimously agree that such excess speaker programs should be conducted, then, as a condition of the payment by Valeant of its share of such costs, Valeant shall have the right to review and approve (acting reasonably and in good faith) any such excess speaker programs, including with respect to the number of speakers approved to speak on the Product as part of the speaker programs, the rates paid to speakers at such speaker programs and the rules regarding attendees who may attend such speaker programs (including frequency of attendance). For greater certainty, if Valeant does not agree to conduct speaker programs above the Speaker Program Threshold, then the costs described herein for any speaker programs conducted by Dova in excess of the Speaker Program Threshold shall not be shared by the Parties, but shall be borne solely by Dova. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 3.5.2, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.\\n\\n ARTICLE 4  VALEANT ACTIVITIES FOR THE PRODUCT\\n\\n4.1 Valeant Activities.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'For greater certainty, if Valeant does not agree to conduct speaker programs above the Speaker Program Threshold, then the costs described herein for any speaker programs conducted by Dova in excess of the Speaker Program Threshold shall not be shared by the Parties, but shall be borne solely by Dova. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 3.5.2, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.\\n\\n ARTICLE 4  VALEANT ACTIVITIES FOR THE PRODUCT\\n\\n4.1 Valeant Activities.\\n\\n 4.1.1 General. Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTerritory in accordance with this Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'ARTICLE 4  VALEANT ACTIVITIES FOR THE PRODUCT\\n\\n4.1 Valeant Activities.\\n\\n 4.1.1 General. Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTerritory in accordance with this Agreement.\\n\\n 4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory.'],\n",
       "  ['REFERENCE',\n",
       "   'Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nTerritory in accordance with this Agreement.\\n\\n 4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.\\n\\n 4.1.3 Target Incentive Compensation.'],\n",
       "  ['REFERENCE',\n",
       "   'Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.\\n\\n 4.1.3 Target Incentive Compensation. In addition, [***] and continuing throughout the remainder of the Term, Valeant shall ensure the incentive compensation package for each Sales Representatives requires that at least fifty percent (50%) of the target incentive compensation is derived from achieving target sales of the Product. On at least a quarterly basis, the Parties will meet, through the JSC, to review the target incentive compensation and the actual incentive compensation paid out to the Sales Representatives to discuss, in good faith, any appropriate adjustments to the sales targets and goals related to the Product (but not to the above-mentioned fifty percent (50%) threshold of the target incentive compensation), with the intent of achieving, on average, an actual payout to the Sales Representatives of 50% of their incentive compensation relating to sales of the Product.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '4.1.3 Target Incentive Compensation. In addition, [***] and continuing throughout the remainder of the Term, Valeant shall ensure the incentive compensation package for each Sales Representatives requires that at least fifty percent (50%) of the target incentive compensation is derived from achieving target sales of the Product. On at least a quarterly basis, the Parties will meet, through the JSC, to review the target incentive compensation and the actual incentive compensation paid out to the Sales Representatives to discuss, in good faith, any appropriate adjustments to the sales targets and goals related to the Product (but not to the above-mentioned fifty percent (50%) threshold of the target incentive compensation), with the intent of achieving, on average, an actual payout to the Sales Representatives of 50% of their incentive compensation relating to sales of the Product.\\n\\n 4.1.4 Alliance Managers. Each Party shall appoint a person who shall oversee interactions between the Parties for all matters related to this Agreement, and any related agreements between the Parties (each an \"Alliance Manager\").'],\n",
       "  ['REFERENCE',\n",
       "   'On at least a quarterly basis, the Parties will meet, through the JSC, to review the target incentive compensation and the actual incentive compensation paid out to the Sales Representatives to discuss, in good faith, any appropriate adjustments to the sales targets and goals related to the Product (but not to the above-mentioned fifty percent (50%) threshold of the target incentive compensation), with the intent of achieving, on average, an actual payout to the Sales Representatives of 50% of their incentive compensation relating to sales of the Product.\\n\\n 4.1.4 Alliance Managers. Each Party shall appoint a person who shall oversee interactions between the Parties for all matters related to this Agreement, and any related agreements between the Parties (each an \"Alliance Manager\"). The Alliance Managers shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as a single point of contact for all matters arising under this Agreement. The Alliance Managers shall have the right to attend all JSC meetings and if applicable, subcommittee meetings as non-voting participants and may bring to the attention of the JSC or, if applicable, subcommittee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing.'],\n",
       "  ['REFERENCE',\n",
       "   'Each Party shall appoint a person who shall oversee interactions between the Parties for all matters related to this Agreement, and any related agreements between the Parties (each an \"Alliance Manager\"). The Alliance Managers shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as a single point of contact for all matters arising under this Agreement. The Alliance Managers shall have the right to attend all JSC meetings and if applicable, subcommittee meetings as non-voting participants and may bring to the attention of the JSC or, if applicable, subcommittee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. Each Party may designate different Alliance Mangers by notice in writing to the other Party.\\n\\n 4.1.5 Institutional Account Management Team.'],\n",
       "  ['REFERENCE',\n",
       "   \"The Alliance Managers shall have the right to attend all JSC meetings and if applicable, subcommittee meetings as non-voting participants and may bring to the attention of the JSC or, if applicable, subcommittee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. Each Party may designate different Alliance Mangers by notice in writing to the other Party.\\n\\n 4.1.5 Institutional Account Management Team. Upon prior mutual agreement of the Parties in writing, Valeant may maintain a team of institutional account managers who, among other products, promote the Product in the Territory at liver transplant centers and large academic institutions only, and for purposes of this Section 4.1.5 only, both inside and outside the Specialty. Prior to any promotion of the Product by any institutional account managers, the Parties will discuss in good faith (acting reasonably) the number of institutional account managers that will promote the Product in the Territory, the appropriate portion of such institutional account managers' target incentive compensation to be derived from sales of the Product and the liver transplant centers or large academic institutions such institutional account managers will be responsible for.\"],\n",
       "  ['REFERENCE',\n",
       "   \"4.1.5 Institutional Account Management Team. Upon prior mutual agreement of the Parties in writing, Valeant may maintain a team of institutional account managers who, among other products, promote the Product in the Territory at liver transplant centers and large academic institutions only, and for purposes of this Section 4.1.5 only, both inside and outside the Specialty. Prior to any promotion of the Product by any institutional account managers, the Parties will discuss in good faith (acting reasonably) the number of institutional account managers that will promote the Product in the Territory, the appropriate portion of such institutional account managers' target incentive compensation to be derived from sales of the Product and the liver transplant centers or large academic institutions such institutional account managers will be responsible for. Such institutional account managers shall not be counted for purposes of determining the Quarterly Average Sales Force Size or the Quarterly Minimum Details. The Parties agree that these institutional account managers shall not be required to achieve any minimum number of Details.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Prior to any promotion of the Product by any institutional account managers, the Parties will discuss in good faith (acting reasonably) the number of institutional account managers that will promote the Product in the Territory, the appropriate portion of such institutional account managers' target incentive compensation to be derived from sales of the Product and the liver transplant centers or large academic institutions such institutional account managers will be responsible for. Such institutional account managers shall not be counted for purposes of determining the Quarterly Average Sales Force Size or the Quarterly Minimum Details. The Parties agree that these institutional account managers shall not be required to achieve any minimum number of Details. The Parties agree that such team may be added or removed by the mutual written agreement of the Parties without the need to amend this Agreement in accordance with Section 13.8.\\n\\n 4.2 Detailing.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'The Parties agree that these institutional account managers shall not be required to achieve any minimum number of Details. The Parties agree that such team may be added or removed by the mutual written agreement of the Parties without the need to amend this Agreement in accordance with Section 13.8.\\n\\n 4.2 Detailing.\\n\\n 4.2.1 Detail Requirements.\\n\\n (a) Commencing promptly upon completion of training of the Field Force Personnel that are engaged in Detailing the Product as described in Section 4.4.1 (but on the condition that Promotional Materials have been approved and delivered), Valeant shall deploy its Field Force Personnel that are engaged in Detailing to Detail the Product in accordance with the terms of this Agreement.'],\n",
       "  ['REFERENCE',\n",
       "   '4.2 Detailing.\\n\\n 4.2.1 Detail Requirements.\\n\\n (a) Commencing promptly upon completion of training of the Field Force Personnel that are engaged in Detailing the Product as described in Section 4.4.1 (but on the condition that Promotional Materials have been approved and delivered), Valeant shall deploy its Field Force Personnel that are engaged in Detailing to Detail the Product in accordance with the terms of this Agreement. Subject to compliance with the terms of this Agreement, Valeant shall be responsible, in its discretion, acting reasonably, for determining the manner in which it allocates and prioritizes the Details, provided that, in so allocating the Details, Valeant shall take into consideration geographic territory, frequency of calls, prescribing levels and other reasonable considerations. Except as set forth in this Agreement, without the prior written consent of Dova (not to be unreasonably withheld, delayed or conditioned), Valeant shall not conduct any Valeant Activities, other than Detailing, with respect to the Product.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '(a) Commencing promptly upon completion of training of the Field Force Personnel that are engaged in Detailing the Product as described in Section 4.4.1 (but on the condition that Promotional Materials have been approved and delivered), Valeant shall deploy its Field Force Personnel that are engaged in Detailing to Detail the Product in accordance with the terms of this Agreement. Subject to compliance with the terms of this Agreement, Valeant shall be responsible, in its discretion, acting reasonably, for determining the manner in which it allocates and prioritizes the Details, provided that, in so allocating the Details, Valeant shall take into consideration geographic territory, frequency of calls, prescribing levels and other reasonable considerations. Except as set forth in this Agreement, without the prior written consent of Dova (not to be unreasonably withheld, delayed or conditioned), Valeant shall not conduct any Valeant Activities, other than Detailing, with respect to the Product.\\n\\n (b) [***]\\n\\n(c) Beginning after [***], Valeant may initiate discussions with Dova, upon at least [***] notice to Dova (which notice shall specify the proposed Alternate Product), regarding the potential replacement of the Designated Product with an Alternate Product.'],\n",
       "  ['REFERENCE',\n",
       "   'Except as set forth in this Agreement, without the prior written consent of Dova (not to be unreasonably withheld, delayed or conditioned), Valeant shall not conduct any Valeant Activities, other than Detailing, with respect to the Product.\\n\\n (b) [***]\\n\\n(c) Beginning after [***], Valeant may initiate discussions with Dova, upon at least [***] notice to Dova (which notice shall specify the proposed Alternate Product), regarding the potential replacement of the Designated Product with an Alternate Product. Following such notice period the Parties shall meet, through the JSC, and discuss in good faith (acting reasonably), for a period of up to [***], the potential replacement of the Designated Product with the Alternate Product. If the Parties agree on an Alternate Product, then the Parties shall make such agreement in writing and thereafter such Alternate Product shall be the Designated Product for purposes of this Agreement.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]\\n\\n(c) Beginning after [***], Valeant may initiate discussions with Dova, upon at least [***] notice to Dova (which notice shall specify the proposed Alternate Product), regarding the potential replacement of the Designated Product with an Alternate Product. Following such notice period the Parties shall meet, through the JSC, and discuss in good faith (acting reasonably), for a period of up to [***], the potential replacement of the Designated Product with the Alternate Product. If the Parties agree on an Alternate Product, then the Parties shall make such agreement in writing and thereafter such Alternate Product shall be the Designated Product for purposes of this Agreement. If the Parties cannot agree on the Alternate Product during such period, then Valeant may give to Dova a written notice (the \"Alternate Product Notice\") designating the proposed Alternate Product as the Alternate Product and, effective [***] after the Alternate Product Notice, such designated Alternate Product shall be the Designated Product for purposes of this Agreement; provided however that, notwithstanding the foregoing, Dova shall have the right to terminate this Agreement upon [***] written notice to Valeant after the Alternate Product Notice, provided further that if the Alternate Product is being proposed by Valeant as a result of an anticipated or the existence of a generic version of the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nDesignated Product, a decision, judgment, ruling or other requirement of a Government Authority, including the FDA relating to or impacting the Designated Product in the Territory, a material safety concern regarding the Designated Product or a mandatory recall or withdrawal of the Designated Product, then Dova shall have no right to terminate this Agreement pursuant to this Section 4.2.1(c).\\n\\n (d)'],\n",
       "  ['REFERENCE',\n",
       "   'If the Parties agree on an Alternate Product, then the Parties shall make such agreement in writing and thereafter such Alternate Product shall be the Designated Product for purposes of this Agreement. If the Parties cannot agree on the Alternate Product during such period, then Valeant may give to Dova a written notice (the \"Alternate Product Notice\") designating the proposed Alternate Product as the Alternate Product and, effective [***] after the Alternate Product Notice, such designated Alternate Product shall be the Designated Product for purposes of this Agreement; provided however that, notwithstanding the foregoing, Dova shall have the right to terminate this Agreement upon [***] written notice to Valeant after the Alternate Product Notice, provided further that if the Alternate Product is being proposed by Valeant as a result of an anticipated or the existence of a generic version of the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nDesignated Product, a decision, judgment, ruling or other requirement of a Government Authority, including the FDA relating to or impacting the Designated Product in the Territory, a material safety concern regarding the Designated Product or a mandatory recall or withdrawal of the Designated Product, then Dova shall have no right to terminate this Agreement pursuant to this Section 4.2.1(c).\\n\\n (d) [***]\\n\\n(e) Notwithstanding the terms of this Section 4.2.1, Valeant shall have the right, from time to time, during the Term, to include in the incentive compensation package of all or some of the Sales Representatives a spiff, spiv or other similar incentive bonus that is based on [***], provided that the actual, maximum payout from such incentive bonuses does not exceed, in the aggregate, an amount equal to [***] for each Sales Representative for each Calendar Quarter. Any such spiff, spiv or other similar incentive bonus shall not be included in the calculation of the applicable Sales Representatives incentive compensation package in determining Valeant\\'s compliance with the terms of Section 4.1.3.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   \"(d) [***]\\n\\n(e) Notwithstanding the terms of this Section 4.2.1, Valeant shall have the right, from time to time, during the Term, to include in the incentive compensation package of all or some of the Sales Representatives a spiff, spiv or other similar incentive bonus that is based on [***], provided that the actual, maximum payout from such incentive bonuses does not exceed, in the aggregate, an amount equal to [***] for each Sales Representative for each Calendar Quarter. Any such spiff, spiv or other similar incentive bonus shall not be included in the calculation of the applicable Sales Representatives incentive compensation package in determining Valeant's compliance with the terms of Section 4.1.3.\\n\\n 4.2.2 Records and Reports.\\n\\n (a) Valeant shall keep accurate and complete records, consistent with pharmaceutical industry standards, of each Detail and its obligations hereunder in connection therewith.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Any such spiff, spiv or other similar incentive bonus shall not be included in the calculation of the applicable Sales Representatives incentive compensation package in determining Valeant's compliance with the terms of Section 4.1.3.\\n\\n 4.2.2 Records and Reports.\\n\\n (a) Valeant shall keep accurate and complete records, consistent with pharmaceutical industry standards, of each Detail and its obligations hereunder in connection therewith. Such records shall be kept for the longer of (i) [***] after the end of the Calendar Year to which they relate and (ii) such period of time as required by Applicable Laws.\"],\n",
       "  ['REFERENCE',\n",
       "   '(a) Valeant shall keep accurate and complete records, consistent with pharmaceutical industry standards, of each Detail and its obligations hereunder in connection therewith. Such records shall be kept for the longer of (i) [***] after the end of the Calendar Year to which they relate and (ii) such period of time as required by Applicable Laws. Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Detail Report\"), setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such Calendar Quarter) (the \"Quarterly Average Sales Force Size\"), and (ii) the aggregate actual number of Details for the Product made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the Target Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***] after the end of the Calendar Year to which they relate and (ii) such period of time as required by Applicable Laws. Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Detail Report\"), setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such Calendar Quarter) (the \"Quarterly Average Sales Force Size\"), and (ii) the aggregate actual number of Details for the Product made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the Target Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.\\n\\n (b) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compensation Report\"), which describes (i) the details of the incentive compensation package of each Sales Representative as it relates to the Product and the Designated Product (or Alternate Product, as the case may be) (but, in the case of the Designated Product or Alternate Product, such details shall be limited to information regarding what portion of the Sales Representatives\\' target incentive compensation package is derived from achieving sales targets or goals of the Designated Product (or Alternate Product) , but shall not include any sales targets or goals for the Designated Product (or Alternate Product)), and (ii) the actual incentive compensation payouts for each Sales Representatives as described in Section 4.1.3.'],\n",
       "  ['REFERENCE',\n",
       "   'Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.\\n\\n (b) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compensation Report\"), which describes (i) the details of the incentive compensation package of each Sales Representative as it relates to the Product and the Designated Product (or Alternate Product, as the case may be) (but, in the case of the Designated Product or Alternate Product, such details shall be limited to information regarding what portion of the Sales Representatives\\' target incentive compensation package is derived from achieving sales targets or goals of the Designated Product (or Alternate Product) , but shall not include any sales targets or goals for the Designated Product (or Alternate Product)), and (ii) the actual incentive compensation payouts for each Sales Representatives as described in Section 4.1.3. Through the JSC, the Parties shall agree on a mutually acceptable form of Compensation Report.\\n\\n (c)'],\n",
       "  ['REFERENCE',\n",
       "   'Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compensation Report\"), which describes (i) the details of the incentive compensation package of each Sales Representative as it relates to the Product and the Designated Product (or Alternate Product, as the case may be) (but, in the case of the Designated Product or Alternate Product, such details shall be limited to information regarding what portion of the Sales Representatives\\' target incentive compensation package is derived from achieving sales targets or goals of the Designated Product (or Alternate Product) , but shall not include any sales targets or goals for the Designated Product (or Alternate Product)), and (ii) the actual incentive compensation payouts for each Sales Representatives as described in Section 4.1.3. Through the JSC, the Parties shall agree on a mutually acceptable form of Compensation Report.\\n\\n (c) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compliance Report\"), which sets out a summary of Valeant\\'s compliance monitoring and auditing of the Field Force Personnel that are engaged in Detailing (as such monitoring is further described in Section 4.5.1(b)), a summary of any compliance-related disciplinary actions relating to any Field Force Personnel that are engaged in Detailing and any associated remedial actions, a summary of all compliance investigations conducted by Valeant of any of the Field Force Personnel that are engaged in Detailing and any associated outcome, and, for the fourth Calendar Quarter only, a summary of the compliance-related training (including a reasonable description of each training topic) received by each Field Force Personnel that are engaged in Detailing during the Calendar Year. Through the JSC, the Parties shall agree on a mutually acceptable form of Compliance Report.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '(c) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Compliance Report\"), which sets out a summary of Valeant\\'s compliance monitoring and auditing of the Field Force Personnel that are engaged in Detailing (as such monitoring is further described in Section 4.5.1(b)), a summary of any compliance-related disciplinary actions relating to any Field Force Personnel that are engaged in Detailing and any associated remedial actions, a summary of all compliance investigations conducted by Valeant of any of the Field Force Personnel that are engaged in Detailing and any associated outcome, and, for the fourth Calendar Quarter only, a summary of the compliance-related training (including a reasonable description of each training topic) received by each Field Force Personnel that are engaged in Detailing during the Calendar Year. Through the JSC, the Parties shall agree on a mutually acceptable form of Compliance Report.\\n\\n 4.3 Compliance with Applicable Law.\\n\\n 4.3.1 In conducting the Valeant Activities hereunder, Valeant shall, and shall require all Field Force Personnel to, comply in all respects with Applicable Laws.'],\n",
       "  ['REFERENCE',\n",
       "   'Through the JSC, the Parties shall agree on a mutually acceptable form of Compliance Report.\\n\\n 4.3 Compliance with Applicable Law.\\n\\n 4.3.1 In conducting the Valeant Activities hereunder, Valeant shall, and shall require all Field Force Personnel to, comply in all respects with Applicable Laws. In addition, Dova shall, and shall require all of its sales representatives to, comply in all respects with Applicable Laws in connection with its promotion of the Product in the Territory.\\n\\n 4.3.2 Neither Valeant nor Field Force Personnel shall offer, pay, solicit or receive any remuneration to or from Target Professionals, in order to induce referrals of or purchase of the Product.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '4.3.1 In conducting the Valeant Activities hereunder, Valeant shall, and shall require all Field Force Personnel to, comply in all respects with Applicable Laws. In addition, Dova shall, and shall require all of its sales representatives to, comply in all respects with Applicable Laws in connection with its promotion of the Product in the Territory.\\n\\n 4.3.2 Neither Valeant nor Field Force Personnel shall offer, pay, solicit or receive any remuneration to or from Target Professionals, in order to induce referrals of or purchase of the Product.\\n\\n 4.3.3 In performing the activities contemplated by this Agreement, neither Valeant nor Field Force Personnel shall make any payment, either directly or indirectly, of money or other assets to government or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing where such payment would constitute violation of any Applicable Law. In addition, Valeant shall not make any payment either directly or indirectly to officials if such payment is for the purpose of unlawfully influencing decisions or actions with respect to the subject matter of this Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '4.3.2 Neither Valeant nor Field Force Personnel shall offer, pay, solicit or receive any remuneration to or from Target Professionals, in order to induce referrals of or purchase of the Product.\\n\\n 4.3.3 In performing the activities contemplated by this Agreement, neither Valeant nor Field Force Personnel shall make any payment, either directly or indirectly, of money or other assets to government or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing where such payment would constitute violation of any Applicable Law. In addition, Valeant shall not make any payment either directly or indirectly to officials if such payment is for the purpose of unlawfully influencing decisions or actions with respect to the subject matter of this Agreement.\\n\\n 4.3.4 No employee of Valeant or its Affiliates shall have authority to give any direction, either written or oral,\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nrelating to the making of any commitment by Dova or its agents to any Third Party in violation of terms of this or any other provision of this Agreement\\n\\n4.3.5 Neither Valeant nor Dova shall undertake any activity under or in connection with this Agreement which violates any Applicable Law.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   \"In addition, Valeant shall not make any payment either directly or indirectly to officials if such payment is for the purpose of unlawfully influencing decisions or actions with respect to the subject matter of this Agreement.\\n\\n 4.3.4 No employee of Valeant or its Affiliates shall have authority to give any direction, either written or oral,\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nrelating to the making of any commitment by Dova or its agents to any Third Party in violation of terms of this or any other provision of this Agreement\\n\\n4.3.5 Neither Valeant nor Dova shall undertake any activity under or in connection with this Agreement which violates any Applicable Law.\\n\\n 4.3.6 Valeant's or Dova's material failure to abide by the provisions of this Section 4.3 shall be deemed a material breach of this Agreement by Valeant or Dova (as the case may be) and subject to the terms of Section 12.2 hereof.\\n\\n 4.3.7 Dova shall ensure that any patient assistance program used in connection with the Product (and the services performed thereby in connection with the Product) shall be operated in accordance with Applicable Law.\"],\n",
       "  ['REFERENCE',\n",
       "   \"No employee of Valeant or its Affiliates shall have authority to give any direction, either written or oral,\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nrelating to the making of any commitment by Dova or its agents to any Third Party in violation of terms of this or any other provision of this Agreement\\n\\n4.3.5 Neither Valeant nor Dova shall undertake any activity under or in connection with this Agreement which violates any Applicable Law.\\n\\n 4.3.6 Valeant's or Dova's material failure to abide by the provisions of this Section 4.3 shall be deemed a material breach of this Agreement by Valeant or Dova (as the case may be) and subject to the terms of Section 12.2 hereof.\\n\\n 4.3.7 Dova shall ensure that any patient assistance program used in connection with the Product (and the services performed thereby in connection with the Product) shall be operated in accordance with Applicable Law. Notwithstanding the immediately preceding sentence, Dova shall have no liability with respect to any breach or non-compliance with Applicable Law relating to any patient assistance program used in connection with the Product to the extent caused by the act or omission of any Field Force Personnel, which act or omission is not in compliance with the terms of this Agreement, Applicable Law or instructions of Dova.\\n\\n 4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support from Dova with respect to the Product.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   '4.3.7 Dova shall ensure that any patient assistance program used in connection with the Product (and the services performed thereby in connection with the Product) shall be operated in accordance with Applicable Law. Notwithstanding the immediately preceding sentence, Dova shall have no liability with respect to any breach or non-compliance with Applicable Law relating to any patient assistance program used in connection with the Product to the extent caused by the act or omission of any Field Force Personnel, which act or omission is not in compliance with the terms of this Agreement, Applicable Law or instructions of Dova.\\n\\n 4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support from Dova with respect to the Product.\\n\\n 4.3.9 Dova shall ensure that its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product are in full compliance with all Applicable Laws.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support from Dova with respect to the Product.\\n\\n 4.3.9 Dova shall ensure that its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product are in full compliance with all Applicable Laws.\\n\\n 4.3.10 If, during the Term, Valeant becomes aware of a material violation or failure to comply with Applicable Law or the terms of this Agreement by a member of the Field Force Personnel that are engaged in Detailing, it shall promptly, but no later than two (2) Business Days after it becomes aware, notify Dova of such violation and, as promptly as possible thereafter, shall notify the steps it has taken or intends to take to remediate such violation.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall ensure that its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product are in full compliance with all Applicable Laws.\\n\\n 4.3.10 If, during the Term, Valeant becomes aware of a material violation or failure to comply with Applicable Law or the terms of this Agreement by a member of the Field Force Personnel that are engaged in Detailing, it shall promptly, but no later than two (2) Business Days after it becomes aware, notify Dova of such violation and, as promptly as possible thereafter, shall notify the steps it has taken or intends to take to remediate such violation.\\n\\n 4.3.11 Compliance Managers. As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise (each, a \"Compliance Manager\").'],\n",
       "  ['REFERENCE',\n",
       "   'If, during the Term, Valeant becomes aware of a material violation or failure to comply with Applicable Law or the terms of this Agreement by a member of the Field Force Personnel that are engaged in Detailing, it shall promptly, but no later than two (2) Business Days after it becomes aware, notify Dova of such violation and, as promptly as possible thereafter, shall notify the steps it has taken or intends to take to remediate such violation.\\n\\n 4.3.11 Compliance Managers. As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise (each, a \"Compliance Manager\"). From time to time, each Party may change its Compliance Manager by giving written notice to the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related matters.'],\n",
       "  ['REFERENCE',\n",
       "   'As soon as practicable, but no later than thirty (30) days after the Effective Date, each Party shall appoint a representative to act as its compliance manager under this Agreement, each of which is routinely responsible for advising such Party on compliance matters and has suitable seniority and other relevant experience and expertise (each, a \"Compliance Manager\"). From time to time, each Party may change its Compliance Manager by giving written notice to the other Party. The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters.'],\n",
       "  ['REFERENCE',\n",
       "   \"The Compliance Managers shall serve as a key point of contact between the Parties for compliance-related matters. Each Compliance Manager shall facilitate the resolution of any compliance issue with the Compliance Manager of the other Party. The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product.\"],\n",
       "  ['REFERENCE',\n",
       "   \"The Compliance Managers will use good faith efforts to reach consensus on all compliance matters. If the Compliance Managers do not reach consensus on an issue promptly, then such issue shall be submitted to dispute resolution process described in Section 13.6. Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant's compliance program policies and compliance training materials which are applicable to the Field Force Personnel's promotion of the Product. Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection with the compliance-related provisions herein.\\n\\n 4.4 Field Force Personnel Training; Product Materials.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Upon the reasonable request of Dova from to time, Valeant shall deliver to Dova copies of Valeant\\'s compliance program policies and compliance training materials which are applicable to the Field Force Personnel\\'s promotion of the Product. Other than as expressly stated herein, Valeant shall not be required to modify its compliance policies or practices in connection with the compliance-related provisions herein.\\n\\n 4.4 Field Force Personnel Training; Product Materials.\\n\\n 4.4.1 Training, Training Materials and Promotional Materials.\\n\\n (a) Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product training materials for Field Force Personnel (the \"Product Training Materials\") and (ii) all Product marketing and educational materials (the \"Promotional Materials\") (the Product Training Materials and the Promotional Materials, collectively, the \"Product Materials\").'],\n",
       "  ['REFERENCE',\n",
       "   '4.4 Field Force Personnel Training; Product Materials.\\n\\n 4.4.1 Training, Training Materials and Promotional Materials.\\n\\n (a) Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product training materials for Field Force Personnel (the \"Product Training Materials\") and (ii) all Product marketing and educational materials (the \"Promotional Materials\") (the Product Training Materials and the Promotional Materials, collectively, the \"Product Materials\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova, the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant to review such content and provide verbal feedback to Dova in advance of use of the Product Materials.'],\n",
       "  ['REFERENCE',\n",
       "   '(a) Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product training materials for Field Force Personnel (the \"Product Training Materials\") and (ii) all Product marketing and educational materials (the \"Promotional Materials\") (the Product Training Materials and the Promotional Materials, collectively, the \"Product Materials\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova, the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable in the promotion of the Product; provided that in any event, to the extent that Dova reasonably believes that such changes are not in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right to conclusively determine such matter.'],\n",
       "  ['REFERENCE',\n",
       "   'Once approved by Dova, the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable in the promotion of the Product; provided that in any event, to the extent that Dova reasonably believes that such changes are not in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product Materials approved by Dova in the performance of Valeant Activities under this Agreement; provided, however, that Valeant shall not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprovided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant reserves the right not to use certain Product Materials.'],\n",
       "  ['REFERENCE',\n",
       "   'In the event of any disagreement between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product Materials approved by Dova in the performance of Valeant Activities under this Agreement; provided, however, that Valeant shall not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprovided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant.'],\n",
       "  ['REFERENCE',\n",
       "   'Valeant shall use only Product Materials approved by Dova in the performance of Valeant Activities under this Agreement; provided, however, that Valeant shall not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprovided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall be responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as reasonably practical.\\n\\n (b) Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty.'],\n",
       "  ['REFERENCE',\n",
       "   'In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as reasonably practical.\\n\\n (b) Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of Valeant regarding the Promotional Materials.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '(b) Commencing with the Promotional Materials to be used for Calendar Year 2019 and for the remainder of the Term, Valeant and Dova shall meet to discuss the content of such Promotional Materials in order to ensure that such Promotional Materials appropriately address any messaging that may be desired for the Target Professionals in the Specialty. Such discussions may take place in the forum of the JSC. Dova shall in good faith reasonably consider all comments and suggestions of Valeant regarding the Promotional Materials.\\n\\n (c) Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order to support such training.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall in good faith reasonably consider all comments and suggestions of Valeant regarding the Promotional Materials.\\n\\n (c) Promptly after the Effective Date, the Parties will collaborate to plan and schedule training for the Sales Representatives at a mutually acceptable time(s) and date(s), including a launch meeting for the Sales Representatives at a mutually acceptable location. Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the responsibility of Valeant.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova will lead such initial training and Valeant shall cooperate with any reasonable requests of Dova in order to support such training. The costs and expenses of such launch meeting will be shared equally by the Parties, other than travel and lodging for the Sales Representatives which shall be the responsibility of Valeant. All other training costs and expenses shall be the responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova.'],\n",
       "  ['REFERENCE',\n",
       "   \"All other training costs and expenses shall be the responsibility of Valeant. After the initial training, the Parties will collaborate to provide additional training at such frequency, times and places as the circumstances warrant and the Parties mutually agree. Valeant shall have the right, but not the obligation, to conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\\n\\n (d) Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any Valeant Activities.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Valeant shall have the right, but not the obligation, to conduct such additional training itself, provided that the Valeant trainers have been trained by Dova, and provided further that Dova shall have the right to attend such training upon reasonable notice by Valeant to Dova. Valeant will certify in writing to Dova that all Field Force Personnel have completed the training described in this Section 4.4.1(b).\\n\\n (d) Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\\n\\n (e) Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall Detail the Product without having undergone such training.\"],\n",
       "  ['REFERENCE',\n",
       "   \"(d) Valeant and all Field Force Personnel that are engaged in Valeant Activities shall comply with the applicable provisions of the Code, and shall be trained on Valeant's compliance policies, including those that are consistent with the applicable provisions of Sec. 1128B(b) of the Social Security Act and the American Medical Association Ethical Guidelines for Gifts to Physicians from Industry (which such training may have been accomplished prior to the Term), prior to commencing any Valeant Activities. Valeant agrees that it shall train any employee or agent of Valeant who is involved in performing the activities contemplated by this Agreement on anti-corruption and anti-bribery at its own expense.\\n\\n (e) Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on- going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the pharmaceutical industry.\\n\\n 4.4.2 Ownership of Product Materials.\"],\n",
       "  ['REFERENCE',\n",
       "   '(e) Field Force Personnel that are engaged in Detailing shall conduct the Valeant Activities only after having undergone the training described in this Section 4.4 and, without limiting the foregoing, no Field Force Personnel member shall Detail the Product without having undergone such training. Subject to the foregoing, Valeant shall have the responsibility for on- going training of its Field Force Personnel that are engaged in Detailing in accordance with customary practice in the pharmaceutical industry.\\n\\n 4.4.2 Ownership of Product Materials. As between the Parties, Dova shall own all right, title and interest in and to any Product Materials (and all content contained therein) and any Product Labeling (and all content contained therein), including applicable copyrights and trademarks (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling), and to the extent Valeant (or any of its Affiliates) obtains or otherwise has a claim to any of the foregoing, Valeant hereby assigns (and shall cause any applicable Affiliate to assign) all of its right, title and interest in and to such Product Materials (and content) and Product Labeling (and content) (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling) to Dova and Valeant agrees to (and shall cause its applicable Affiliate to) execute all documents and take all actions as are reasonably requested by Dova to vest title to such Product Materials (and content) and Product Labeling (and content) in Dova (or its designated Affiliate).\\n\\n 4.5 Provisions Related to Field Force Personnel.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '4.4.2 Ownership of Product Materials. As between the Parties, Dova shall own all right, title and interest in and to any Product Materials (and all content contained therein) and any Product Labeling (and all content contained therein), including applicable copyrights and trademarks (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling), and to the extent Valeant (or any of its Affiliates) obtains or otherwise has a claim to any of the foregoing, Valeant hereby assigns (and shall cause any applicable Affiliate to assign) all of its right, title and interest in and to such Product Materials (and content) and Product Labeling (and content) (other than any name, trademark, trade name or logo of Valeant or its Affiliates that may appear on such Product materials or Product Labeling) to Dova and Valeant agrees to (and shall cause its applicable Affiliate to) execute all documents and take all actions as are reasonably requested by Dova to vest title to such Product Materials (and content) and Product Labeling (and content) in Dova (or its designated Affiliate).\\n\\n 4.5 Provisions Related to Field Force Personnel.\\n\\n 4.5.1 Activities of Field Force Personnel. Valeant hereby agrees and acknowledges that the following shall apply with respect to itself and the Field Force Personnel that are engaged in Detailing:\\n\\n(a) Valeant shall instruct and cause the Field Force Personnel that are engaged in Detailing to use only the Product Labeling and, subject to the terms of Section 4.4, Product Materials approved by Dova for the conduct of the Valeant Activities for the Product and consistent with Applicable Laws.'],\n",
       "  ['REFERENCE',\n",
       "   \"4.5 Provisions Related to Field Force Personnel.\\n\\n 4.5.1 Activities of Field Force Personnel. Valeant hereby agrees and acknowledges that the following shall apply with respect to itself and the Field Force Personnel that are engaged in Detailing:\\n\\n(a) Valeant shall instruct and cause the Field Force Personnel that are engaged in Detailing to use only the Product Labeling and, subject to the terms of Section 4.4, Product Materials approved by Dova for the conduct of the Valeant Activities for the Product and consistent with Applicable Laws. Valeant shall instruct the Field Force Personnel that are engaged in Detailing to, and will monitor the Field Force Personnel that are engaged in Detailing to ensure that such Field Force Personnel, limit their claims of efficacy and safety for the Product to those claims which are consistent with and do not exceed the Product Labeling and any Promotional Materials.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) Valeant shall instruct the Field Force Personnel that are engaged in Detailing to conduct the Valeant Activities for the Product, and will monitor and audit (in accordance with Valeant's standard practice) the Field Force Personnel that are engaged in Detailing so that such personnel conduct the Valeant Activities for the Product in adherence in all respects with Applicable Laws.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"Valeant hereby agrees and acknowledges that the following shall apply with respect to itself and the Field Force Personnel that are engaged in Detailing:\\n\\n(a) Valeant shall instruct and cause the Field Force Personnel that are engaged in Detailing to use only the Product Labeling and, subject to the terms of Section 4.4, Product Materials approved by Dova for the conduct of the Valeant Activities for the Product and consistent with Applicable Laws. Valeant shall instruct the Field Force Personnel that are engaged in Detailing to, and will monitor the Field Force Personnel that are engaged in Detailing to ensure that such Field Force Personnel, limit their claims of efficacy and safety for the Product to those claims which are consistent with and do not exceed the Product Labeling and any Promotional Materials.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) Valeant shall instruct the Field Force Personnel that are engaged in Detailing to conduct the Valeant Activities for the Product, and will monitor and audit (in accordance with Valeant's standard practice) the Field Force Personnel that are engaged in Detailing so that such personnel conduct the Valeant Activities for the Product in adherence in all respects with Applicable Laws.\\n\\n (c) Valeant shall instruct the Field Force Personnel that are engaged in Detailing regarding provisions of this Agreement applicable to Details of the Product, including Section 4.2 and this Section 4.5.1.\\n\\n (d) Valeant acknowledges and agrees that Dova will not maintain or procure any worker's compensation, healthcare, or other insurance for or on behalf of the Field Force Personnel, all of which shall be Valeant's sole responsibility.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) Valeant shall instruct the Field Force Personnel that are engaged in Detailing to conduct the Valeant Activities for the Product, and will monitor and audit (in accordance with Valeant\\'s standard practice) the Field Force Personnel that are engaged in Detailing so that such personnel conduct the Valeant Activities for the Product in adherence in all respects with Applicable Laws.\\n\\n (c) Valeant shall instruct the Field Force Personnel that are engaged in Detailing regarding provisions of this Agreement applicable to Details of the Product, including Section 4.2 and this Section 4.5.1.\\n\\n (d) Valeant acknowledges and agrees that Dova will not maintain or procure any worker\\'s compensation, healthcare, or other insurance for or on behalf of the Field Force Personnel, all of which shall be Valeant\\'s sole responsibility.\\n\\n (e) Valeant acknowledges and agrees that all Field Force Personnel are employees of Valeant and are not, and are not intended to be treated as, employees of Dova or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any \"employee benefit plans\" (as such term is defined in section 3(3) of ERISA) that are sponsored by Dova or any of its Affiliates or that are offered from time to time by Dova or its Affiliates to their own employees. All matters of compensation, benefits and other terms of employment for any such Field Force Personnel shall be solely a matter between Valeant and such individual.'],\n",
       "  ['REFERENCE',\n",
       "   '(d) Valeant acknowledges and agrees that Dova will not maintain or procure any worker\\'s compensation, healthcare, or other insurance for or on behalf of the Field Force Personnel, all of which shall be Valeant\\'s sole responsibility.\\n\\n (e) Valeant acknowledges and agrees that all Field Force Personnel are employees of Valeant and are not, and are not intended to be treated as, employees of Dova or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any \"employee benefit plans\" (as such term is defined in section 3(3) of ERISA) that are sponsored by Dova or any of its Affiliates or that are offered from time to time by Dova or its Affiliates to their own employees. All matters of compensation, benefits and other terms of employment for any such Field Force Personnel shall be solely a matter between Valeant and such individual. Dova shall not be responsible to Valeant, or to the Field Force Personnel, for any compensation, expense reimbursements or benefits (including vacation and holiday remuneration, healthcare coverage or insurance, life insurance, severance or termination of employment benefits, pension or profit-sharing benefits and disability benefits), payroll-related taxes or withholdings, or any governmental charges or benefits (including unemployment and disability insurance contributions or benefits and workmen\\'s compensation contributions or benefits) that may be imposed upon or be related to the performance by Valeant or such individuals of this Agreement, all of which shall be the sole responsibility of Valeant, even if it is subsequently determined by any Governmental Authority that any such individual may be an employee or a common law employee of Dova or any of its Affiliates or is otherwise entitled to such payments and benefits.\\n\\n (f) Valeant shall be solely responsible for the acts or omissions of the Field Force Personnel that are not in compliance with Applicable Law and the terms of this Agreement while performing any of the activities under this Agreement.'],\n",
       "  ['REFERENCE',\n",
       "   \"All matters of compensation, benefits and other terms of employment for any such Field Force Personnel shall be solely a matter between Valeant and such individual. Dova shall not be responsible to Valeant, or to the Field Force Personnel, for any compensation, expense reimbursements or benefits (including vacation and holiday remuneration, healthcare coverage or insurance, life insurance, severance or termination of employment benefits, pension or profit-sharing benefits and disability benefits), payroll-related taxes or withholdings, or any governmental charges or benefits (including unemployment and disability insurance contributions or benefits and workmen's compensation contributions or benefits) that may be imposed upon or be related to the performance by Valeant or such individuals of this Agreement, all of which shall be the sole responsibility of Valeant, even if it is subsequently determined by any Governmental Authority that any such individual may be an employee or a common law employee of Dova or any of its Affiliates or is otherwise entitled to such payments and benefits.\\n\\n (f) Valeant shall be solely responsible for the acts or omissions of the Field Force Personnel that are not in compliance with Applicable Law and the terms of this Agreement while performing any of the activities under this Agreement. Valeant shall be solely responsible and liable for all probationary and termination actions taken by it, as well as for the formulation, content and dissemination (including content) of all employment policies and rules (including written probationary and termination policies) applicable to its employees.\\n\\n 4.5.2 Termination of Employment; Cessation of Valeant Activities.\"],\n",
       "  ['REFERENCE',\n",
       "   '(f) Valeant shall be solely responsible for the acts or omissions of the Field Force Personnel that are not in compliance with Applicable Law and the terms of this Agreement while performing any of the activities under this Agreement. Valeant shall be solely responsible and liable for all probationary and termination actions taken by it, as well as for the formulation, content and dissemination (including content) of all employment policies and rules (including written probationary and termination policies) applicable to its employees.\\n\\n 4.5.2 Termination of Employment; Cessation of Valeant Activities. If any Field Force Personnel leaves the employ of Valeant (or any of its Affiliates), or otherwise ceases to conduct the Valeant Activities for the Product, Valeant shall, to the extent consistent with, and in a manner similar to, its practices with respect to departures of the sales representatives or other field force personnel, as applicable, promoting, marketing or detailing other products for Valeant, account for, and shall cause such departing Field Force Personnel to return to Valeant and delete from his/her computer files (to the extent such materials or information have been provided in, or converted into, electronic form) all materials relating to the Product that have been provided to such individual, including the Product Materials and account level information, including all copies of the foregoing.\\n\\n 4.5.3 Discipline.'],\n",
       "  ['REFERENCE',\n",
       "   '4.5.2 Termination of Employment; Cessation of Valeant Activities. If any Field Force Personnel leaves the employ of Valeant (or any of its Affiliates), or otherwise ceases to conduct the Valeant Activities for the Product, Valeant shall, to the extent consistent with, and in a manner similar to, its practices with respect to departures of the sales representatives or other field force personnel, as applicable, promoting, marketing or detailing other products for Valeant, account for, and shall cause such departing Field Force Personnel to return to Valeant and delete from his/her computer files (to the extent such materials or information have been provided in, or converted into, electronic form) all materials relating to the Product that have been provided to such individual, including the Product Materials and account level information, including all copies of the foregoing.\\n\\n 4.5.3 Discipline. If Dova has a reasonable basis for believing any member of the Field Force Personnel that are engaged in Detailing has violated any Applicable Laws, or failed to comply with this Agreement, then Dova shall notify Valeant of the alleged violation and Valeant shall promptly investigate the matter and, if the allegation turns out to be true, shall take the appropriate remedial action. Subject to the foregoing, Valeant shall be solely responsible for taking any disciplinary actions in connection with its Field Force Personnel that are engaged in Detailing.'],\n",
       "  ['REFERENCE',\n",
       "   \"4.5.3 Discipline. If Dova has a reasonable basis for believing any member of the Field Force Personnel that are engaged in Detailing has violated any Applicable Laws, or failed to comply with this Agreement, then Dova shall notify Valeant of the alleged violation and Valeant shall promptly investigate the matter and, if the allegation turns out to be true, shall take the appropriate remedial action. Subject to the foregoing, Valeant shall be solely responsible for taking any disciplinary actions in connection with its Field Force Personnel that are engaged in Detailing. If, at any time, Dova has any other compliance-related concerns regarding any Field Force Personnel Detailing, Dova's Compliance Manager shall notify Valeant's Compliance Manager of such concerns in writing and the Compliance Managers will discuss and resolve such matters pursuant to Section 4.3.9.\\n\\n 4.6 Responsibility for Valeant Activity Costs and Expenses.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Subject to the foregoing, Valeant shall be solely responsible for taking any disciplinary actions in connection with its Field Force Personnel that are engaged in Detailing. If, at any time, Dova has any other compliance-related concerns regarding any Field Force Personnel Detailing, Dova's Compliance Manager shall notify Valeant's Compliance Manager of such concerns in writing and the Compliance Managers will discuss and resolve such matters pursuant to Section 4.3.9.\\n\\n 4.6 Responsibility for Valeant Activity Costs and Expenses. Other than as expressly set out herein, Valeant shall be solely responsible for any and all costs and expenses incurred by Valeant or any of its Affiliates in connection with the conduct of the Valeant Activities for the Product hereunder, including all costs and expenses in connection with Sales Representatives, including salaries, travel expenses and other expenses, credentialing, licensing, providing benefits, deducting federal, state and local payroll taxes, and paying workers' compensation premiums, unemployment insurance contributions and any other payments required by Applicable Laws to be made on behalf of employees.\\n\\n 4.7 Data Sharing.\"],\n",
       "  ['REFERENCE',\n",
       "   \"4.6 Responsibility for Valeant Activity Costs and Expenses. Other than as expressly set out herein, Valeant shall be solely responsible for any and all costs and expenses incurred by Valeant or any of its Affiliates in connection with the conduct of the Valeant Activities for the Product hereunder, including all costs and expenses in connection with Sales Representatives, including salaries, travel expenses and other expenses, credentialing, licensing, providing benefits, deducting federal, state and local payroll taxes, and paying workers' compensation premiums, unemployment insurance contributions and any other payments required by Applicable Laws to be made on behalf of employees.\\n\\n 4.7 Data Sharing. Dova shall provide to Valeant certain information relating to the sale, commercialization, marketing and promotion of the Product, as may be mutually agreed by the Parties from time to time, for use by Valeant and the Field Force Personnel in connection with the Valeant Activities. Such information may include data from the applicable reimbursement HUB, specialty data aggregator, market research, and market access contracting and Third Party-provided brand performance data ([***]).\"],\n",
       "  ['REFERENCE',\n",
       "   '4.7 Data Sharing. Dova shall provide to Valeant certain information relating to the sale, commercialization, marketing and promotion of the Product, as may be mutually agreed by the Parties from time to time, for use by Valeant and the Field Force Personnel in connection with the Valeant Activities. Such information may include data from the applicable reimbursement HUB, specialty data aggregator, market research, and market access contracting and Third Party-provided brand performance data ([***]). The timing of the delivery of such information shall be mutually agreed upon by the Parties, acting reasonably.\\n\\n ARTICLE 5  REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n5.1 Dova Responsibility.'],\n",
       "  ['REFERENCE',\n",
       "   'Such information may include data from the applicable reimbursement HUB, specialty data aggregator, market research, and market access contracting and Third Party-provided brand performance data ([***]). The timing of the delivery of such information shall be mutually agreed upon by the Parties, acting reasonably.\\n\\n ARTICLE 5  REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n5.1 Dova Responsibility. As between the Parties, except as expressly set out herein, all regulatory matters regarding the Product shall be the responsibility of Dova, including responsibility for all communications with Governmental Authorities, including but not limited to FDA, related to the Product, and Dova shall have sole responsibility to seek and/or obtain any necessary approvals of any Product Labeling and the Promotional Materials used in connection with the Product, and for determining whether the same requires approval. As between the Parties, Dova shall be responsible for any reporting of matters regarding the manufacture, sale or promotion of the Product (including Adverse Events) to or with the FDA and other relevant regulatory authorities, in accordance with Applicable Laws.'],\n",
       "  ['REFERENCE',\n",
       "   \"ARTICLE 5  REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n5.1 Dova Responsibility. As between the Parties, except as expressly set out herein, all regulatory matters regarding the Product shall be the responsibility of Dova, including responsibility for all communications with Governmental Authorities, including but not limited to FDA, related to the Product, and Dova shall have sole responsibility to seek and/or obtain any necessary approvals of any Product Labeling and the Promotional Materials used in connection with the Product, and for determining whether the same requires approval. As between the Parties, Dova shall be responsible for any reporting of matters regarding the manufacture, sale or promotion of the Product (including Adverse Events) to or with the FDA and other relevant regulatory authorities, in accordance with Applicable Laws. Dova shall maintain, at its cost, the Regulatory Approvals for the Product and shall comply with all Applicable Law relevant to the conduct of Dova's business with respect to the Product or pursuant to this Agreement, including, without limitation, all applicable requirements under the Act.\\n\\n 5.2 Valeant Involvement.\"],\n",
       "  ['REFERENCE',\n",
       "   \"As between the Parties, Dova shall be responsible for any reporting of matters regarding the manufacture, sale or promotion of the Product (including Adverse Events) to or with the FDA and other relevant regulatory authorities, in accordance with Applicable Laws. Dova shall maintain, at its cost, the Regulatory Approvals for the Product and shall comply with all Applicable Law relevant to the conduct of Dova's business with respect to the Product or pursuant to this Agreement, including, without limitation, all applicable requirements under the Act.\\n\\n 5.2 Valeant Involvement. Except as expressly permitted herein, Valeant shall not, without Dova's prior written consent, correspond or communicate with the FDA or with any other Governmental Authority concerning the Product, or otherwise take any action concerning any Regulatory Approval or other authorization under which the Product is marketed or sold. If not prohibited by any Government Authority or Applicable Law, Valeant shall provide to Dova, promptly upon receipt, copies of any communication from the FDA or other Governmental Authority related to the Product.\"],\n",
       "  ['REFERENCE',\n",
       "   \"5.2 Valeant Involvement. Except as expressly permitted herein, Valeant shall not, without Dova's prior written consent, correspond or communicate with the FDA or with any other Governmental Authority concerning the Product, or otherwise take any action concerning any Regulatory Approval or other authorization under which the Product is marketed or sold. If not prohibited by any Government Authority or Applicable Law, Valeant shall provide to Dova, promptly upon receipt, copies of any communication from the FDA or other Governmental Authority related to the Product. If not prohibited by any Government Authority or Applicable Law, Dova has the right to review and comment on Valeant's draft responses to any Governmental Authorities relevant to Detail of the Product prior to Valeant's issuance of such response; and Valeant agrees to consider any comments or suggestions from Dova in good faith.\\n\\n5.3 Inspections.\\n\\n 5.3.1 If not prohibited by any Government Authority or Applicable Law, Valeant shall notify Dova immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Valeant reasonably believes may impact any aspect of the Valeant Activities.\"],\n",
       "  ['REFERENCE',\n",
       "   \"If not prohibited by any Government Authority or Applicable Law, Valeant shall provide to Dova, promptly upon receipt, copies of any communication from the FDA or other Governmental Authority related to the Product. If not prohibited by any Government Authority or Applicable Law, Dova has the right to review and comment on Valeant's draft responses to any Governmental Authorities relevant to Detail of the Product prior to Valeant's issuance of such response; and Valeant agrees to consider any comments or suggestions from Dova in good faith.\\n\\n5.3 Inspections.\\n\\n 5.3.1 If not prohibited by any Government Authority or Applicable Law, Valeant shall notify Dova immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Valeant reasonably believes may impact any aspect of the Valeant Activities. If not prohibited by any Government Authority or Applicable Law, Dova shall have the right to have a representative present at any such portion of the inspection involving any Valeant Activities. In such cases, Valeant shall (i) keep Dova fully informed of the progress and status of any such inspection or investigation, (ii) prior to undertaking any action pursuant to this Section 5.3.1, notify Dova of the inspection or investigation, and disclose to Dova in writing the Governmental Authorities' assertions, findings and related results of such inspection or investigation pertaining to the Valeant Activities, and (iii) provide full disclosure to Dova with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.1 prior to acting as it pertains to the Valeant Activities.\"],\n",
       "  ['REFERENCE',\n",
       "   \"5.3.1 If not prohibited by any Government Authority or Applicable Law, Valeant shall notify Dova immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Valeant reasonably believes may impact any aspect of the Valeant Activities. If not prohibited by any Government Authority or Applicable Law, Dova shall have the right to have a representative present at any such portion of the inspection involving any Valeant Activities. In such cases, Valeant shall (i) keep Dova fully informed of the progress and status of any such inspection or investigation, (ii) prior to undertaking any action pursuant to this Section 5.3.1, notify Dova of the inspection or investigation, and disclose to Dova in writing the Governmental Authorities' assertions, findings and related results of such inspection or investigation pertaining to the Valeant Activities, and (iii) provide full disclosure to Dova with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.1 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n 5.3.2 If not prohibited by any Government Authority or Applicable Law, Dova shall notify Valeant immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Dova reasonably believes may impact the Valeant Activities.\"],\n",
       "  ['REFERENCE',\n",
       "   \"In such cases, Valeant shall (i) keep Dova fully informed of the progress and status of any such inspection or investigation, (ii) prior to undertaking any action pursuant to this Section 5.3.1, notify Dova of the inspection or investigation, and disclose to Dova in writing the Governmental Authorities' assertions, findings and related results of such inspection or investigation pertaining to the Valeant Activities, and (iii) provide full disclosure to Dova with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.1 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n 5.3.2 If not prohibited by any Government Authority or Applicable Law, Dova shall notify Valeant immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Dova reasonably believes may impact the Valeant Activities. In such cases, Dova shall (i) keep Valeant fully informed of the progress and status of any such inspection or investigation, (ii) disclose to Valeant in writing the Governmental Authorities' assertions, findings and related results of such inspection or investigation pertaining to the Product or its promotion, and (iii) provide full disclosure to Valeant with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.2 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   '5.3.2 If not prohibited by any Government Authority or Applicable Law, Dova shall notify Valeant immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Dova reasonably believes may impact the Valeant Activities. In such cases, Dova shall (i) keep Valeant fully informed of the progress and status of any such inspection or investigation, (ii) disclose to Valeant in writing the Governmental Authorities\\' assertions, findings and related results of such inspection or investigation pertaining to the Product or its promotion, and (iii) provide full disclosure to Valeant with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.2 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n 5.4 Pharmacovigilance. Subject to the terms of this Agreement, as soon as practicable following the Effective Date (but in no event later than [***]), Dova and Valeant (under the guidance of their respective pharmacovigilance departments, or equivalent thereof) shall identify and finalize the responsibilities the Parties shall employ to protect patients and promote their well- being in a separate safety data exchange agreement (\"Pharmacovigilance Agreement\").'],\n",
       "  ['REFERENCE',\n",
       "   'In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification; provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.\\n\\n 5.4 Pharmacovigilance. Subject to the terms of this Agreement, as soon as practicable following the Effective Date (but in no event later than [***]), Dova and Valeant (under the guidance of their respective pharmacovigilance departments, or equivalent thereof) shall identify and finalize the responsibilities the Parties shall employ to protect patients and promote their well- being in a separate safety data exchange agreement (\"Pharmacovigilance Agreement\"). These responsibilities shall include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication and exchange (as between the Parties) of safety information such as Adverse Events, lack of efficacy, misuse/abuse, and any other information concerning the safety of the Product. Such guidelines and procedures will be in accordance with, and enable the Parties and their Affiliates to fulfill, regulatory reporting obligations to Governmental Authorities.'],\n",
       "  ['REFERENCE',\n",
       "   'Subject to the terms of this Agreement, as soon as practicable following the Effective Date (but in no event later than [***]), Dova and Valeant (under the guidance of their respective pharmacovigilance departments, or equivalent thereof) shall identify and finalize the responsibilities the Parties shall employ to protect patients and promote their well- being in a separate safety data exchange agreement (\"Pharmacovigilance Agreement\"). These responsibilities shall include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication and exchange (as between the Parties) of safety information such as Adverse Events, lack of efficacy, misuse/abuse, and any other information concerning the safety of the Product. Such guidelines and procedures will be in accordance with, and enable the Parties and their Affiliates to fulfill, regulatory reporting obligations to Governmental Authorities. The Pharmacovigilance Agreement shall provide that: (i) Dova shall be responsible for all pharmacovigilance activities regarding the Product, including signal detection, medical surveillance, risk management, medical literature review and monitoring, Adverse Event reporting and responses to Governmental Authority requests or enquiries, and shall provide information related thereto to Valeant, and (ii) in the event Valeant receives safety information regarding the Product, or information regarding any safety-related regulatory request or inquiry, Valeant shall notify Dova as soon as practicable, but, in any event, within the timelines set forth in the Pharmacovigilance Agreement.\\n\\n 5.5 Unsolicited Requests for Medical Information.'],\n",
       "  ['REFERENCE',\n",
       "   'Such guidelines and procedures will be in accordance with, and enable the Parties and their Affiliates to fulfill, regulatory reporting obligations to Governmental Authorities. The Pharmacovigilance Agreement shall provide that: (i) Dova shall be responsible for all pharmacovigilance activities regarding the Product, including signal detection, medical surveillance, risk management, medical literature review and monitoring, Adverse Event reporting and responses to Governmental Authority requests or enquiries, and shall provide information related thereto to Valeant, and (ii) in the event Valeant receives safety information regarding the Product, or information regarding any safety-related regulatory request or inquiry, Valeant shall notify Dova as soon as practicable, but, in any event, within the timelines set forth in the Pharmacovigilance Agreement.\\n\\n 5.5 Unsolicited Requests for Medical Information. Valeant shall direct to Dova any unsolicited requests for off-label medical information from health care professionals with respect to the Product promptly following receipt by Valeant (but in no\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nevent later than [***] after receipt). Dova shall, within [***] following receipt of any such request from Valeant, address any such requests directly.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '5.5 Unsolicited Requests for Medical Information. Valeant shall direct to Dova any unsolicited requests for off-label medical information from health care professionals with respect to the Product promptly following receipt by Valeant (but in no\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nevent later than [***] after receipt). Dova shall, within [***] following receipt of any such request from Valeant, address any such requests directly.\\n\\n 5.6 Recalls and Market Withdrawals. As between the Parties, Dova shall have the sole right to determine whether to implement, and to implement, a recall, field alert, withdrawal or other corrective action related to the Product.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall, within [***] following receipt of any such request from Valeant, address any such requests directly.\\n\\n 5.6 Recalls and Market Withdrawals. As between the Parties, Dova shall have the sole right to determine whether to implement, and to implement, a recall, field alert, withdrawal or other corrective action related to the Product. Dova shall bear the cost and expense of any such recall, field alert, withdrawal or other corrective action. Each Party shall promptly (but in any case, not later than [***]) notify the other Party in writing of any order, request or directive of a court or other Governmental Authority to recall or withdraw the Product.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'As between the Parties, Dova shall have the sole right to determine whether to implement, and to implement, a recall, field alert, withdrawal or other corrective action related to the Product. Dova shall bear the cost and expense of any such recall, field alert, withdrawal or other corrective action. Each Party shall promptly (but in any case, not later than [***]) notify the other Party in writing of any order, request or directive of a court or other Governmental Authority to recall or withdraw the Product.\\n\\n 5.7 Certain Reporting Responsibilities. Notwithstanding the foregoing provisions of this ARTICLE 5, each Party shall be responsible for its own federal, state and local government pricing reporting and payment transparency reporting in the Territory arising from its Product promotional activities and related expenditures pursuant to Applicable Law.'],\n",
       "  ['REFERENCE',\n",
       "   \"Each Party shall promptly (but in any case, not later than [***]) notify the other Party in writing of any order, request or directive of a court or other Governmental Authority to recall or withdraw the Product.\\n\\n 5.7 Certain Reporting Responsibilities. Notwithstanding the foregoing provisions of this ARTICLE 5, each Party shall be responsible for its own federal, state and local government pricing reporting and payment transparency reporting in the Territory arising from its Product promotional activities and related expenditures pursuant to Applicable Law. It is the intention of the Parties that any payments or transfer of value by a Party as it relates to the Product shall constitute transfers of value by that Party and such Party shall be responsible for the reporting described in the immediately preceding sentence. However, if a Party is deemed to have provided any payments or transfers of value to a Third Party on behalf of the other Party as it relates to the Product, then such Party shall provide to the other Party, in a format reasonably acceptable to such other Party, the data and other information on a timely basis (i.e., in the case of manual reporting of such data and other information, within [***] following the end of each Calendar Quarter, and, in the case of automated reporting of such data and other information, on a periodic basis during each Calendar Quarter as reasonably requested by such other Party) for such other Party's reporting under the Physician Payments Sunshine Act and other Applicable Laws.\\n\\n5.8 Booking of Sales Revenues.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Notwithstanding the foregoing provisions of this ARTICLE 5, each Party shall be responsible for its own federal, state and local government pricing reporting and payment transparency reporting in the Territory arising from its Product promotional activities and related expenditures pursuant to Applicable Law. It is the intention of the Parties that any payments or transfer of value by a Party as it relates to the Product shall constitute transfers of value by that Party and such Party shall be responsible for the reporting described in the immediately preceding sentence. However, if a Party is deemed to have provided any payments or transfers of value to a Third Party on behalf of the other Party as it relates to the Product, then such Party shall provide to the other Party, in a format reasonably acceptable to such other Party, the data and other information on a timely basis (i.e., in the case of manual reporting of such data and other information, within [***] following the end of each Calendar Quarter, and, in the case of automated reporting of such data and other information, on a periodic basis during each Calendar Quarter as reasonably requested by such other Party) for such other Party's reporting under the Physician Payments Sunshine Act and other Applicable Laws.\\n\\n5.8 Booking of Sales Revenues. Dova shall retain ownership of the rights to the Product and record on its books all revenues from sales of the Product. Dova shall be exclusively responsible for accepting and filling purchase orders, billing, and returns with respect to the Product.\"],\n",
       "  ['REFERENCE',\n",
       "   \"However, if a Party is deemed to have provided any payments or transfers of value to a Third Party on behalf of the other Party as it relates to the Product, then such Party shall provide to the other Party, in a format reasonably acceptable to such other Party, the data and other information on a timely basis (i.e., in the case of manual reporting of such data and other information, within [***] following the end of each Calendar Quarter, and, in the case of automated reporting of such data and other information, on a periodic basis during each Calendar Quarter as reasonably requested by such other Party) for such other Party's reporting under the Physician Payments Sunshine Act and other Applicable Laws.\\n\\n5.8 Booking of Sales Revenues. Dova shall retain ownership of the rights to the Product and record on its books all revenues from sales of the Product. Dova shall be exclusively responsible for accepting and filling purchase orders, billing, and returns with respect to the Product. If Valeant receives an order for the Product, it shall promptly transmit such order to Dova (or its designee) for acceptance or rejection. Dova shall have sole responsibility for shipping, distribution and warehousing of Product, and for the invoicing and billing of purchasers of the Product and for the collection of receivables resulting from the sales of the Product in the Territory.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall be exclusively responsible for accepting and filling purchase orders, billing, and returns with respect to the Product. If Valeant receives an order for the Product, it shall promptly transmit such order to Dova (or its designee) for acceptance or rejection. Dova shall have sole responsibility for shipping, distribution and warehousing of Product, and for the invoicing and billing of purchasers of the Product and for the collection of receivables resulting from the sales of the Product in the Territory.\\n\\n 5.9 Returns. Valeant is not authorized to accept any Product returns.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall have sole responsibility for shipping, distribution and warehousing of Product, and for the invoicing and billing of purchasers of the Product and for the collection of receivables resulting from the sales of the Product in the Territory.\\n\\n 5.9 Returns. Valeant is not authorized to accept any Product returns. Valeant shall advise any customer who attempts to return any Product to Valeant (or its Affiliates) that such Product must be shipped by the customer to the facility designated by Dova from time to time (and in accordance with other instructions provided by Dova). Dova shall provide to Valeant written instructions as to how Valeant should handle any Product that is actually physically returned to Valeant.'],\n",
       "  ['REFERENCE',\n",
       "   'Valeant is not authorized to accept any Product returns. Valeant shall advise any customer who attempts to return any Product to Valeant (or its Affiliates) that such Product must be shipped by the customer to the facility designated by Dova from time to time (and in accordance with other instructions provided by Dova). Dova shall provide to Valeant written instructions as to how Valeant should handle any Product that is actually physically returned to Valeant. Valeant shall take no other actions with respect to such return without the prior written consent of Dova.\\n\\n5.10 Manufacturing; Distribution; Marketing. Dova shall have the sole authority, at its cost, to manufacture, package, label, warehouse, sell and distribute the Product in the Territory.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall provide to Valeant written instructions as to how Valeant should handle any Product that is actually physically returned to Valeant. Valeant shall take no other actions with respect to such return without the prior written consent of Dova.\\n\\n5.10 Manufacturing; Distribution; Marketing. Dova shall have the sole authority, at its cost, to manufacture, package, label, warehouse, sell and distribute the Product in the Territory. Dova shall use commercially reasonable efforts to cause sufficient quantities of the Product to be available in inventory to promptly fill orders throughout the Territory and otherwise meet the forecasted demand for the Product in the Territory. If, despite such efforts, there is insufficient supply of Product to meet demand, then Dova shall use commercially reasonable efforts to promptly address such insufficiency.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall have the sole authority, at its cost, to manufacture, package, label, warehouse, sell and distribute the Product in the Territory. Dova shall use commercially reasonable efforts to cause sufficient quantities of the Product to be available in inventory to promptly fill orders throughout the Territory and otherwise meet the forecasted demand for the Product in the Territory. If, despite such efforts, there is insufficient supply of Product to meet demand, then Dova shall use commercially reasonable efforts to promptly address such insufficiency. Dova shall contractually require (and shall use commercially reasonable efforts to enforce such contractual provisions) that all Product is manufactured, shipped, sold and distributed in accordance with all Product specifications and all Applicable Law and that its contract manufacturers and/or suppliers of Product operate their facilities in accordance with Applicable Law. Dova shall ensure that all Product Labeling complies with the applicable Regulatory Approval for the Product and Applicable Law.'],\n",
       "  ['REFERENCE',\n",
       "   'If, despite such efforts, there is insufficient supply of Product to meet demand, then Dova shall use commercially reasonable efforts to promptly address such insufficiency. Dova shall contractually require (and shall use commercially reasonable efforts to enforce such contractual provisions) that all Product is manufactured, shipped, sold and distributed in accordance with all Product specifications and all Applicable Law and that its contract manufacturers and/or suppliers of Product operate their facilities in accordance with Applicable Law. Dova shall ensure that all Product Labeling complies with the applicable Regulatory Approval for the Product and Applicable Law. Other than as set forth in this Agreement, Dova shall be responsible for all marketing of the Product in the Territory, provided that Dova shall continue to invest in marketing that is targeted towards the Specialty.\\n\\n ARTICLE 6  FINANCIAL PROVISIONS\\n\\n6.1 Promotion Fee.\\n\\n6.1.1 Calculation of Promotion Fee.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall ensure that all Product Labeling complies with the applicable Regulatory Approval for the Product and Applicable Law. Other than as set forth in this Agreement, Dova shall be responsible for all marketing of the Product in the Territory, provided that Dova shall continue to invest in marketing that is targeted towards the Specialty.\\n\\n ARTICLE 6  FINANCIAL PROVISIONS\\n\\n6.1 Promotion Fee.\\n\\n6.1.1 Calculation of Promotion Fee. Commencing with the Calendar Quarter commencing on October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as follows:\\n\\n(a) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales;\\n\\n(b) For any portion of Net Sales in excess of [***] and up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales; and\\n\\n(c) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such portion of Net Sales.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n6.1.2 Adjustment of Promotion Fee.'],\n",
       "  ['REFERENCE',\n",
       "   'ARTICLE 6  FINANCIAL PROVISIONS\\n\\n6.1 Promotion Fee.\\n\\n6.1.1 Calculation of Promotion Fee. Commencing with the Calendar Quarter commencing on October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as follows:\\n\\n(a) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales;\\n\\n(b) For any portion of Net Sales in excess of [***] and up to and equal [***] in a Calendar Year, an amount equal to [***] of such portion of Net Sales; and\\n\\n(c) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such portion of Net Sales.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n6.1.2 Adjustment of Promotion Fee. The percentages set forth in Section 6.1.1 [***] shall each be referred to as an \"Applicable Percentage\".\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n6.1.2 Adjustment of Promotion Fee. The percentages set forth in Section 6.1.1 [***] shall each be referred to as an \"Applicable Percentage\".\\n\\n (a) If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\\n\\n(b) If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\\n\\n (c) In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated under subsections (a) and (b).\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***] shall each be referred to as an \"Applicable Percentage\".\\n\\n (a) If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\\n\\n(b) If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for an applicable Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].\\n\\n (c) In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated under subsections (a) and (b).\\n\\n 6.2 Milestone Payment. In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the Calendar Quarter in which such Net Sales are reached.'],\n",
       "  ['REFERENCE',\n",
       "   '(c) In the event that subsections (a) above and (b) above are both applicable in an applicable Calendar Quarter, then the Applicable Percentage shall be reduced to a new percentage equal to the lower of the percentages calculated under subsections (a) and (b).\\n\\n 6.2 Milestone Payment. In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\\n\\n 6.3 Reports; Payments.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'In addition to the promotion fee above and as additional consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a milestone payment in the amount of Two Million Five Hundred Thousand Dollars ($2,500,000) when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after the end of the Calendar Quarter in which such Net Sales are reached. For clarity, such payment shall be made only once during the Term.\\n\\n 6.3 Reports; Payments.\\n\\n 6.3.1 Quarterly Reports and Payments. Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii) the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries) to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for such Calendar Quarter).'],\n",
       "  ['REFERENCE',\n",
       "   '6.3 Reports; Payments.\\n\\n 6.3.1 Quarterly Reports and Payments. Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii) the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries) to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for such Calendar Quarter). Within sixty (60) days after the end of each Calendar Quarter during the Term, Dova shall pay to Valeant the undisputed portion of the promotion fee payable in respect of such Net Sales in accordance with Section 6.1. If this Agreement terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   \"Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii) the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries) to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for such Calendar Quarter). Within sixty (60) days after the end of each Calendar Quarter during the Term, Dova shall pay to Valeant the undisputed portion of the promotion fee payable in respect of such Net Sales in accordance with Section 6.1. If this Agreement terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.\\n\\n 6.3.2 Monthly Reports. Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good faith estimate of the Net Sales and the estimated promotion fee payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the promotion fee pursuant to Section 6.1.2).\"],\n",
       "  ['REFERENCE',\n",
       "   \"If this Agreement terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.\\n\\n 6.3.2 Monthly Reports. Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good faith estimate of the Net Sales and the estimated promotion fee payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the promotion fee pursuant to Section 6.1.2). The Parties acknowledge and agree that the monthly reports will only set forth Dova's good faith estimates of the items contained therein and are being provided to Valeant for information purposes only and shall not be determinative of the any amounts due hereunder.\\n\\n 6.3.3 Disputes.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Within fifteen (15) days of the end of each month within each Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good faith estimate of the Net Sales and the estimated promotion fee payable in respect of such Net Sales for each of such calendar month and the Calendar Quarter-to-date period, together with its good faith estimates of each of the items described in Section 6.3.1 above (assuming there will be no adjustments made to the promotion fee pursuant to Section 6.1.2). The Parties acknowledge and agree that the monthly reports will only set forth Dova's good faith estimates of the items contained therein and are being provided to Valeant for information purposes only and shall not be determinative of the any amounts due hereunder.\\n\\n 6.3.3 Disputes. Promptly upon receipt of the quarterly or monthly reports described in this Section 6.3, Valeant shall review such reports and, in the event that Valeant disputes any of the items described in such report, Valeant shall promptly notify Dova of any such disputes. The Parties shall meet promptly thereafter to attempt to resolve such disputes.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   '6.3.3 Disputes. Promptly upon receipt of the quarterly or monthly reports described in this Section 6.3, Valeant shall review such reports and, in the event that Valeant disputes any of the items described in such report, Valeant shall promptly notify Dova of any such disputes. The Parties shall meet promptly thereafter to attempt to resolve such disputes.\\n\\n 6.3.4 Data for Net Sales. During the Term, in the event Dova (or its Affiliates) enters into agreements with any specialty pharmacies (other than Non-Retail Institutions) in order to sell and/or ship units of the Product directly to such specialty pharmacies, Dova shall use commercially reasonable efforts to include in the agreements provisions relating to the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales or shall use commercially reasonable efforts to enter into separate data agreements with such specialty pharmacies that provide for the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'The Parties shall meet promptly thereafter to attempt to resolve such disputes.\\n\\n 6.3.4 Data for Net Sales. During the Term, in the event Dova (or its Affiliates) enters into agreements with any specialty pharmacies (other than Non-Retail Institutions) in order to sell and/or ship units of the Product directly to such specialty pharmacies, Dova shall use commercially reasonable efforts to include in the agreements provisions relating to the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales or shall use commercially reasonable efforts to enter into separate data agreements with such specialty pharmacies that provide for the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales.\\n\\n 6.3.5 Manner of Payment. All payments under this Agreement shall be made in US Dollars by wire transfer or\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nACH to a bank account designated in writing by Valeant or Dova, as applicable, which shall be designated at least five (5) Business Days before such payment is due.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'During the Term, in the event Dova (or its Affiliates) enters into agreements with any specialty pharmacies (other than Non-Retail Institutions) in order to sell and/or ship units of the Product directly to such specialty pharmacies, Dova shall use commercially reasonable efforts to include in the agreements provisions relating to the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales or shall use commercially reasonable efforts to enter into separate data agreements with such specialty pharmacies that provide for the supply of data by such specialty pharmacies to Dova that can be used to support the calculation of Net Sales.\\n\\n 6.3.5 Manner of Payment. All payments under this Agreement shall be made in US Dollars by wire transfer or\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nACH to a bank account designated in writing by Valeant or Dova, as applicable, which shall be designated at least five (5) Business Days before such payment is due.\\n\\n 6.3.6 Late Payments. If Valeant does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Valeant from the due date until the date of payment at the Prime Rate plus [***] or the maximum rate allowable by Applicable Law, whichever is less; provided, however, if it is discovered that any payment is past due as of the result of any audit conduct by Valeant pursuant to Section 7.2, such interest shall not accrue until [***] after the completion of such audit and not at the time the payment was originally due.'],\n",
       "  ['REFERENCE',\n",
       "   'All payments under this Agreement shall be made in US Dollars by wire transfer or\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nACH to a bank account designated in writing by Valeant or Dova, as applicable, which shall be designated at least five (5) Business Days before such payment is due.\\n\\n 6.3.6 Late Payments. If Valeant does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Valeant from the due date until the date of payment at the Prime Rate plus [***] or the maximum rate allowable by Applicable Law, whichever is less; provided, however, if it is discovered that any payment is past due as of the result of any audit conduct by Valeant pursuant to Section 7.2, such interest shall not accrue until [***] after the completion of such audit and not at the time the payment was originally due. Notwithstanding the foregoing, if the reason for any late payment is resulting from or arising out of any act or omission on the part of Valeant, including but not limited to any delay providing the requisite reports in Section 4.2.2, or the payment instructions pursuant to Section 6.3.4, such interest shall not accrue.\\n\\n 6.4 Taxes.'],\n",
       "  ['REFERENCE',\n",
       "   'If Valeant does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Valeant from the due date until the date of payment at the Prime Rate plus [***] or the maximum rate allowable by Applicable Law, whichever is less; provided, however, if it is discovered that any payment is past due as of the result of any audit conduct by Valeant pursuant to Section 7.2, such interest shall not accrue until [***] after the completion of such audit and not at the time the payment was originally due. Notwithstanding the foregoing, if the reason for any late payment is resulting from or arising out of any act or omission on the part of Valeant, including but not limited to any delay providing the requisite reports in Section 4.2.2, or the payment instructions pursuant to Section 6.3.4, such interest shall not accrue.\\n\\n 6.4 Taxes. To the extent Dova is required to deduct and withhold taxes from any payment to Valeant, Dova shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Valeant an official tax receipt or other evidence of timely payment sufficient to enable Valeant to claim the payment of such taxes as a deduction or tax credit. Valeant may provide to Dova any tax forms that may be reasonably necessary in order for Dova to not withhold tax and Dova shall dispense with withholding, as applicable.'],\n",
       "  ['REFERENCE',\n",
       "   '6.4 Taxes. To the extent Dova is required to deduct and withhold taxes from any payment to Valeant, Dova shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Valeant an official tax receipt or other evidence of timely payment sufficient to enable Valeant to claim the payment of such taxes as a deduction or tax credit. Valeant may provide to Dova any tax forms that may be reasonably necessary in order for Dova to not withhold tax and Dova shall dispense with withholding, as applicable. Dova shall provide Valeant with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes.\\n\\n 6.5 Determination of Specialty.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   \"Valeant may provide to Dova any tax forms that may be reasonably necessary in order for Dova to not withhold tax and Dova shall dispense with withholding, as applicable. Dova shall provide Valeant with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes.\\n\\n 6.5 Determination of Specialty.\\n\\n 6.5.1 No later than [***] (or in the case of the first full Calendar Quarter following the Effective Date, promptly following the Effective Date), Dova shall provide Valeant with a list of Target Professionals in the Territory, together with their primary and secondary specialty designation, as generated by Dova's Third Party Data Source. Promptly following receipt by Valeant of such list, but no later than [***] after receipt of the list of Target Professionals, Valeant may present to Dova a list of Target Professionals that, acting in good faith, it reasonably believes have a primary specialty designation of or otherwise currently practice in the specialty of Gastroenterology, Colorectal Surgery or Proctology.\"],\n",
       "  ['REFERENCE',\n",
       "   \"6.5 Determination of Specialty.\\n\\n 6.5.1 No later than [***] (or in the case of the first full Calendar Quarter following the Effective Date, promptly following the Effective Date), Dova shall provide Valeant with a list of Target Professionals in the Territory, together with their primary and secondary specialty designation, as generated by Dova's Third Party Data Source. Promptly following receipt by Valeant of such list, but no later than [***] after receipt of the list of Target Professionals, Valeant may present to Dova a list of Target Professionals that, acting in good faith, it reasonably believes have a primary specialty designation of or otherwise currently practice in the specialty of Gastroenterology, Colorectal Surgery or Proctology. For greater certainty, this list may include, but not be limited to, Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, for which Valeant wishes to confirm the primary specialty.\\n\\n 6.5.2 Promptly following receipt by Dova of such list from Valeant, the Parties shall meet and discuss, acting reasonably and in good faith, such list and their appropriate primary specialty.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Promptly following receipt by Valeant of such list, but no later than [***] after receipt of the list of Target Professionals, Valeant may present to Dova a list of Target Professionals that, acting in good faith, it reasonably believes have a primary specialty designation of or otherwise currently practice in the specialty of Gastroenterology, Colorectal Surgery or Proctology. For greater certainty, this list may include, but not be limited to, Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, for which Valeant wishes to confirm the primary specialty.\\n\\n 6.5.2 Promptly following receipt by Dova of such list from Valeant, the Parties shall meet and discuss, acting reasonably and in good faith, such list and their appropriate primary specialty. If the parties agree that the Target Professional included on such list has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova's Third Party Data Source for each such Target Professional, requesting that Dova's Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional. In addition, if the Parties do not agree, but Valeant, acting reasonably and in good faith, still believes that the Target Professional has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova's Third Party Data Source for each such Target Professional, requesting that Dova's Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional.\"],\n",
       "  ['REFERENCE',\n",
       "   \"6.5.2 Promptly following receipt by Dova of such list from Valeant, the Parties shall meet and discuss, acting reasonably and in good faith, such list and their appropriate primary specialty. If the parties agree that the Target Professional included on such list has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova's Third Party Data Source for each such Target Professional, requesting that Dova's Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional. In addition, if the Parties do not agree, but Valeant, acting reasonably and in good faith, still believes that the Target Professional has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova's Third Party Data Source for each such Target Professional, requesting that Dova's Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional. The Parties shall equally share in the incremental costs to Dova of any such investigations by Dova's Third Party Data Source. For greater certainty, if, under Dova's agreement with Dova's Third Party Data Source, Dova is entitled to a certain number of investigations at no additional cost, and such investigations requested by Valeant causes Dova to incur additional costs that it would not have, but for such investigations requested by Valeant, then Valeant shall still be required to share in any costs of investigations (pursuant to Dova's Third Party Data Source's standard rates) that would otherwise be a no-cost investigations.\"],\n",
       "  ['REFERENCE',\n",
       "   \"In addition, if the Parties do not agree, but Valeant, acting reasonably and in good faith, still believes that the Target Professional has (or should have) a primary specialty designation of or otherwise currently practices in the specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an inquiry to Dova's Third Party Data Source for each such Target Professional, requesting that Dova's Third Party Data Source conduct an investigation to determine the primary specialty designation of each such Target Professional. The Parties shall equally share in the incremental costs to Dova of any such investigations by Dova's Third Party Data Source. For greater certainty, if, under Dova's agreement with Dova's Third Party Data Source, Dova is entitled to a certain number of investigations at no additional cost, and such investigations requested by Valeant causes Dova to incur additional costs that it would not have, but for such investigations requested by Valeant, then Valeant shall still be required to share in any costs of investigations (pursuant to Dova's Third Party Data Source's standard rates) that would otherwise be a no-cost investigations. In the event that Dova incurs costs for which Valeant is responsible under this Section 6.5, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.\\n\\n 6.5.3\"],\n",
       "  ['REFERENCE',\n",
       "   \"For greater certainty, if, under Dova's agreement with Dova's Third Party Data Source, Dova is entitled to a certain number of investigations at no additional cost, and such investigations requested by Valeant causes Dova to incur additional costs that it would not have, but for such investigations requested by Valeant, then Valeant shall still be required to share in any costs of investigations (pursuant to Dova's Third Party Data Source's standard rates) that would otherwise be a no-cost investigations. In the event that Dova incurs costs for which Valeant is responsible under this Section 6.5, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3.\\n\\n 6.5.3 In the event that Dova's Third Party Data Source agrees to conduct such investigation, and then based on the results of such investigation, Dova's Third Party Data Source changes the primary designation of the Target Professional to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, confirms that the primary specialty designation should remain Gastroenterology, Colorectal Surgery or Proctology, then, commencing with the Calendar Quarter in which such investigations were conducted, such Target Professionals shall be deemed to be in the Specialty (regardless of whether their secondary specialty designation remains or becomes Hepatology). In the event that, following such investigation, Dova's Third Party Data source does not change the primary specialty designation to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, changes the primary specialty designation to a specialty other than Gastroenterology, Colorectal Surgery or Proctology, then those Target Professionals shall be deemed not to be in the Specialty.\"],\n",
       "  ['REFERENCE',\n",
       "   \"6.5.3 In the event that Dova's Third Party Data Source agrees to conduct such investigation, and then based on the results of such investigation, Dova's Third Party Data Source changes the primary designation of the Target Professional to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, confirms that the primary specialty designation should remain Gastroenterology, Colorectal Surgery or Proctology, then, commencing with the Calendar Quarter in which such investigations were conducted, such Target Professionals shall be deemed to be in the Specialty (regardless of whether their secondary specialty designation remains or becomes Hepatology). In the event that, following such investigation, Dova's Third Party Data source does not change the primary specialty designation to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, changes the primary specialty designation to a specialty other than Gastroenterology, Colorectal Surgery or Proctology, then those Target Professionals shall be deemed not to be in the Specialty. For those Target Professionals that were not the subject of an inquiry to or an investigation by Dova's Third Party Data Source, then the specialty designations set out in the original list generated by Dova's Third Party Data Source shall apply for such Calendar Quarter, namely those Target Professionals that have either a\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprimary or a secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and that do not have either a primary or a secondary specialty designation of Hepatology shall be deemed to be in the Specialty.\\n\\n 6.5.4 The process described in this Section 6.5 shall be repeated for each Calendar Quarter of the Term; provided, however, that, pursuant to the process described above, if Dova's Third Party Data Source has confirmed that a Target Professional's primary specialty designation should be or should remain Gastroenterology, Colorectal Surgery or Proctology, it is not necessary for Valeant to seek this confirmation in subsequent Calendar Quarters; provided, further, that, if Dova's Third Party Data Source is subsequently updated (by Dova or any Third Party) to change the specialty designation (primary or secondary) of a Target Professional, pursuant to a request by Dova or a Third Party, then the process described in this Section 6.5 shall be repeated with respect to such Target Professional.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"In the event that, following such investigation, Dova's Third Party Data source does not change the primary specialty designation to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, changes the primary specialty designation to a specialty other than Gastroenterology, Colorectal Surgery or Proctology, then those Target Professionals shall be deemed not to be in the Specialty. For those Target Professionals that were not the subject of an inquiry to or an investigation by Dova's Third Party Data Source, then the specialty designations set out in the original list generated by Dova's Third Party Data Source shall apply for such Calendar Quarter, namely those Target Professionals that have either a\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nprimary or a secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and that do not have either a primary or a secondary specialty designation of Hepatology shall be deemed to be in the Specialty.\\n\\n 6.5.4 The process described in this Section 6.5 shall be repeated for each Calendar Quarter of the Term; provided, however, that, pursuant to the process described above, if Dova's Third Party Data Source has confirmed that a Target Professional's primary specialty designation should be or should remain Gastroenterology, Colorectal Surgery or Proctology, it is not necessary for Valeant to seek this confirmation in subsequent Calendar Quarters; provided, further, that, if Dova's Third Party Data Source is subsequently updated (by Dova or any Third Party) to change the specialty designation (primary or secondary) of a Target Professional, pursuant to a request by Dova or a Third Party, then the process described in this Section 6.5 shall be repeated with respect to such Target Professional.\\n\\n ARTICLE 7  AUDIT RIGHTS\\n\\n7.1 Recordkeeping. Each Party shall maintain complete and accurate books and records in sufficient detail, in accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable verification of the performance of such Party's obligations under this Agreement and any payments due to a Party under this Agreement.\"],\n",
       "  ['REFERENCE',\n",
       "   \"6.5.4 The process described in this Section 6.5 shall be repeated for each Calendar Quarter of the Term; provided, however, that, pursuant to the process described above, if Dova's Third Party Data Source has confirmed that a Target Professional's primary specialty designation should be or should remain Gastroenterology, Colorectal Surgery or Proctology, it is not necessary for Valeant to seek this confirmation in subsequent Calendar Quarters; provided, further, that, if Dova's Third Party Data Source is subsequently updated (by Dova or any Third Party) to change the specialty designation (primary or secondary) of a Target Professional, pursuant to a request by Dova or a Third Party, then the process described in this Section 6.5 shall be repeated with respect to such Target Professional.\\n\\n ARTICLE 7  AUDIT RIGHTS\\n\\n7.1 Recordkeeping. Each Party shall maintain complete and accurate books and records in sufficient detail, in accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable verification of the performance of such Party's obligations under this Agreement and any payments due to a Party under this Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\\n\\n 7.2 Valeant Rights.\"],\n",
       "  ['REFERENCE',\n",
       "   'Each Party shall maintain complete and accurate books and records in sufficient detail, in accordance with GAAP (to the extent applicable and in accordance with the Agreement) and all Applicable Law, to enable verification of the performance of such Party\\'s obligations under this Agreement and any payments due to a Party under this Agreement. Unless otherwise specified herein, the books and records for a given Calendar Year of the Term shall be maintained for a period of [***] after the end of such Calendar Year or longer if required by Applicable Law.\\n\\n 7.2 Valeant Rights. Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the applicable records and books maintained by Dova for purposes of verifying Dova\\'s payment obligations within this Agreement, including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder; provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Valeant shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant problems relating to Dova\\'s payment obligations hereunder. Dova shall reasonably cooperate in any such inspection or audit conducted by Valeant.'],\n",
       "  ['REFERENCE',\n",
       "   '7.2 Valeant Rights. Valeant shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through certified public accounting firm or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to inspect and audit the applicable records and books maintained by Dova for purposes of verifying Dova\\'s payment obligations within this Agreement, including the applicable records and books of account maintained by Dova, or any Affiliate, as applicable, with respect to Net Sales in order to confirm the accuracy and completeness of such records and books of account and all payments hereunder; provided, however, that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Valeant shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant problems relating to Dova\\'s payment obligations hereunder. Dova shall reasonably cooperate in any such inspection or audit conducted by Valeant. Any undisputed adjustments required as a result of overpayments or underpayments identified through the exercise of audit rights shall be made by payment to the Party owed such adjustment within [***] after identification of such adjustment. Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall reasonably cooperate in any such inspection or audit conducted by Valeant. Any undisputed adjustments required as a result of overpayments or underpayments identified through the exercise of audit rights shall be made by payment to the Party owed such adjustment within [***] after identification of such adjustment. Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\n 7.3 Dova Rights. Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant\\'s compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant\\'s obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities.'],\n",
       "  ['REFERENCE',\n",
       "   'Valeant shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed under-reporting or underpayment for that audited period in excess of [***] of the amounts properly determined, in which case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\n 7.3 Dova Rights. Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant\\'s compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant\\'s obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities. For purposes of clarity, any such inspection or audit described in this Section 7.3 shall be limited to only those books and records of Valeant that are applicable to Valeant\\'s performance of its obligations under this Agreement. Where necessary, on reasonable request, Dova\\'s audit rights shall include interviewing Sales Representatives and other employees of Valeant.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall have the right, at its own expense, during normal business hours and upon reasonable prior notice, through a certified public accounting firm or other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to inspect and audit the applicable records and books maintained by Valeant relating to the Valeant Activities for purposes of verifying Valeant\\'s compliance with the terms of this Agreement, provided that (i) such examination shall not take place more often than once per every twelve (12) months during the Term and once during the one (1) year period following the end of the Term, and (ii) such examination shall not cover a period of time that has previously been audited; provided that Dova shall have the right to conduct additional \"for cause\" audits to the extent necessary to address significant compliance problems relating to Valeant\\'s obligations hereunder or in response to any inquiry, inspection, investigation or other requirements of a Government Authority in the Territory relating to the Valeant Activities. For purposes of clarity, any such inspection or audit described in this Section 7.3 shall be limited to only those books and records of Valeant that are applicable to Valeant\\'s performance of its obligations under this Agreement. Where necessary, on reasonable request, Dova\\'s audit rights shall include interviewing Sales Representatives and other employees of Valeant. Valeant shall reasonably cooperate in any such inspection or audit conducted by Dova. Any undisputed adjustments required as a result of overreporting the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter or the Quarterly Average Sales Force Size identified through the exercise of audit rights shall be made by payment by Valeant to Dova within [***] after identification of such adjustment.'],\n",
       "  ['REFERENCE',\n",
       "   \"Where necessary, on reasonable request, Dova's audit rights shall include interviewing Sales Representatives and other employees of Valeant. Valeant shall reasonably cooperate in any such inspection or audit conducted by Dova. Any undisputed adjustments required as a result of overreporting the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter or the Quarterly Average Sales Force Size identified through the exercise of audit rights shall be made by payment by Valeant to Dova within [***] after identification of such adjustment. Dova shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed over- payment for that audited period in excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse Dova for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\n ARTICLE 8  INTELLECTUAL PROPERTY\\n\\n8.1 Ownership of Intellectual Property.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Any undisputed adjustments required as a result of overreporting the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter or the Quarterly Average Sales Force Size identified through the exercise of audit rights shall be made by payment by Valeant to Dova within [***] after identification of such adjustment. Dova shall bear the out-of-pocket costs and expenses incurred by the Parties in connection with any such inspection or audit, unless the audit shows an undisputed over- payment for that audited period in excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse Dova for its audit fees and reasonable out-of-pocket expenses in connection with said audit, which reimbursement shall be due and payable within [***] of receiving appropriate invoices and other support for such audit-related costs.\\n\\n ARTICLE 8  INTELLECTUAL PROPERTY\\n\\n8.1 Ownership of Intellectual Property.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n8.1.1 Valeant Property. Dova acknowledges that Valeant owns or is licensed to use certain Know-How relating to the proprietary sales and marketing information, methods and plans that has been independently developed or licensed by Valeant (such Know-How, the \"Valeant Property\").'],\n",
       "  ['REFERENCE',\n",
       "   'ARTICLE 8  INTELLECTUAL PROPERTY\\n\\n8.1 Ownership of Intellectual Property.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n8.1.1 Valeant Property. Dova acknowledges that Valeant owns or is licensed to use certain Know-How relating to the proprietary sales and marketing information, methods and plans that has been independently developed or licensed by Valeant (such Know-How, the \"Valeant Property\"). The Parties agree that any improvement, enhancement or modification made, discovered, conceived, or reduced to practice by Valeant to any Valeant Property in performing its activities pursuant to this Agreement which is not primarily related to the Product, or which is not otherwise derived from the Confidential Information of Dova, shall be deemed Valeant Property. [***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova\\'s promotion or other commercialization of the Product in the Territory.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Dova acknowledges that Valeant owns or is licensed to use certain Know-How relating to the proprietary sales and marketing information, methods and plans that has been independently developed or licensed by Valeant (such Know-How, the \"Valeant Property\"). The Parties agree that any improvement, enhancement or modification made, discovered, conceived, or reduced to practice by Valeant to any Valeant Property in performing its activities pursuant to this Agreement which is not primarily related to the Product, or which is not otherwise derived from the Confidential Information of Dova, shall be deemed Valeant Property. [***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova\\'s promotion or other commercialization of the Product in the Territory.\\n\\n 8.1.2 Dova Property. Subject to the terms of Section 8.1.1, Dova shall have and retain sole and exclusive right, title and interest in and to all inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs, improvements and other technology, whether or not patentable or copyrightable, and any patent applications, patents, or copyrights based thereon (collectively, \"Intellectual Property\") relating to the Product that are (i) owned or controlled by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice or generated by Dova (or its employees or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice or generated by Valeant (or its employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily related to the Product or which is otherwise derived from the Confidential Information of Dova (\"Inventions\").'],\n",
       "  ['REFERENCE',\n",
       "   '[***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non- exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova\\'s promotion or other commercialization of the Product in the Territory.\\n\\n 8.1.2 Dova Property. Subject to the terms of Section 8.1.1, Dova shall have and retain sole and exclusive right, title and interest in and to all inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs, improvements and other technology, whether or not patentable or copyrightable, and any patent applications, patents, or copyrights based thereon (collectively, \"Intellectual Property\") relating to the Product that are (i) owned or controlled by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice or generated by Dova (or its employees or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice or generated by Valeant (or its employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily related to the Product or which is otherwise derived from the Confidential Information of Dova (\"Inventions\"). Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention. For clarity, any and all Inventions and any information contained therein or related thereto shall constitute Confidential Information of Dova.\\n\\n8.2 Title to Trademarks and Copyrights.'],\n",
       "  ['REFERENCE',\n",
       "   'Subject to the terms of Section 8.1.1, Dova shall have and retain sole and exclusive right, title and interest in and to all inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs, improvements and other technology, whether or not patentable or copyrightable, and any patent applications, patents, or copyrights based thereon (collectively, \"Intellectual Property\") relating to the Product that are (i) owned or controlled by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice or generated by Dova (or its employees or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice or generated by Valeant (or its employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily related to the Product or which is otherwise derived from the Confidential Information of Dova (\"Inventions\"). Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention. For clarity, any and all Inventions and any information contained therein or related thereto shall constitute Confidential Information of Dova.\\n\\n8.2 Title to Trademarks and Copyrights. The ownership, and all goodwill from the use, of any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the foregoing to Dova.\\n\\n8.3 Protection of Trademarks and Copyrights. As between the Parties, Dova shall have the sole right (but not the obligation), as determined by Dova in its sole discretion, to (i) maintain the Dova Trademarks and Copyrights and/or (ii) protect, enforce and defend the Dova Trademarks and Copyrights.'],\n",
       "  ['REFERENCE',\n",
       "   \"For clarity, any and all Inventions and any information contained therein or related thereto shall constitute Confidential Information of Dova.\\n\\n8.2 Title to Trademarks and Copyrights. The ownership, and all goodwill from the use, of any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the foregoing to Dova.\\n\\n8.3 Protection of Trademarks and Copyrights. As between the Parties, Dova shall have the sole right (but not the obligation), as determined by Dova in its sole discretion, to (i) maintain the Dova Trademarks and Copyrights and/or (ii) protect, enforce and defend the Dova Trademarks and Copyrights. Valeant shall give notice to Dova of any infringement of, or challenge to, the validity or enforceability of the Dova Trademarks and Copyrights promptly after learning of such infringement or challenge. If Dova institutes an action against Third Party infringers or takes action to defend the Dova Trademarks and Copyrights, Valeant shall reasonably cooperate with Dova, at Dova's cost and expense.\"],\n",
       "  ['REFERENCE',\n",
       "   \"As between the Parties, Dova shall have the sole right (but not the obligation), as determined by Dova in its sole discretion, to (i) maintain the Dova Trademarks and Copyrights and/or (ii) protect, enforce and defend the Dova Trademarks and Copyrights. Valeant shall give notice to Dova of any infringement of, or challenge to, the validity or enforceability of the Dova Trademarks and Copyrights promptly after learning of such infringement or challenge. If Dova institutes an action against Third Party infringers or takes action to defend the Dova Trademarks and Copyrights, Valeant shall reasonably cooperate with Dova, at Dova's cost and expense. Any recovery obtained by Dova as a result of such proceeding or other actions, whether obtained by settlement or otherwise, shall be retained by Dova. Valeant shall not have any right to institute any action to defend or enforce the Dova Trademarks and Copyrights.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"If Dova institutes an action against Third Party infringers or takes action to defend the Dova Trademarks and Copyrights, Valeant shall reasonably cooperate with Dova, at Dova's cost and expense. Any recovery obtained by Dova as a result of such proceeding or other actions, whether obtained by settlement or otherwise, shall be retained by Dova. Valeant shall not have any right to institute any action to defend or enforce the Dova Trademarks and Copyrights.\\n\\n 8.4 Disclosure of Know-How. For clarity, the Parties hereby agree and acknowledge that to the extent that either Party hereto has disclosed, or in the future discloses, to the other Party any Know-How or other intellectual property of such Party or its Affiliates pursuant to this Agreement, the other Party shall not acquire any ownership rights in such Know-How or other intellectual property by virtue of this Agreement or otherwise, and as between the Parties, all ownership rights therein shall remain with the disclosing Party (or its Affiliate).\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Valeant shall not have any right to institute any action to defend or enforce the Dova Trademarks and Copyrights.\\n\\n 8.4 Disclosure of Know-How. For clarity, the Parties hereby agree and acknowledge that to the extent that either Party hereto has disclosed, or in the future discloses, to the other Party any Know-How or other intellectual property of such Party or its Affiliates pursuant to this Agreement, the other Party shall not acquire any ownership rights in such Know-How or other intellectual property by virtue of this Agreement or otherwise, and as between the Parties, all ownership rights therein shall remain with the disclosing Party (or its Affiliate).\\n\\n ARTICLE 9  CONFIDENTIALITY\\n\\n9.1 Confidential Information.\\n\\n 9.1.1 Confidentiality and Non-Use.'],\n",
       "  ['REFERENCE',\n",
       "   'For clarity, the Parties hereby agree and acknowledge that to the extent that either Party hereto has disclosed, or in the future discloses, to the other Party any Know-How or other intellectual property of such Party or its Affiliates pursuant to this Agreement, the other Party shall not acquire any ownership rights in such Know-How or other intellectual property by virtue of this Agreement or otherwise, and as between the Parties, all ownership rights therein shall remain with the disclosing Party (or its Affiliate).\\n\\n ARTICLE 9  CONFIDENTIALITY\\n\\n9.1 Confidential Information.\\n\\n 9.1.1 Confidentiality and Non-Use. Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and contractors do not disclose or make any unauthorized use of such Confidential Information.'],\n",
       "  ['REFERENCE',\n",
       "   '9.1.1 Confidentiality and Non-Use. Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party will use at least the same standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the other\\'s Confidential Information. Any and all information and materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality Agreement\") shall be deemed Confidential Information disclosed pursuant to this Agreement.'],\n",
       "  ['REFERENCE',\n",
       "   'Without limiting the foregoing, each Party will use at least the same standard of care as it uses to protect its own Confidential Information to ensure that its employees, agents, consultants and contractors do not disclose or make any unauthorized use of such Confidential Information. Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the other\\'s Confidential Information. Any and all information and materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality Agreement\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party\\'s Confidential Information that the receiving Party can demonstrate by competent tangible evidence:\\n\\n(a) was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;\\n\\n(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement;\\n\\n(d) was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate); or\\n\\n(e) was independently discovered or developed by the receiving Party or its Affiliate without access to or aid, application, use of the other Party\\'s Confidential Information, as evidenced by a contemporaneous writing.\\n\\n 9.1.2 Authorized Disclosure.'],\n",
       "  ['REFERENCE',\n",
       "   'Any and all information and materials disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated [***] (the \"Confidentiality Agreement\") shall be deemed Confidential Information disclosed pursuant to this Agreement. The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party\\'s Confidential Information that the receiving Party can demonstrate by competent tangible evidence:\\n\\n(a) was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;\\n\\n(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement;\\n\\n(d) was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party (or its Affiliate); or\\n\\n(e) was independently discovered or developed by the receiving Party or its Affiliate without access to or aid, application, use of the other Party\\'s Confidential Information, as evidenced by a contemporaneous writing.\\n\\n 9.1.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party\\'s Confidential Information and the terms of this Agreement to the extent:\\n\\n(a) such disclosure is reasonably necessary (x) to comply with the requirements of Governmental Authorities; or (y) for the prosecuting or defending litigation as contemplated by this Agreement;\\n\\n(b) such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality and non-use; or\\n\\n(c) such disclosure is reasonably necessary to comply with Applicable Laws, including regulations promulgated by applicable securities exchanges, court order, administrative subpoena or order.\\n\\n Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party\\'s Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party\\'s cost) in obtaining, a protective order preventing or limiting the required disclosure.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   \"9.1.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 9.1.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:\\n\\n(a) such disclosure is reasonably necessary (x) to comply with the requirements of Governmental Authorities; or (y) for the prosecuting or defending litigation as contemplated by this Agreement;\\n\\n(b) such disclosure is reasonably necessary to its Affiliates, employees, agents, consultants and contractors on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this Agreement and the disclosing Party shall be liable for any failures of such disclosees to abide by such obligations of confidentiality and non-use; or\\n\\n(c) such disclosure is reasonably necessary to comply with Applicable Laws, including regulations promulgated by applicable securities exchanges, court order, administrative subpoena or order.\\n\\n Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a protective order preventing or limiting the required disclosure.\\n\\n 9.2 Public Announcements. The press release announcing the execution of this Agreement shall be issued in the form attached hereto as Exhibit A.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party's cost) in obtaining, a protective order preventing or limiting the required disclosure.\\n\\n 9.2 Public Announcements. The press release announcing the execution of this Agreement shall be issued in the form attached hereto as Exhibit A. No public announcement or statements (including presentations to investor meetings and customer updates) concerning the existence of or terms of this Agreement or incorporating the marks of the other Party or their respective Affiliates shall be made, either directly or indirectly, by either Party or a Party's Affiliates, without first obtaining the written approval of the other Party and agreement upon the nature, text and timing of such announcement or disclosure. Either Party shall have the right to make any such public announcement or other disclosure required by Applicable Law after such Party has provided to the other Party a copy of such announcement or disclosure and an opportunity to comment thereon and the disclosing Party shall reasonably consider the other Party's comments.\"],\n",
       "  ['REFERENCE',\n",
       "   \"The press release announcing the execution of this Agreement shall be issued in the form attached hereto as Exhibit A. No public announcement or statements (including presentations to investor meetings and customer updates) concerning the existence of or terms of this Agreement or incorporating the marks of the other Party or their respective Affiliates shall be made, either directly or indirectly, by either Party or a Party's Affiliates, without first obtaining the written approval of the other Party and agreement upon the nature, text and timing of such announcement or disclosure. Either Party shall have the right to make any such public announcement or other disclosure required by Applicable Law after such Party has provided to the other Party a copy of such announcement or disclosure and an opportunity to comment thereon and the disclosing Party shall reasonably consider the other Party's comments. Each Party agrees that it shall cooperate fully with the other with respect to all disclosures regarding this Agreement to the Securities Exchange Commission and any other Governmental Authorities, including requests for confidential treatment of proprietary information of either Party included in any such disclosure. Once any written statement is approved for disclosure by the Parties or information is otherwise made public in accordance with this Section 9.2, either Party may make a subsequent public disclosure of the same contents of such statement in the same context as such statement without further approval of the other Party.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Either Party shall have the right to make any such public announcement or other disclosure required by Applicable Law after such Party has provided to the other Party a copy of such announcement or disclosure and an opportunity to comment thereon and the disclosing Party shall reasonably consider the other Party's comments. Each Party agrees that it shall cooperate fully with the other with respect to all disclosures regarding this Agreement to the Securities Exchange Commission and any other Governmental Authorities, including requests for confidential treatment of proprietary information of either Party included in any such disclosure. Once any written statement is approved for disclosure by the Parties or information is otherwise made public in accordance with this Section 9.2, either Party may make a subsequent public disclosure of the same contents of such statement in the same context as such statement without further approval of the other Party. Notwithstanding anything to the contrary contained herein, in no event shall either Party disclose any financial information of the other without the prior written consent of such other Party, unless such financial information already has been publicly disclosed by the Party owning the financial information or otherwise has been made part of the public domain by no breach of a Party of its obligations under this ARTICLE 9.\\n\\n8\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.\"],\n",
       "  ['REFERENCE',\n",
       "   'Once any written statement is approved for disclosure by the Parties or information is otherwise made public in accordance with this Section 9.2, either Party may make a subsequent public disclosure of the same contents of such statement in the same context as such statement without further approval of the other Party. Notwithstanding anything to the contrary contained herein, in no event shall either Party disclose any financial information of the other without the prior written consent of such other Party, unless such financial information already has been publicly disclosed by the Party owning the financial information or otherwise has been made part of the public domain by no breach of a Party of its obligations under this ARTICLE 9.\\n\\n8\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 10  REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS\\n\\n10.1 Representations and Warranties of Dova.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 10  REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS\\n\\n10.1 Representations and Warranties of Dova. Dova represents and warrants to Valeant as of the Effective Date that:\\n\\n 10.1.1'],\n",
       "  ['REFERENCE',\n",
       "   \"Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nARTICLE 10  REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS\\n\\n10.1 Representations and Warranties of Dova. Dova represents and warrants to Valeant as of the Effective Date that:\\n\\n 10.1.1 it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.1.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.1.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.1.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.1.5 the execution, delivery and performance of this Agreement by Dova does not require the consent of any Person (including under the Third Party Agreements) or the authorization of (by notice or otherwise) any Governmental Authority including the FDA;\\n\\n10.1.6 there is no action, suit or proceeding pending or, to the knowledge of Dova, threatened, against Dova or any of its Affiliates, or to the knowledge of Dova, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement, including its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product have been in compliance with all Applicable Laws;\\n\\n10.1.8 it has the right to market and sell the Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.1.9 it has the exclusive right to promote the Product in the Territory to the Target Professionals in the Specialty and the rights granted by it to Valeant hereunder do not conflict with any rights granted by Dova to any Third Party;\\n\\n10.1.10 to the knowledge of Dova, all manufacturing, stability testing, labeling, packaging, storing, shipping and distribution operations conducted by or on behalf of Dova relating to the commercial supply of the Product have been conducted in compliance with Applicable Law and it has no knowledge of any information indicating that Dova would be unable to manufacture and supply (or have manufactured and supplied) the Product in sufficient quantities to meet the reasonable demands in the Territory;\\n\\n10.1.11 it has no knowledge of any information relating to the safety or efficacy of the Product or any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Dova's ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.12 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.1.13 each of the Third Party Agreements constitutes a valid and binding obligation of Dova or its Affiliate, as applicable, and is enforceable against Dova or its Affiliate, as applicable, and, to the knowledge of Dova, each of the Third Party Agreements constitutes a valid and binding obligation of the counterparty thereto and is enforceable against such counterparty, except in each case as may be limited by bankruptcy, insolvency, fraudulent transfer, moratorium, reorganization, preference or similar laws of general applicability relating to or affecting the rights of creditors generally and subject to general principles of equity (regardless of whether enforcement is sought in equity or at law).\"],\n",
       "  ['REFERENCE',\n",
       "   \"10.1.1 it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.1.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.1.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.1.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.1.5 the execution, delivery and performance of this Agreement by Dova does not require the consent of any Person (including under the Third Party Agreements) or the authorization of (by notice or otherwise) any Governmental Authority including the FDA;\\n\\n10.1.6 there is no action, suit or proceeding pending or, to the knowledge of Dova, threatened, against Dova or any of its Affiliates, or to the knowledge of Dova, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement, including its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product have been in compliance with all Applicable Laws;\\n\\n10.1.8 it has the right to market and sell the Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.1.9 it has the exclusive right to promote the Product in the Territory to the Target Professionals in the Specialty and the rights granted by it to Valeant hereunder do not conflict with any rights granted by Dova to any Third Party;\\n\\n10.1.10 to the knowledge of Dova, all manufacturing, stability testing, labeling, packaging, storing, shipping and distribution operations conducted by or on behalf of Dova relating to the commercial supply of the Product have been conducted in compliance with Applicable Law and it has no knowledge of any information indicating that Dova would be unable to manufacture and supply (or have manufactured and supplied) the Product in sufficient quantities to meet the reasonable demands in the Territory;\\n\\n10.1.11 it has no knowledge of any information relating to the safety or efficacy of the Product or any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Dova's ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.12 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.1.13 each of the Third Party Agreements constitutes a valid and binding obligation of Dova or its Affiliate, as applicable, and is enforceable against Dova or its Affiliate, as applicable, and, to the knowledge of Dova, each of the Third Party Agreements constitutes a valid and binding obligation of the counterparty thereto and is enforceable against such counterparty, except in each case as may be limited by bankruptcy, insolvency, fraudulent transfer, moratorium, reorganization, preference or similar laws of general applicability relating to or affecting the rights of creditors generally and subject to general principles of equity (regardless of whether enforcement is sought in equity or at law). Dova or its Affiliate, as applicable, and to the knowledge of Dova, the applicable counterparty thereto, are not in material breach of or default under either of the Third Party Agreements. The\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncounterparty to each of the Third Party Agreements has not exercised or, to the knowledge of Dova, threatened in writing to exercise any termination right with respect to the applicable Third Party Agreement.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.1.5 the execution, delivery and performance of this Agreement by Dova does not require the consent of any Person (including under the Third Party Agreements) or the authorization of (by notice or otherwise) any Governmental Authority including the FDA;\\n\\n10.1.6 there is no action, suit or proceeding pending or, to the knowledge of Dova, threatened, against Dova or any of its Affiliates, or to the knowledge of Dova, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement, including its donations to, and interactions with, any 501(c)(3) charitable foundation that provides co-pay assistance to government-insured patients with respect to the Product have been in compliance with all Applicable Laws;\\n\\n10.1.8 it has the right to market and sell the Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.1.9 it has the exclusive right to promote the Product in the Territory to the Target Professionals in the Specialty and the rights granted by it to Valeant hereunder do not conflict with any rights granted by Dova to any Third Party;\\n\\n10.1.10 to the knowledge of Dova, all manufacturing, stability testing, labeling, packaging, storing, shipping and distribution operations conducted by or on behalf of Dova relating to the commercial supply of the Product have been conducted in compliance with Applicable Law and it has no knowledge of any information indicating that Dova would be unable to manufacture and supply (or have manufactured and supplied) the Product in sufficient quantities to meet the reasonable demands in the Territory;\\n\\n10.1.11 it has no knowledge of any information relating to the safety or efficacy of the Product or any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Dova's ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.1.12 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.1.13 each of the Third Party Agreements constitutes a valid and binding obligation of Dova or its Affiliate, as applicable, and is enforceable against Dova or its Affiliate, as applicable, and, to the knowledge of Dova, each of the Third Party Agreements constitutes a valid and binding obligation of the counterparty thereto and is enforceable against such counterparty, except in each case as may be limited by bankruptcy, insolvency, fraudulent transfer, moratorium, reorganization, preference or similar laws of general applicability relating to or affecting the rights of creditors generally and subject to general principles of equity (regardless of whether enforcement is sought in equity or at law). Dova or its Affiliate, as applicable, and to the knowledge of Dova, the applicable counterparty thereto, are not in material breach of or default under either of the Third Party Agreements. The\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncounterparty to each of the Third Party Agreements has not exercised or, to the knowledge of Dova, threatened in writing to exercise any termination right with respect to the applicable Third Party Agreement.\\n\\n 10.1.14 neither Dova nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Dova or any of its personnel becomes or is the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Dova shall immediately notify Valeant, and Valeant shall have the option to prohibit such Person from performing work relating to this Agreement or the Product; and\\n\\n10.1.15 any patient assistance program used in connection with the Product used in connection with the Product have each been operated in accordance with Applicable Law.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"The\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncounterparty to each of the Third Party Agreements has not exercised or, to the knowledge of Dova, threatened in writing to exercise any termination right with respect to the applicable Third Party Agreement.\\n\\n 10.1.14 neither Dova nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Dova or any of its personnel becomes or is the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Dova shall immediately notify Valeant, and Valeant shall have the option to prohibit such Person from performing work relating to this Agreement or the Product; and\\n\\n10.1.15 any patient assistance program used in connection with the Product used in connection with the Product have each been operated in accordance with Applicable Law.\\n\\n 10.2 Representations and Warranties of Valeant. Valeant represents and warrants to Dova as of the Effective Date that:\\n\\n10.2.1 it is a limited liability company duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.2.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.2.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.2.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.2.5 the execution, delivery and performance of this Agreement by Valeant does not require the consent of any Person or the authorization of (by notice or otherwise) any Governmental Authority or the FDA;\\n\\n10.2.6 there is no action, suit or proceeding pending or, to the knowledge of Valeant, threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement;\\n\\n10.2.8 it has the right to market and sell the Designated Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.2.9 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.2.10 it has no knowledge of any information relating to any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Valeant's ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.11 neither Valeant nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are\\n\\nSource:\"],\n",
       "  ['REFERENCE',\n",
       "   \"If, during the Term, Dova or any of its personnel becomes or is the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Dova shall immediately notify Valeant, and Valeant shall have the option to prohibit such Person from performing work relating to this Agreement or the Product; and\\n\\n10.1.15 any patient assistance program used in connection with the Product used in connection with the Product have each been operated in accordance with Applicable Law.\\n\\n 10.2 Representations and Warranties of Valeant. Valeant represents and warrants to Dova as of the Effective Date that:\\n\\n10.2.1 it is a limited liability company duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.2.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.2.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.2.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.2.5 the execution, delivery and performance of this Agreement by Valeant does not require the consent of any Person or the authorization of (by notice or otherwise) any Governmental Authority or the FDA;\\n\\n10.2.6 there is no action, suit or proceeding pending or, to the knowledge of Valeant, threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement;\\n\\n10.2.8 it has the right to market and sell the Designated Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.2.9 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.2.10 it has no knowledge of any information relating to any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Valeant's ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.11 neither Valeant nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nexcluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Valeant or any of its personnel become or are the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Valeant shall immediately notify Dova, and Dova shall have the option to prohibit such Person from performing work under this Agreement; and\\n\\n10.2.12 all Field Force Personnel that are engaged in Detailing are, and will be, licensed to the extent required and in accordance with all Applicable Laws.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"Valeant represents and warrants to Dova as of the Effective Date that:\\n\\n10.2.1 it is a limited liability company duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\\n\\n10.2.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\\n\\n10.2.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\\n\\n10.2.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\\n\\n10.2.5 the execution, delivery and performance of this Agreement by Valeant does not require the consent of any Person or the authorization of (by notice or otherwise) any Governmental Authority or the FDA;\\n\\n10.2.6 there is no action, suit or proceeding pending or, to the knowledge of Valeant, threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement;\\n\\n10.2.8 it has the right to market and sell the Designated Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\\n\\n10.2.9 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\\n\\n10.2.10 it has no knowledge of any information relating to any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Valeant's ability to perform its obligations and enjoy the benefits of this Agreement;\\n\\n10.2.11 neither Valeant nor any of its personnel (i) have been debarred under the 21 U.S.C.  335a, (ii) are\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nexcluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Valeant or any of its personnel become or are the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Valeant shall immediately notify Dova, and Dova shall have the option to prohibit such Person from performing work under this Agreement; and\\n\\n10.2.12 all Field Force Personnel that are engaged in Detailing are, and will be, licensed to the extent required and in accordance with all Applicable Laws.\\n\\n 10.3 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) MAKE NO REPRESENTATIONS AND NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR\"],\n",
       "  ['REFERENCE',\n",
       "   \"If, during the Term, Valeant or any of its personnel become or are the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C.  335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Valeant shall immediately notify Dova, and Dova shall have the option to prohibit such Person from performing work under this Agreement; and\\n\\n10.2.12 all Field Force Personnel that are engaged in Detailing are, and will be, licensed to the extent required and in accordance with all Applicable Laws.\\n\\n 10.3 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) MAKE NO REPRESENTATIONS AND NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) EACH SPECIFICALLY DISCLAIM ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY INTELLECTUAL PROPERTY OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.\\n\\n 10.4 Additional Covenants.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) MAKE NO REPRESENTATIONS AND NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND DOVA (AND ITS AFFILIATES) AND VALEANT (AND ITS AFFILIATES) EACH SPECIFICALLY DISCLAIM ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY INTELLECTUAL PROPERTY OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.\\n\\n 10.4 Additional Covenants.\\n\\n 10.4.1 Initial Orders to Non-Retail Institutions. For initial orders of Product from Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions, Dova shall not engage in any \"channel stuffing\" or any similar program, activity or other action (including any rebate, discount, chargeback or refund policy or practice) that in each case is intended by Dova to result in purchases by the Non-Retail Institutions that are materially in excess of purchases in the ordinary course of business or that is intended to materially adversely impact Valeant\\'s promotion fee pursuant to this Agreement; provided, however, this Section10.4.1 shall not be applicable to any activity or action taken by Dova which applies to all or substantially all customers for the Product, or any activity or action taken by Dova in good faith and consistent with customary sales and marketing practices in the pharmaceutical industry.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '10.4 Additional Covenants.\\n\\n 10.4.1 Initial Orders to Non-Retail Institutions. For initial orders of Product from Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions, Dova shall not engage in any \"channel stuffing\" or any similar program, activity or other action (including any rebate, discount, chargeback or refund policy or practice) that in each case is intended by Dova to result in purchases by the Non-Retail Institutions that are materially in excess of purchases in the ordinary course of business or that is intended to materially adversely impact Valeant\\'s promotion fee pursuant to this Agreement; provided, however, this Section10.4.1 shall not be applicable to any activity or action taken by Dova which applies to all or substantially all customers for the Product, or any activity or action taken by Dova in good faith and consistent with customary sales and marketing practices in the pharmaceutical industry.\\n\\n 10.4.2 Third Party Agreements. Dova shall remain solely responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties on (or in connection with) the sale of Product in the Territory, including under the Third Party Agreements.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'For initial orders of Product from Dova (or its Affiliates or its Intermediaries) to the Non-Retail Institutions, Dova shall not engage in any \"channel stuffing\" or any similar program, activity or other action (including any rebate, discount, chargeback or refund policy or practice) that in each case is intended by Dova to result in purchases by the Non-Retail Institutions that are materially in excess of purchases in the ordinary course of business or that is intended to materially adversely impact Valeant\\'s promotion fee pursuant to this Agreement; provided, however, this Section10.4.1 shall not be applicable to any activity or action taken by Dova which applies to all or substantially all customers for the Product, or any activity or action taken by Dova in good faith and consistent with customary sales and marketing practices in the pharmaceutical industry.\\n\\n 10.4.2 Third Party Agreements. Dova shall remain solely responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties on (or in connection with) the sale of Product in the Territory, including under the Third Party Agreements.\\n\\n ARTICLE 11  INDEMNIFICATION; LIMITATIONS ON LIABILITY\\n\\n11.1 Indemnification by Dova. Dova shall defend, indemnify and hold harmless Valeant and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims, and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Dova under this Agreement, (b) the negligence, willful misconduct or violation of Applicable Laws by Dova (or any of its Affiliates or its or their respective officers, directors, employees, agents or representatives), (c) the infringement of the intellectual property rights of any Third Party in connection with the Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling or Product Materials in accordance with this Agreement, (d) death or personal injury to any person related to use of the Product, or (e) the failure to comply with Applicable Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501(c)(3) charitable foundation used in connection with the Product; except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Valeant is obligated to indemnify Dova pursuant to Section 11.2.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall remain solely responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties on (or in connection with) the sale of Product in the Territory, including under the Third Party Agreements.\\n\\n ARTICLE 11  INDEMNIFICATION; LIMITATIONS ON LIABILITY\\n\\n11.1 Indemnification by Dova. Dova shall defend, indemnify and hold harmless Valeant and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims, and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Dova under this Agreement, (b) the negligence, willful misconduct or violation of Applicable Laws by Dova (or any of its Affiliates or its or their respective officers, directors, employees, agents or representatives), (c) the infringement of the intellectual property rights of any Third Party in connection with the Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling or Product Materials in accordance with this Agreement, (d) death or personal injury to any person related to use of the Product, or (e) the failure to comply with Applicable Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501(c)(3) charitable foundation used in connection with the Product; except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Valeant is obligated to indemnify Dova pursuant to Section 11.2.\\n\\n 11.2 Indemnification by Valeant. Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b) the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nofficers, directors, employees, agents or representatives); except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Dova shall defend, indemnify and hold harmless Valeant and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims, and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Dova under this Agreement, (b) the negligence, willful misconduct or violation of Applicable Laws by Dova (or any of its Affiliates or its or their respective officers, directors, employees, agents or representatives), (c) the infringement of the intellectual property rights of any Third Party in connection with the Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling or Product Materials in accordance with this Agreement, (d) death or personal injury to any person related to use of the Product, or (e) the failure to comply with Applicable Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501(c)(3) charitable foundation used in connection with the Product; except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Valeant is obligated to indemnify Dova pursuant to Section 11.2.\\n\\n 11.2 Indemnification by Valeant. Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b) the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nofficers, directors, employees, agents or representatives); except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\\n\\n 11.3 Indemnification Procedures. The Party seeking indemnification under Section 11.1 or 11.2, as applicable (the \"Indemnified Party\") shall give prompt notice to the Party against whom indemnity is sought (the \"Indemnifying Party\") of the assertion or commencement of any Claim in respect of which indemnity may be sought under Section 11.1 or 11.2, as applicable, and will provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request.'],\n",
       "  ['REFERENCE',\n",
       "   'Valeant shall defend, indemnify and hold harmless Dova and its Affiliates and its and their respective officers, directors, employees, agents, representatives, successors and assigns from and against all Claims and all associated Losses, to the extent incurred or suffered by any of them to the extent resulting from or arising out of (a) any misrepresentation or breach of any representations, warranties, agreements or covenants of Valeant under this Agreement, or (b) the negligence, willful misconduct, or violation of Applicable Laws by Valeant (or any of its Affiliates or its and their respective\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nofficers, directors, employees, agents or representatives); except in each case to the extent any such Claims, and all associated Losses, are caused by an item for which Dova is obligated to indemnify Valeant pursuant to Section 11.1.\\n\\n 11.3 Indemnification Procedures. The Party seeking indemnification under Section 11.1 or 11.2, as applicable (the \"Indemnified Party\") shall give prompt notice to the Party against whom indemnity is sought (the \"Indemnifying Party\") of the assertion or commencement of any Claim in respect of which indemnity may be sought under Section 11.1 or 11.2, as applicable, and will provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request. The failure to give such notice will relieve the Indemnifying Party of any liability hereunder only to the extent that the Indemnifying Party has suffered actual prejudice thereby. The Indemnifying Party shall assume and control the defense and settlement of any such action, suit or proceeding at its own expense.'],\n",
       "  ['REFERENCE',\n",
       "   'The Party seeking indemnification under Section 11.1 or 11.2, as applicable (the \"Indemnified Party\") shall give prompt notice to the Party against whom indemnity is sought (the \"Indemnifying Party\") of the assertion or commencement of any Claim in respect of which indemnity may be sought under Section 11.1 or 11.2, as applicable, and will provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request. The failure to give such notice will relieve the Indemnifying Party of any liability hereunder only to the extent that the Indemnifying Party has suffered actual prejudice thereby. The Indemnifying Party shall assume and control the defense and settlement of any such action, suit or proceeding at its own expense. The Indemnified Party shall, if requested by the Indemnifying Party, cooperate in all reasonable respects in such defense, at the Indemnifying Party\\'s expense. The Indemnified Party will be entitled at its own expense to participate in such defense and to employ separate counsel for such purpose.'],\n",
       "  ['REFERENCE',\n",
       "   \"The Indemnifying Party shall assume and control the defense and settlement of any such action, suit or proceeding at its own expense. The Indemnified Party shall, if requested by the Indemnifying Party, cooperate in all reasonable respects in such defense, at the Indemnifying Party's expense. The Indemnified Party will be entitled at its own expense to participate in such defense and to employ separate counsel for such purpose. For so long as the Indemnifying Party is diligently defending any proceeding pursuant to this Section 11.3, the Indemnifying Party will not be liable under Section 11.1 or 11.2, as applicable, for any settlement effected without its consent. No Party shall enter into any compromise or settlement which commits the other Party to take, or to forbear to take, any action without the other Party's prior written consent (and unless such compromise or settlement includes no payments by the Indemnified Party, an unconditional release of, and no admission of liability by, the Indemnified Party from all liability in respect of such Claim).\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"The Indemnified Party will be entitled at its own expense to participate in such defense and to employ separate counsel for such purpose. For so long as the Indemnifying Party is diligently defending any proceeding pursuant to this Section 11.3, the Indemnifying Party will not be liable under Section 11.1 or 11.2, as applicable, for any settlement effected without its consent. No Party shall enter into any compromise or settlement which commits the other Party to take, or to forbear to take, any action without the other Party's prior written consent (and unless such compromise or settlement includes no payments by the Indemnified Party, an unconditional release of, and no admission of liability by, the Indemnified Party from all liability in respect of such Claim).\\n\\n 11.4 Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.\"],\n",
       "  ['REFERENCE',\n",
       "   \"No Party shall enter into any compromise or settlement which commits the other Party to take, or to forbear to take, any action without the other Party's prior written consent (and unless such compromise or settlement includes no payments by the Indemnified Party, an unconditional release of, and no admission of liability by, the Indemnified Party from all liability in respect of such Claim).\\n\\n 11.4 Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR (2) DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 9.\\n\\n11.5 Insurance. Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated.\"],\n",
       "  ['REFERENCE',\n",
       "   \"NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN (OTHER THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4), IN NO EVENT SHALL DOVA (OR ITS AFFILIATES) OR VALEANT (OR ITS AFFILIATES) BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING SENTENCE SHALL NOT LIMIT (1) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR (2) DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 9.\\n\\n11.5 Insurance. Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated. Each Party shall provide reasonable written proof of the existence of such insurance to the other Party upon request. Dova does not and will not maintain or procure any worker's compensation, healthcare, or other insurance for or on behalf of any Field Force Personnel, all of which shall be Valeant's sole responsibility.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Each Party acknowledges and agrees that during the Term, it shall maintain, through purchase or self- insurance, adequate insurance, including products liability coverage and comprehensive general liability insurance, adequate to cover its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated. Each Party shall provide reasonable written proof of the existence of such insurance to the other Party upon request. Dova does not and will not maintain or procure any worker's compensation, healthcare, or other insurance for or on behalf of any Field Force Personnel, all of which shall be Valeant's sole responsibility. For clarity, the insurance requirements of this Section 11.5 shall not be construed to create a limit of either Party's liability with respect to its indemnification obligations under this ARTICLE 11.\\n\\n ARTICLE 12  TERM AND TERMINATION\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Dova does not and will not maintain or procure any worker\\'s compensation, healthcare, or other insurance for or on behalf of any Field Force Personnel, all of which shall be Valeant\\'s sole responsibility. For clarity, the insurance requirements of this Section 11.5 shall not be construed to create a limit of either Party\\'s liability with respect to its indemnification obligations under this ARTICLE 11.\\n\\n ARTICLE 12  TERM AND TERMINATION\\n\\n 12.1 Term. This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'ARTICLE 12  TERM AND TERMINATION\\n\\n 12.1 Term. This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").\\n\\n 12.2 Early Termination for Cause. A Party shall have the right to terminate this Agreement before the end of the Term as follows:\\n\\n12.2.1 by a Party upon written notice to the other Party in the event of a material breach of this Agreement by such other Party where such breach is not cured (if able to be cured) within [***] following such other Party\\'s receipt of written notice of such breach (and any such termination shall become effective at the end of such [***] period unless the breaching Party has cured such breach prior to the expiration of such [***] period);\\n\\n12.2.2 by Dova if the Quarterly Average Sales Force Size is less than [***] Sales Representatives for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the Quarterly Average Sales Force Size is less than [***] Sales Representatives;\\n\\n12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.2.4 by either Party upon [***] written notice to the other Party following the withdrawal of the Product from the market by Dova (or the decision by Dova to withdraw the Product from the market) due to (i) any decision, judgment, ruling or other requirement of the FDA, or (ii) material safety concern;\\n\\n12.2.5 by Dova upon [***] written notice to Valeant upon the cessation of marketing by Valeant of the Designated Product (or the Alternate Product in accordance with Section 4.2.1(c), as the case may be);\\n\\n12.2.6 by Dova pursuant to Section 4.2.1(c); and\\n\\n12.2.7 by a Party immediately upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to such other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by such other Party, or in the event a receiver or custodian is appointed for such other Party\\'s business or a substantial portion of such other Party\\'s business is subject to attachment or similar process; provided, however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'This Agreement shall become effective as of the Effective Date and, unless earlier terminated as provided in this ARTICLE 12, shall extend until the four (4) year anniversary of the Effective Date (the \"Term\").\\n\\n 12.2 Early Termination for Cause. A Party shall have the right to terminate this Agreement before the end of the Term as follows:\\n\\n12.2.1 by a Party upon written notice to the other Party in the event of a material breach of this Agreement by such other Party where such breach is not cured (if able to be cured) within [***] following such other Party\\'s receipt of written notice of such breach (and any such termination shall become effective at the end of such [***] period unless the breaching Party has cured such breach prior to the expiration of such [***] period);\\n\\n12.2.2 by Dova if the Quarterly Average Sales Force Size is less than [***] Sales Representatives for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the Quarterly Average Sales Force Size is less than [***] Sales Representatives;\\n\\n12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.2.4 by either Party upon [***] written notice to the other Party following the withdrawal of the Product from the market by Dova (or the decision by Dova to withdraw the Product from the market) due to (i) any decision, judgment, ruling or other requirement of the FDA, or (ii) material safety concern;\\n\\n12.2.5 by Dova upon [***] written notice to Valeant upon the cessation of marketing by Valeant of the Designated Product (or the Alternate Product in accordance with Section 4.2.1(c), as the case may be);\\n\\n12.2.6 by Dova pursuant to Section 4.2.1(c); and\\n\\n12.2.7 by a Party immediately upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to such other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by such other Party, or in the event a receiver or custodian is appointed for such other Party\\'s business or a substantial portion of such other Party\\'s business is subject to attachment or similar process; provided, however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.\\n\\n 12.3 Other Early Termination.\\n\\n12.3.1 Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]);'],\n",
       "  ['REFERENCE',\n",
       "   \"A Party shall have the right to terminate this Agreement before the end of the Term as follows:\\n\\n12.2.1 by a Party upon written notice to the other Party in the event of a material breach of this Agreement by such other Party where such breach is not cured (if able to be cured) within [***] following such other Party's receipt of written notice of such breach (and any such termination shall become effective at the end of such [***] period unless the breaching Party has cured such breach prior to the expiration of such [***] period);\\n\\n12.2.2 by Dova if the Quarterly Average Sales Force Size is less than [***] Sales Representatives for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the Quarterly Average Sales Force Size is less than [***] Sales Representatives;\\n\\n12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details;\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n12.2.4 by either Party upon [***] written notice to the other Party following the withdrawal of the Product from the market by Dova (or the decision by Dova to withdraw the Product from the market) due to (i) any decision, judgment, ruling or other requirement of the FDA, or (ii) material safety concern;\\n\\n12.2.5 by Dova upon [***] written notice to Valeant upon the cessation of marketing by Valeant of the Designated Product (or the Alternate Product in accordance with Section 4.2.1(c), as the case may be);\\n\\n12.2.6 by Dova pursuant to Section 4.2.1(c); and\\n\\n12.2.7 by a Party immediately upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to such other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by such other Party, or in the event a receiver or custodian is appointed for such other Party's business or a substantial portion of such other Party's business is subject to attachment or similar process; provided, however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.\\n\\n 12.3 Other Early Termination.\\n\\n12.3.1 Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]); [***].\\n\\n12.3.2 Either Party shall have the right to terminate this Agreement before the end of the Term upon [***] written notice to the other Party delivered within [***] after the conclusion of any Calendar Quarter, beginning with the Calendar Quarter commencing on [***], in which the Net Sales in such Calendar Quarter are less [***] (and any such termination shall become effective at the end of such [***] period); provided that Valeant shall not have the right to terminate this Agreement pursuant to this Section 12.3.2 with respect to any Calendar Quarter for which the Quarterly Average Sales Force Size is less than [***] Sales Representatives.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   \"Either Party shall have the right to terminate this Agreement before the end of the Term for its convenience upon [***] written notice to the other Party (and any such termination shall become effective at the end of such [***]); [***].\\n\\n12.3.2 Either Party shall have the right to terminate this Agreement before the end of the Term upon [***] written notice to the other Party delivered within [***] after the conclusion of any Calendar Quarter, beginning with the Calendar Quarter commencing on [***], in which the Net Sales in such Calendar Quarter are less [***] (and any such termination shall become effective at the end of such [***] period); provided that Valeant shall not have the right to terminate this Agreement pursuant to this Section 12.3.2 with respect to any Calendar Quarter for which the Quarterly Average Sales Force Size is less than [***] Sales Representatives.\\n\\n 12.4 Effects of Termination. Upon the expiration or effective date of termination of this Agreement, (i) all rights and obligations of both Parties hereunder shall immediately terminate, subject to any survival as set forth in Sections 12.5 and 12.6, (ii) Valeant, at Dova's direction, shall immediately return to Dova or destroy in accordance with all Applicable Laws all Product Materials, reports and other tangible items provided by or on behalf of Dova to Valeant or otherwise developed or obtained by Valeant pursuant to the terms of this Agreement (other than Valeant Property) (and at the request of Dova, Valeant shall certify destruction of such materials if Valeant does not to return such materials to Dova), (iii) Valeant shall immediately cease all Valeant Activities with respect to the Product, and (iv) each of Dova and Valeant shall, at the other Party's direction, either return to such other Party or destroy all Confidential Information of such other Party.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Either Party shall have the right to terminate this Agreement before the end of the Term upon [***] written notice to the other Party delivered within [***] after the conclusion of any Calendar Quarter, beginning with the Calendar Quarter commencing on [***], in which the Net Sales in such Calendar Quarter are less [***] (and any such termination shall become effective at the end of such [***] period); provided that Valeant shall not have the right to terminate this Agreement pursuant to this Section 12.3.2 with respect to any Calendar Quarter for which the Quarterly Average Sales Force Size is less than [***] Sales Representatives.\\n\\n 12.4 Effects of Termination. Upon the expiration or effective date of termination of this Agreement, (i) all rights and obligations of both Parties hereunder shall immediately terminate, subject to any survival as set forth in Sections 12.5 and 12.6, (ii) Valeant, at Dova's direction, shall immediately return to Dova or destroy in accordance with all Applicable Laws all Product Materials, reports and other tangible items provided by or on behalf of Dova to Valeant or otherwise developed or obtained by Valeant pursuant to the terms of this Agreement (other than Valeant Property) (and at the request of Dova, Valeant shall certify destruction of such materials if Valeant does not to return such materials to Dova), (iii) Valeant shall immediately cease all Valeant Activities with respect to the Product, and (iv) each of Dova and Valeant shall, at the other Party's direction, either return to such other Party or destroy all Confidential Information of such other Party. Notwithstanding the foregoing, each Party may retain archival copies of any Confidential Information to the extent required by law, regulation or professional standards or copies of Confidential Information created pursuant to the automatic backing-up of electronic files where the delivery or destruction of such files would cause undue hardship to the receiving Party, so long as any such archival or electronic file back-up copies are accessible only to its legal or IT personnel, provided that such Confidential Information will continue to be subject to the terms of this Agreement.\\n\\n 12.5 Tail Period.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Upon the expiration or effective date of termination of this Agreement, (i) all rights and obligations of both Parties hereunder shall immediately terminate, subject to any survival as set forth in Sections 12.5 and 12.6, (ii) Valeant, at Dova's direction, shall immediately return to Dova or destroy in accordance with all Applicable Laws all Product Materials, reports and other tangible items provided by or on behalf of Dova to Valeant or otherwise developed or obtained by Valeant pursuant to the terms of this Agreement (other than Valeant Property) (and at the request of Dova, Valeant shall certify destruction of such materials if Valeant does not to return such materials to Dova), (iii) Valeant shall immediately cease all Valeant Activities with respect to the Product, and (iv) each of Dova and Valeant shall, at the other Party's direction, either return to such other Party or destroy all Confidential Information of such other Party. Notwithstanding the foregoing, each Party may retain archival copies of any Confidential Information to the extent required by law, regulation or professional standards or copies of Confidential Information created pursuant to the automatic backing-up of electronic files where the delivery or destruction of such files would cause undue hardship to the receiving Party, so long as any such archival or electronic file back-up copies are accessible only to its legal or IT personnel, provided that such Confidential Information will continue to be subject to the terms of this Agreement.\\n\\n 12.5 Tail Period. Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated. Such payments shall be made within [***] following the end of each calendar quarter in the Tail Period.\"],\n",
       "  ['REFERENCE',\n",
       "   '12.5 Tail Period. Solely in the event that Dova has terminated this Agreement pursuant to Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion services performed by Valeant during the Term, with respect to the Tail Period, Dova shall make payments to Valeant in an amount equal to [***] of the amounts that would have been payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had the Agreement not been so terminated. Such payments shall be made within [***] following the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall apply, mutatis mutandis, to such Tail Period payments. For clarity, no tail payment shall be due following any expiration or termination of this Agreement except as set forth in this Section 12.5.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Such payments shall be made within [***] following the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall apply, mutatis mutandis, to such Tail Period payments. For clarity, no tail payment shall be due following any expiration or termination of this Agreement except as set forth in this Section 12.5.\\n\\n 12.6 Survival. Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration.'],\n",
       "  ['REFERENCE',\n",
       "   'For clarity, no tail payment shall be due following any expiration or termination of this Agreement except as set forth in this Section 12.5.\\n\\n 12.6 Survival. Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement, such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6, Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and, solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\\n\\n ARTICLE 13  MISCELLANEOUS\\n\\n13.1 Force Majeure.'],\n",
       "  ['REFERENCE',\n",
       "   'Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Notwithstanding any expiration or termination of this Agreement, such expiration or termination shall not relieve any Party from obligations which are expressly or by implication intended to survive expiration or termination, including Sections 2.3, , 4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6, Articles 7, 8, 9 and 13 (to the extent applicable to implementation of the survival of the preceding Sections and Articles) and, solely as it relates to the last Calendar Quarter, Sections 6.1, 6.2 and 6.3, which shall survive and be in full force and effect.\\n\\n ARTICLE 13  MISCELLANEOUS\\n\\n13.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncaused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances and re-commence its performance hereunder as soon as practicable.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'ARTICLE 13  MISCELLANEOUS\\n\\n13.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ncaused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances and re-commence its performance hereunder as soon as practicable.\\n\\n 13.2 Assignment. Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment.'],\n",
       "  ['REFERENCE',\n",
       "   \"The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances and re-commence its performance hereunder as soon as practicable.\\n\\n 13.2 Assignment. Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment. In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party. Notwithstanding the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova's assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld); provided that a merger, sale of stock or comparable transaction shall not constitute an assignment. In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party's written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party. Notwithstanding the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova's assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. Any attempted assignment not in accordance with this Section 13.2 shall be void.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Notwithstanding the foregoing, (a) either Party may, without the other Party's consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova's assets or rights relating to the Product; provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. Any attempted assignment not in accordance with this Section 13.2 shall be void. This Agreement shall be binding on, and inure to the benefit of, each Party, and its permitted successors and assigns.\\n\\n 13.3 Severability.\"],\n",
       "  ['REFERENCE',\n",
       "   'Any attempted assignment not in accordance with this Section 13.2 shall be void. This Agreement shall be binding on, and inure to the benefit of, each Party, and its permitted successors and assigns.\\n\\n 13.3 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '13.3 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.\\n\\n 13.4 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by e-mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier, or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:\\n\\nif to Dova, to: Dova Pharmaceuticals, Inc.'],\n",
       "  ['REFERENCE',\n",
       "   'The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.\\n\\n 13.4 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by e-mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier, or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:\\n\\nif to Dova, to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707 Attention: Chief Executive Officer Email: asapir@dova.com\\n\\nWith a copy to: Dova Pharmaceuticals, Inc.'],\n",
       "  ['REFERENCE',\n",
       "   'All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by e-mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier, or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:\\n\\nif to Dova, to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707 Attention: Chief Executive Officer Email: asapir@dova.com\\n\\nWith a copy to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707 Attention: General Counsel Email: mbanjak@dova.com\\n\\nif to Valeant, to: Valeant Pharmaceuticals North America LLC 400'],\n",
       "  ['REFERENCE',\n",
       "   'Attention: Chief Executive Officer Email: asapir@dova.com\\n\\nWith a copy to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707 Attention: General Counsel Email: mbanjak@dova.com\\n\\nif to Valeant, to: Valeant Pharmaceuticals North America LLC 400 Somerset Corporate Boulevard Bridgewater, NJ 08807 Attention: XXXXXXXXX Email: XXXXXXXX\\n\\nWith a copy to: XXXXXXXX Attention: XXXXXXXX Fax: XXXXXXXX Email: XXXXXXXX\\n\\nor to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.'],\n",
       "  ['REFERENCE',\n",
       "   'Attention: General Counsel Email: mbanjak@dova.com\\n\\nif to Valeant, to: Valeant Pharmaceuticals North America LLC 400 Somerset Corporate Boulevard Bridgewater, NJ 08807 Attention: XXXXXXXXX Email: XXXXXXXX\\n\\nWith a copy to: XXXXXXXX Attention: XXXXXXXX Fax: XXXXXXXX Email: XXXXXXXX\\n\\nor to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered; (b) on the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nBusiness Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) Business Day following the date of mailing, if sent by mail.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Attention: XXXXXXXXX Email: XXXXXXXX\\n\\nWith a copy to: XXXXXXXX Attention: XXXXXXXX Fax: XXXXXXXX Email: XXXXXXXX\\n\\nor to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered; (b) on the\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nBusiness Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) Business Day following the date of mailing, if sent by mail.\\n\\n 13.5 Governing Law. This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nBusiness Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) Business Day following the date of mailing, if sent by mail.\\n\\n 13.5 Governing Law. This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.\\n\\n 13.6 Dispute Resolution.\\n\\n13.6.1 JSC; Escalation for Other Disputes. Except for disputes resolved by the procedures set forth in Section 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"Dispute\"), then either Party shall have the right to refer such dispute to the Senior Officers who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith negotiations.'],\n",
       "  ['REFERENCE',\n",
       "   'This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the internal laws of the [***] applicable to agreements made and to be performed entirely in such state, including its statutes of limitation but without giving effect to the conflict of law principles thereof.\\n\\n 13.6 Dispute Resolution.\\n\\n13.6.1 JSC; Escalation for Other Disputes. Except for disputes resolved by the procedures set forth in Section 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"Dispute\"), then either Party shall have the right to refer such dispute to the Senior Officers who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith negotiations. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. If such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Except for disputes resolved by the procedures set forth in Section 3.4, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a \"Dispute\"), then either Party shall have the right to refer such dispute to the Senior Officers who shall confer within [***] after such Dispute was first referred to them to attempt to resolve the Dispute by good faith negotiations. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. If such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\\n\\n 13.6.2 Arbitration of Other Disputes. If a Dispute is not resolved by the Senior Officers pursuant to Section 13.6.1, such Dispute shall be submitted to and finally settled by [***] The Parties hereby submit to the exclusive jurisdiction of the federal and state courts located in [***] for the purposes of an order to compel arbitration, for preliminary relief in aid of arbitration and for a preliminary injunction to maintain the status quo or prevent irreparable harm prior to the appointment of the arbitrators and to the non-exclusive jurisdiction of such courts for the enforcement of any ward issued hereunder.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'If such Senior Officers do not agree on the resolution of an issue within [***] after such issue was first referred to them, either Party may, by written notice to the other Party, initiate arbitration for resolution of such Dispute pursuant to Section 13.6.2.\\n\\n 13.6.2 Arbitration of Other Disputes. If a Dispute is not resolved by the Senior Officers pursuant to Section 13.6.1, such Dispute shall be submitted to and finally settled by [***] The Parties hereby submit to the exclusive jurisdiction of the federal and state courts located in [***] for the purposes of an order to compel arbitration, for preliminary relief in aid of arbitration and for a preliminary injunction to maintain the status quo or prevent irreparable harm prior to the appointment of the arbitrators and to the non-exclusive jurisdiction of such courts for the enforcement of any ward issued hereunder.\\n\\n 13.7 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'If a Dispute is not resolved by the Senior Officers pursuant to Section 13.6.1, such Dispute shall be submitted to and finally settled by [***] The Parties hereby submit to the exclusive jurisdiction of the federal and state courts located in [***] for the purposes of an order to compel arbitration, for preliminary relief in aid of arbitration and for a preliminary injunction to maintain the status quo or prevent irreparable harm prior to the appointment of the arbitrators and to the non-exclusive jurisdiction of such courts for the enforcement of any ward issued hereunder.\\n\\n 13.7 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.\\n\\n 13.8 Entire Agreement; Amendments. This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof.'],\n",
       "  ['REFERENCE',\n",
       "   'EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.\\n\\n 13.8 Entire Agreement; Amendments. This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof (including the Confidentiality Agreement, but solely with respect to information which is deemed Confidential Information hereunder) are superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement.'],\n",
       "  ['REFERENCE',\n",
       "   'This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof (including the Confidentiality Agreement, but solely with respect to information which is deemed Confidential Information hereunder) are superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto.\\n\\n 13.9 Headings.'],\n",
       "  ['REFERENCE',\n",
       "   'The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto.\\n\\n 13.9 Headings. The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof.\\n\\n 13.10 Independent Contractors.'],\n",
       "  ['REFERENCE',\n",
       "   '13.9 Headings. The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof.\\n\\n 13.10 Independent Contractors. It is expressly agreed that Valeant and Dova shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '13.10 Independent Contractors. It is expressly agreed that Valeant and Dova shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.\\n\\n 13.11 Third Party Beneficiaries. Except as set forth in ARTICLE 11, no Person other than Dova or Valeant (and their respective Affiliates and permitted successors and assignees hereunder) shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Neither Valeant nor Dova shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.\\n\\n 13.11 Third Party Beneficiaries. Except as set forth in ARTICLE 11, no Person other than Dova or Valeant (and their respective Affiliates and permitted successors and assignees hereunder) shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.\\n\\n 13.12 Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Except as set forth in ARTICLE 11, no Person other than Dova or Valeant (and their respective Affiliates and permitted successors and assignees hereunder) shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.\\n\\n 13.12 Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.\\n\\n 13.13 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.\\n\\n 13.13 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.\\n\\n 13.14 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.'],\n",
       "  ['REFERENCE',\n",
       "   'No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.\\n\\n 13.14 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.\\n\\n 13.15 Use of Names.'],\n",
       "  ['REFERENCE',\n",
       "   'Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.\\n\\n 13.15 Use of Names. Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement.\\n\\n 13.16 Further Actions and Documents.'],\n",
       "  ['REFERENCE',\n",
       "   '13.15 Use of Names. Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement.\\n\\n 13.16 Further Actions and Documents. Each Party agrees to execute, acknowledge and deliver all such further\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ninstruments, and to do all such further acts, as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.\\n\\n 13.17 Certain Conventions.'],\n",
       "  ['REFERENCE',\n",
       "   '13.16 Further Actions and Documents. Each Party agrees to execute, acknowledge and deliver all such further\\n\\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\ninstruments, and to do all such further acts, as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.\\n\\n 13.17 Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as \"herein\", \"hereof\", and \"hereunder\" refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term \"including\" (or \"includes\"), such term shall be deemed to mean \"including without limitation\" (or \"includes without limitations\"), and (e) references to any Articles or Sections include Sections and subsections that are part of the references\\' Article or Section (e.g., a section numbered \"Section 2.2.1\" would be part of \"Section 2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section 2.2.1\").\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '13.17 Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as \"herein\", \"hereof\", and \"hereunder\" refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term \"including\" (or \"includes\"), such term shall be deemed to mean \"including without limitation\" (or \"includes without limitations\"), and (e) references to any Articles or Sections include Sections and subsections that are part of the references\\' Article or Section (e.g., a section numbered \"Section 2.2.1\" would be part of \"Section 2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section 2.2.1\").\\n\\n 13.18 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.'],\n",
       "  ['REFERENCE',\n",
       "   'Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as \"herein\", \"hereof\", and \"hereunder\" refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term \"including\" (or \"includes\"), such term shall be deemed to mean \"including without limitation\" (or \"includes without limitations\"), and (e) references to any Articles or Sections include Sections and subsections that are part of the references\\' Article or Section (e.g., a section numbered \"Section 2.2.1\" would be part of \"Section 2.2\", and references to \"ARTICLE 2\" or \"Section 2.2\" would refer to material contained in the subsection described as \"Section 2.2.1\").\\n\\n 13.18 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or electronic mail (including pdf) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes and shall have the same force and effect as original signatures.\\n\\n [signature page follows]\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or electronic mail (including pdf) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes and shall have the same force and effect as original signatures.\\n\\n [signature page follows]\\n\\n [Signature page to Co-Promotion Agreement]\\n\\nIN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.\\n\\nDOVA PHARMACEUTICALS, INC.\\n\\n By: __/s/'],\n",
       "  ['REFERENCE',\n",
       "   '[signature page follows]\\n\\n [Signature page to Co-Promotion Agreement]\\n\\nIN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.\\n\\nDOVA PHARMACEUTICALS, INC.\\n\\n By: __/s/ Alex C. Sapir______________________\\n\\nName: Alex C. Sapir\\n\\nTitle: CEO\\n\\nVALEANT PHARMACEUTICALS NORTH AMERICA LLC\\n\\nBy: ___/s/'],\n",
       "  ['REFERENCE',\n",
       "   'By: __/s/ Alex C. Sapir______________________\\n\\nName: Alex C. Sapir\\n\\nTitle: CEO\\n\\nVALEANT PHARMACEUTICALS NORTH AMERICA LLC\\n\\nBy: ___/s/ Joseph C. Papa_______________\\n\\nName: Joseph C. Papa\\n\\nTitle: Chief Executive Officer and President\\n\\n9\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   'Alex C. Sapir\\n\\nTitle: CEO\\n\\nVALEANT PHARMACEUTICALS NORTH AMERICA LLC\\n\\nBy: ___/s/ Joseph C. Papa_______________\\n\\nName: Joseph C. Papa\\n\\nTitle: Chief Executive Officer and President\\n\\n9\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nEXHIBIT A\\n\\nJoint Press Release\\n\\nDURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nEXHIBIT A\\n\\nJoint Press Release\\n\\nDURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (\"Dova\") (DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (\"Salix\"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that they have entered into an exclusive agreement to co-promote Dova\\'s DOPTELET (avatrombopag) in the United States (U.S.). The U.S. Food and Drug Administration (\"FDA\") approved DOPTELET on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nEXHIBIT A\\n\\nJoint Press Release\\n\\nDURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (\"Dova\") (DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (\"Salix\"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that they have entered into an exclusive agreement to co-promote Dova\\'s DOPTELET (avatrombopag) in the United States (U.S.). The U.S. Food and Drug Administration (\"FDA\") approved DOPTELET on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. DOPTELET represents the first thrombopoietin (TPO) receptor agonist approved in the United States for this indication.\\n\\n Thrombocytopenia, a condition in which patients have a low platelet count, is the most common hematological abnormality in patients with CLD that often worsens with the severity of liver disease.'],\n",
       "  ['REFERENCE',\n",
       "   'The U.S. Food and Drug Administration (\"FDA\") approved DOPTELET on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. DOPTELET represents the first thrombopoietin (TPO) receptor agonist approved in the United States for this indication.\\n\\n Thrombocytopenia, a condition in which patients have a low platelet count, is the most common hematological abnormality in patients with CLD that often worsens with the severity of liver disease. It is estimated that approximately 15 percent of the 7.5 million patients with CLD have some form of thrombocytopenia. In a study published in 2010, patients with severe thrombocytopenia (<75,000/L) had a 31 percent incidence of procedure-related bleeding.'],\n",
       "  ['REFERENCE',\n",
       "   'Thrombocytopenia, a condition in which patients have a low platelet count, is the most common hematological abnormality in patients with CLD that often worsens with the severity of liver disease. It is estimated that approximately 15 percent of the 7.5 million patients with CLD have some form of thrombocytopenia. In a study published in 2010, patients with severe thrombocytopenia (<75,000/L) had a 31 percent incidence of procedure-related bleeding. As a result of the associated increased rate of bleeding, there is an increased risk for the CLD patient when undergoing common scheduled medical procedures such as liver biopsy, colonoscopy, endoscopy, and routine dental procedures.\\n\\n As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals.'],\n",
       "  ['REFERENCE',\n",
       "   'In a study published in 2010, patients with severe thrombocytopenia (<75,000/L) had a 31 percent incidence of procedure-related bleeding. As a result of the associated increased rate of bleeding, there is an increased risk for the CLD patient when undergoing common scheduled medical procedures such as liver biopsy, colonoscopy, endoscopy, and routine dental procedures.\\n\\n As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals. The Salix sales force will begin selling DOPTELET in mid-October 2018. Dova will continue its commercial efforts targeting primarily hepatologists and interventional radiologists and certain other specialties.'],\n",
       "  ['REFERENCE',\n",
       "   'As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals. The Salix sales force will begin selling DOPTELET in mid-October 2018. Dova will continue its commercial efforts targeting primarily hepatologists and interventional radiologists and certain other specialties. Pursuant to the agreement, Dova will pay Salix a quarterly fee based on net sales (as defined in the agreement) of DOPTELET prescribed by gastroenterologists in the U.S.\\n\\n\"We are delighted to be working with Salix, a company considered by many to have the preeminent gastroenterology sales force in the United States,\" said Alex C. Sapir, president and chief executive officer, Dova Pharmaceuticals. \"Given Salix\\'s presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to DOPTELET and to patients.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova will continue its commercial efforts targeting primarily hepatologists and interventional radiologists and certain other specialties. Pursuant to the agreement, Dova will pay Salix a quarterly fee based on net sales (as defined in the agreement) of DOPTELET prescribed by gastroenterologists in the U.S.\\n\\n\"We are delighted to be working with Salix, a company considered by many to have the preeminent gastroenterology sales force in the United States,\" said Alex C. Sapir, president and chief executive officer, Dova Pharmaceuticals. \"Given Salix\\'s presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to DOPTELET and to patients. \"\\n\\n\"Salix considers liver disease a strategic therapeutic area of focus, given our history and knowledge with XIFAXAN (rifaximin), an innovative medicine indicated for the treatment of overt hepatic encephalopathy (HE), a condition that is often a consequence of chronic liver disease,\" said Mark McKenna, president, Salix Pharmaceuticals. \"Adding DOPTELET to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet need in the marketplace.'],\n",
       "  ['REFERENCE',\n",
       "   '\"Given Salix\\'s presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to DOPTELET and to patients. \"\\n\\n\"Salix considers liver disease a strategic therapeutic area of focus, given our history and knowledge with XIFAXAN (rifaximin), an innovative medicine indicated for the treatment of overt hepatic encephalopathy (HE), a condition that is often a consequence of chronic liver disease,\" said Mark McKenna, president, Salix Pharmaceuticals. \"Adding DOPTELET to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet need in the marketplace. \"\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   '\"Adding DOPTELET to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet need in the marketplace. \"\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nAbout DOPTELET  DOPTELET (avatrombopag) is a second generation, once daily, orally administered TPO receptor agonist approved for the treatment of thrombocytopenia in adult patients with CLD who are scheduled to undergo a procedure.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nAbout DOPTELET  DOPTELET (avatrombopag) is a second generation, once daily, orally administered TPO receptor agonist approved for the treatment of thrombocytopenia in adult patients with CLD who are scheduled to undergo a procedure. DOPTELET is designed to mimic the effects of TPO, the primary regulator of normal platelet production.\\n\\n Two global Phase 3, double-blind, placebo-controlled trials (ADAPT-1 [N=231] and ADAPT-2'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nAbout DOPTELET  DOPTELET (avatrombopag) is a second generation, once daily, orally administered TPO receptor agonist approved for the treatment of thrombocytopenia in adult patients with CLD who are scheduled to undergo a procedure. DOPTELET is designed to mimic the effects of TPO, the primary regulator of normal platelet production.\\n\\n Two global Phase 3, double-blind, placebo-controlled trials (ADAPT-1 [N=231] and ADAPT-2 [N=204]), conducted in adults with thrombocytopenia (platelet count of less than 50,000/L) and CLD, supported the FDA approval. Patients were assigned to either 40 mg or 60 mg of avatrombopag daily for five days based on their Baseline platelet counts (40 to <50,000/mL or <40,000/mL, respectively).'],\n",
       "  ['REFERENCE',\n",
       "   'Two global Phase 3, double-blind, placebo-controlled trials (ADAPT-1 [N=231] and ADAPT-2 [N=204]), conducted in adults with thrombocytopenia (platelet count of less than 50,000/L) and CLD, supported the FDA approval. Patients were assigned to either 40 mg or 60 mg of avatrombopag daily for five days based on their Baseline platelet counts (40 to <50,000/mL or <40,000/mL, respectively). Avatrombopag was shown to be superior to placebo in increasing the proportion of patients not requiring platelet transfusions or rescue procedures for bleeding up to seven days following a scheduled procedure in both trials in both the 40 mg (ADAPT-1, 88% vs. 38%, p <0.0001; ADAPT-2, 88% vs. 33%; p<0.0001), and 60 mg (ADAPT-1, 66% vs. 23%, p <0.0001; ADAPT-2, 69% vs. 35%; p=0.0006) treatment groups. Avatrombopag was also superior to placebo at the two secondary efficacy endpoints in each trial.'],\n",
       "  ['REFERENCE',\n",
       "   'Patients were assigned to either 40 mg or 60 mg of avatrombopag daily for five days based on their Baseline platelet counts (40 to <50,000/mL or <40,000/mL, respectively). Avatrombopag was shown to be superior to placebo in increasing the proportion of patients not requiring platelet transfusions or rescue procedures for bleeding up to seven days following a scheduled procedure in both trials in both the 40 mg (ADAPT-1, 88% vs. 38%, p <0.0001; ADAPT-2, 88% vs. 33%; p<0.0001), and 60 mg (ADAPT-1, 66% vs. 23%, p <0.0001; ADAPT-2, 69% vs. 35%; p=0.0006) treatment groups. Avatrombopag was also superior to placebo at the two secondary efficacy endpoints in each trial. In the avatrombopag treatment groups, there was an increased proportion of patients achieving the target platelet count of 50,000/mL on procedure day, and a greater magnitude of the change in mean platelet count from baseline to procedure day; all treatment differences between the avatrombopag and placebo treatment groups for each secondary endpoint were highly statistically significant with p values <0.0001. The most common adverse reactions with avatrombopag included pyrexia, abdominal pain, nausea, headache, fatigue and edema peripheral.'],\n",
       "  ['REFERENCE',\n",
       "   'Avatrombopag was also superior to placebo at the two secondary efficacy endpoints in each trial. In the avatrombopag treatment groups, there was an increased proportion of patients achieving the target platelet count of 50,000/mL on procedure day, and a greater magnitude of the change in mean platelet count from baseline to procedure day; all treatment differences between the avatrombopag and placebo treatment groups for each secondary endpoint were highly statistically significant with p values <0.0001. The most common adverse reactions with avatrombopag included pyrexia, abdominal pain, nausea, headache, fatigue and edema peripheral. Portal vein thromboses have been reported in patients with CLD and in patients receiving TPO receptor agonists. One treatment-emergent event of portal vein thrombosis was reported in the ADAPT trials in an avatrombopag-treated patient.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'The most common adverse reactions with avatrombopag included pyrexia, abdominal pain, nausea, headache, fatigue and edema peripheral. Portal vein thromboses have been reported in patients with CLD and in patients receiving TPO receptor agonists. One treatment-emergent event of portal vein thrombosis was reported in the ADAPT trials in an avatrombopag-treated patient.\\n\\n INDICATION\\n\\nDOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.\\n\\n IMPORTANT SAFETY INFORMATION\\n\\nWARNINGS AND PRECAUTIONS\\n\\nDOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease.'],\n",
       "  ['REFERENCE',\n",
       "   'One treatment-emergent event of portal vein thrombosis was reported in the ADAPT trials in an avatrombopag-treated patient.\\n\\n INDICATION\\n\\nDOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.\\n\\n IMPORTANT SAFETY INFORMATION\\n\\nWARNINGS AND PRECAUTIONS\\n\\nDOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was one treatment- emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'IMPORTANT SAFETY INFORMATION\\n\\nWARNINGS AND PRECAUTIONS\\n\\nDOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was one treatment- emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET.\\n\\n Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).\\n\\n DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'In the ADAPT-1 and ADAPT-2 clinical trials, there was one treatment- emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET.\\n\\n Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).\\n\\n DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.\\n\\n CONTRAINDICATIONS: None\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   'DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.\\n\\n CONTRAINDICATIONS: None\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED'],\n",
       "  ['REFERENCE',\n",
       "   'None\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nADVERSE REACTIONS\\n\\nMost common adverse reactions ( 3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.\\n\\n Please see full Prescribing Information for DOPTELET (avatrombopag) www.doptelet.com\\n\\nAbout XIFAXAN  XIFAXAN is a nonsystemic* antibiotic that slows the growth of bacteria in the gut that are believed to be linked to symptoms of overt hepatic encephalopathy (HE).'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nADVERSE REACTIONS\\n\\nMost common adverse reactions ( 3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.\\n\\n Please see full Prescribing Information for DOPTELET (avatrombopag) www.doptelet.com\\n\\nAbout XIFAXAN  XIFAXAN is a nonsystemic* antibiotic that slows the growth of bacteria in the gut that are believed to be linked to symptoms of overt hepatic encephalopathy (HE). It has been proven to reduce the risk of overt HE recurrence and HE-related hospitalizations in adults.\\n\\n *There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment.'],\n",
       "  ['REFERENCE',\n",
       "   'Please see full Prescribing Information for DOPTELET (avatrombopag) www.doptelet.com\\n\\nAbout XIFAXAN  XIFAXAN is a nonsystemic* antibiotic that slows the growth of bacteria in the gut that are believed to be linked to symptoms of overt hepatic encephalopathy (HE). It has been proven to reduce the risk of overt HE recurrence and HE-related hospitalizations in adults.\\n\\n *There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.\\n\\n INDICATION  XIFAXAN (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '*There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.\\n\\n INDICATION  XIFAXAN (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.\\n\\n IMPORTANT SAFETY INFORMATION\\n\\nXIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'INDICATION  XIFAXAN (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.\\n\\n IMPORTANT SAFETY INFORMATION\\n\\nXIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.\\n\\n If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis.'],\n",
       "  ['REFERENCE',\n",
       "   'Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.\\n\\n If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.\\n\\n Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.\\n\\n Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.\\n\\n Tell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.\\n\\n In clinical studies, the most common side effects of XIFAXAN were: HE: Peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen)  IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes\\n\\nXIFAXAN may affect warfarin activity when taken together.'],\n",
       "  ['REFERENCE',\n",
       "   'Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.\\n\\n Tell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.\\n\\n In clinical studies, the most common side effects of XIFAXAN were: HE: Peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen)  IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes\\n\\nXIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if you are taking warfarin because the dose of warfarin may need to be adjusted to maintain proper blood-thinning effect.\\n\\n If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.'],\n",
       "  ['REFERENCE',\n",
       "   'In clinical studies, the most common side effects of XIFAXAN were: HE: Peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen)  IBS-D: Nausea (feeling sick to your stomach) and an increase in liver enzymes\\n\\nXIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if you are taking warfarin because the dose of warfarin may need to be adjusted to maintain proper blood-thinning effect.\\n\\n If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800- FDA-1088.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800- FDA-1088.\\n\\n CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   'Visit www.fda.gov/medwatch or call 1-800- FDA-1088.\\n\\n CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n For product information, adverse event reports, and product complaint reports, please contact:  Salix Product Information Call Center  Phone: 1-800-321-4576  Fax: 1-510-595-8183  Email: salixmc@dlss.com   Please click here for full Prescribing Information.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\n For product information, adverse event reports, and product complaint reports, please contact:  Salix Product Information Call Center  Phone: 1-800-321-4576  Fax: 1-510-595-8183  Email: salixmc@dlss.com   Please click here for full Prescribing Information.\\n\\n About Dova Pharmaceuticals, Inc.   Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia.'],\n",
       "  ['REFERENCE',\n",
       "   \"Please click here for full Prescribing Information.\\n\\n About Dova Pharmaceuticals, Inc.   Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova's proprietary pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia in adult patients with CLD scheduled to undergo a procedure.\\n\\n About Salix  Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova's proprietary pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia in adult patients with CLD scheduled to undergo a procedure.\\n\\n About Salix  Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care.\"],\n",
       "  ['REFERENCE',\n",
       "   \"About Salix  Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.\\n\\n About Bausch Health  Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.\"],\n",
       "  ['REFERENCE',\n",
       "   \"Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.\\n\\n About Bausch Health  Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.\"],\n",
       "  ['REFERENCE',\n",
       "   \"About Bausch Health  Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.\\n\\n Dova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements  \"],\n",
       "  ['REFERENCE',\n",
       "   'We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.\\n\\n Dova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements   Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \"anticipated\", \"believe\", \"expect\", \"may\", \"plan\", \"potential\", \"will\", and similar expressions, and are based on Dova\\'s current beliefs and expectations.'],\n",
       "  ['REFERENCE',\n",
       "   'Dova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements   Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \"anticipated\", \"believe\", \"expect\", \"may\", \"plan\", \"potential\", \"will\", and similar expressions, and are based on Dova\\'s current beliefs and expectations. These forward-looking statements include the potential benefits of the collaboration, the timing of the Salix sales force beginning to sell DOPTELET and other information relating to the transaction between Dova and Salix. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.'],\n",
       "  ['REFERENCE',\n",
       "   'These statements may be identified by words such as \"anticipated\", \"believe\", \"expect\", \"may\", \"plan\", \"potential\", \"will\", and similar expressions, and are based on Dova\\'s current beliefs and expectations. These forward-looking statements include the potential benefits of the collaboration, the timing of the Salix sales force beginning to sell DOPTELET and other information relating to the transaction between Dova and Salix. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Dova\\'s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Dova\\'s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2018, and Dova\\'s other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   \"These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Dova's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Dova's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2018, and Dova's other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED\"],\n",
       "  ['REFERENCE',\n",
       "   'Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nof the date of this release, and Dova assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.\\n\\n Bausch Health Forward-looking Statements  This news release may contain forward-looking statements, which may generally be identified by the use of the words \"anticipates,\" \"expects,\" \"intends,\" \"plans,\" \"should,\" \"could,\" \"would,\" \"may,\" \"will,\" \"believes,\" \"estimates,\" \"potential,\" \"target,\" or \"continue\" and variations or similar expressions.'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nof the date of this release, and Dova assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.\\n\\n Bausch Health Forward-looking Statements  This news release may contain forward-looking statements, which may generally be identified by the use of the words \"anticipates,\" \"expects,\" \"intends,\" \"plans,\" \"should,\" \"could,\" \"would,\" \"may,\" \"will,\" \"believes,\" \"estimates,\" \"potential,\" \"target,\" or \"continue\" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Bausch Health\\'s most recent annual or quarterly report and detailed from time to time in Bausch Health\\'s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.'],\n",
       "  ['REFERENCE',\n",
       "   'Bausch Health Forward-looking Statements  This news release may contain forward-looking statements, which may generally be identified by the use of the words \"anticipates,\" \"expects,\" \"intends,\" \"plans,\" \"should,\" \"could,\" \"would,\" \"may,\" \"will,\" \"believes,\" \"estimates,\" \"potential,\" \"target,\" or \"continue\" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Bausch Health\\'s most recent annual or quarterly report and detailed from time to time in Bausch Health\\'s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Bausch Health believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements.'],\n",
       "  ['REFERENCE',\n",
       "   \"These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Bausch Health's most recent annual or quarterly report and detailed from time to time in Bausch Health's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Bausch Health believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health and Salix undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.\\n\\n\"],\n",
       "  ['REFERENCE',\n",
       "   'Bausch Health believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health and Salix undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.\\n\\n Dova Investor Contacts:  Mark W. Hahn  Chief Financial Officer  mhahn@dova.com  (919) 338-7936\\n\\nSalix Investor Contact:  Arthur Shannon  Arthur.Shannon@bauschhealth.com  514-856-3855  877-281-6642 (toll free)\\n\\nWestwicke Partners  John Woolford  john.woolford@westwicke.com  (443) 213-0506\\n\\nSalix Media Contacts:  Lainie Keller  Lainie.Keller@bauschhealth.com  908-927-0617\\n\\nKaren Paff\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   'Bausch Health and Salix undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.\\n\\n Dova Investor Contacts:  Mark W. Hahn  Chief Financial Officer  mhahn@dova.com  (919) 338-7936\\n\\nSalix Investor Contact:  Arthur Shannon  Arthur.Shannon@bauschhealth.com  514-856-3855  877-281-6642 (toll free)\\n\\nWestwicke Partners  John Woolford  john.woolford@westwicke.com  (443) 213-0506\\n\\nSalix Media Contacts:  Lainie Keller  Lainie.Keller@bauschhealth.com  908-927-0617\\n\\nKaren Paff\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nKaren.Paff@salix.com  908-927-1190\\n\\nAkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc., is the exclusive licensee and distributor of DOPTELET in the United States and its territories.'],\n",
       "  ['REFERENCE',\n",
       "   '[***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nKaren.Paff@salix.com  908-927-1190\\n\\nAkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc., is the exclusive licensee and distributor of DOPTELET in the United States and its territories. 2018  DOPTELET is a registered trademark of AkaRx, Inc.\\n\\nPM-US-DOP-0072\\n\\nThe Xifaxan 550 mg product and the Xifaxan trademark are licensed by Alfasigma S.p.A.to Salix Pharmaceuticals or its affiliates.\\n\\n SAL.0103.USA.18\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.'],\n",
       "  ['REFERENCE',\n",
       "   'Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nKaren.Paff@salix.com  908-927-1190\\n\\nAkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc., is the exclusive licensee and distributor of DOPTELET in the United States and its territories. 2018  DOPTELET is a registered trademark of AkaRx, Inc.\\n\\nPM-US-DOP-0072\\n\\nThe Xifaxan 550 mg product and the Xifaxan trademark are licensed by Alfasigma S.p.A.to Salix Pharmaceuticals or its affiliates.\\n\\n SAL.0103.USA.18\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED'],\n",
       "  ['REFERENCE',\n",
       "   'SAL.0103.USA.18\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n'],\n",
       "  ['REFERENCE',\n",
       "   'OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nSchedule 1.65\\n\\nThird Party Agreements\\n\\n1. Stock Purchase Agreement dated March 29, 2016 (as amended) between PBM AKX Holdings, LLC and Eisai, Inc.\\n\\n2.'],\n",
       "  ['REFERENCE',\n",
       "   'A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\\n\\n\\n\\n\\n\\nSchedule 1.65\\n\\nThird Party Agreements\\n\\n1. Stock Purchase Agreement dated March 29, 2016 (as amended) between PBM AKX Holdings, LLC and Eisai, Inc.\\n\\n2. License Agreement dated August 15, 2005 (as amended) between Astellas Pharma Inc. and AkaRx, Inc.\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST.'],\n",
       "  ['REFERENCE',\n",
       "   'Stock Purchase Agreement dated March 29, 2016 (as amended) between PBM AKX Holdings, LLC and Eisai, Inc.\\n\\n2. License Agreement dated August 15, 2005 (as amended) between Astellas Pharma Inc. and AkaRx, Inc.\\n\\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***].'],\n",
       "  ['REFERENCE',\n",
       "   'THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\\n\\n Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018']]}"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_dataset['test'][100]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e97a873e42a04eadba3c67fb1f93bb6f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Uploading the dataset shards:   0%|          | 0/1 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b4d9eacf3b9044afb9d18cff32bea333",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Creating parquet from Arrow format:   0%|          | 0/1 [00:00<?, ?ba/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0911c66d4ee8492cb856c97c2317148e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Uploading the dataset shards:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "00f8f123afdf4aaea2a9e9f5abcb0c98",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Creating parquet from Arrow format:   0%|          | 0/3 [00:00<?, ?ba/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "edaa055ed29748faaed0a9d6b0910dfd",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Creating parquet from Arrow format:   0%|          | 0/3 [00:00<?, ?ba/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "68756406e7624a96b9ae2f8e347f4212",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "README.md:   0%|          | 0.00/709 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "CommitInfo(commit_url='https://huggingface.co/datasets/ylkhayat/CUAD-generation-workshop/commit/5988da3a0f40f66e246608ec55881387bb3df39b', commit_message='Upload dataset', commit_description='', oid='5988da3a0f40f66e246608ec55881387bb3df39b', pr_url=None, repo_url=RepoUrl('https://huggingface.co/datasets/ylkhayat/CUAD-generation-workshop', endpoint='https://huggingface.co', repo_type='dataset', repo_id='ylkhayat/CUAD-generation-workshop'), pr_revision=None, pr_num=None)"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_dataset.push_to_hub('ylkhayat/CUAD-generation-workshop', data_dir='data')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# - complete documents\n",
    "# text is extracted from context\n",
    "\n",
    "# - align score (gen and the answer) correctness\n",
    "#  ( gen and top k) faithfulness\n",
    " \n",
    "#  - we need to break the context into chunks (paragraphs) - normal spacy -> to get sentences and then put in paragraph \n",
    " \n",
    " \n",
    " \n",
    "#  - instruct to mention no answer explicitly (challenge)\n",
    " \n",
    "#  - challenge correctness (for no answer, manually state that there is no answer for better scores)\n",
    "#  - challenge faithfulness (exclude no answers OR base don generations (if exists evaluate faithfulness, otherwise exclude the record))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "retrieval",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
